<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36139423</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>18</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>A Role for PGC-1a in the Control of Abnormal Mitochondrial Dynamics in Alzheimer's Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2849</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11182849</ELocationID><Abstract><AbstractText>Emerging evidence suggests that the proper control of mitochondrial dynamics provides a window for therapeutic intervention for Alzheimer's disease (AD) progression. The transcriptional coactivator peroxisome proliferator activated receptor gamma coactivator 1 (PGC-1a) has been shown to regulate mitochondrial biogenesis in neurons. Thus far, the roles of PGC-1a in Alzheimer's disease and its potential value for restoring mitochondrial dysfunction remain largely unknown. In the present study, we explored the impacts of PGC-1a on AD pathology and neurobehavioral dysfunction and its potential mechanisms with a particular focus on mitochondrial dynamics. Paralleling AD-related pathological deposits, neuronal apoptosis, abnormal mitochondrial dynamics and lowered membrane potential, a remarkable reduction in the expression of PGC-1a was shown in the cortex of APP/PS1 mice at 6 months of age. By infusing AAV-<i>Ppargc1α</i> into the lateral parietal association (LPtA) cortex of the APP/PS1 brain, we found that PGC-1a ameliorated AD-like behavioral abnormalities, such as deficits in spatial reference memory, working memory and sensorimotor gating. Notably, overexpressed PGC-1a in LPtA rescued mitochondrial swelling and damage in neurons, likely through correcting the altered balance in mitochondrial fission-fusion and its abnormal distribution. Our findings support the notion that abnormal mitochondrial dynamics is likely an important mechanism that leading to mitochondrial dysfunction and AD-related pathological and cognitive impairments, and they indicate the potential value of PGC-1a for restoring mitochondrial dynamics as an innovative therapeutic target for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang 212013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wen-Jun</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang 212013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Hou-Zhen</ForeName><Initials>HZ</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang 212013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Hong-Ru</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang 212013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Jin-Jun</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei-Ning</ForeName><Initials>WN</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang 212013, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BE2022782</GrantID><Agency>Jiangsu Science and Technology Consulting Association</Agency><Country/></Grant><Grant><GrantID>GJ2021010</GrantID><Agency>International cooperation projects of Zhenjiang City</Agency><Country/></Grant><Grant><GrantID>SH2021041</GrantID><Agency>Science and Technology Planning Social Development Project of Zhenjiang City</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071248">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485290">Ppargc1a protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063154" MajorTopicYN="Y">Mitochondrial Dynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001678" MajorTopicYN="N">Organelle Biogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047495" MajorTopicYN="N">PPAR gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071248" MajorTopicYN="Y">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">PGC-1a</Keyword><Keyword MajorTopicYN="N">mitochondrial distribution</Keyword><Keyword MajorTopicYN="N">mitochondrial dynamics</Keyword><Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36139423</ArticleId><ArticleId IdType="pii">cells11182849</ArticleId><ArticleId IdType="doi">10.3390/cells11182849</ArticleId><ArticleId IdType="pmc">PMC9496770</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Front Mol Neurosci. 2021 Sep 16;14:727552</Citation><ArticleIdList><ArticleId IdType="pubmed">34602978</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2020 Apr;157:128-139</Citation><ArticleIdList><ArticleId IdType="pubmed">32057952</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2016 Oct;1862(10):1909-17</Citation><ArticleIdList><ArticleId IdType="pubmed">27460705</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2019;78(4):182-188</Citation><ArticleIdList><ArticleId IdType="pubmed">31266022</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2010 Mar 1;27(3):181-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20210366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurol (Paris). 2000 Feb;156(2):123-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10743009</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2006 Jun;55(6):1783-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16731843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2017 Nov 1;26(21):4118-4131</Citation><ArticleIdList><ArticleId IdType="pubmed">28973308</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2013 May 15;238:258-69</Citation><ArticleIdList><ArticleId IdType="pubmed">23485808</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pineal Res. 2018 Sep;65(2):e12491</Citation><ArticleIdList><ArticleId IdType="pubmed">29575122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Process. 2012 May;13(2):93-110</Citation><ArticleIdList><ArticleId IdType="pubmed">22160349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2017 Jul;54(5):3783-3797</Citation><ArticleIdList><ArticleId IdType="pubmed">27271125</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2014 Oct 29;34(44):14717-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25355224</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2012 Jun;35(6):364-72</Citation><ArticleIdList><ArticleId IdType="pubmed">22578891</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2005 Sep 12;170(6):959-69</Citation><ArticleIdList><ArticleId IdType="pubmed">16157705</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Feb 25;307(5713):1282-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2019;72(s1):S95-S116</Citation><ArticleIdList><ArticleId IdType="pubmed">30932888</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2021 Jan 23;744:135598</Citation><ArticleIdList><ArticleId IdType="pubmed">33373677</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2022;2497:129-140</Citation><ArticleIdList><ArticleId IdType="pubmed">35771440</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Physiol Educ. 2006 Dec;30(4):145-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17108241</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2022;86(3):1255-1273</Citation><ArticleIdList><ArticleId IdType="pubmed">35180113</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Jul 1;280(26):25060-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15878861</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2013 Apr 1;242:166-77</Citation><ArticleIdList><ArticleId IdType="pubmed">23276606</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2020 May;45(5):972-988</Citation><ArticleIdList><ArticleId IdType="pubmed">32170673</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2015 Oct;25(10):3547-60</Citation><ArticleIdList><ArticleId IdType="pubmed">25205661</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2012 Jan;36(1):297-309</Citation><ArticleIdList><ArticleId IdType="pubmed">21741401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2005 Feb;28(2):347-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15691715</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Dec 15;4(12):e8310</Citation><ArticleIdList><ArticleId IdType="pubmed">20016833</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2013 Aug;38(3):2350-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23725294</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Jun 14;8(6):e65646</Citation><ArticleIdList><ArticleId IdType="pubmed">23799030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2015 Dec;25(12):1517-31</Citation><ArticleIdList><ArticleId IdType="pubmed">25926084</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2010 Mar 24;30(12):4232-40</Citation><ArticleIdList><ArticleId IdType="pubmed">20335458</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2016 Apr;1862(4):814-828</Citation><ArticleIdList><ArticleId IdType="pubmed">26708942</ArticleId></ArticleIdList></Reference><Reference><Citation>Traffic. 2018 Aug;19(8):569-577</Citation><ArticleIdList><ArticleId IdType="pubmed">29663589</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Perspect Biol. 2020 Apr 1;12(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">31570337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 2006 Apr;17(4):2057-68</Citation><ArticleIdList><ArticleId IdType="pubmed">16467387</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2018 Nov;136(5):747-757</Citation><ArticleIdList><ArticleId IdType="pubmed">30191401</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19318-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19050078</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36139395</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>18</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Increased K<sub>V</sub>2.1 Channel Clustering Underlies the Reduction of Delayed Rectifier K<sup>+</sup> Currents in Hippocampal Neurons of the Tg2576 Alzheimer's Disease Mouse.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2820</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11182820</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive deterioration of cognitive functions. Cortical and hippocampal hyperexcitability intervenes in the pathological derangement of brain activity leading to cognitive decline. As key regulators of neuronal excitability, the voltage-gated K<sup>+</sup> channels (K<sub>V</sub>) might play a crucial role in the AD pathophysiology. Among them, the K<sub>V</sub>2.1 channel, the main α subunit mediating the delayed rectifier K<sup>+</sup> currents (I<sub>DR</sub>) and controlling the intrinsic excitability of pyramidal neurons, has been poorly examined in AD. In the present study, we investigated the K<sub>V</sub>2.1 protein expression and activity in hippocampal neurons from the Tg2576 mouse, a widely used transgenic model of AD. To this aim we performed whole-cell patch-clamp recordings, Western blotting, and immunofluorescence analyses. Our Western blotting results reveal that K<sub>V</sub>2.1 was overexpressed in the hippocampus of 3-month-old Tg2576 mice and in primary hippocampal neurons from Tg2576 mouse embryos compared with the WT counterparts. Electrophysiological experiments unveiled that the whole I<sub>DR</sub> were reduced in the Tg2576 primary neurons compared with the WT neurons, and that this reduction was due to the loss of the K<sub>V</sub>2.1 current component. Moreover, we found that the reduction of the K<sub>V</sub>2.1-mediated currents was due to increased channel clustering, and that glutamate, a stimulus inducing K<sub>V</sub>2.1 declustering, was able to restore the I<sub>DR</sub> to levels comparable to those of the WT neurons. These findings add new information about the dysregulation of ionic homeostasis in the Tg2576 AD mouse model and identify K<sub>V</sub>2.1 as a possible player in the AD-related alterations of neuronal excitability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piccialli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, 80131 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sisalli</LastName><ForeName>Maria José</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, 80131 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Rosa</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, 80131 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boscia</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1572-0484</Identifier><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, 80131 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedeschi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, 80131 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Secondo</LastName><ForeName>Agnese</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5054-4098</Identifier><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, 80131 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pannaccione</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, 80131 Napoli, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>linea-1 54_2020_FRA</GrantID><Agency>Programma di finanziamento</Agency><Country/></Grant><Grant><GrantID>CA.04_CDA_n_103 27 March 2019</GrantID><Agency>Progetto Speciale di Ateneo</Agency><Country/></Grant><Grant><GrantID>linea-1 54_2020_FRA</GrantID><Agency>Programma di finanziamento</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051669">Shab Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWP5GA015D</RegistryNumber><NameOfSubstance UI="D011188">Potassium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011188" MajorTopicYN="N">Potassium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051669" MajorTopicYN="Y">Shab Potassium Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">KV2.1</Keyword><Keyword MajorTopicYN="N">Tg2576 mouse</Keyword><Keyword MajorTopicYN="N">channel clustering</Keyword><Keyword MajorTopicYN="N">delayed rectifier K+ currents</Keyword><Keyword MajorTopicYN="N">electrophysiology</Keyword><Keyword MajorTopicYN="N">hippocampal neurons</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36139395</ArticleId><ArticleId IdType="pii">cells11182820</ArticleId><ArticleId IdType="doi">10.3390/cells11182820</ArticleId><ArticleId IdType="pmc">PMC9497218</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20566856</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2019 Sep 19;9(1):13592</Citation><ArticleIdList><ArticleId IdType="pubmed">31537873</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotoxicology. 2005 Oct;26(5):743-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15950285</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 2012 Aug;23(15):2917-29</Citation><ArticleIdList><ArticleId IdType="pubmed">22648171</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Dec 27;26(52):13505-14</Citation><ArticleIdList><ArticleId IdType="pubmed">17192433</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2022 Apr;350:113969</Citation><ArticleIdList><ArticleId IdType="pubmed">34973962</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2013 Dec 15;126(Pt 24):5566-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24101730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2017 Apr;16(4):311-322</Citation><ArticleIdList><ArticleId IdType="pubmed">28327340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 2018 Oct 1;29(20):2410-2432</Citation><ArticleIdList><ArticleId IdType="pubmed">30091655</ArticleId></ArticleIdList></Reference><Reference><Citation>Elife. 2019 Oct 30;8:</Citation><ArticleIdList><ArticleId IdType="pubmed">31663850</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2021 Jan;147:105141</Citation><ArticleIdList><ArticleId IdType="pubmed">33132203</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Sep 20;26(38):9609-18</Citation><ArticleIdList><ArticleId IdType="pubmed">16988031</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1999 Mar 1;19(5):1728-35</Citation><ArticleIdList><ArticleId IdType="pubmed">10024359</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxins (Basel). 2020 Dec 31;13(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">33396295</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Apr 17;33(16):7020-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23595759</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Aug 20;28(34):8529-38</Citation><ArticleIdList><ArticleId IdType="pubmed">18716211</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1998 May;84(1):37-48</Citation><ArticleIdList><ArticleId IdType="pubmed">9522360</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2014 Jun;39(11):1771-83</Citation><ArticleIdList><ArticleId IdType="pubmed">24606584</ArticleId></ArticleIdList></Reference><Reference><Citation>Channels (Austin). 2019 Dec;13(1):88-101</Citation><ArticleIdList><ArticleId IdType="pubmed">30712450</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2019 Jul;127:605-615</Citation><ArticleIdList><ArticleId IdType="pubmed">30999010</ArticleId></ArticleIdList></Reference><Reference><Citation>Channels (Austin). 2009 Jan-Feb;3(1):46-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19276663</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurosci. 2008 Nov 13;9:112</Citation><ArticleIdList><ArticleId IdType="pubmed">19014551</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2014 Aug 1;522(11):2594-608</Citation><ArticleIdList><ArticleId IdType="pubmed">24477962</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Brain Behav. 2014 Apr;13(4):394-408</Citation><ArticleIdList><ArticleId IdType="pubmed">24494598</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2000 Jan 1;522 Pt 1:19-31</Citation><ArticleIdList><ArticleId IdType="pubmed">10618149</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2013 Jan;34(1):211-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22727275</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 2007 Sep;72(3):665-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17495071</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2001;108(1):69-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11738132</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2005 Nov;20(2):187-98</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2014 Sep;35(9):1982-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24792906</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Jan 16;33(3):1259-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23325261</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2020 Sep;16(9):1312-1329</Citation><ArticleIdList><ArticleId IdType="pubmed">32543726</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2017 Jun;54:187-198</Citation><ArticleIdList><ArticleId IdType="pubmed">28390823</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 2007 Nov;35(Pt 5):1064-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17956280</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2018 Aug 29;38(35):7562-7584</Citation><ArticleIdList><ArticleId IdType="pubmed">30012696</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2017 Apr 03;8:14727</Citation><ArticleIdList><ArticleId IdType="pubmed">28367951</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Sep 6;55(5):697-711</Citation><ArticleIdList><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Jan 28;362(4):329-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Sep 6;55(5):677-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17785172</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2018 Aug;116:142-154</Citation><ArticleIdList><ArticleId IdType="pubmed">29778899</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Apr 7;24(14):3592-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Aug 18;313(5789):976-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16917065</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7331-E7340</Citation><ArticleIdList><ArticleId IdType="pubmed">29941597</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1997 Mar;20(3):125-31</Citation><ArticleIdList><ArticleId IdType="pubmed">9061867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2016 Mar;53(2):1365-1376</Citation><ArticleIdList><ArticleId IdType="pubmed">25633096</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Mar 13;10(3):e0119910</Citation><ArticleIdList><ArticleId IdType="pubmed">25768013</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2018 Jul 26;9(8):820</Citation><ArticleIdList><ArticleId IdType="pubmed">30050035</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Calcium. 2020 May;87:102190</Citation><ArticleIdList><ArticleId IdType="pubmed">32199208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2015 Jun 1;128(11):2096-105</Citation><ArticleIdList><ArticleId IdType="pubmed">25908859</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Jan 11;26(2):685-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16407566</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2004 Jul;7(7):711-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15195093</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2022 Jul 26;119(30):e2117135119</Citation><ArticleIdList><ArticleId IdType="pubmed">35862456</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2015 Nov 04;35(44):14922-42</Citation><ArticleIdList><ArticleId IdType="pubmed">26538660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2020 Dec;25(12):3380-3398</Citation><ArticleIdList><ArticleId IdType="pubmed">31431685</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2007 Jun 15;581(Pt 3):941-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17379638</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2005 Aug;94(3):572-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15969743</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Physiol. 2004;66:477-519</Citation><ArticleIdList><ArticleId IdType="pubmed">14977411</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2014 Sep 19;580:62-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25102326</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2015 Jul;25(7):786-97</Citation><ArticleIdList><ArticleId IdType="pubmed">25515596</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 May 29;109(22):8740-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurologia (Engl Ed). 2021 Sep 8;:</Citation><ArticleIdList><ArticleId IdType="pubmed">34509401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1997 Nov;52(5):821-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9351973</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1996 Oct 4;274(5284):99-102</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2013 Sep 1;70(9):1158-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23835471</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2011 Jan;14(1):69-76</Citation><ArticleIdList><ArticleId IdType="pubmed">21151119</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2004 Jul 1;77(1):94-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15197742</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2012 May 10;74(3):467-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22578498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2014 Oct;76(4):529-540</Citation><ArticleIdList><ArticleId IdType="pubmed">25164438</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2017 Nov 29;37(48):11523-11536</Citation><ArticleIdList><ArticleId IdType="pubmed">29042434</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Physiol. 2015 Nov;146(5):399-410</Citation><ArticleIdList><ArticleId IdType="pubmed">26503721</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2009 Feb 17;72(7):664-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19221301</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2018 Jan 3;97(1):32-58</Citation><ArticleIdList><ArticleId IdType="pubmed">29301104</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2016 Feb 18;7:e2100</Citation><ArticleIdList><ArticleId IdType="pubmed">26890139</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2021 Dec 08;12:775271</Citation><ArticleIdList><ArticleId IdType="pubmed">34955845</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2013 Oct 1;591(19):4807-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23878373</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18132-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22006306</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2011 Sep;32(9):1725-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19828212</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Sep 27;8(9):e76497</Citation><ArticleIdList><ArticleId IdType="pubmed">24086745</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2005 Feb 10;157(1):91-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15617775</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2010 Dec 10;486(2):60-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20600597</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36139364</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>18</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Demand Coupling Drives Neurodegeneration: A Model of Age-Related Cognitive Decline and Dementia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2789</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11182789</ELocationID><Abstract><AbstractText>The societal burden of Alzheimer's Disease (AD) and other major forms of dementia continues to grow, and multiple pharmacological agents directed towards modifying the pathological "hallmarks" of AD have yielded disappointing results. Though efforts continue towards broadening and deepening our knowledge and understanding of the mechanistic and neuropathological underpinnings of AD, our previous failures motivate a re-examination of how we conceptualize AD pathology and progression. In addition to not yielding effective treatments, the phenotypically heterogeneous biological processes that have been the primary area of focus to date have not been adequately shown to be necessary or sufficient to explain the risk and progression of AD. On the other hand, a growing body of evidence indicates that lifestyle and environment represent the ultimate level of causation for AD and age-related cognitive decline. Specifically, the decline in cognitive demands over the lifespan plays a central role in driving the structural and functional deteriorations of the brain. In the absence of adequate cognitive stimulus, physiological demand-function coupling leads to downregulation of growth, repair, and homeostatic processes, resulting in deteriorating brain tissue health, function, and capacity. In this setting, the heterogeneity of associated neuropathological tissue hallmarks then occurs as a consequence of an individual's genetic and environmental background and are best considered downstream markers of the disease process rather than specific targets for direct intervention. In this manuscript we outline the evidence for a demand-driven model of age-related cognitive decline and dementia and why it mandates a holistic approach to dementia treatment and prevention that incorporates the primary upstream role of cognitive demand.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turknett</LastName><ForeName>Josh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Brainjo Center for Neurology and Cognitive Enhancement, Atlanta, GA 30076, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0002-1130-2720</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, University of Washington, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Human and Machine Cognition, Pensacola, FL 32502, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s</Keyword><Keyword MajorTopicYN="N">cognitive decline</Keyword><Keyword MajorTopicYN="N">cognitive demand</Keyword><Keyword MajorTopicYN="N">dementia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36139364</ArticleId><ArticleId IdType="pii">cells11182789</ArticleId><ArticleId IdType="doi">10.3390/cells11182789</ArticleId><ArticleId IdType="pmc">PMC9496827</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3440-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11248097</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2018 Jan;33(1):e14-e21</Citation><ArticleIdList><ArticleId IdType="pubmed">28509380</ArticleId></ArticleIdList></Reference><Reference><Citation>Exerc Sport Sci Rev. 2017 Jul;45(3):181-186</Citation><ArticleIdList><ArticleId IdType="pubmed">28419000</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Regul Integr Comp Physiol. 2014 Oct 15;307(8):R956-69</Citation><ArticleIdList><ArticleId IdType="pubmed">25121614</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 2014 Apr 15;88(4):584-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24316434</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Clin. 2017 May;35(2):263-281</Citation><ArticleIdList><ArticleId IdType="pubmed">28410659</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychon Bull Rev. 2020 Oct;27(5):952-965</Citation><ArticleIdList><ArticleId IdType="pubmed">32462636</ArticleId></ArticleIdList></Reference><Reference><Citation>Innov Aging. 2018 Jan;2(1):igy007</Citation><ArticleIdList><ArticleId IdType="pubmed">30003146</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2016 Apr 12;8:78</Citation><ArticleIdList><ArticleId IdType="pubmed">27148046</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2014 Sep 9;83(11):967-73</Citation><ArticleIdList><ArticleId IdType="pubmed">25186857</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2017 Jan 01;40(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">28364458</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine (Baltimore). 2021 May 21;100(20):e26071</Citation><ArticleIdList><ArticleId IdType="pubmed">34011128</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Jul 27;337(6093):481-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22678360</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2021 Oct 25;:1-22</Citation><ArticleIdList><ArticleId IdType="pubmed">34694201</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2008 Apr 15;40(3):1044-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18295509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Behav Med. 2020 Nov 1;54(11):805-826</Citation><ArticleIdList><ArticleId IdType="pubmed">32338719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2015 Jun 6;385(9984):2255-63</Citation><ArticleIdList><ArticleId IdType="pubmed">25771249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2021 Sep;27(8):805-812</Citation><ArticleIdList><ArticleId IdType="pubmed">34308814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2013 Jun 6;153(6):1194-217</Citation><ArticleIdList><ArticleId IdType="pubmed">23746838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Nov;21(11):1633-1642</Citation><ArticleIdList><ArticleId IdType="pubmed">27001615</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Mar 11;120(5):701-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS J. 2018 Oct;285(19):3566-3575</Citation><ArticleIdList><ArticleId IdType="pubmed">29125686</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Ment Health. 2018 Aug;22(8):964-971</Citation><ArticleIdList><ArticleId IdType="pubmed">28521542</ArticleId></ArticleIdList></Reference><Reference><Citation>J Appl Physiol (1985). 2015 Apr 15;118(8):971-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25678702</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2013 Apr;93(2):681-766</Citation><ArticleIdList><ArticleId IdType="pubmed">23589831</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2022 May 3;98(18):e1837-e1845</Citation><ArticleIdList><ArticleId IdType="pubmed">35264428</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Regen Res. 2022 Aug;17(8):1666-1674</Citation><ArticleIdList><ArticleId IdType="pubmed">35017413</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pathobiol Rep. 2017 Jun;5(2):177-186</Citation><ArticleIdList><ArticleId IdType="pubmed">29057166</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2017 Nov 07;3(4):603-611</Citation><ArticleIdList><ArticleId IdType="pubmed">29201994</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2011;26 Suppl 3:349-57</Citation><ArticleIdList><ArticleId IdType="pubmed">21971474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1201-1209</Citation><ArticleIdList><ArticleId IdType="pubmed">32690803</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Jun 1;25(22):5356-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15930384</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2017 Jun 15;11:305</Citation><ArticleIdList><ArticleId IdType="pubmed">28674488</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2021 Apr 20;12(1):2289</Citation><ArticleIdList><ArticleId IdType="pubmed">33879784</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Jun;18(6):794-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26007212</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2022 Feb 01;182(2):134-141</Citation><ArticleIdList><ArticleId IdType="pubmed">34870676</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Sci. 2014 Jan;25(1):103-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24214244</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Behav Med. 2014 Sep;4(3):260-74</Citation><ArticleIdList><ArticleId IdType="pubmed">25264466</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2021 Jul;17(7):1166-1178</Citation><ArticleIdList><ArticleId IdType="pubmed">34255432</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2020 Nov 26;10(1):20687</Citation><ArticleIdList><ArticleId IdType="pubmed">33244175</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2020 Oct;35(10):1243-1249</Citation><ArticleIdList><ArticleId IdType="pubmed">32557831</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2001 Jul 1;21(13):4923-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11425920</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Sci Sleep. 2017 May 19;9:151-161</Citation><ArticleIdList><ArticleId IdType="pubmed">28579842</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetologia. 2018 Apr;61(4):839-848</Citation><ArticleIdList><ArticleId IdType="pubmed">29368156</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Jan 10;368(2):100-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23301730</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Nov 16;31(46):16808-13</Citation><ArticleIdList><ArticleId IdType="pubmed">22090506</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Sci. 2021 Jan 06;11(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">33419228</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1995 Mar;45(3 Pt 1):482-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7898701</ArticleId></ArticleIdList></Reference><Reference><Citation>eNeuro. 2022 Feb 10;9(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">35144999</ArticleId></ArticleIdList></Reference><Reference><Citation>Autophagy. 2012 Oct;8(10):1548-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22892563</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2022 Apr;604(7907):697-707</Citation><ArticleIdList><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Endocrinol (Lausanne). 2018 May 25;9:258</Citation><ArticleIdList><ArticleId IdType="pubmed">29887832</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2022 Jun 14;:</Citation><ArticleIdList><ArticleId IdType="pubmed">35701596</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Epidemiol. 2014 May;29(5):353-61</Citation><ArticleIdList><ArticleId IdType="pubmed">24791704</ArticleId></ArticleIdList></Reference><Reference><Citation>APL Bioeng. 2019 Oct 23;3(4):040901</Citation><ArticleIdList><ArticleId IdType="pubmed">31673672</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2014 Nov;10(6):869-72</Citation><ArticleIdList><ArticleId IdType="pubmed">25130656</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Struct Funct. 2018 Jan;223(1):297-305</Citation><ArticleIdList><ArticleId IdType="pubmed">28815301</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Med (Lond). 2016 Jun;16(3):247-53</Citation><ArticleIdList><ArticleId IdType="pubmed">27251914</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2022 Feb 10;:</Citation><ArticleIdList><ArticleId IdType="pubmed">35142437</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurosci. 2020 Aug 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32804681</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2021 Mar;17(3):327-406</Citation><ArticleIdList><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2022 Jan;23(1):53-66</Citation><ArticleIdList><ArticleId IdType="pubmed">34815562</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(6):e38268</Citation><ArticleIdList><ArticleId IdType="pubmed">22675535</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 2015 Jul;102(1):215-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25877495</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2021 Jul 1;276:119129</Citation><ArticleIdList><ArticleId IdType="pubmed">33515559</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13900-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20643928</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2020 Apr 21;10(1):112</Citation><ArticleIdList><ArticleId IdType="pubmed">32317627</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2021 Dec 1;4(12):e2138526</Citation><ArticleIdList><ArticleId IdType="pubmed">34913979</ArticleId></ArticleIdList></Reference><Reference><Citation>Elife. 2016 Jun 02;5:</Citation><ArticleIdList><ArticleId IdType="pubmed">27253067</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2022 Mar 29;98(13):e1337-e1348</Citation><ArticleIdList><ArticleId IdType="pubmed">35131906</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (Amst). 2022 Jul 13;14(1):e12337</Citation><ArticleIdList><ArticleId IdType="pubmed">35845262</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2022 Sep;237:108171</Citation><ArticleIdList><ArticleId IdType="pubmed">35304223</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2017 Apr;31(4):1508-1515</Citation><ArticleIdList><ArticleId IdType="pubmed">28031319</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2022 Jul 19;14:948219</Citation><ArticleIdList><ArticleId IdType="pubmed">35928995</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Jun;18(6):800-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Aug 8;396(10248):413-446</Citation><ArticleIdList><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2019 Feb;15(2):73-88</Citation><ArticleIdList><ArticleId IdType="pubmed">30610216</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Regen Res. 2021 May;16(5):813-819</Citation><ArticleIdList><ArticleId IdType="pubmed">33229714</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2022 Jan;18(1):25-39</Citation><ArticleIdList><ArticleId IdType="pubmed">34750588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2013 Feb;12(2):129-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23246540</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Nov 07;8(11):e79771</Citation><ArticleIdList><ArticleId IdType="pubmed">24244562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2014 Jun;75(6):959-63</Citation><ArticleIdList><ArticleId IdType="pubmed">24890334</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2020 Aug 13;14:843</Citation><ArticleIdList><ArticleId IdType="pubmed">32903751</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2005 Mar;26(3):341-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15639312</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychol. 2022 Jun;45:101299</Citation><ArticleIdList><ArticleId IdType="pubmed">35219156</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2019 Nov;82:396-405</Citation><ArticleIdList><ArticleId IdType="pubmed">31513875</ArticleId></ArticleIdList></Reference><Reference><Citation>Orthopedics. 2014 Feb;37(2):e194-200</Citation><ArticleIdList><ArticleId IdType="pubmed">24679208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;66(4):1619-1633</Citation><ArticleIdList><ArticleId IdType="pubmed">30452410</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2007 Jan;56(1):211-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17192484</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2022 Feb 23;12(2):e053936</Citation><ArticleIdList><ArticleId IdType="pubmed">35197341</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2013 Oct 18;342(6156):373-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Geriatr. 2022 Feb 19;22(1):141</Citation><ArticleIdList><ArticleId IdType="pubmed">35183116</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2022 Jun;18(6):323-332</Citation><ArticleIdList><ArticleId IdType="pubmed">35332316</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Cell. 2020 Jul 20;54(2):268-281</Citation><ArticleIdList><ArticleId IdType="pubmed">32693059</ArticleId></ArticleIdList></Reference><Reference><Citation>Elife. 2021 Oct 26;10:</Citation><ArticleIdList><ArticleId IdType="pubmed">34699347</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):205-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19812460</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1998 Nov;4(11):1313-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>SSM Popul Health. 2021 Jun 26;15:100855</Citation><ArticleIdList><ArticleId IdType="pubmed">34258375</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2014 Dec 10;1592:113-23</Citation><ArticleIdList><ArticleId IdType="pubmed">25451096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2021 Mar;17(3):157-172</Citation><ArticleIdList><ArticleId IdType="pubmed">33318676</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2020 Nov 20;739:135437</Citation><ArticleIdList><ArticleId IdType="pubmed">33132180</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nutr ESPEN. 2022 Aug;50:270-276</Citation><ArticleIdList><ArticleId IdType="pubmed">35871935</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2013 Sep 9;23(17):R774-88</Citation><ArticleIdList><ArticleId IdType="pubmed">24028961</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2018 Apr 16;342:19-26</Citation><ArticleIdList><ArticleId IdType="pubmed">29317248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2021 Jan 11;11(1):423</Citation><ArticleIdList><ArticleId IdType="pubmed">33432038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2006 Jan;59(1):182-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16278853</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2022;88(4):1411-1421</Citation><ArticleIdList><ArticleId IdType="pubmed">35811518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Appl Physiol (1985). 2017 Mar 1;122(3):541-548</Citation><ArticleIdList><ArticleId IdType="pubmed">27742803</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1989 Mar;12(3):94-101</Citation><ArticleIdList><ArticleId IdType="pubmed">2469224</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):4483-4488</Citation><ArticleIdList><ArticleId IdType="pubmed">29632177</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Jan 18;481(7382):511-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22258505</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 Jan;7(1):80-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21255746</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rep. 2018 Apr;6(7):e13651</Citation><ArticleIdList><ArticleId IdType="pubmed">29626392</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2017 Apr 25;9:112</Citation><ArticleIdList><ArticleId IdType="pubmed">28487649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageing Res Rev. 2022 Apr;76:101591</Citation><ArticleIdList><ArticleId IdType="pubmed">35182742</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Rev Aging Phys Act. 2019 Jul 10;16:10</Citation><ArticleIdList><ArticleId IdType="pubmed">31333805</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3017-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21282661</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2022 Jan 12;42(2):288-298</Citation><ArticleIdList><ArticleId IdType="pubmed">34810231</ArticleId></ArticleIdList></Reference><Reference><Citation>J Appl Physiol (1985). 2000 Feb;88(2):774-87</Citation><ArticleIdList><ArticleId IdType="pubmed">10658050</ArticleId></ArticleIdList></Reference><Reference><Citation>Stud Hist Philos Biol Biomed Sci. 2018 Apr - Jun;68-69:34-41</Citation><ArticleIdList><ArticleId IdType="pubmed">29653763</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2018 Aug 28;91(9):395-402</Citation><ArticleIdList><ArticleId IdType="pubmed">30089620</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 2013 Jul;15(7):713-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23817233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2012;28(1):223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">21971400</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Jun 19;348(25):2508-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12815136</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Fam Physician. 1993 Jun;39:1428-32, 1435-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8324411</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Alzheimers Dis Other Demen. 2016 Aug;31(5):443-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27307143</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2018 Nov;14(11):653-666</Citation><ArticleIdList><ArticleId IdType="pubmed">30291317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cells. 2021 Jun 03;10(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">34205102</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nutr. 2022 May;41(5):1046-1051</Citation><ArticleIdList><ArticleId IdType="pubmed">35390728</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2020 Jan 23;13:1455</Citation><ArticleIdList><ArticleId IdType="pubmed">32038149</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2017 Oct 1;74(10):1237-1245</Citation><ArticleIdList><ArticleId IdType="pubmed">28846764</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2019 Jul 3;2(7):e198112</Citation><ArticleIdList><ArticleId IdType="pubmed">31365110</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2011 Dec 20;21(24):2109-14</Citation><ArticleIdList><ArticleId IdType="pubmed">22169537</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2015 Aug;29(8):3515-26</Citation><ArticleIdList><ArticleId IdType="pubmed">25957282</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Jul 14;9(7):e102031</Citation><ArticleIdList><ArticleId IdType="pubmed">25020061</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2020 Dec 15;17(12):e1003474</Citation><ArticleIdList><ArticleId IdType="pubmed">33320852</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Hum Behav. 2020 Jun;4(6):603-612</Citation><ArticleIdList><ArticleId IdType="pubmed">32231280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mediators Inflamm. 2022 Jun 27;2022:2396487</Citation><ArticleIdList><ArticleId IdType="pubmed">35795405</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2022 Jan 7;:</Citation><ArticleIdList><ArticleId IdType="pubmed">34994517</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2021 May;27(5):871-881</Citation><ArticleIdList><ArticleId IdType="pubmed">33927414</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2008 Sep 30;71(14):1057-64</Citation><ArticleIdList><ArticleId IdType="pubmed">18367704</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 Jul 4;345(6192):1236828</Citation><ArticleIdList><ArticleId IdType="pubmed">24994657</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2019 Dec;18(12):923-948</Citation><ArticleIdList><ArticleId IdType="pubmed">31477883</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Feb 3;11(1):667</Citation><ArticleIdList><ArticleId IdType="pubmed">32015339</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2012 Jan;96(1):32-45</Citation><ArticleIdList><ArticleId IdType="pubmed">22067440</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36139084</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>09</Month><Day>06</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Iron in Alzheimer's Disease: From Physiology to Disease Disabilities.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1248</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom12091248</ELocationID><Abstract><AbstractText>Reactive oxygen species (ROS) play a key role in the neurodegeneration processes. Increased oxidative stress damages lipids, proteins, and nucleic acids in brain tissue, and it is tied to the loss of biometal homeostasis. For this reason, attention has been focused on transition metals involved in several biochemical reactions producing ROS. Even though a bulk of evidence has uncovered the role of metals in the generation of the toxic pathways at the base of Alzheimer's disease (AD), this matter has been sidelined by the advent of the Amyloid Cascade Hypothesis. However, the link between metals and AD has been investigated in the last two decades, focusing on their local accumulation in brain areas known to be critical for AD. Recent evidence revealed a relation between iron and AD, particularly in relation to its capacity to increase the risk of the disease through ferroptosis. In this review, we briefly summarize the major points characterizing the function of iron in our body and highlight why, even though it is essential for our life, we have to monitor its dysfunction, particularly if we want to control our risk of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Amit</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9916-3309</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Kalyani 741245, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerchiaro</LastName><ForeName>Giselle</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8606-5400</Identifier><AffiliationInfo><Affiliation>Center for Natural Sciences and Humanities, Federal University of ABC (UFABC), Avenida dos Estados, 5001, Bl.B, Santo André 09210-580, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rani</LastName><ForeName>Isha</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Maharishi Markandeshwar University (MMU), Mullana, Ambala 133203, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ventriglia</LastName><ForeName>Mariacarla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fatebenefratelli Foundation for Health Research and Education, AFaR Division, 00186 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rongioletti</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Research and Development Division, Fatebenefratelli Isola Tiberina, Gemelli Isola, 00186 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longobardi</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8292-6434</Identifier><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Squitti</LastName><ForeName>Rosanna</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5624-1140</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Research and Development Division, Fatebenefratelli Isola Tiberina, Gemelli Isola, 00186 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>EudraCT 2019-000604-15</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008670">Metals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009696">Nucleic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014131">Trace Elements</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008670" MajorTopicYN="N">Metals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009696" MajorTopicYN="Y">Nucleic Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014131" MajorTopicYN="Y">Trace Elements</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">ceruloplasmin</Keyword><Keyword MajorTopicYN="N">ferroptosis</Keyword><Keyword MajorTopicYN="N">iron</Keyword><Keyword MajorTopicYN="N">reactive oxygen species</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36139084</ArticleId><ArticleId IdType="pii">biom12091248</ArticleId><ArticleId IdType="doi">10.3390/biom12091248</ArticleId><ArticleId IdType="pmc">PMC9496246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angew Chem Int Ed Engl. 2009;48(17):3030-59</Citation><ArticleIdList><ArticleId IdType="pubmed">19330877</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1994 Oct 28;269(43):26618-21</Citation><ArticleIdList><ArticleId IdType="pubmed">7929392</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 2015 Mar 1;466(2):233-42</Citation><ArticleIdList><ArticleId IdType="pubmed">25471541</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2011;62:347-60</Citation><ArticleIdList><ArticleId IdType="pubmed">20887198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1994 Nov;36(5):747-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7979220</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Dec 02;9(12):e114174</Citation><ArticleIdList><ArticleId IdType="pubmed">25464026</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2019 Mar;133:221-233</Citation><ArticleIdList><ArticleId IdType="pubmed">30266679</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2020;78(4):1373-1380</Citation><ArticleIdList><ArticleId IdType="pubmed">33185611</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2018 Apr;14(4):535-562</Citation><ArticleIdList><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Chem Soc. 2002 Oct 30;124(43):12666-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12392406</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotherapeutics. 2008 Jul;5(3):421-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18625454</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2002 Nov 22;277(47):45518-28</Citation><ArticleIdList><ArticleId IdType="pubmed">12198135</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2019;68(2):493-510</Citation><ArticleIdList><ArticleId IdType="pubmed">30883346</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2012 Jan 29;18(2):291-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22286308</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2006 Nov;10(2-3):267-76</Citation><ArticleIdList><ArticleId IdType="pubmed">17119292</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):348-66</Citation><ArticleIdList><ArticleId IdType="pubmed">26775689</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2006 Aug 15;108(4):1388-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16609065</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2016 Sep 22;332:191-202</Citation><ArticleIdList><ArticleId IdType="pubmed">27403880</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Med Chem. 2011;11(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">21189128</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1997 Jan 1;89(1):1-25</Citation><ArticleIdList><ArticleId IdType="pubmed">8978272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1970 Dec;49(12):2408-17</Citation><ArticleIdList><ArticleId IdType="pubmed">5480864</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2010 May;119(5):555-66</Citation><ArticleIdList><ArticleId IdType="pubmed">20217101</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2008 May;14(1):69-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18525129</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2009 Jun;1793(6):1058-67</Citation><ArticleIdList><ArticleId IdType="pubmed">19111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2000 Feb 17;403(6771):776-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10693807</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2004 Mar;1012:153-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15105262</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2005 Nov;49(3):633-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16269323</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2019 Mar 9;23(1):81</Citation><ArticleIdList><ArticleId IdType="pubmed">30850005</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Saf. 2010 Mar;9(2):201-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20059374</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2001;24:1121-59</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Biol (Noisy-le-grand). 2000 Jun;46(4):777-83</Citation><ArticleIdList><ArticleId IdType="pubmed">10875439</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Alzheimers Dis. 2010 Dec 27;2011:231595</Citation><ArticleIdList><ArticleId IdType="pubmed">21234401</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1999 Feb;21(2):195-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9988272</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2000 Jul 3;93(1):58-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10861683</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem Cell Biol. 2004 Nov;36(11):2137-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15313461</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2021 May;28(5):1548-1562</Citation><ArticleIdList><ArticleId IdType="pubmed">33398092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2006 Aug;9(3):225-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16914832</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2012 Mar;1820(3):188-202</Citation><ArticleIdList><ArticleId IdType="pubmed">22085723</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2003 May 15;119B(1):48-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12707938</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomolecules. 2020 Aug 09;10(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">32784855</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2012;29(3):493-501</Citation><ArticleIdList><ArticleId IdType="pubmed">22258517</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2003 Mar 18;42(10):2768-73</Citation><ArticleIdList><ArticleId IdType="pubmed">12627941</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2009;17(3):457-68</Citation><ArticleIdList><ArticleId IdType="pubmed">19363258</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2000 Jun 30;275(26):19906-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10747949</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2011 Feb 2;217(1):10-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20888863</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1995 Aug;65(2):717-24</Citation><ArticleIdList><ArticleId IdType="pubmed">7616228</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2009 Jul;1790(7):589-99</Citation><ArticleIdList><ArticleId IdType="pubmed">18929623</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2014 Oct;35(10):2288-301</Citation><ArticleIdList><ArticleId IdType="pubmed">24863668</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2017 Mar 15;8(3):629-637</Citation><ArticleIdList><ArticleId IdType="pubmed">27958708</ArticleId></ArticleIdList></Reference><Reference><Citation>Metallomics. 2016 Sep 1;8(9):863-73</Citation><ArticleIdList><ArticleId IdType="pubmed">27499330</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2005 Jan 1-15;79(1-2):254-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15578731</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2020 Jun;139:104810</Citation><ArticleIdList><ArticleId IdType="pubmed">32087292</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2005 Dec;57(4):547-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16382108</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2012 Aug;33(8):1633-41</Citation><ArticleIdList><ArticleId IdType="pubmed">21514009</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2012 Jul 24;51(29):5705-24</Citation><ArticleIdList><ArticleId IdType="pubmed">22703180</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Jul 19;297(5580):353-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 1998 May;67(5 Suppl):972S-977S</Citation><ArticleIdList><ArticleId IdType="pubmed">9587138</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2010 Sep;92(1):1-18</Citation><ArticleIdList><ArticleId IdType="pubmed">20444428</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Nutr. 2008;28:197-213</Citation><ArticleIdList><ArticleId IdType="pubmed">18489257</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1984 Apr 15;219(2):505-10</Citation><ArticleIdList><ArticleId IdType="pubmed">6743230</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Res. 2006;39(1):15-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16629161</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr. 2007 Dec;137(12):2809-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18029504</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1993 Sep;61(3):1171-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8360682</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2021 Apr 30;13:653591</Citation><ArticleIdList><ArticleId IdType="pubmed">33994996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2004 Mar;1012:1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15105251</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 2010 Dec;345(1-2):91-104</Citation><ArticleIdList><ArticleId IdType="pubmed">20730621</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 1965;16:119-34</Citation><ArticleIdList><ArticleId IdType="pubmed">14276559</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2005 Nov;19(13):1851-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16150804</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1998 Jun 11;158(1):47-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9667777</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1981 Oct 1;199(1):259-61</Citation><ArticleIdList><ArticleId IdType="pubmed">7337708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Sep 9;122(5):789-801</Citation><ArticleIdList><ArticleId IdType="pubmed">16143108</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1978 Mar 25;253(6):1930-7</Citation><ArticleIdList><ArticleId IdType="pubmed">204636</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1991 Jan 15;30(2):324-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1988034</ArticleId></ArticleIdList></Reference><Reference><Citation>Biull Eksp Biol Med. 1984 Dec;98(12):668-71</Citation><ArticleIdList><ArticleId IdType="pubmed">6095951</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2006 Jan;7(1):41-53</Citation><ArticleIdList><ArticleId IdType="pubmed">16371949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Aspects Med. 2020 Oct;75:100867</Citation><ArticleIdList><ArticleId IdType="pubmed">32654761</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Dec 23;341(26):1986-95</Citation><ArticleIdList><ArticleId IdType="pubmed">10607817</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 1995 Dec;41(12 Pt 2):1819-28</Citation><ArticleIdList><ArticleId IdType="pubmed">7497639</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trace Elem Med Biol. 2021 Sep;67:126779</Citation><ArticleIdList><ArticleId IdType="pubmed">34034029</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2021 Mar;17(3):327-406</Citation><ArticleIdList><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1994 Sep 2;265(5177):1464-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8073293</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2004 Apr;25(4):465-74</Citation><ArticleIdList><ArticleId IdType="pubmed">15013567</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2014 Jun;13(6):614-29</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Biol. 2001 Mar;204(Pt 6):1053-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11222124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Inorg Chem. 2019 Dec;24(8):1141-1157</Citation><ArticleIdList><ArticleId IdType="pubmed">31650248</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1999 Sep 25;842(2):439-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10526140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 2011 Jul 15;306(1-2):98-102</Citation><ArticleIdList><ArticleId IdType="pubmed">21497832</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotherapeutics. 2021 Jan;18(1):252-264</Citation><ArticleIdList><ArticleId IdType="pubmed">33111259</ArticleId></ArticleIdList></Reference><Reference><Citation>Haematologica. 2006 Jul;91(7):873-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16818273</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Dis. 2017 Apr 1;8(2):215-227</Citation><ArticleIdList><ArticleId IdType="pubmed">28400987</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Dec 23;8(12):e82662</Citation><ArticleIdList><ArticleId IdType="pubmed">24376563</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2007 Oct;83(3):149-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17870230</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(2):e31211</Citation><ArticleIdList><ArticleId IdType="pubmed">22359574</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2002 Feb 22;291(2):220-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11846393</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Drug Targets. 2004 Aug;5(6):535-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15270200</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Jul 11;67(1):76-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16832081</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2018 Jul 18;9(7):1849-1857</Citation><ArticleIdList><ArticleId IdType="pubmed">29722955</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2004 Nov;5(11):863-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15496864</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2006 Jul;1763(7):652-67</Citation><ArticleIdList><ArticleId IdType="pubmed">16843540</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2004 Mar 19;1001(1-2):108-17</Citation><ArticleIdList><ArticleId IdType="pubmed">14972659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2001 Jul-Aug;22(4):563-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11445256</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr. 2011 Apr 1;141(4):729S-739S</Citation><ArticleIdList><ArticleId IdType="pubmed">21346098</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1999 Jun 15;38(24):7609-16</Citation><ArticleIdList><ArticleId IdType="pubmed">10386999</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Chem Biol. 2017 Oct 19;24(10):1205-1215.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">28890316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2008;18(4):398-410</Citation><ArticleIdList><ArticleId IdType="pubmed">18189309</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2009;16(3):471-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19276540</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2018 Dec;39(12):1049-1063</Citation><ArticleIdList><ArticleId IdType="pubmed">30352697</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1999 Sep 17;458(2):133-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10481051</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Med Chem. 2010 Jan;2(1):51-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20161623</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2000 Jan;156(1):15-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2020;1195:105-116</Citation><ArticleIdList><ArticleId IdType="pubmed">32468465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageing Res Rev. 2020 Nov;63:101152</Citation><ArticleIdList><ArticleId IdType="pubmed">32846222</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1969 Oct 25;244(20):5757-8</Citation><ArticleIdList><ArticleId IdType="pubmed">5360468</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem Cell Biol. 1999 Oct;31(10):1111-37</Citation><ArticleIdList><ArticleId IdType="pubmed">10582342</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2007;30:317-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17367269</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2010 Oct 8;285(41):31217-32</Citation><ArticleIdList><ArticleId IdType="pubmed">20558735</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging (Albany NY). 2014 Nov;6(11):975-91</Citation><ArticleIdList><ArticleId IdType="pubmed">25554795</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2017 Oct 5;171(2):273-285</Citation><ArticleIdList><ArticleId IdType="pubmed">28985560</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Alzheimers Dis Other Demen. 2010 Nov;25(7):572-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20841345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Jan 8;274(2):1116-23</Citation><ArticleIdList><ArticleId IdType="pubmed">9873059</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9866-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9275217</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Neurobiol. 2013;110:125-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24209437</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2006 Oct 9;406(3):189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16919875</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2004 Apr;41(4):261-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15060098</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2007;114(6):777-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17406962</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Jan;57(1):47-53</Citation><ArticleIdList><ArticleId IdType="pubmed">10632232</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2021 Jul 19;22(14):</Citation><ArticleIdList><ArticleId IdType="pubmed">34299316</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Biopharm. 2005 Feb;59(2):263-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15661498</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr J. 2009 Aug 10;8:36</Citation><ArticleIdList><ArticleId IdType="pubmed">19664270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Aug 13;460(7257):831-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19675643</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1990;81(2):105-10</Citation><ArticleIdList><ArticleId IdType="pubmed">2082650</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Chem. 2015;22(3):373-404</Citation><ArticleIdList><ArticleId IdType="pubmed">25386820</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Apr 25;54(8):1698-700</Citation><ArticleIdList><ArticleId IdType="pubmed">10762522</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 Jan 30;279(5351):714-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9445478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1991 Jun 1;337(8753):1304-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1674295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2019 Mar;51(3):414-430</Citation><ArticleIdList><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Jul 31;388(6641):482-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9242408</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 Aug;23(8):1807-1812</Citation><ArticleIdList><ArticleId IdType="pubmed">28696433</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Dec 17;306(5704):2090-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15514116</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2021 Jul;17(7):1244-1256</Citation><ArticleIdList><ArticleId IdType="pubmed">33491917</ArticleId></ArticleIdList></Reference><Reference><Citation>J Inorg Biochem. 2017 Jun;171:29-36</Citation><ArticleIdList><ArticleId IdType="pubmed">28364616</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2000 Jan 15;28(2):289-309</Citation><ArticleIdList><ArticleId IdType="pubmed">11281297</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1997 Aug;69(2):443-54</Citation><ArticleIdList><ArticleId IdType="pubmed">9231702</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2018 May;89(5):456-460</Citation><ArticleIdList><ArticleId IdType="pubmed">28939683</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Park Dis Dement Sect. 1994;7(2):109-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7710663</ArticleId></ArticleIdList></Reference><Reference><Citation>Org Biomol Chem. 2005 Aug 7;3(15):2685-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16032345</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Apr 28;6:24873</Citation><ArticleIdList><ArticleId IdType="pubmed">27121137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2000 Feb;5(2):299-309</Citation><ArticleIdList><ArticleId IdType="pubmed">10882071</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1992 Mar;31(3):286-92</Citation><ArticleIdList><ArticleId IdType="pubmed">1637136</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2007 Dec;103(5):1730-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17953660</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Neurol. 2001 Aug;25(2):118-29</Citation><ArticleIdList><ArticleId IdType="pubmed">11551742</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2004 Jan 20;43(2):560-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14717612</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Life Sci. 2002 Sep;59(9):1413-27</Citation><ArticleIdList><ArticleId IdType="pubmed">12440766</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neurol Neurosci Rep. 2011 Jun;11(3):254-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21286947</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 2011 Mar 15;434(3):365-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21348856</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2021 Apr 30;11(1):9363</Citation><ArticleIdList><ArticleId IdType="pubmed">33931662</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1982 Feb 15;710(2):197-211</Citation><ArticleIdList><ArticleId IdType="pubmed">7066358</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2016;50(4):1181-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26836154</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Jul 01;4(7):e6115</Citation><ArticleIdList><ArticleId IdType="pubmed">19568430</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Sep 15;110(6):2182-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17540841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Biol (Noisy-le-grand). 2000 Jun;46(4):761-76</Citation><ArticleIdList><ArticleId IdType="pubmed">10875438</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2013 Sep;62:52-64</Citation><ArticleIdList><ArticleId IdType="pubmed">23376471</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutat Res. 2003 Oct 29;531(1-2):81-92</Citation><ArticleIdList><ArticleId IdType="pubmed">14637247</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Genet. 2017 Dec 21;8:223</Citation><ArticleIdList><ArticleId IdType="pubmed">29312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1984 Nov 8-14;312(5990):162-3</Citation><ArticleIdList><ArticleId IdType="pubmed">6095085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2016;51(3):737-45</Citation><ArticleIdList><ArticleId IdType="pubmed">26890777</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2008 Jan 10;51(1):126-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18078312</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Biol (Noisy-le-grand). 2000 Jun;46(4):821-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10875443</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Chem Biol. 2000 Apr;4(2):184-91</Citation><ArticleIdList><ArticleId IdType="pubmed">10742195</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Immunol. 2017 Nov 1;29(9):401-409</Citation><ArticleIdList><ArticleId IdType="pubmed">28541437</ArticleId></ArticleIdList></Reference><Reference><Citation>J Toxicol Environ Health B Crit Rev. 2010 Aug;13(6):449-52; author reply 453-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20711927</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2002 Oct 15;33(8):1037-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12374615</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2001 Jun 15;21(12):4183-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11404403</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2011;24(1):175-85</Citation><ArticleIdList><ArticleId IdType="pubmed">21187586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;19(1):363-72</Citation><ArticleIdList><ArticleId IdType="pubmed">20061651</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2009;16(4):879-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19387120</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Cells Mol Dis. 2002 Jul-Aug;29(1):41-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12482402</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2012 Jan;33(1):202.e1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">20817350</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2015 May 19;6:6760</Citation><ArticleIdList><ArticleId IdType="pubmed">25988319</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1997 Aug 8;272(32):20185-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9242695</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36139033</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>08</Month><Day>28</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Head-to-Head Comparison of Different Blood Collecting Tubes for Quantification of Alzheimer's Disease Biomarkers in Plasma.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1194</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom12091194</ELocationID><Abstract><AbstractText>To examine whether the type of blood collection tubes affects the quantification of plasma biomarkers for Alzheimer's disease analyzed with a single-molecule array (Simoa), we recruited a healthy cohort (n = 34, 11 males, mean age = 28.7 ± 7.55) and collected plasma in the following tubes: dipotassium ethylenediaminetetraacetic acid (K2-EDTA), heparin lithium (Li-Hep), and heparin sodium (Na-Hep). Plasma tau, phosphorylated tau 181 (p-tau181), amyloid β (1-40) (Aβ40), and amyloid β (1-42) (Aβ42) were quantified using Simoa. We compared the value of plasma analytes, as well as the effects of sex on the measurements. We found that plasma collected in Li-Hep and Na-Hep tubes yielded significantly higher tau and p-tau181 levels compared to plasma collected in K2-EDTA tubes from the same person, but there was no difference in the measured values of the Aβ40, Aβ42, and Aβ42/40 ratio. Therefore, the type of blood collecting tubes should be considered when planning studies that measure plasma tau.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lijun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Mental Health Center and Department of Neurology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Xulong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Mental Health Center and Department of Neurology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou 215125, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenxiao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Deyang Mental Health Center, Deyang 618099, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaobin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Deyang Mental Health Center, Deyang 618099, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mental Health Center and Department of Neurology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology, Affiliated Mental Health Center &amp; Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou 310063, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC and CAMS Key Laboratory of Medical Neurobiology, MOE Frontier Science Center for Brain Science and Brain-machine Integration, School of Brain Science and Brain Medicine, Zhejiang University, Hangzhou 310012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Peng</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5652-1962</Identifier><AffiliationInfo><Affiliation>Mental Health Center and Department of Neurology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>9G34HU7RV0</RegistryNumber><NameOfSubstance UI="D004492">Edetic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004492" MajorTopicYN="N">Edetic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">EDTA</Keyword><Keyword MajorTopicYN="N">Simoa</Keyword><Keyword MajorTopicYN="N">blood collection tubes</Keyword><Keyword MajorTopicYN="N">heparin</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36139033</ArticleId><ArticleId IdType="pii">biom12091194</ArticleId><ArticleId IdType="doi">10.3390/biom12091194</ArticleId><ArticleId IdType="pmc">PMC9496121</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Med. 2021 Jun;27(6):954-963</Citation><ArticleIdList><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>MedComm (2020). 2020 May 22;1(1):74-76</Citation><ArticleIdList><ArticleId IdType="pubmed">34766110</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2019 Mar 1;142(3):771-786</Citation><ArticleIdList><ArticleId IdType="pubmed">30668647</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2022 Aug;18(8):1484-1497</Citation><ArticleIdList><ArticleId IdType="pubmed">34845818</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14683-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9405673</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2018 May 2;13(5):e0196025</Citation><ArticleIdList><ArticleId IdType="pubmed">29719006</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet J. 2004 May;167(3):294-301</Citation><ArticleIdList><ArticleId IdType="pubmed">15080879</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Lab. 2016;62(4):705-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27215091</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2021;80(4):1353-1362</Citation><ArticleIdList><ArticleId IdType="pubmed">33682718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2021 Oct;26(10):5967-5976</Citation><ArticleIdList><ArticleId IdType="pubmed">32665603</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2019 Apr;175:54-76</Citation><ArticleIdList><ArticleId IdType="pubmed">30605723</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Clin Biochem. 2014 Jul;29(3):327-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24966481</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2004 Feb 17;43(6):1704-14</Citation><ArticleIdList><ArticleId IdType="pubmed">14769048</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2021 Nov 1;78(11):1375-1382</Citation><ArticleIdList><ArticleId IdType="pubmed">34542571</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2005 Jan 3;1739(2-3):167-78</Citation><ArticleIdList><ArticleId IdType="pubmed">15615636</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (Amst). 2016 Dec 10;7:33-40</Citation><ArticleIdList><ArticleId IdType="pubmed">28229128</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem Lab Med. 2007;45(5):565-76</Citation><ArticleIdList><ArticleId IdType="pubmed">17484616</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem Lab Med. 2004 Apr;42(4):435-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15147155</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2020 Sep;140(3):267-278</Citation><ArticleIdList><ArticleId IdType="pubmed">32720099</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2010 Feb 5;285(6):3592-3599</Citation><ArticleIdList><ArticleId IdType="pubmed">19959468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1996 Sep;67(3):1183-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8752125</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem Lab Med. 2008;46(3):396-400</Citation><ArticleIdList><ArticleId IdType="pubmed">18254716</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Mar;26(3):387-397</Citation><ArticleIdList><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2008 Dec;29(36):4808-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18801571</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2018 Aug;14(8):989-997</Citation><ArticleIdList><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Mar;26(3):379-386</Citation><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2019 May 1;76(5):598-606</Citation><ArticleIdList><ArticleId IdType="pubmed">30830207</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2010 Jun;28(6):595-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurotrauma. 2019 Jul 15;36(14):2190-2199</Citation><ArticleIdList><ArticleId IdType="pubmed">30834814</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Neurodegener. 2021 Mar 12;10(1):10</Citation><ArticleIdList><ArticleId IdType="pubmed">33712071</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2017 Nov;24(11):1326-e77</Citation><ArticleIdList><ArticleId IdType="pubmed">28816001</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1996 Oct 10;383(6600):550-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36139003</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>08</Month><Day>23</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Spreading of P301S Aggregated Tau Investigated in Organotypic Mouse Brain Slice Cultures.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1164</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom12091164</ELocationID><Abstract><AbstractText>Tau pathology extends throughout the brain in a prion-like fashion through connected brain regions. However, the details of the underlying mechanisms are incompletely understood. The present study aims to examine the spreading of P301S aggregated tau, a mutation that is implicated in tauopathies, using organotypic slice cultures. Coronal hippocampal organotypic brain slices (170 µm) were prepared from postnatal (day 8-10) C57BL6 wild-type mice. Collagen hydrogels loaded with P301S aggregated tau were applied to slices and the spread of tau was assessed by immunohistochemistry after 8 weeks in culture. Collagen hydrogels prove to be an effective protein delivery system subject to natural degradation in 14 days and they release tau proteins up to 8 weeks. Slices with un- and hyperphosphorylated P301S aggregated tau demonstrate significant spreading to the ventral parts of the hippocampal slices compared to empty collagen hydrogels after 8 weeks. Moreover, the spread of P301S aggregated tau occurs in a time-dependent manner, which was interrupted when the neuroanatomical pathways are lesioned. We illustrate that the spreading of tau can be investigated in organotypic slice cultures using collagen hydrogels to achieve a localized application and slow release of tau proteins. P301S aggregated tau significantly spreads to the ventral areas of the slices, suggesting that the disease-relevant aggregated tau form possesses spreading potential. Thus, the results offer a novel experimental approach to investigate tau pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Korde</LastName><ForeName>Dhwani S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0002-4076-211X</Identifier><AffiliationInfo><Affiliation>Laboratory of Psychiatry and Experimental Alzheimer's Research, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humpel</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7641-4240</Identifier><AffiliationInfo><Affiliation>Laboratory of Psychiatry and Experimental Alzheimer's Research, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020100">Hydrogels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020100" MajorTopicYN="N">Hydrogels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="Y">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer</Keyword><Keyword MajorTopicYN="N">collagen hydrogels</Keyword><Keyword MajorTopicYN="N">organotypic brain slices</Keyword><Keyword MajorTopicYN="N">spreading</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36139003</ArticleId><ArticleId IdType="pii">biom12091164</ArticleId><ArticleId IdType="doi">10.3390/biom12091164</ArticleId><ArticleId IdType="pmc">PMC9496515</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurochem Int. 2021 Jun;146:105033</Citation><ArticleIdList><ArticleId IdType="pubmed">33785419</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2015 Jan;73:83-95</Citation><ArticleIdList><ArticleId IdType="pubmed">25220759</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2002 Dec;19(3):317-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12540058</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2021 Mar 12;9(1):41</Citation><ArticleIdList><ArticleId IdType="pubmed">33712082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2012;2:700</Citation><ArticleIdList><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Apr;580(7803):381-385</Citation><ArticleIdList><ArticleId IdType="pubmed">32296178</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2018 Apr 19;10:113</Citation><ArticleIdList><ArticleId IdType="pubmed">29725295</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Alzheimers Dis. 2012;2012:731526</Citation><ArticleIdList><ArticleId IdType="pubmed">22690349</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2014 May;127(5):667-83</Citation><ArticleIdList><ArticleId IdType="pubmed">24531916</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomolecules. 2020 Jul 20;10(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">32698402</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2016 Nov 23;92(4):796-812</Citation><ArticleIdList><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2016 Nov 14;213(12):2635-2654</Citation><ArticleIdList><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2010 Jan;45(1):30-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19853650</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2015 Jun;129(6):875-94</Citation><ArticleIdList><ArticleId IdType="pubmed">25862635</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2017 May;133(5):665-704</Citation><ArticleIdList><ArticleId IdType="pubmed">28386764</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2009 May 8;284(19):12845-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2000 May 15;20(10):3606-11</Citation><ArticleIdList><ArticleId IdType="pubmed">10804202</ArticleId></ArticleIdList></Reference><Reference><Citation>F1000Res. 2018 May 15;7:592</Citation><ArticleIdList><ArticleId IdType="pubmed">29904599</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2016 Nov 4;4(1):117</Citation><ArticleIdList><ArticleId IdType="pubmed">27809932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189</Citation><ArticleIdList><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Nov 16;338(6109):949-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2015 Feb;129(2):221-37</Citation><ArticleIdList><ArticleId IdType="pubmed">25534024</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Nov;18(11):1584-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 2009 Jul;11(7):909-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Rep. 2013 Apr;14(4):389-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9535-40</Citation><ArticleIdList><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2018 Jul 9;28(13):2181-2189.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">30008334</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 9;97(10):5129-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2020 Jan;139(1):27-43</Citation><ArticleIdList><ArticleId IdType="pubmed">31542807</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Immunol. 2018 Nov;123(1):e59</Citation><ArticleIdList><ArticleId IdType="pubmed">30311739</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2016 Dec;139(Pt 12):3237-3252</Citation><ArticleIdList><ArticleId IdType="pubmed">27797812</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2013 Mar 5;41:36-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23159795</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Investig. 2018 Feb;15(2):205-213</Citation><ArticleIdList><ArticleId IdType="pubmed">29475217</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomolecules. 2022 Jan 19;12(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">35204664</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1996 Sep;67(3):1183-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8752125</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2019 Jul;149:86-95</Citation><ArticleIdList><ArticleId IdType="pubmed">31004735</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2017 Jan 13;12(1):5</Citation><ArticleIdList><ArticleId IdType="pubmed">28086931</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2016 Jun 10;11(1):44</Citation><ArticleIdList><ArticleId IdType="pubmed">27287430</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun Health. 2021 Mar 17;14:100242</Citation><ArticleIdList><ArticleId IdType="pubmed">34589757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1995 Oct;38(4):649-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7574462</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2018 May 15;23(7):2039-2055</Citation><ArticleIdList><ArticleId IdType="pubmed">29768203</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Mater. 2019 Jan;31(1):e1801651</Citation><ArticleIdList><ArticleId IdType="pubmed">30126066</ArticleId></ArticleIdList></Reference><Reference><Citation>Prion. 2016 Sep 2;10(5):344-351</Citation><ArticleIdList><ArticleId IdType="pubmed">27715442</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2020 Dec 08;25(24):</Citation><ArticleIdList><ArticleId IdType="pubmed">33302541</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(9):e45017</Citation><ArticleIdList><ArticleId IdType="pubmed">22984603</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2019;70(3):667-680</Citation><ArticleIdList><ArticleId IdType="pubmed">31256134</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2000 Aug;33(1):95-130</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47</Citation><ArticleIdList><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2017 Dec 19;5(1):99</Citation><ArticleIdList><ArticleId IdType="pubmed">29258615</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Life Sci. 2020 May;77(9):1721-1744</Citation><ArticleIdList><ArticleId IdType="pubmed">31667556</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2016 Jan 21;10:3</Citation><ArticleIdList><ArticleId IdType="pubmed">26834532</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2015 Oct 1;305:86-98</Citation><ArticleIdList><ArticleId IdType="pubmed">26254240</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2011 Apr 29;286(17):15317-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2020 Jan;16(1):30-42</Citation><ArticleIdList><ArticleId IdType="pubmed">31827267</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Dis Primers. 2015 Oct 15;1:15056</Citation><ArticleIdList><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomolecules. 2021 Mar 15;11(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">33804246</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2015 Apr 09;7:47</Citation><ArticleIdList><ArticleId IdType="pubmed">25914642</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Dev Biol. 2018 Dec 20;6:163</Citation><ArticleIdList><ArticleId IdType="pubmed">30619849</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):11025-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1999 Jun;58(6):667-77</Citation><ArticleIdList><ArticleId IdType="pubmed">10374757</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2005 Jan 3;1739(2-3):240-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Jan 16;33(3):1024-37</Citation><ArticleIdList><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2016 Aug;19(8):1085-92</Citation><ArticleIdList><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2021 May 13;11(1):10309</Citation><ArticleIdList><ArticleId IdType="pubmed">33986302</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 2018 Feb 1;295:77-86</Citation><ArticleIdList><ArticleId IdType="pubmed">29221639</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2001;102(1):129-38</Citation><ArticleIdList><ArticleId IdType="pubmed">11226676</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2015 May 26;11(8):1176-83</Citation><ArticleIdList><ArticleId IdType="pubmed">25981034</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Jun 27;9(6):e100760</Citation><ArticleIdList><ArticleId IdType="pubmed">24971751</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36138950</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-3425</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Brain sciences</Title><ISOAbbreviation>Brain Sci</ISOAbbreviation></Journal><ArticleTitle>What Do We Know about Social and Non-Social Factors Influencing the Pathway from Cognitive Health to Dementia? A Systematic Review of Reviews.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1214</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/brainsci12091214</ELocationID><Abstract><AbstractText>The heterogeneous and multi-factorial nature of dementia requires the consideration of all health aspects when predicting the risk of its development and planning strategies for its prevention. This systematic review of reviews provides a comprehensive synthesis of those factors associated with cognition in the context of dementia, identifying the role of social aspects and evidencing knowledge gaps in this area of research. Systematic reviews and meta-analyses from 2009-2021 were searched for within Medline, PsycINFO, CINAHL Complete, Cochrane, and Epistemonikos. Reviewers independently screened, reviewed, and assessed the records, following the PRISMA-2020 guidelines. From 314 included studies, 624 cognitive-related factors were identified, most of them risk factors (61.2%), mainly belonging to the group of 'somatic comorbidities' (cardiovascular disease and diabetes) and 'genetic predispositions'. The protective factors (20%) were mainly related to lifestyle, pointing to the Mediterranean diet, regular physical activity, and cognitively stimulating activities. Social factors constituted 9.6% of all identified factors. Research on biological and medical factors dominates the reviewed literature. Greater social support and frequent contact may confer some protection against cognitive decline and dementia by delaying its onset or reducing the overall risk; however, overall, our findings are inconsistent. Further research is needed in the fields of lifestyle, psychology, social health, and the protective factors against cognitive decline and dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lenart-Bugla</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6651-2234</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Wroclaw Medical University, 50-367 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Łuc</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Wroclaw Medical University, 50-367 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawłowski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Wroclaw Medical University, 50-367 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szcześniak</LastName><ForeName>Dorota</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Wroclaw Medical University, 50-367 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seifert</LastName><ForeName>Imke</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department for Health Services Research, Institute of Public Health and Nursing Research, University of Bremen, 28359 Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiegelmann</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nursing Science Research, Institute of Public Health and Nursing Research, University of Bremen, 28359 Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhardus</LastName><ForeName>Ansgar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department for Health Services Research, Institute of Public Health and Nursing Research, University of Bremen, 28359 Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf-Ostermann</LastName><ForeName>Karin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8513-3125</Identifier><AffiliationInfo><Affiliation>Department of Nursing Science Research, Institute of Public Health and Nursing Research, University of Bremen, 28359 Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouwette</LastName><ForeName>Etiënne A J A</ForeName><Initials>EAJA</Initials><Identifier Source="ORCID">0000-0001-7178-8219</Identifier><AffiliationInfo><Affiliation>Institute for Management Research, Radboud University, 6525 XZ Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC University Medical Center, 3015 GD Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9487-6617</Identifier><AffiliationInfo><Affiliation>Centre for Healthy Brain Ageing (CHeBA), Discipline of Psychiatry and Mental Health, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Yun-Hee</ForeName><Initials>YH</Initials><Identifier Source="ORCID">0000-0003-2031-9134</Identifier><AffiliationInfo><Affiliation>Susan Wakil School of Nursing and Midwifery, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maddock</LastName><ForeName>Jane</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7975-4221</Identifier><AffiliationInfo><Affiliation>MRC Unit of Lifelong Health and Ageing, Faculty of Population Health Science, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marseglia</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melis</LastName><ForeName>René J F</ForeName><Initials>RJF</Initials><AffiliationInfo><Affiliation>Radboud University Medical Center, Radboud Institute for Health Sciences, Radboudumc Alzheimer Center, 6525 XZ Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samtani</LastName><ForeName>Suraj</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9957-1916</Identifier><AffiliationInfo><Affiliation>Centre for Healthy Brain Ageing (CHeBA), Discipline of Psychiatry and Mental Health, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui-Xin</ForeName><Initials>HX</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stress Research Institute, Stockholm University, 114 19 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welmer</LastName><ForeName>Anna-Karin</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stockholm Gerontology Research Center, 113 46 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Women's Health and Allied Health Professionals Theme, Medical Unit Medical Psychology, Karolinska University Hospital, 141 86 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vernooij-Dassen</LastName><ForeName>Myrra</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Radboud University Medical Center, Radboud Institute for Health Sciences, Radboudumc Alzheimer Center, 6525 XZ Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rymaszewska</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8985-3592</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Wroclaw Medical University, 50-367 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JPND/06/2020</GrantID><Agency>JPND and National Center for Research and Development (NCBiR, Poland)</Agency><Country/></Grant><Grant><GrantID>2018-01888 to AK Welmer</GrantID><Agency>The Swedish Research Council for Health, Working Life, and Welfare</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Sci</MedlineTA><NlmUniqueID>101598646</NlmUniqueID><ISSNLinking>2076-3425</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cognitive decline</Keyword><Keyword MajorTopicYN="N">cognitive function</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">protective factors</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">social factors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36138950</ArticleId><ArticleId IdType="pii">brainsci12091214</ArticleId><ArticleId IdType="doi">10.3390/brainsci12091214</ArticleId><ArticleId IdType="pmc">PMC9497077</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2016 Feb 04;11(2):e0144405</Citation><ArticleIdList><ArticleId IdType="pubmed">26845035</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2012 Jun;9(5):574-88</Citation><ArticleIdList><ArticleId IdType="pubmed">22300405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2020 Jun;19(6):533-543</Citation><ArticleIdList><ArticleId IdType="pubmed">32470425</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2015 Aug;27(8):1263-75</Citation><ArticleIdList><ArticleId IdType="pubmed">25592720</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 2016 Aug;45(4):1169-1206</Citation><ArticleIdList><ArticleId IdType="pubmed">27272181</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2018 Dec;53(12):1289-1301</Citation><ArticleIdList><ArticleId IdType="pubmed">30255384</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Evid Based Healthc. 2015 Sep;13(3):132-40</Citation><ArticleIdList><ArticleId IdType="pubmed">26360830</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2017 Apr;13(4):406-418</Citation><ArticleIdList><ArticleId IdType="pubmed">27599208</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2007 Jul;20(4):380-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17551353</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;66(4):1619-1633</Citation><ArticleIdList><ArticleId IdType="pubmed">30452410</ArticleId></ArticleIdList></Reference><Reference><Citation>Syst Rev. 2018 Mar 1;7(1):39</Citation><ArticleIdList><ArticleId IdType="pubmed">29490699</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotoxicology. 2017 Jul;61:143-187</Citation><ArticleIdList><ArticleId IdType="pubmed">28363508</ArticleId></ArticleIdList></Reference><Reference><Citation>Syst Rev. 2017 Dec 19;6(1):259</Citation><ArticleIdList><ArticleId IdType="pubmed">29258596</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Jul 26;343:d4163</Citation><ArticleIdList><ArticleId IdType="pubmed">21791490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2020;78(4):1439-1451</Citation><ArticleIdList><ArticleId IdType="pubmed">33185601</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2014;42(1):119-35</Citation><ArticleIdList><ArticleId IdType="pubmed">24799342</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Ment Health. 2021 Feb;25(2):206-212</Citation><ArticleIdList><ArticleId IdType="pubmed">31771338</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2017 Mar 21;14(3):e1002259</Citation><ArticleIdList><ArticleId IdType="pubmed">28323829</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Sep 03;10(9):e0136181</Citation><ArticleIdList><ArticleId IdType="pubmed">26334524</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2019 Jan 25;9(1):e022846</Citation><ArticleIdList><ArticleId IdType="pubmed">30782689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2021;79(2):743-762</Citation><ArticleIdList><ArticleId IdType="pubmed">33361599</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2019 Aug 17;5:388-397</Citation><ArticleIdList><ArticleId IdType="pubmed">31463361</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2019 Nov 13;11:310</Citation><ArticleIdList><ArticleId IdType="pubmed">31798441</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2017 Dec 01;9:392</Citation><ArticleIdList><ArticleId IdType="pubmed">29249962</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis Rep. 2020 Oct 24;4(1):459-478</Citation><ArticleIdList><ArticleId IdType="pubmed">33283167</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2014 Jun 26;14:653</Citation><ArticleIdList><ArticleId IdType="pubmed">24969686</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Prev Med. 2017 Aug;53(2):241-251</Citation><ArticleIdList><ArticleId IdType="pubmed">28455123</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(6):e38268</Citation><ArticleIdList><ArticleId IdType="pubmed">22675535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;62(3):913-932</Citation><ArticleIdList><ArticleId IdType="pubmed">29562532</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Geriatr. 2016 Oct 12;16(1):175</Citation><ArticleIdList><ArticleId IdType="pubmed">27729011</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Chronic Dis. 2017 Aug;8(8-9):121-136</Citation><ArticleIdList><ArticleId IdType="pubmed">28815009</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Res Methodol. 2007 Feb 15;7:10</Citation><ArticleIdList><ArticleId IdType="pubmed">17302989</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2002 Mar;8(3):448-60</Citation><ArticleIdList><ArticleId IdType="pubmed">11939702</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2015 Apr;27(4):541-53</Citation><ArticleIdList><ArticleId IdType="pubmed">25554219</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2006 Apr;36(4):441-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16207391</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Ment Health. 2017 Jan;21(1):4-17</Citation><ArticleIdList><ArticleId IdType="pubmed">27869503</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Ment Health. 2018 Aug;22(8):915-926</Citation><ArticleIdList><ArticleId IdType="pubmed">28703027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2010 Aug 3;153(3):182-93</Citation><ArticleIdList><ArticleId IdType="pubmed">20547887</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):231-238</Citation><ArticleIdList><ArticleId IdType="pubmed">29183957</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2015 Oct 24;15:1089</Citation><ArticleIdList><ArticleId IdType="pubmed">26499254</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2019;70(s1):S165-S186</Citation><ArticleIdList><ArticleId IdType="pubmed">31306123</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2021 Mar 29;372:n160</Citation><ArticleIdList><ArticleId IdType="pubmed">33781993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;20(3):689-97</Citation><ArticleIdList><ArticleId IdType="pubmed">20182015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2019 Sep;25(9):1364-1369</Citation><ArticleIdList><ArticleId IdType="pubmed">31451782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageing Res Rev. 2020 Sep;62:101122</Citation><ArticleIdList><ArticleId IdType="pubmed">32659336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageing Res Rev. 2015 Jul;22:39-57</Citation><ArticleIdList><ArticleId IdType="pubmed">25956016</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2018;45(3-4):190-197</Citation><ArticleIdList><ArticleId IdType="pubmed">29870984</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36138485</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Characteristics of very late-onset schizophrenia-like psychosis as prodromal dementia with Lewy bodies: a cross-sectional study.</ArticleTitle><Pagination><MedlinePgn>137</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-022-01080-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to identify cases of potential prodromal DLB in very late-onset schizophrenia-like psychosis (VLOSLP), using indicative biomarkers of dementia with Lewy bodies (DLB), and to evaluate the characteristics of psychosis as prodromal DLB.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data of patients with VLOSLP without dementia and Parkinsonism, who underwent testing for at least one indicative biomarker of DLB, were retrospectively collected from the database of the psychiatry clinic at the Osaka University Hospital. Patients were divided into two groups based on the positive (VLOSLP+LB) and negative (VLOSLP-LB) results of the indicative biomarkers of DLB. Age, gender, cognitive battery scores, prevalence of each type of delusions and hallucinations, cerebral volume, and cerebral perfusion were compared between the two groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven VLOSLP+LB and 23 VLOSLP-LB participants were enrolled. There were no significant differences in age, proportion of females, and MMSE scores between the two groups. The standardized score of the digit symbol substitution test was significantly lower in the VLOSLP+LB than in VLOSLP-LB group (6.9 [3.1] vs. 10.0 [2.7], p = 0.005). The prevalence of visual hallucinations was significantly higher in the VLOSLP+LB group than in the VLOSLP-LB group (81.8% vs. 26.1%, p = 0.003). Auditory hallucinations were prevalent in both groups (43.5% in VLOSLP-LB, and 45.5% in VLOSLP+LB). Among patients with auditory hallucinations, auditory hallucinations without coexistent visual hallucinations tended to be more prevalent in VLOSLP-LB (7 out of 10) than in VLOSLP+LB patients (1 out of 5). Although cerebral volume was not different in any region, cerebral perfusion in the posterior region, including the occipital lobe, was significantly lower in the VLOSLP+LB group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Psychomotor slowing, visual hallucinations, and reduced perfusion in the occipital lobe may be suggestive of prodromal DLB in VLOSLP patients, even though the clinical manifestations were similar in many respects between VLOSLP+LB and VLOSLP-LB. Although auditory hallucinations were prevalent in both groups, most patients in VLOSLP+LB complained of auditory hallucinations along with visual hallucinations. Future studies with a larger number of patients without selection bias are desirable.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kanemoto</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-3662-1469</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. hkanemoto@psy.med.osaka-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satake</LastName><ForeName>Yuto</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suehiro</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taomoto</LastName><ForeName>Daiki</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koizumi</LastName><ForeName>Fuyuki</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wada</LastName><ForeName>Tamiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsunaga</LastName><ForeName>Keiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimosegawa</LastName><ForeName>Eku</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Mamoru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kindai University Faculty of Medicine, Sayama, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshiyama</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Graduate School of Medicine, D3 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dementia with Lewy bodies</Keyword><Keyword MajorTopicYN="N">Imaging biomarkers</Keyword><Keyword MajorTopicYN="N">Occipital hypoperfusion</Keyword><Keyword MajorTopicYN="N">Psychomotor deterioration</Keyword><Keyword MajorTopicYN="N">Very late-onset schizophrenia-like psychosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36138485</ArticleId><ArticleId IdType="doi">10.1186/s13195-022-01080-x</ArticleId><ArticleId IdType="pii">10.1186/s13195-022-01080-x</ArticleId><ArticleId IdType="pmc">PMC9503193</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Med. 2019 Feb;49(3):396-402</Citation><ArticleIdList><ArticleId IdType="pubmed">29692275</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Nucl Med. 2016 Apr;30(3):188-99</Citation><ArticleIdList><ArticleId IdType="pubmed">26897008</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychogeriatrics. 2015 Sep;15(3):198-203</Citation><ArticleIdList><ArticleId IdType="pubmed">25737011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2009 Oct;50(10):1638-45</Citation><ArticleIdList><ArticleId IdType="pubmed">19759102</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2002 Apr;103(4):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11904750</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2021 Jun 10;12:665868</Citation><ArticleIdList><ArticleId IdType="pubmed">34177653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageing Res Rev. 2016 Sep;30:114-21</Citation><ArticleIdList><ArticleId IdType="pubmed">26802555</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2018 Jun;72(6):423-434</Citation><ArticleIdList><ArticleId IdType="pubmed">29536584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2018 Jul;5(7):553-563</Citation><ArticleIdList><ArticleId IdType="pubmed">29880238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2007 Apr;6(4):305-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17362834</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2017 Jul 4;89(1):88-100</Citation><ArticleIdList><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2021 Jun 8;96(23):e2801-e2811</Citation><ArticleIdList><ArticleId IdType="pubmed">33883238</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2018 May/Jun;79(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">29742332</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1405-1416</Citation><ArticleIdList><ArticleId IdType="pubmed">29478082</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2021 May;218(5):276-282</Citation><ArticleIdList><ArticleId IdType="pubmed">33355065</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2014 Jun;264(4):317-31</Citation><ArticleIdList><ArticleId IdType="pubmed">24272318</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2021 May 25;:1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">34030750</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2022 Apr;18(4):591-601</Citation><ArticleIdList><ArticleId IdType="pubmed">34761850</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 2016 Sep;45(5):688-95</Citation><ArticleIdList><ArticleId IdType="pubmed">27496932</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 Dec;146(12):1568-74</Citation><ArticleIdList><ArticleId IdType="pubmed">2574011</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychogeriatrics. 2020 Sep;20(5):737-745</Citation><ArticleIdList><ArticleId IdType="pubmed">32743894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2005 May;112(5):677-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15375677</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Mar 20;10(3):e0120540</Citation><ArticleIdList><ArticleId IdType="pubmed">25793585</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Feb;157(2):172-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10671383</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2008 Jun;16(6):478-87</Citation><ArticleIdList><ArticleId IdType="pubmed">18515692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ment Sci. 1961 Jul;107:649-86</Citation><ArticleIdList><ArticleId IdType="pubmed">13752013</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2020 Apr 28;94(17):743-755</Citation><ArticleIdList><ArticleId IdType="pubmed">32241955</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 1995 Jul;36(7):1238-48</Citation><ArticleIdList><ArticleId IdType="pubmed">7790950</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2009 Jan;24(1):61-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18561206</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2012 Jul;72(1):41-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22829268</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2007 Mar;27(3):597-605</Citation><ArticleIdList><ArticleId IdType="pubmed">16804550</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1997 May;48(5 Suppl 6):S10-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9153155</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2003 Sep;183:213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12948993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2015;50(3):751-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26757183</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2015 Jun;30(6):663-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25335897</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2013 Feb;25(2):320-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23088846</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2021 Sep 14;12:742659</Citation><ArticleIdList><ArticleId IdType="pubmed">34594255</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):745-750</Citation><ArticleIdList><ArticleId IdType="pubmed">33563809</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36138153</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Temporal order of clinical and biomarker changes in familial frontotemporal dementia.</ArticleTitle><Pagination><MedlinePgn>2194-2206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-022-01942-9</ELocationID><Abstract><AbstractText>Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a major hurdle to designing disease prevention trials. We developed multimodal models for f-FTD disease progression and estimated clinical trial sample sizes in C9orf72, GRN and MAPT mutation carriers. Models included longitudinal clinical and neuropsychological scores, regional brain volumes and plasma neurofilament light chain (NfL) in 796 carriers and 412 noncarrier controls. We found that the temporal ordering of clinical and biomarker progression differed by genotype. In prevention-trial simulations using model-based patient selection, atrophy and NfL were the best endpoints, whereas clinical measures were potential endpoints in early symptomatic trials. f-FTD prevention trials are feasible but will likely require global recruitment efforts. These disease progression models will facilitate the planning of f-FTD clinical trials, including the selection of optimal endpoints and enrollment criteria to maximize power to detect treatment effects.</AbstractText><CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Staffaroni</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-3903-9805</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. adam.staffaroni@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintana</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1763-2704</Identifier><AffiliationInfo><Affiliation>Berry Consultants, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendelberger</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-4426-9602</Identifier><AffiliationInfo><Affiliation>Berry Consultants, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuer</LastName><ForeName>Hilary W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Lucy L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-5023-5893</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobigo</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0354-4092</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goh</LastName><ForeName>Sheng-Yang Matt</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania F</ForeName><Initials>TF</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7335-2627</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heller</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1934-6162</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Annie L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Jack Carson</ForeName><Initials>JC</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-6431-9956</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wise</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsberg</LastName><ForeName>Leah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brushaber</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Julio C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>VandeVrede</LastName><ForeName>Lawren</ForeName><Initials>L</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8304-6711</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ljubenkov</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casaletto</LastName><ForeName>Kaitlin B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appleby</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordelon</LastName><ForeName>Yvette</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botha</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-4390-685X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domoto-Reilly</LastName><ForeName>Kimiko</ForeName><Initials>K</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7396-1633</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fields</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5549-2212</Identifier><AffiliationInfo><Affiliation>Indiana University School of Medicine, National Centralized Repository for Alzheimer's, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavrilova</LastName><ForeName>Ralitza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-2896-3450</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Precision Health, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghoshal</LastName><ForeName>Nupur</ForeName><Initials>N</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-6680-6731</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, Washington University School of Medicine, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Jonathon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Matthew G H</ForeName><Initials>MGH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek</ForeName><Initials>GY</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8017-0856</Identifier><AffiliationInfo><Affiliation>Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huey</LastName><ForeName>Edward D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>David T</ForeName><Initials>DT</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-4807-9833</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-6544-066X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremers</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lago</LastName><ForeName>Argentina Lario</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapid</LastName><ForeName>Maria I</ForeName><Initials>MI</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1163-5584</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-3485-3445</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucente</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Mario F</ForeName><Initials>MF</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-6441-7989</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mester</LastName><ForeName>Carly</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi U</ForeName><Initials>CU</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-4049-0863</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanan</LastName><ForeName>Vijay K</ForeName><Initials>VK</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-6591-8734</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Eliana Marisa</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Meghana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rascovsky</LastName><ForeName>Katya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rankin</LastName><ForeName>Katherine P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1810-9763</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savica</LastName><ForeName>Rodolfo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>M Carmela</ForeName><Initials>MC</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5944-8497</Identifier><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7833-616X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouzigues</LastName><ForeName>Arabella</ForeName><Initials>A</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0267-8590</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swift</LastName><ForeName>Imogen J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peakman</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-3319-138X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocchetta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1814-5024</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Emily G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Convery</LastName><ForeName>Rhian S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7216-8679</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust and Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-9284-5953</Identifier><AffiliationInfo><Affiliation>Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiraboschi</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seelaar</LastName><ForeName>Harro</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1989-7527</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiskoot</LastName><ForeName>Lize C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0380-6670</Identifier><AffiliationInfo><Affiliation>Department of Neurofarba, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Chris R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhard</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8071-6062</Identifier><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Geriatric Medicine and Nuclear Medicine, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langheinrich</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-4714-8657</Identifier><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cerebral Function Unit, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laforce</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-2031-490X</Identifier><AffiliationInfo><Affiliation>Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec City, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7750-896X</Identifier><AffiliationInfo><Affiliation>Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendonça</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Lisbon, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Fermin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Synofzik</LastName><ForeName>Matthis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducharme</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McConnell Brain Imaging Centre, Montreal Neurological Institute, Department of Neurology &amp; Neurosurgery, McGill University, Montreal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-8857-5383</Identifier><AffiliationInfo><Affiliation>Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-9880-9788</Identifier><AffiliationInfo><Affiliation>University of Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Service, Faculty of Medicine, University Hospital of Coimbra (HUC), University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-4153-8187</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1215-5064</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. adam.boxer@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Frontotemporal Dementia Prevention Initiative (FPI) Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23AG061253</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS092089</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>AG063911</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>AG062677</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>AG045390</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>AG038791</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>12 HD001459</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>AG032306</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>AG019724</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>K24AG045333</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>SUAG/092 G116768</GrantID><Agency>RCUK | Medical Research Council (MRC)</Agency><Country/></Grant><Grant><GrantID>MR/M023664/1</GrantID><Agency>RCUK | Medical Research Council (MRC)</Agency><Country/></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barmada</LastName><ForeName>Sami</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bozoki</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Darby</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>Ian M</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lapid</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Suzee</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leger</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masdeux</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGinnis</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pascual</LastName><ForeName>M Belen</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pressman</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramanan</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ritter</LastName><ForeName>Aaron</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Syrjanen</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Jack C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esteve</LastName><ForeName>Aitana Sogorb</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>Annabel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greaves</LastName><ForeName>Caroline V</ForeName><Initials>CV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benotmane</LastName><ForeName>Hanya</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samra</LastName><ForeName>Kiran</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shafei</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timberlake</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cope</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rittman</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benussi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Premi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasparotti</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Archetti</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gazzina</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantoni</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arighi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borracci</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giacomina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giaccone</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Fede</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caroppo</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prioni</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redaelli</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang-Wai</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castelo-Branco</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freedman</LastName><ForeName>Morris</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keren</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoesmith</LastName><ForeName>Christen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Robart</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poos</LastName><ForeName>Jackie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papma</LastName><ForeName>Janne M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giannini</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Minkelen</LastName><ForeName>Rick</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Camilla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polito</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Gemma</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bessi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veldsman</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersson</LastName><ForeName>Christin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thonberg</LastName><ForeName>Hakan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Öijerstedt</LastName><ForeName>Linn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jelic</LastName><ForeName>Vesna</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lladó</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonell</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olives</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balasa</LastName><ForeName>Mircea</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bargalló</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrego-Ecija</LastName><ForeName>Sergi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verdelho</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maruta</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Catarina B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miltenberger</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simões do Couto</LastName><ForeName>Frederico</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabilondo</LastName><ForeName>Alazne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorostidi</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanua</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cañada</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tainta</LastName><ForeName>Mikel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zulaica</LastName><ForeName>Miren</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barandiaran</LastName><ForeName>Myriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alves</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bender</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilke</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graf</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vogels</LastName><ForeName>Annick</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandenbulcke</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruffaerts</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poesen</LastName><ForeName>Koen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camuzat</LastName><ForeName>Agnès</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Funkiewiez</LastName><ForeName>Aurélie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Daisy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saracino</LastName><ForeName>Dario</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colliot</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sayah</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prix</LastName><ForeName>Catharina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wlasich</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wagemann</LastName><ForeName>Olivia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loosli</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schönecker</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoegen</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Jolina</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderl-Straub</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rollin</LastName><ForeName>Adeline</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuchcinski</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertoux</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebouvier</LastName><ForeName>Thibaud</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santiago</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duro</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leitão</LastName><ForeName>Maria João</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Almeida</LastName><ForeName>Maria Rosario</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tábuas-Pereira</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Afonso</LastName><ForeName>Sónia</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36138153</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01942-9</ArticleId><ArticleId IdType="pii">10.1038/s41591-022-01942-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Knopman, D. S. &amp; Roberts, R. O. Estimating the number of persons with frontotemporal lobar degeneration in the US population. J. Mol. Neurosci. 45, 330–335 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21584654</ArticleId><ArticleId IdType="pmcid">3208074</ArticleId><ArticleId IdType="doi">10.1007/s12031-011-9538-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves, C. V. &amp; Rohrer, J. D. An update on genetic frontotemporal dementia. J. Neurol. 266, 2075–2086 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31119452</ArticleId><ArticleId IdType="pmcid">6647117</ArticleId><ArticleId IdType="doi">10.1007/s00415-019-09363-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai, R. M. &amp; Boxer, A. L. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J. Neurochem. 138, 211–221 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27306957</ArticleId><ArticleId IdType="pmcid">5217534</ArticleId><ArticleId IdType="doi">10.1111/jnc.13640</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y. &amp; Rohrer, J. D. Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurol. 21, 258–272 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35182511</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(21)00341-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri, E. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625–635 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29443664</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1710504</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, T. et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 383, 109–119 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman, R. J. et al. The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8–19 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27583651</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2016.07.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway, S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat. Med. 27, 1187–1196 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34155411</ArticleId><ArticleId IdType="pmcid">8988051</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01369-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer, A. L. et al. New directions in clinical trials for frontotemporal lobar degeneration: methods and outcome measures. Alzheimer’s Dement. 16, 131–143 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.06.4956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 367, 795–804 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22784036</ArticleId><ArticleId IdType="pmcid">3474597</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz, J. B. et al. A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain 130, 1360–1374 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17439980</ArticleId><ArticleId IdType="doi">10.1093/brain/awm069</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, K. M. et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 19, 145–156 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31810826</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(19)30394-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer, J. D. &amp; Boxer, A. L. The Frontotemporal Dementia Prevention Initiative: linking together genetic frontotemporal dementia cohort studies. Adv. Exp. Med. Biol. 1281, 113–121 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33433872</ArticleId><ArticleId IdType="doi">10.1007/978-3-030-51140-1_8</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food &amp; Drug Administration. Human Gene Therapy for Neurodegenerative Diseases. Draft Guidance for Industry. FDA-2020-D-2101 (2021).</Citation></Reference><Reference><Citation>Rentz, D. M. et al. Building clinically relevant outcomes across the Alzheimer’s disease spectrum. Alzheimer’s Dement. Transl. Res. Clin. Interv. 7, e12181 (2021).</Citation></Reference><Reference><Citation>Staffaroni, A. M. et al. Rates of brain atrophy across disease stages in familial frontotemporal dementia associated with MAPT, GRN, and C9orf72 pathogenic variants. JAMA Netw. Open 3, e2022847 (2020).</Citation></Reference><Reference><Citation>Rohrer, J. D. et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 14, 253–262 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25662776</ArticleId><ArticleId IdType="pmcid">6742501</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Q. et al. Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer’s Dement. Transl. Res. Clin. Interv. 5, 338–346 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.05.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. E. et al. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. NeuroImage Clin. 14, 286–297 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28337409</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2016.12.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Caverzasi, E. et al. Gyrification abnormalities in presymptomatic c9orf72 expansion carriers. J. Neurol. Neurosurg. Psychiatry 90, 1005–1010 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31079065</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2018-320265</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell, J. L. et al. Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur. J. Neurol. 22, 745–752 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25683866</ArticleId><ArticleId IdType="pmcid">4390434</ArticleId><ArticleId IdType="doi">10.1111/ene.12675</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer, J. D. et al. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage 53, 1070–1076 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20045477</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2009.12.088</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, S. A. et al. Brain volumetric deficits in MAPT mutation carriers: a multisite study. Ann. Clin. Transl. Neurol. 8, 95–110 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33247623</ArticleId><ArticleId IdType="doi">10.1002/acn3.51249</ArticleId></ArticleIdList></Reference><Reference><Citation>Young, A. L. et al. Characterizing the clinical features and atrophy patterns of MAPT-related frontotemporal dementia with disease progression modeling. Neurology 97, e941–e952 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34158384</ArticleId><ArticleId IdType="pmcid">8408507</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000012410</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende, E. L. et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 18, 1103–1111 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31701893</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(19)30354-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Illán-Gala, I. et al. Plasma Tau and neurofilament light in frontotemporal lobar degeneration and alzheimer disease. Neurology 96, e671–e683 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33199433</ArticleId><ArticleId IdType="pmcid">7884995</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000011226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron, T. F. et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep. Med. 3, 100607 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35492244</ArticleId><ArticleId IdType="pmcid">9044101</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2022.100607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035–1048 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31206160</ArticleId><ArticleId IdType="pmcid">6580449</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.1534</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherling, C. S. et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann. Neurol. 75, 116–126 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24242746</ArticleId><ArticleId IdType="pmcid">4020786</ArticleId><ArticleId IdType="doi">10.1002/ana.24052</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas, J. C. et al. Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration. Neurology 96, e2296–e2312 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33827960</ArticleId><ArticleId IdType="pmcid">8166434</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000011848</ArticleId></ArticleIdList></Reference><Reference><Citation>Panman, J. L. et al. Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 92, 494–501 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33452053</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-323541</ArticleId></ArticleIdList></Reference><Reference><Citation>Saracino, D. et al. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. J. Neurol. Neurosurg. Psychiatry 92, 1278–1288 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34349004</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-326914</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasmacher, S. A., Wong, C., Pearson, I. E. &amp; Pal, S. Survival and prognostic factors in C9orf72 repeat expansion carriers: a systematic review and meta-analysis. JAMA Neurol. 77, 367–376 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31738367</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.3924</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, K. et al. A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Appl. Neuropsychol. Adult 29, 112–119 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">32024404</ArticleId><ArticleId IdType="doi">10.1080/23279095.2020.1716357</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni, A. M. et al. Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. Alzheimers Dement. 16, 11–21 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31914230</ArticleId><ArticleId IdType="pmcid">6842665</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2019.01.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker, M. S. et al. Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex 139, 99–115 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33857770</ArticleId><ArticleId IdType="pmcid">8119343</ArticleId><ArticleId IdType="doi">10.1016/j.cortex.2021.03.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Poos, J. M. et al. Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimers Res. Ther. 14, 10 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35045872</ArticleId><ArticleId IdType="pmcid">8772227</ArticleId><ArticleId IdType="doi">10.1186/s13195-022-00958-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana, M. et al. Bayesian model of disease progression in GNE myopathy. Stat. Med. 38, 1459–1474 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30511500</ArticleId><ArticleId IdType="doi">10.1002/sim.8050</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni, S. et al. Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development. Ann. Neurol. 91, 165–175 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34935174</ArticleId><ArticleId IdType="doi">10.1002/ana.26285</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier, C. et al. Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol. 17, 548–558 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29724592</ArticleId><ArticleId IdType="pmcid">6237181</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(18)30126-1</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende, E. L. et al. A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain 145, 1805–1817 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34633446</ArticleId><ArticleId IdType="doi">10.1093/brain/awab382</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni, A. M. et al. Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer’s Dement. 16, 37–48 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.04.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxtoby, N. P. et al. Data-driven models of dominantly-inherited Alzheimer’s disease progression. Brain 141, 1529–1544 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29579160</ArticleId><ArticleId IdType="pmcid">5920320</ArticleId><ArticleId IdType="doi">10.1093/brain/awy050</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyike, C. U., Shinagawa, S. &amp; Ellajosyula, R. Frontotemporal dementia: a cross-cultural perspective. Adv. Exp. Med. Biol. 1281, 141–150 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33433874</ArticleId><ArticleId IdType="doi">10.1007/978-3-030-51140-1_10</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, K. et al. Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol. Aging 33, 209.e3–8 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.08.005</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee, J. et al. A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain 129, 841–852 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16495329</ArticleId><ArticleId IdType="doi">10.1093/brain/awl029</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve, B. et al. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer’s Dement. 16, 22–36 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.06.4947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos, E. M. et al. Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. Alzheimers Dement. 16, 118–130 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31914217</ArticleId><ArticleId IdType="pmcid">7199807</ArticleId><ArticleId IdType="doi">10.1002/alz.12011</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa, T. et al. Utility of the global CDR plus NACC FTLD rating and development of scoring rules: data from the ARTFL/LEFFTDS Consortium. Alzheimers Dement. 16, 106–117 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31914218</ArticleId><ArticleId IdType="pmcid">7202045</ArticleId><ArticleId IdType="doi">10.1002/alz.12033</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni, A. M. et al. Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain 142, 443–459 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30698757</ArticleId><ArticleId IdType="pmcid">6351779</ArticleId><ArticleId IdType="doi">10.1093/brain/awy319</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa, T. et al. Use of the CDR plus NACC FTLD in mild FTLD: data from the ARTFL/LEFFTDS consortium. Alzheimer’s Dement. 16, 79–90 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.05.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub, S. et al. Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis. Assoc. Disord. 32, 10–17 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29240561</ArticleId><ArticleId IdType="pmcid">5821520</ArticleId><ArticleId IdType="doi">10.1097/WAD.0000000000000223</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsell, S. E. et al. Results from the NACC uniform data set neuropsychological battery crosswalk study. Alzheimer Dis. Assoc. Disord. 30, 134–139 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26485498</ArticleId><ArticleId IdType="pmcid">4834278</ArticleId><ArticleId IdType="doi">10.1097/WAD.0000000000000111</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack, C. R. et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 49, 786–794 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9305341</ArticleId><ArticleId IdType="doi">10.1212/WNL.49.3.786</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney, N. T. et al. Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer’s Dement. 16, 49–59 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.08.196</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell, L. L. et al. Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex 133, 384–398 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33221702</ArticleId><ArticleId IdType="pmcid">7754789</ArticleId><ArticleId IdType="doi">10.1016/j.cortex.2020.08.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Sled, J. G., Zijdenbos, A. P. &amp; Evans, A. C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17, 87–97 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9617910</ArticleId><ArticleId IdType="doi">10.1109/42.668698</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner, J. &amp; Friston, K. J. Unified segmentation. Neuroimage 26, 839–851 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2005.02.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner, J. &amp; Friston, K. J. Diffeomorphic registration using geodesic shooting and Gauss-Newton optimisation. Neuroimage 55, 954–967 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21216294</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2010.12.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968–980 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta, M. et al. Thalamic atrophy in frontotemporal dementia: not just a C9orf72 problem. NeuroImage. Clin. 18, 675–681 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29876259</ArticleId><ArticleId IdType="pmcid">5988457</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2018.02.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Young, A. L. et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat. Commun. 9, 4273 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30323170</ArticleId><ArticleId IdType="pmcid">6189176</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-05892-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta, M. et al. Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage. Clin. 30, 102646 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33895632</ArticleId><ArticleId IdType="pmcid">8099608</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2021.102646</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36138003</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-3635</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>09</Month><Day>23</Day></PubDate></JournalIssue><Title>Signal transduction and targeted therapy</Title><ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation></Journal><ArticleTitle>Clusterin transduces Alzheimer-risk signals to amyloidogenesis.</ArticleTitle><Pagination><MedlinePgn>325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-022-01157-x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Geriatric Disease, Department of Neurology, Advanced Innovation Center for Human Brain Protection, Xuanwu Hospital, Capital Medical University, Beijing, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Che</LastName><ForeName>Rongbo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Shandong Collaborative Innovation Center for Diagnosis, Treatment &amp; Behavioral Interventions of Mental Disorders, Institute of Mental Health, Jining Medical University, Jining, Shandong, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liang</LastName><ForeName>Wenping</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Geriatric Disease, Department of Neurology, Advanced Innovation Center for Human Brain Protection, Xuanwu Hospital, Capital Medical University, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Geriatric Disease, Department of Neurology, Advanced Innovation Center for Human Brain Protection, Xuanwu Hospital, Capital Medical University, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Liyong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Geriatric Disease, Department of Neurology, Advanced Innovation Center for Human Brain Protection, Xuanwu Hospital, Capital Medical University, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Geriatric Disease, Department of Neurology, Advanced Innovation Center for Human Brain Protection, Xuanwu Hospital, Capital Medical University, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Weihong</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-9928-889X</Identifier><AffiliationInfo><Affiliation>The National Clinical Research Center for Geriatric Disease, Department of Neurology, Advanced Innovation Center for Human Brain Protection, Xuanwu Hospital, Capital Medical University, Beijing, PR China. weihong@wmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Shandong Collaborative Innovation Center for Diagnosis, Treatment &amp; Behavioral Interventions of Mental Disorders, Institute of Mental Health, Jining Medical University, Jining, Shandong, PR China. weihong@wmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, School of Mental Health and The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, PR China. weihong@wmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yili</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Shandong Collaborative Innovation Center for Diagnosis, Treatment &amp; Behavioral Interventions of Mental Disorders, Institute of Mental Health, Jining Medical University, Jining, Shandong, PR China. wuyili@wmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, School of Mental Health and The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, PR China. wuyili@wmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-4255-6763</Identifier><AffiliationInfo><Affiliation>The National Clinical Research Center for Geriatric Disease, Department of Neurology, Advanced Innovation Center for Human Brain Protection, Xuanwu Hospital, Capital Medical University, Beijing, PR China. wangz@xwhosp.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Signal Transduct Target Ther</MedlineTA><NlmUniqueID>101676423</NlmUniqueID><ISSNLinking>2059-3635</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="Y">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36138003</ArticleId><ArticleId IdType="doi">10.1038/s41392-022-01157-x</ArticleId><ArticleId IdType="pii">10.1038/s41392-022-01157-x</ArticleId><ArticleId IdType="pmc">PMC9499966</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Struct Mol Biol. 2010 Feb;17(2):151-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20062056</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging (Albany NY). 2019 Aug 30;11(16):6175-6198</Citation><ArticleIdList><ArticleId IdType="pubmed">31469660</ArticleId></ArticleIdList></Reference><Reference><Citation>JCI Insight. 2019 Jan 10;4(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">30626751</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2019 Feb 28;13:164</Citation><ArticleIdList><ArticleId IdType="pubmed">30872998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2016 May 05;7:e2215</Citation><ArticleIdList><ArticleId IdType="pubmed">27148688</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36137977</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1945-0524</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>08</Month><Day>01</Day></PubDate></JournalIssue><Title>Frontiers in bioscience (Scholar edition)</Title><ISOAbbreviation>Front Biosci (Schol Ed)</ISOAbbreviation></Journal><ArticleTitle>Raman Spectroscopy Techniques for the Investigation and Diagnosis of Alzheimer's Disease.</ArticleTitle><Pagination><MedlinePgn>22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31083/j.fbs1403022</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most common neurodegenerative disorder, resulting in memory loss, cognitive decline, bodily function impairment, and finally death. The growing number of people suffering from AD increasingly urges the development of effective early diagnosis and monitoring techniques. Here, we review the most recent developments in the field of Raman-based techniques, which have shown a significant potential in identifying AD by detecting specific biomarkers in biological fluids, as well as in providing fundamental insights into key molecules involved in the disease progression or in the analysis of histological specimens of patients with AD. These techniques comprise spontaneous and resonant Raman spectroscopies, exploit plasmon- or fiber- enhanced effects, such as surface-, tip- or fiber- enhanced Raman spectroscopies, or involve non-linear techniques like coherent Raman scattering. The scientific efforts employed up to now as well as the rapid technological advancements in optical detection instruments (spectrometers, lasers, substrates for analysis, etc.) and the diffusion of advanced data processing methods suggest a leading role of Raman techniques in the perspective of a preclinical or clinical detection of AD.</AbstractText><CopyrightInformation>© 2022 The Author(s). Published by IMR Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Polykretis</LastName><ForeName>Panagis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Applied Physics "Nello Carrara", National Research Council, 50019 Sesto Fiorentino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banchelli</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Applied Physics "Nello Carrara", National Research Council, 50019 Sesto Fiorentino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Andrea</LastName><ForeName>Cristiano</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Applied Physics "Nello Carrara", National Research Council, 50019 Sesto Fiorentino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Angelis</LastName><ForeName>Marella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Applied Physics "Nello Carrara", National Research Council, 50019 Sesto Fiorentino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matteini</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Applied Physics "Nello Carrara", National Research Council, 50019 Sesto Fiorentino, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Front Biosci (Schol Ed)</MedlineTA><NlmUniqueID>101485241</NlmUniqueID><ISSNLinking>1945-0516</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013059" MajorTopicYN="N">Spectrum Analysis, Raman</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Raman spectroscopy</Keyword><Keyword MajorTopicYN="N">biological fluids</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">early diagnosis</Keyword><Keyword MajorTopicYN="N">label-free methods</Keyword><Keyword MajorTopicYN="N">optical detection</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>23</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36137977</ArticleId><ArticleId IdType="pii">S1945-0516(22)00061-2</ArticleId><ArticleId IdType="doi">10.31083/j.fbs1403022</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36137949</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0219-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>Journal of integrative neuroscience</Title><ISOAbbreviation>J Integr Neurosci</ISOAbbreviation></Journal><ArticleTitle>Repetitive Transcranial Magnetic Stimulation Decreases Serum Amyloid-β and Increases Ectodomain of p75 Neurotrophin Receptor in Patients with Alzheimer's Disease.</ArticleTitle><Pagination><MedlinePgn>140</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31083/j.jin2105140</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study investigated the impact of repetitive transcranial magnetic stimulation (rTMS) on serum levels of Amyloid-β (Aβ) as well as the ectodomain of p75 neurotrophin receptor (p75ECD) in patients with Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 46 patients diagnosed with AD between June 1, 2020 and December 31, 2021 were randomized to undergo either 20 Hz rTMS treatment of the left dorsolateral prefrontal cortex (DLPFC) or sham procedure. Cognitive function and activity of daily living were evaluated. Neuropsychological tests and blood samples were gathered at baseline and at 2, 3, 4, and 6 weeks after rTMS therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no evident differences between rTMS group and sham group in serum Aβ40, Aβ42, total Aβ, ApoE, and p75ECD standards at baseline (<i>p</i> &gt; 0.05). Serum levels of Aβ40, Aβ42, as well as total Aβ, were significantly lower in the rTMS group at 3, 4 and 6 weeks relative to the sham group (<i>p</i> &lt; 0.05). Serum p75ECD levels in the rTMS group were significantly higher than those of the sham group at 3, 4 and 6 weeks (<i>p</i> &lt; 0.05). Levels of serum Aβ40 (r: -0.78, -0.83, -0.68, respectively), Aβ42 (r: -0.76, -0.76, -0.61, respectively) and total Aβ (r: -0.74, -0.81, -0.66, respectively) were negatively correlated with MoCA, MMSE and MBI scores, while serum p75ECD levels (r: 0.84, 0.90, 0.72, respectively) were positively correlated (<i>p</i> &lt; 0.01). The level of serum Aβ40 (r = 0.77), Aβ42 (r = 0.69) as well as total Aβ (r = 0.73) were positively correlated with ADAS-cog score, while p75ECD levels (r = -0.86) were negatively correlated (<i>p</i> &lt; 0.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of this study suggest that rTMS may decrease serum Aβ levels and increase serum p75ECD levels in patients with AD, offering insight into a potential underpinning mechanism of rTMS.</AbstractText><CopyrightInformation>© 2022 The Author(s). Published by IMR Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, Daping Hospital, Army Medical University, 400042 Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Daping Hospital, Army Medical University, 400042 Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Daping Hospital, Army Medical University, 400042 Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Xiangqin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, Daping Hospital, Army Medical University, 400042 Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Lingyi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, Daping Hospital, Army Medical University, 400042 Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Dongwan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Daping Hospital, Army Medical University, 400042 Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Changyue</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, Daping Hospital, Army Medical University, 400042 Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>J Integr Neurosci</MedlineTA><NlmUniqueID>101156357</NlmUniqueID><ISSNLinking>0219-6352</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020800">Receptor, Nerve Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012457">Salicylamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>8Q07182D0T</RegistryNumber><NameOfSubstance UI="C005703">salicylhydroxamic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020800" MajorTopicYN="N">Receptor, Nerve Growth Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012457" MajorTopicYN="N">Salicylamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Amyloid-β</Keyword><Keyword MajorTopicYN="N">ectodomain of p75 neurotrophin receptor</Keyword><Keyword MajorTopicYN="N">repetitive transcranial magnetic stimulation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>22</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36137949</ArticleId><ArticleId IdType="pii">S0219-6352(22)00350-3</ArticleId><ArticleId IdType="doi">10.31083/j.jin2105140</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36137824</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Four Distinct Subtypes of Alzheimer's Disease Based on Resting-State Connectivity Biomarkers.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0006-3223(22)01368-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2022.06.019</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) is a neurodegenerative disorder with significant heterogeneity. Different AD phenotypes may be associated with specific brain network changes. Uncovering disease heterogeneity by using functional networks could provide insights into precise diagnoses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We investigated the subtypes of AD using nonnegative matrix factorization clustering on the previously identified 216 resting-state functional connectivities that differed between AD and normal control subjects. We conducted the analysis using a discovery dataset (n = 809) and a validated dataset (n = 291). Next, we grouped individuals with mild cognitive impairment according to the model obtained in the AD groups. Finally, the clinical measures and brain structural characteristics were compared among the subtypes to assess their relationship with differences in the functional network.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Individuals with AD were clustered into 4 subtypes reproducibly, which included those with 1) diffuse and mild functional connectivity disruption (subtype 1), 2) predominantly decreased connectivity in the default mode network accompanied by an increase in the prefrontal circuit (subtype 2), 3) predominantly decreased connectivity in the anterior cingulate cortex accompanied by an increase in prefrontal cortex connectivity (subtype 3), and 4) predominantly decreased connectivity in the basal ganglia accompanied by an increase in prefrontal cortex connectivity (subtype 4). In addition to these differences in functional connectivity, differences between the AD subtypes were found in cognition, structural measures, and cognitive decline patterns.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These comprehensive results offer new insights that may advance precision medicine for AD and facilitate strategies for future clinical trials.</AbstractText><CopyrightInformation>Copyright © 2022 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Pindong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Brainnetome Center &amp; National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Hongxiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiology, the Second Medical Centre, National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tijms</LastName><ForeName>Betty M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Location VUmc, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Pan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tianjin Huanhu Hospital, Tianjin University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dawei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology, Qilu Hospital of Shandong University, Ji'nan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Chengyuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Qilu Hospital of Shandong University, Ji'nan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hongwei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiology, Xuanwu Hospital of Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zengqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Branch of Chinese PLA General Hospital, Sanya, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Biomedical Engineering, School of Biological Science &amp; Medical Engineering, Beihang University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Yida</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Brainnetome Center &amp; National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Xiaopeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Brainnetome Center &amp; National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Brainnetome Center &amp; National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Lingzhong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Brainnetome Center &amp; National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiology, Tianjin Huanhu Hospital, Tianjin University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chunshui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, the Second Medical Centre, National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Tianzi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Brainnetome Center &amp; National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yuying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tianjin Huanhu Hospital, Tianjin University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Xuanwu Hospital of Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China; Beijing Institute of Geriatrics, Beijing, China; National Clinical Research Center for Geriatric Disorders, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cognition Neuroscience &amp; Learning, Beijing Normal University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, the Second Medical Centre, National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China. Electronic address: zhoubo@301hospital.com.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Brainnetome Center &amp; National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China; School of Artificial Intelligence, Beijing University of Posts and Telecommunications, Beijing, China. Electronic address: yongliu@bupt.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">Functional connectivity</Keyword><Keyword MajorTopicYN="N">Heterogeneity</Keyword><Keyword MajorTopicYN="N">Mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">Nonnegative matrix factorization</Keyword><Keyword MajorTopicYN="N">Subtype</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>06</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>22</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36137824</ArticleId><ArticleId IdType="pii">S0006-3223(22)01368-3</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2022.06.019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36137760</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-5667</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J Nucl Med</ISOAbbreviation></Journal><ArticleTitle>The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">jnumed.122.264031</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.122.264031</ELocationID><Abstract><AbstractText>A standardized approach to acquiring amyloid PET images increases their value as disease and drug response biomarkers. The majority of <sup>18</sup>F PET amyloid brain scans often are assessed only visually (per regulatory labels), with a binary decision indicating the presence or absence of Alzheimer's disease amyloid pathology. Minimizing technical variance allows precise, quantitative, standardized uptake value ratios (SUVRs) for early detection of a𝛽 amyloid plaques and the effectiveness of anti-amyloid treatments to be assessed with serial studies. <b>Methods:</b> The Quantitative Imaging Biomarkers Alliance (QIBA) Amyloid PET Biomarker Committee developed and validated a Profile to characterize and reduce the variability of SUVRs, increasing statistical power for these assessments. <b>Results:</b> Upon achieving conformance, sites can justify a claim that brain amyloid burden reflected by the SUVR is measurable to a within-subject coefficient of variation (wCV) of ≤1.94% when the same radiopharmaceutical, scanner, acquisition and analysis protocols are used. <b>Conclusion:</b> This overview explains the claim, requirements, barriers and potential future developments of the Profile to achieve precision in clinical and research amyloid PET imaging.</AbstractText><CopyrightInformation>Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-6478-3540</Identifier><AffiliationInfo><Affiliation>Siemens Medical Solutions USA Inc., United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obuchowski</LastName><ForeName>Nancy A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1891-7477</Identifier><AffiliationInfo><Affiliation>Quantitative Health Services, Cleveland Clinic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Norman L</ForeName><Initials>NL</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-9969-2160</Identifier><AffiliationInfo><Affiliation>University of Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozley</LastName><ForeName>P David</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Weill Medical College of Cornell University, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lammertsma</LastName><ForeName>Adriaan A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1237-2891</Identifier><AffiliationInfo><Affiliation>VU University Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahl</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7306-2590</Identifier><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunderland</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0891-1234</Identifier><AffiliationInfo><Affiliation>University of Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderheyden</LastName><ForeName>Jean-Luc E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7042-2650</Identifier><AffiliationInfo><Affiliation>JLVMI CONSULTING, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8114-0552</Identifier><AffiliationInfo><Affiliation>Washington University of St. Louis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinahan</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-6461-3306</Identifier><AffiliationInfo><Affiliation>University of Washington Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Dean F</ForeName><Initials>DF</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-9343-8367</Identifier><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlman</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-3099-1664</Identifier><AffiliationInfo><Affiliation>Perlman Advisory Group.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minoshima</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0043-3047</Identifier><AffiliationInfo><Affiliation>University of Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Dawn</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0516-7470</Identifier><AffiliationInfo><Affiliation>ADM Diagnostices, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's Disease</Keyword><Keyword MajorTopicYN="N">Molecular Imaging</Keyword><Keyword MajorTopicYN="N">Neurology</Keyword><Keyword MajorTopicYN="N">QIBA</Keyword><Keyword MajorTopicYN="N">Quality Assurance</Keyword><Keyword MajorTopicYN="N">amyloid PET</Keyword><Keyword MajorTopicYN="N">guidelines</Keyword><Keyword MajorTopicYN="N">quantitative imaging biomarkers</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>02</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36137760</ArticleId><ArticleId IdType="pii">jnumed.122.264031</ArticleId><ArticleId IdType="doi">10.2967/jnumed.122.264031</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36136290</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-2891</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Forensic science, medicine, and pathology</Title><ISOAbbreviation>Forensic Sci Med Pathol</ISOAbbreviation></Journal><ArticleTitle>Laryngeal oncocytic cystadenoma and sudden death.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12024-022-00530-0</ELocationID><Abstract><AbstractText>An 86-year-old woman with Alzheimer disease collapsed in her nursing home and was not able to be resuscitated. At autopsy, the major findings were in the larynx where a pedunculated oncocytic cystadenoma had occluded the glottis. Oncocytic cysts or cystadenomas of the larynx are rare histologically benign lesions that account for only 0.1-1% of laryngeal lesions. While the usual presentation is of a sensation of a mass in the throat, hoarseness, or stridor, very occasionally, there may be acute airway compromise and sudden death. Oncocytic cystadenoma should, therefore, be included in the differential diagnosis of potentially lethal obstructive laryngeal lesions.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Pathology, Forensic Science SA, SA, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byard</LastName><ForeName>Roger W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Pathology, Forensic Science SA, SA, Adelaide, Australia. roger.byard@sa.gov.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedicine, The University of Adelaide, Frome Road, Adelaide, South Australia, 5005, Australia. roger.byard@sa.gov.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Forensic Sci Med Pathol</MedlineTA><NlmUniqueID>101236111</NlmUniqueID><ISSNLinking>1547-769X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Airway obstruction; Sudden death</Keyword><Keyword MajorTopicYN="N">Larynx</Keyword><Keyword MajorTopicYN="N">Oncocytic cyst</Keyword><Keyword MajorTopicYN="N">Oncocytic cystadenoma</Keyword><Keyword MajorTopicYN="N">Stridor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>11</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36136290</ArticleId><ArticleId IdType="doi">10.1007/s12024-022-00530-0</ArticleId><ArticleId IdType="pii">10.1007/s12024-022-00530-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiho L, Byard RW. Acute fatal upper airway obstruction from an occult cavernous hemangioma of the larynx. J Forensic Sci. 2015;60(Suppl 1):S93–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1556-4029.12587</ArticleId></ArticleIdList></Reference><Reference><Citation>Quick E, Byard RW. Acute upper airway obstruction and post-operative cervical soft tissue hemorrhage. J Forensic Sci. 2013;58(Suppl 1):S264–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1556-4029.12026</ArticleId></ArticleIdList></Reference><Reference><Citation>Byard RW, Bourne AJ, Silver MM. The association of lingual thyroglossal duct remnants with sudden death in infancy. Int J Pediatr Otolaryngol. 1990;20:107–12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5876(90)90075-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauvageau A, Belley-Côte E, Racette S. Fatal asphyxia by a thyroglossal duct cyst in an adult. J Clin Forensic Med. 2006;13:349–52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcfm.2006.06.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Byard RW, Heath K. Variable mechanisms of sudden and unexpected death in cases of occult carcinoma of the larynx. Am J Forensic Med Pathol. 2021;42:92–5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PAF.0000000000000604</ArticleId></ArticleIdList></Reference><Reference><Citation>Favret A, Zanelli E, Germani C, Giorgi R, Grasso DL, Ventura A. A significant increase in potentially life-threatening disease: parapharyngeal abscess. Acta Paediatr. 2013;102:e390–1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.12303</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalrymple A, Gilbert JD, Byard RW. Delayed fatal upper airway obstruction due to laryngopharyngeal burns and thermal epiglottitis. Med Sci Law. 2020;60(3):223–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0025802420918040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wick R, Gilbert JD, Byard RW. Café coronary syndrome – fatal choking on food: An autopsy approach. J Clin Forensic Med. 2006;13:135–8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcfm.2005.10.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiemensma M, Fitzpatrick R, Raven MD, Byard RW. Acute respiratory obstruction due to accidental inhalation of perlite: a novel mechanism for upper airway occlusion and cast formation. J Forensic Sci. 2020;65:1354–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1556-4029.14308</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanguay J, Pollanen M. Sudden death by laryngeal polyp: a case report and review of the literature. Forensic Sci Med Pathol. 2009;5:17–21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12024-008-9061-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalho LNZ, Martin CCS, Zerbini T. Sudden death caused by fibro-vascular esophageal polyp. Case report and study review. Am J ForensicMed Pathol. 2010;31:103–5.</Citation></Reference><Reference><Citation>Kilinç ANU, Ünlü Y, Yücel A. Laryngeal oncocytic cystadenoma with rare location and clinicopathogical aspects. Head Neck Pathol. 2021;15:1004–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12105-020-01232-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Svejdova A, Kalfert D, Skoloudik L, et al. Oncocytic papillary cystadenoma of the larynx: comparative study of ten cases and review of the literature. Eur Arch Oto Rhino Laryngol. 2021;278:3381–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-021-06841-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno G, Mignogna C, Cavaliere M, D’Angelo L, Galli V. Oncocytic cyst of the larynx: an unusual occurrence. Acta Otorhinolayryngol Ital. 2007;27:212–5.</Citation></Reference><Reference><Citation>Feinstein AJ, Peng KA, Bhuta SM, Abemayor E, Mendelsohn AH. Laryngeal oncocytic cystadenomas masquerading as laryngoceles. Am J Otolaryngol Head Neck Med Surg. 2016;37:17–21.</Citation></Reference><Reference><Citation>Lungren J, Oloffson J. Hellquist H Oncocytic lesions of the larynx. Acta Otolaryngol. 1982;94:335–44.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00016488209128921</ArticleId></ArticleIdList></Reference><Reference><Citation>Protts FLMS, Goh S. Unusual cause of airway obstruction: subglottic oncocytic cyst. BMJ Case Rep. 2019;12: e228663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2018-228663</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyes R, Tomblinson CM, Lott DG. Multiple and recurrent oncocytic cysts of the larynx. Ear Nose Throat J 2020;99:NP54–5.</Citation></Reference><Reference><Citation>Brandwein M, Huvos A. Laryngeal oncocytic cytadenomas. Eight cases and a literature review. Arch Otolaryngol Head Neck Surg 1995;121:1302–5.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36136156</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">0948-5023</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of molecular modeling</Title><ISOAbbreviation>J Mol Model</ISOAbbreviation></Journal><ArticleTitle>Mechanistic insight into the tautomerization of histidine initiated by water-catalyzed N-H and C-H cleavages.</ArticleTitle><Pagination><MedlinePgn>325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00894-022-05222-8</ELocationID><Abstract><AbstractText>The N-H and C-H activation is of great significance in organic chemistry and chemical industry fields, especially, in the utilization of petroleum raw materials. High NδH (tautomer of natural histidine) content would increase Alzheimer's disease risk. To inhibit this and improve the activation of N-H and C-H bonds, the isomerization mechanism from NδH to NεH of histidine-containing dipeptide catalyzed by water cluster was explored. The results discovered that water cluster assists this reaction by reducing the activation energies from 68.20 to 9.60 kcal mol<sup>-1</sup>, and its size not only affects the reaction rate but also determines the reaction pathway in a degree. Moreover, water cluster, taken as a potential green catalyst, is more effective on the reactions involving N-H and C-H bond cleavages than reported common toxic organometallic compounds and has different catalytic mechanisms. This work also provides some theoretical guidance for the modulation of Alzheimer's disease induced by histidine isomerization.</AbstractText><CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xueying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, University of Jinan, Jinan, 250022, People's Republic of China. chm_zhuxy@ujn.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zijiao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology, Xinjiang University, Aksu, 843100, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ai</LastName><ForeName>Hongqi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, University of Jinan, Jinan, 250022, People's Republic of China. chm_aihq@ujn.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>National Natural Science</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Mol Model</MedlineTA><NlmUniqueID>9806569</NlmUniqueID><ISSNLinking>0948-5023</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010578">Petroleum</NameOfSubstance></Chemical><Chemical><RegistryNumber>059QF0KO0R</RegistryNumber><NameOfSubstance UI="D014867">Water</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QD397987E</RegistryNumber><NameOfSubstance UI="D006639">Histidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002384" MajorTopicYN="N">Catalysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006639" MajorTopicYN="N">Histidine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009942" MajorTopicYN="Y">Organometallic Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010578" MajorTopicYN="Y">Petroleum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">CAM-B3LYP functional</Keyword><Keyword MajorTopicYN="N">Catalytic mechanism</Keyword><Keyword MajorTopicYN="N">Cleavage of C–H bond</Keyword><Keyword MajorTopicYN="N">Isomerization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36136156</ArticleId><ArticleId IdType="doi">10.1007/s00894-022-05222-8</ArticleId><ArticleId IdType="pii">10.1007/s00894-022-05222-8</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Scott LT (2016) J Organic Chem 81:11535–11547</Citation></Reference><Reference><Citation>Shimba N, Serber Z, Ledwidge R, Miller SM, Craik CS (2003) Biochem 42:9227–9234</Citation></Reference><Reference><Citation>Nagano S, Tanaka M, Ishimori K, Watanabe Y, Morishima I (1996) Biochem 35:14251–14258</Citation></Reference><Reference><Citation>Ihm JE, Han KO, Hwang CS, Kang JH, Ahn KD, Han IK, Han DK, Hubbell JA, Cho CS (2005) Acta Biomaterialia 1:165–172</Citation><ArticleIdList><ArticleId IdType="pubmed">16701793</ArticleId></ArticleIdList></Reference><Reference><Citation>Markley JL (1975) Acc Chem Res 8:70–80</Citation></Reference><Reference><Citation>Li S, Hong M (2011) J Am Chem Soc 133:1534–1544</Citation><ArticleIdList><ArticleId IdType="pubmed">21207964</ArticleId><ArticleId IdType="pmcid">4082993</ArticleId></ArticleIdList></Reference><Reference><Citation>Vila, J.A., Arnautova, Y.A,, Vorobjev, Y., Scheraga H.A.: Proceedings of the National Academy of Sciences 108, 5602 (2011)</Citation></Reference><Reference><Citation>Henry B, Tekely P, Delpuech JJ (2002) J Am Chem Soc 124:2025–2034</Citation><ArticleIdList><ArticleId IdType="pubmed">11866617</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid PE, Culling CFA, Ramey CW, Dunn WL, Clay MG (1977) Can J Biochem 55:493–503</Citation><ArticleIdList><ArticleId IdType="pubmed">560241</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Kang B, Lee JY (2016) J Phys Chem B 120:11405–11411</Citation><ArticleIdList><ArticleId IdType="pubmed">27750416</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing X, Zhao W, Hu D, Kang B, Shi H, Lee JY, Ai H (2019) ACS Chem Neurosci 10:2602–2608</Citation><ArticleIdList><ArticleId IdType="pubmed">30813720</ArticleId></ArticleIdList></Reference><Reference><Citation>Markova N, Enchev V (2004) J Mol Struct: THEOCHEM 679:195–205</Citation></Reference><Reference><Citation>Liang W, Li H, Hu X, Han S (2004) J Phys Chem A 108:10219–10224</Citation></Reference><Reference><Citation>Daniela GA, Ricardo IR, Soledad GO, Bárbara H, Alejandro TL (2016) Theor Chem Accounts 135:37</Citation></Reference><Reference><Citation>Cerón-Carrasco JP, Requena A, Zúñiga J, Michaux C, Perpète EA, Jacquemin D (2009) J Phys Chem A 113:10549–10556</Citation><ArticleIdList><ArticleId IdType="pubmed">19736955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai H, Chen J, Zhang C (2012) J Phys Chemi B 116:13624–13636</Citation></Reference><Reference><Citation>Li D, Ai H (2009) J Phys Chem B 113:11732–11742</Citation><ArticleIdList><ArticleId IdType="pubmed">19645458</ArticleId></ArticleIdList></Reference><Reference><Citation>Becke AD (1993) J Chem Phys 98:5648–5652</Citation></Reference><Reference><Citation>P. J. Stephens PJ, Jalkanen KJ, Devlin FJ, Chabalowski CF(1993). The Journal of Physical Chemistry 97: 6107–6110</Citation></Reference><Reference><Citation>Tawada Y, Tsuneda T, Yanagisawa S, Yanai T, Hirao K (2004) J Chem Phys 120:8425–8433</Citation><ArticleIdList><ArticleId IdType="pubmed">15267767</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanai T, Tew DP, Handy NC (2004) Chem Phys Lett 393:51–57</Citation></Reference><Reference><Citation>Cai ZL, Crossley MJ, Reimers JR, Kobayashi R, Amos RD (2006) J Phys Chemis B 110:15624–15632</Citation></Reference><Reference><Citation>Clark T, Chandrasekhar J, Spitznagel GW, Schleyer PVR (1983) J Comput Chem 4:294–301</Citation></Reference><Reference><Citation>Francl MM, Pietro WJ, Hehre WJ, Binkley JS, Gordon MS, DeFrees DJ, Pople JA (1982) J Chem Phys 77:3654–3665</Citation></Reference><Reference><Citation>Gordon MS (1980) Chem Phys Lett 76:163–168</Citation></Reference><Reference><Citation>Miertuš S, Scrocco E, Tomasi J (1981) Chem Phys 55:117–129</Citation></Reference><Reference><Citation>Houk KN, Sims J, Duke REJ, Strozier RW, George JK (1973) J Am Chem Soc 95:22</Citation></Reference><Reference><Citation>Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G.A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H.P., Izmaylov, A.F., Bloino, J., Zheng, G., Sonnenberg, J.L., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Montgomery, J.A.J., Peralta, J.E., Ogliaro, F., Bearpark, M., Heyd, J.J., Brothers, E., Kudin, K.N., Staroverov, V.N., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A., Burant, J.C., Iyengar, S.S., Tomasi, J., Cossi, M., Rega, N., Millam, J.M., Klene, M., Knox, J.E., Cross, J.B., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R.E., Yazyev, O., Austin, A.J., Cammi, R., Pomelli, C., Ochterski, J.W., Martin, R.L., Morokuma, K., Zakrzewski, V.G., Voth, G.A., Salvador, P., Dannenberg, J.J., Dapprich, S., Daniels, A.D., Farkas, O., Foresman, J.B., Ortiz, J.V., Cioslowskiand, J., Fox, D.J.: Gaussian 09, Revision A.02; Gaussian, Inc., Wallingford CT (2009)</Citation></Reference><Reference><Citation>Huang Z, Lin Z, Song C (2007) J Phys Chem A 111:4340–4352</Citation><ArticleIdList><ArticleId IdType="pubmed">17474721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov I, Klein ML (2002) J Am Chem Soc 124:13380–13381</Citation><ArticleIdList><ArticleId IdType="pubmed">12418879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai H, Bu Y, Li P (2003) Int J Quantum Chem 94:205–214</Citation></Reference><Reference><Citation>Hore NR, Russell DK (2004) New J Chem 28:606–613</Citation></Reference><Reference><Citation>Jana K, Ganguly B (2018) ACS Omega 3:8429–8439</Citation><ArticleIdList><ArticleId IdType="pubmed">31458971</ArticleId><ArticleId IdType="pmcid">6644555</ArticleId></ArticleIdList></Reference><Reference><Citation>Perepichka DF, Bryce MR (2005) Angew Chem Int Ed 44:5370–5373</Citation></Reference><Reference><Citation>Bulat et al (2021) Comput Theoret Chem 1199:113192</Citation></Reference><Reference><Citation>Politzer Murray (2021) J Mol Model 27:327</Citation><ArticleIdList><ArticleId IdType="pubmed">34687370</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan S, Ryu N, Shibata T (2012) J Am Chem Soc 134:17474–17477</Citation><ArticleIdList><ArticleId IdType="pubmed">23043316</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan, K., Li, Z., Qu, X., Wang, F., Wang, L.: Catalysts. 89 (2016)</Citation></Reference><Reference><Citation>Jiao L, Herdtweck E, Bach T (2012) J Am Chem Soc 134:14563–14572</Citation><ArticleIdList><ArticleId IdType="pubmed">22913367</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao LT, Bach T (2011) J Am Chem Soc 133:12990–12993</Citation><ArticleIdList><ArticleId IdType="pubmed">21806073</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang ZH, Wang Q, Zhuo S, Xu LP (2020) J Organic Chem 85:6981–6991</Citation></Reference><Reference><Citation>Wang X, Lane BS, Sames D (2005) J Am Chem Soc 127:4996–4997</Citation><ArticleIdList><ArticleId IdType="pubmed">15810815</ArticleId></ArticleIdList></Reference><Reference><Citation>Thenraj M, Samuelson AG (2013) Organometallics 32:7141–7152</Citation></Reference><Reference><Citation>Luo, Y.R.: Handbook of bond dissociation energies in organic compounds (2002)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36135988</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-1878</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>BioEssays : news and reviews in molecular, cellular and developmental biology</Title><ISOAbbreviation>Bioessays</ISOAbbreviation></Journal><ArticleTitle>Tubulin deacetylase NDST3 modulates lysosomal acidification: Implications in neurological diseases.</ArticleTitle><Pagination><MedlinePgn>e2200110</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/bies.202200110</ELocationID><Abstract><AbstractText>Neurological diseases (NDs), featured by progressive dysfunctions of the nervous system, have become a growing burden for the aging populations. N-Deacetylase and N-sulfotransferase 3 (NDST3) is known to catalyze deacetylation and N-sulfation on disaccharide substrates. Recently, NDST3 is identified as a novel deacetylase for tubulin, and its newly recognized role in modulating microtubule acetylation and lysosomal acidification provides fresh insights into ND therapeutic approaches using NDST3 as a target. Microtubule acetylation and lysosomal acidification have been reported to be critical for activities in neurons, implying that the regulators of these two biological processes, such as the previously known microtubule deacetylases, histone deacetylase 6 (HDAC6) and sirtuin 2 (SIRT2), could play important roles in various NDs. Aberrant NDST3 expression or tubulin acetylation has been observed in an increasing number of NDs, including amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD), schizophrenia and bipolar disorder, Alzheimer's disease (AD), and Parkinson's disease (PD), suggesting that NDST3 is a key player in the pathogenesis of NDs and may serve as a target for development of new treatment of NDs.</AbstractText><CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiangning</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jiou</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9115-8708</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS074324</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS128494</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS089616</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074324</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS110098</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS110098</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089616</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bioessays</MedlineTA><NlmUniqueID>8510851</NlmUniqueID><ISSNLinking>0265-9247</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014404">Tubulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056565">Sirtuin 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>20971-43-1</RegistryNumber><NameOfSubstance UI="C011442">diazonaphthalenedisulfonic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.8.2.-</RegistryNumber><NameOfSubstance UI="D015238">Sulfotransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004187">Disaccharides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014404" MajorTopicYN="N">Tubulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056565" MajorTopicYN="N">Sirtuin 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015238" MajorTopicYN="N">Sulfotransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004187" MajorTopicYN="N">Disaccharides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease (AD)</Keyword><Keyword MajorTopicYN="N">NDST3</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD)</Keyword><Keyword MajorTopicYN="N">lysosomal acidification</Keyword><Keyword MajorTopicYN="N">lysosomal storage disorder</Keyword><Keyword MajorTopicYN="N">microtubule acetylation</Keyword><Keyword MajorTopicYN="N">neurological diseases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>10</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36135988</ArticleId><ArticleId IdType="doi">10.1002/bies.202200110</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., Fisher, J. L., Fitzmaurice, C., Giussani, G., Glennie, L., James, S. L., Johnson, C. O., Kassebaum, N. J., Logroscino, G., Marin, B., … Vos, T. (2019). (2016). Global. regional, and national burden of neurological disorders, 1990-2016: A systematic analysis for the Global Burden of Disease Study. Lancet Neurology, 18(5), 459-480. https://doi.org/10.1016/S1474-4422(18)30499-X</Citation></Reference><Reference><Citation>Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., &amp; Bohr, V. A. (2019). Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology, 15(10), 565-581. https://doi.org/10.1038/s41582-019-0244-7</Citation></Reference><Reference><Citation>Lu, J., Periz, G., Lu, Y. N., Tang, Q., Liu, Y., Zhang, T., Shah, Y., Thombre, R., Aljumaah, R., Li, W., Mojsilovic-Petrovic, J., Ji, Y., Johnson, K., Kalb, R., &amp; Wang, J. (2019). L3MBTL1 regulates ALS/FTD-associated proteotoxicity and quality control. Nature Neuroscience, 22(6), 875-886. https://doi.org/10.1038/s41593-019-0384-5</Citation></Reference><Reference><Citation>Finkbeiner, S. (2020). The autophagy lysosomal pathway and neurodegeneration. Cold Spring Harbor Perspectives in Biology, 12(3), a033993.</Citation></Reference><Reference><Citation>Sardana, R., &amp; Emr, S. D. (2021). Membrane protein quality control mechanisms in the endo-lysosome system. Trends in Cell Biology, 31(4), 269-283. https://doi.org/10.1016/j.tcb.2020.11.011</Citation></Reference><Reference><Citation>Tang, Q., Liu, M., Liu, Y., Hwang, R., Zhang, T., &amp; Wang, J. (2021). NDST3 deacetylates α-tubulin and suppresses V-ATPase assembly and lysosomal acidification. EMBO Journal, 40, e107204. https://doi.org/10.15252/embj.2020107204</Citation></Reference><Reference><Citation>Roll-Mecak, A. (2020). The tubulin code in microtubule dynamics and information encoding. Developmental Cell, 54(1), 7-20. https://doi.org/10.1016/j.devcel.2020.06.008</Citation></Reference><Reference><Citation>Janke, C., &amp; Montagnac, G. (2017). Causes and consequences of microtubule acetylation. Current Biology, 27(23), R1287-R1292. https://doi.org/10.1016/j.cub.2017.10.044</Citation></Reference><Reference><Citation>Marchisella, F., Coffey, E. T., &amp; Hollos, P. (2016). Microtubule and microtubule associated protein anomalies in psychiatric disease. Cytoskeleton, 73(10), 596-611. https://doi.org/10.1002/cm.21300</Citation></Reference><Reference><Citation>Portran, D., Schaedel, L., Xu, Z., Théry, M., &amp; Nachury, M. V. (2017). Tubulin acetylation protects long-lived microtubules against mechanical ageing. Nature Cell Biology, 19(4), 391-398. https://doi.org/10.1038/ncb3481</Citation></Reference><Reference><Citation>Cappelletti, G., Calogero, A. M., &amp; Rolando, C. (2021). Microtubule acetylation: A reading key to neural physiology and degeneration. Neuroscience Letters, 755, 135900. https://doi.org/10.1016/j.neulet.2021.135900</Citation></Reference><Reference><Citation>Gatica, D., Lahiri, V., &amp; Klionsky, D. J. (2018). Cargo recognition and degradation by selective autophagy. Nature Cell Biology, 20(3), 233-242. https://doi.org/10.1038/s41556-018-0037-z</Citation></Reference><Reference><Citation>Yang, C., &amp; Wang, X. (2021). Lysosome biogenesis: Regulation and functions. Journal of Cell Biology, 220(6), e202102001. https://doi.org/10.1083/jcb.202102001</Citation></Reference><Reference><Citation>Song, Q., Meng, B., Xu, H., &amp; Mao, Z. (2020). The emerging roles of vacuolar-type ATPase-dependent Lysosomal acidification in neurodegenerative diseases. Translational Neurodegeneration, 9, 17. https://doi.org/10.1186/s40035-020-00196-0</Citation></Reference><Reference><Citation>Koh, J. Y., Kim, H. N., Hwang, J. J., Kim, Y. H., &amp; Park, S. E. (2019). Lysosomal dysfunction in proteinopathic neurodegenerative disorders: Possible therapeutic roles of cAMP and zinc. Molecular Brain, 12, 18. https://doi.org/10.1186/s13041-019-0439-2</Citation></Reference><Reference><Citation>Grobe, K., Ledin, J., Ringvall, M., Holmborn, K., Forsberg, E., Esko, J. D., &amp; Kjelle, L. (2002). Heparan sulfate and development: Differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochimica et Biophysica Acta (BBA) - General Subjects, 1573(3), 209-215.</Citation></Reference><Reference><Citation>Aikawa, J.-I. (2002). In N. Taniguchi, K. Honke, M. Fukuda, H. Clausen, K. Furukawa, G. W. Hart, R. Kannagi, T. Kawasaki, T. Kinoshita, T. Muramatsu, M. Saito, J. H. Shaper, K. Sugahara, L. A. Tabak, D. H. Van den Eijnden, M. Yanagishita, J. W. Dennis, K. Furukawa, Y. Hirabayashi, … K. Yamashita (Eds.), Heparan sulfate/heparin N-deacetylase/N-sulfotransferase-3 and -4 BT - Handbook of glycosyltransferases and related genes (pp. 496-500). Springer. https://doi.org/10.1007/978-4-431-67877-9_72</Citation></Reference><Reference><Citation>Rolls, M. M., Thyagarajan, P., &amp; Feng, C. (2021). Microtubule dynamics in healthy and injured neurons. Developmental Neurobiology, 81(3), 321-332. https://doi.org/10.1002/dneu.22746</Citation></Reference><Reference><Citation>Sferra, A., Nicita, F., &amp; Bertini, E. (2020). Microtubule dysfunction: A common feature of neurodegenerative diseases. International Journal of Molecular Sciences, 21(19), 7354. https://doi.org/10.3390/ijms21197354</Citation></Reference><Reference><Citation>Boiarska, Z., &amp; Passarella, D. (2021). Microtubule-targeting agents and neurodegeneration. Drug Discovery Today, 26(2), 604-615. https://doi.org/10.1016/j.drudis.2020.11.033</Citation></Reference><Reference><Citation>Janke, C., &amp; Magiera, M. M. (2020). The tubulin code and its role in controlling microtubule properties and functions. Nature Reviews Molecular Cell Biology, 21, 307-326. https://doi.org/10.1038/s41580-020-0214-3</Citation></Reference><Reference><Citation>Moutin, M. J., Bosc, C., Peris, L., &amp; Andrieux, A. (2021). Tubulin post-translational modifications control neuronal development and functions. Developmental Neurobiology, 81(3), 253-272. https://doi.org/10.1002/dneu.22774</Citation></Reference><Reference><Citation>Eshun-Wilson, L., Zhang, R., Portran, D., Nachury, M. V., Toso, D. B., Löhr, T., Vendruscolo, M., Bonomi, M., Fraser, J. S., &amp; Nogales, E. (2019). Effects of α-tubulin acetylation on microtubule structure and stability. Proceedings of the National Academy of Sciences USA, 116(21), 10366-10371. https://doi.org/10.1073/pnas.1900441116</Citation></Reference><Reference><Citation>Xu, Z., Schaedel, L., Portran, D., Aguilar, A., Gaillard, J., Marinkovich, M. P., Théry, M., &amp; Nachury, M. V. (2017). Microtubules acquire resistance from mechanical breakage through intralumenal acetylation. Science, 356(6335), 328-332. https://doi.org/10.1126/science.aai8764</Citation></Reference><Reference><Citation>Wei, D., Gao, N., Li, L., Zhu, J. X., Diao, L., Huang, J., Han, Q. J., Wang, S., Xue, H., Wang, Q., Wu, Q. F., Zhang, X., &amp; Bao, L. (2018). α-Tubulin acetylation restricts axon overbranching by dampening microtubule plus-end dynamics in neurons. Cerebral Cortex, 28(9), 3332-3346. https://doi.org/10.1093/cercor/bhx225</Citation></Reference><Reference><Citation>Esteves, A. R., &amp; Cardoso, S. M. (2020). Differential protein expression in diverse brain areas of Parkinson's and Alzheimer's disease patients. Scientific Reports., 10(1), 13149. https://doi.org/10.1038/s41598-020-70174-z</Citation></Reference><Reference><Citation>Choi, H., Kim, H. J., Yang, J., Chae, S., Lee, W., Chung, S., Kim, J., Choi, H., Song, H., Lee, C. K., Jun, J. H., Lee, Y. J., Lee, K., Kim, S., Sim, H. R., Choi, Y. I., Ryu, K. H., Park, J. C., Lee, D., … Mook-Jung, I. (2020). Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models. Aging Cell, 19, e13081. https://doi.org/10.1111/acel.13081</Citation></Reference><Reference><Citation>Li, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., &amp; Sun, H. (2021). Inhibition of histone deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review. (2010-2020). European Journal of Medicinal Chemistry, 226, 113874. https://doi.org/10.1016/j.ejmech.2021.113874</Citation></Reference><Reference><Citation>Graziella, C., &amp; Daniele, C. (2019). Acetylation of tubulin: A feasible protective target from neurodevelopment to neurodegeneration. In Neuroprotection in autism, schizophrenia and Alzheimer's disease (pp. 273-294). Elsevier Inc. https://doi.org/10.1016/B978-0-12-814037-6.00009-4</Citation></Reference><Reference><Citation>Dubey, J., Ratnakaran, N., &amp; Koushika, S. P. (2015). Neurodegeneration and microtubule dynamics: Death by a thousand cuts. Frontiers in Cellular Neuroscience, 9, 343. https://doi.org/10.3389/fncel.2015.00343</Citation></Reference><Reference><Citation>Nekooki-Machida, Y., &amp; Hagiwara, H. (2020). Role of tubulin acetylation in cellular functions and diseases. Medical Molecular Morphology, 53(4), 191-197. https://doi.org/10.1007/s00795-020-00260-8</Citation></Reference><Reference><Citation>Kalebic, N., Sorrentino, S., Perlas, E., Bolasco, G., Martinez, C., &amp; Heppenstall, P. A. (2013). αTAT1 is the major α-tubulin acetyltransferase in mice. Nature Communications, 4, 1962. https://doi.org/10.1038/ncomms2962</Citation></Reference><Reference><Citation>North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., &amp; Verdin, E. (2003). The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Molecular Cell, 11(2), 437-444. https://doi.org/10.1016/s1097-2765(03)00038-8</Citation></Reference><Reference><Citation>Hubbert, C., Guardiola, A., &amp; Shao, R. (2002). HDAC6 is a microtubule-associated deacetylase. Nature, 417, 455-458.</Citation></Reference><Reference><Citation>Southwood, C. M., Peppi, M., Dryden, S., Tainsky, M. A., &amp; Gow, A. (2007). Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochemistry International, 32(2), 187-195. https://doi.org/10.1007/s11064-006-9127-6</Citation></Reference><Reference><Citation>Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., Asplund, A., Sjöstedt, E., Lundberg, E., Szigyarto, C. A.-K., Skogs, M., Takanen, J. O., Berling, H., Tegel, H., Mulder, J., … Uhlén, M. (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Molecular &amp; Cellular Proteomics, 13(2), 397-406. https://doi.org/10.1074/mcp.M113.035600</Citation></Reference><Reference><Citation>Aikawa, J., &amp; Esko, J. D. (1999). Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNAcN-deacetylase/N-sulfotransferase family. Journal of Biological Chemistry, 274(5), 2690-2695. https://doi.org/10.1074/jbc.274.5.2690</Citation></Reference><Reference><Citation>Kim, J. Y., Hwang, H. G., Lee, J. Y., Kim, M., &amp; Kim, J. Y. (2020). Cortactin deacetylation by HDAC6 and SIRT2 regulates neuronal migration and dendrite morphogenesis during cerebral cortex development. Molecular Brain, 13, 105. https://doi.org/10.1186/s13041-020-00644-y</Citation></Reference><Reference><Citation>Kalinski, A. L., Kar, A. N., Craver, J., Tosolini, A. P., Sleigh, J. N., Lee, S. J., Hawthorne, A., Brito-Vargas, P., Miller-Randolph, S., Passino, R., Shi, L., Wong, V. S. C., Picci, C., Smith, D. S., Willis, D. E., Havton, L. A., Schiavo, G., Giger, R. J., Langley, B., &amp; Twiss, J. L. (2019). Deacetylation of Miro1 by HDAC6 blocks mitochondrial transport and mediates axon growth inhibition. Journal of Cell Biology, 218(6), 1871-1890. https://doi.org/10.1083/jcb.201702187</Citation></Reference><Reference><Citation>Haigis, M. C., &amp; Haigis, K. M. (2013). HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Molecular Cancer Research, 11(9), 1072-1077. https://doi.org/10.1158/1541-7786.MCR-13-0040-T.HDAC6</Citation></Reference><Reference><Citation>Du, Y., Yang, X., Li, Z., Le, W., Hao, Y., Song, Y., Wang, F., &amp; Guan, Y. (2021). HDAC6-mediated Hsp90 deacetylation reduces aggregation and toxicity of the protein alpha-synuclein by regulating chaperone-mediated autophagy. Neurochemistry International, 149, 105141. https://doi.org/10.1016/j.neuint.2021.105141</Citation></Reference><Reference><Citation>Parmigiani, R. B., Xu, W. S., Venta-Perez, G., Erdjument-Bromage, H., Yaneva, M., Tempst, P., &amp; Marks, P. A. (2008). HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proceedings of the National Academy of Sciences USA, 105(28), 9633-9638. https://doi.org/10.1073/pnas.0803749105</Citation></Reference><Reference><Citation>Vaquero, A., Scher, M. B., Lee, D. H., Sutton, A., Cheng, H.-L., Alt, F. W., Serrano, L., Sternglanz, R., &amp; Reinberg, D. (2006). SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes &amp; Development, 20(10), 1256-1261. https://doi.org/10.1101/gad.1412706</Citation></Reference><Reference><Citation>Zhang, Y., Long, X., Ruan, X., Wei, Q., Zhang, L., Wo, L., Huang, D., Lin, L., Wang, D., Xia, L., Zhao, Q., Liu, J., Zhao, Q., &amp; He, M. (2021). SIRT2-mediated deacetylation and deubiquitination of C/EBPβ prevents ethanol-induced liver injury. Cell Discovery, 7, 93. https://doi.org/10.1038/s41421-021-00326-6</Citation></Reference><Reference><Citation>Kudo, N., Ito, A., Arata, M., Nakata, A., &amp; Yoshida, M. (2018). Identification of a novel small molecule that inhibits deacetylase but not defatty-acylase reaction catalysed by SIRT2. Philosophical Transactions of the Royal Society B: Biological Sciences, 373(1748), 20170070. https://doi.org/10.1098/rstb.2017.0070</Citation></Reference><Reference><Citation>Park, S.-H., Ozden, O., Liu, G., Song, H. Y., Zhu, Y., Yan, Y., Zou, X., Kang, H.-J., Jiang, H., &amp; Principe, D. R. (2016). SIRT2-mediated deacetylation and tetramerization of pyruvate kinase directs glycolysis and tumor growth. Cancer Research, 76(13), 3802-3812.</Citation></Reference><Reference><Citation>Suematsu, T., Li, Y., Kojima, H., Nakajima, K., Oshimura, M., &amp; Inoue, T. (2014). Deacetylation of the mitotic checkpoint protein BubR1 at lysine 250 by SIRT2 and subsequent effects on BubR1 degradation during the prometaphase/anaphase transition. Biochemical and Biophysical Research Communications, 453(3), 588-594. https://doi.org/10.1016/j.bbrc.2014.09.128</Citation></Reference><Reference><Citation>Miyake, Y., Keusch, J. J., Wang, L., Saito, M., Hess, D., Wang, X., Melancon, B. J., Helquist, P., Gut, H., &amp; Matthias, P. (2016). Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nature Chemical Biology, 12(9), 748-754. https://doi.org/10.1038/nchembio.2140</Citation></Reference><Reference><Citation>Abbas, Y. M., Wu, D., Bueler, S. A., Robinson, C. V., &amp; Rubinstein, J. L. (2020). Structure of V-ATPase from the mammalian brain. Science, 367(6483), 1246-1251. https://doi.org/10.1126/science.aba1120</Citation></Reference><Reference><Citation>Mijaljica, D., Prescott, M., &amp; Devenish, R. J. (2011). V-ATPase engagement in autophagic processes. Autophagy, 7(6), 666-668. https://doi.org/10.4161/auto.7.6.15812</Citation></Reference><Reference><Citation>Lee, J., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-vicente, M., Massey, A. C., Sovak, G., Uchiyama, Y., Westaway, D., Cuervo, A. M., &amp; Nixon, R. A. (2010). Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell, 141(7), 1146-1158. https://doi.org/10.1016/j.cell.2010.05.008</Citation></Reference><Reference><Citation>Soyombo, A. A., Tjon-Kon-Sang, S., Rbaibi, Y., Bashllari, E., Bisceglia, J., Muallem, S., &amp; Kiselyov, K. (2006). TRP-ML1 regulates lysosomal pH and acidic lysosomal lipid hydrolytic activity. Journal of Biological Chemistry, 281(11), 7294-7301. https://doi.org/10.1074/jbc.M508211200</Citation></Reference><Reference><Citation>Eriksson, I., Joosten, M., Roberg, K., &amp; Öllinger, K. (2013). The histone deacetylase inhibitor trichostatin A reduces lysosomal pH and enhances cisplatin-induced apoptosis. Experimental Cell Research, 319(1), 12-20. https://doi.org/10.1016/j.yexcr.2012.10.004</Citation></Reference><Reference><Citation>Vinod, V., Padmakrishnan, C. J., Vijayan, B., &amp; Gopala, S. (2014). ‘How can I halt thee?’ The puzzles involved in autophagic inhibition. Pharmacological Research, 82, 1-8. https://doi.org/10.1016/j.phrs.2014.03.005</Citation></Reference><Reference><Citation>Feng, T., Mai, S., Roscoe, J. M., Sheng, R. R., Ullah, M., Zhang, J., Katz, I. I., Yu, H., Xiong, W., &amp; Hu, F. (2020). Loss of TMEM 106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice. EMBO Reports, 21(10), e50219. https://doi.org/10.15252/embr.202050219</Citation></Reference><Reference><Citation>Root, J., Merino, P., Nuckols, A., Johnson, M., &amp; Kukar, T. (2021). Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiology of Disease, 154, 105360. https://doi.org/10.1016/j.nbd.2021.105360</Citation></Reference><Reference><Citation>Courtland, J. L., Bradshaw, T. W. A., Waitt, G., Soderblom, E. J., Ho, T., Rajab, A., Vancini, R., Kim, I. H., &amp; Soderling, S. H. (2021). Genetic disruption of washc4 drives endo-lysosomal dysfunction and cognitive-movement impairments in mice and humans. ELife, 10, e61590. https://doi.org/10.7554/eLife.61590</Citation></Reference><Reference><Citation>Wolfe, D. M., Lee, J. H., Kumar, A., Lee, S., Orenstein, S. J., &amp; Nixon, R. A. (2013). Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. European Journal of Neuroscience, 37(12), 1949-1961. https://doi.org/10.1111/ejn.12169</Citation></Reference><Reference><Citation>Nixon, R. A. (2020). The aging lysosome: An essential catalyst for late-onset neurodegenerative diseases. Biochimica et Biophysica Acta - Proteins and Proteomics, 1868(9), 140443. https://doi.org/10.1016/j.bbapap.2020.140443</Citation></Reference><Reference><Citation>Nixon, R. A. (2013). The role of autophagy in neurodegenerative disease. Nat. Med., 19(8), 983-997. https://doi.org/10.1038/nm.3232</Citation></Reference><Reference><Citation>Lencz, T., Guha, S., Liu, C., Rosenfeld, J., Mukherjee, S., DeRosse, P., John, M., Cheng, L., Zhang, C., &amp; Badner, J. A. (2013). Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nature Communications, 4, 2739.</Citation></Reference><Reference><Citation>Ahmed, R. M., Devenney, E. M., Strikwerda-Brown, C., Hodges, J. R., Piguet, O., &amp; Kiernan, M. C. (2020). Phenotypic variability in ALS-FTD and effect on survival. Neurology, 94(19), e2005-e2013. https://doi.org/10.1212/WNL.0000000000009398</Citation></Reference><Reference><Citation>Liscic, R. M., Alberici, A., Cairns, N. J., Romano, M., &amp; Buratti, E. (2020). From basic research to the clinic: Innovative therapies for ALS and FTD in the pipeline. Molecular Neurodegeneration, 15, 31. https://doi.org/10.1186/s13024-020-00373-9</Citation></Reference><Reference><Citation>Balendra, R., &amp; Isaacs, A. M. (2018). C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nature Reviews Neurology, 14(9), 544-558. https://doi.org/10.1038/s41582-018-0047-2</Citation></Reference><Reference><Citation>Moens, T. G., Partridge, L., &amp; Isaacs, A. M. (2017). Genetic models of C9orf72: What is toxic? Current Opinion in Genetics and Development, 44, 92-101. https://doi.org/10.1016/j.gde.2017.01.006</Citation></Reference><Reference><Citation>Zhu, Q., Jiang, J., Gendron, T. F., McAlonis-Downes, M., Jiang, L., Taylor, A., Garcia, S. D., Dastidar, S. G., Rodriguez, M. J., &amp; King, P. (2020). Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nature Neuroscience, 23(5), 615-624.</Citation></Reference><Reference><Citation>Beckers, J., Tharkeshwar, A. K., &amp; Van Damme, P. (2021). C9orf72 ALS-FTD: Recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy, 17(11), 3306-3322. https://doi.org/10.1080/15548627.2021.1872189</Citation></Reference><Reference><Citation>Saleh, A., King, M., Hamilton, J., Pigott, T., Elkhatib, R., Shah, A., &amp; Selek, S. (2021). Birth seasonality of schizophrenia and bipolar disorder? A review of inpatient records. Journal of Affective Disorders, 287, 15-18. https://doi.org/10.1016/j.jad.2021.03.002</Citation></Reference><Reference><Citation>Sarkar, S., Rajalakshmi, A. R., Avudaiappan, S., &amp; Eswaran, S. (2021). Exploring the role of macular thickness as a potential early biomarker of neurodegeneration in acute schizophrenia. International Ophthalmology, 41(8), 2737-2746. https://doi.org/10.1007/s10792-021-01831-z</Citation></Reference><Reference><Citation>Dols, A., &amp; Lemstra, A. W. (2020). Parkinsonism and bipolar disorder. Bipolar Disorders, 22(4), 413-415. https://doi.org/10.1111/bdi.12888</Citation></Reference><Reference><Citation>Zhang, C., Lu, W., Wang, Z., Ni, J., Zhang, J., Tang, W., &amp; Fang, Y. (2016). A comprehensive analysis of NDST3 for schizophrenia and bipolar disorder in Han Chinese. Translational Psychiatry, 6, e701. https://doi.org/10.1038/tp.2015.199</Citation></Reference><Reference><Citation>Gu, L.-Z., Jiang, T., Cheng, Z.-H., Zhang, Y.-C., Ou, M.-M., Chen, M.-C., Zhou, Z.-H., &amp; Ling, W.-M. (2014). rs11098403 polymorphism near NDST3 is associated with a reduced risk of schizophrenia in a Han Chinese population. Neuroscience Letters, 581, 42-45. https://doi.org/10.1016/j.neulet.2014.08.018</Citation></Reference><Reference><Citation>Wang, L., Chen, J., Li, Z., Sun, W., Chen, B., Li, S., Li, W., Lu, D., Wang, Y., &amp; Shi, Y. (2018). Association study of NDST3 gene for schizophrenia, bipolar disorder, major depressive disorder in the Han Chinese population. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, 177(1), 3-9. https://doi.org/10.1002/ajmg.b.32573</Citation></Reference><Reference><Citation>Luza, S., Opazo, C. M., Bousman, C. A., Pantelis, C., Bush, A. I., &amp; Everall, I. P. (2020). The ubiquitin proteasome system and schizophrenia. The Lancet Psychiatry, 7(6), 528-537. https://doi.org/10.1016/S2215-0366(19)30520-6</Citation></Reference><Reference><Citation>Uranova, N. A., Bonartsev, P. D., Androsova, L. V., Rakhmanova, V. I., &amp; Kaleda, V. G. (2017). Impaired monocyte activation in schizophrenia: Ultrastructural abnormalities and increased IL-1β production. European Archives of Psychiatry and Clinical Neuroscience, 267(5), 417-426. https://doi.org/10.1007/s00406-017-0782-1</Citation></Reference><Reference><Citation>Cox, T. M. (2020). Lysosomal diseases and neuropsychiatry: Opportunities to rebalance the mind. Frontiers in Molecular Biosciences, 7, 177. https://doi.org/10.3389/fmolb.2020.00177</Citation></Reference><Reference><Citation>Toledano-Zaragoza, A., &amp; Ledesma, M. D. (2020). Addressing neurodegeneration in lysosomal storage disorders: Advances in Niemann Pick diseases. Neuropharmacology, 171, 107851. https://doi.org/10.1016/j.neuropharm.2019.107851</Citation></Reference><Reference><Citation>Ahrens-Nicklas, R. C., Tecedor, L., Hall, A. F., Lysenko, E., Cohen, A. S., Davidson, B. L., &amp; Marsh, E. D. (2019). Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder. JCI Insight, 4(21), e131961. https://doi.org/10.1172/jci.insight.131961</Citation></Reference><Reference><Citation>Holopainen, J. M., Saarikoski, J., Kinnunen, P. K. J., &amp; Järvelä, I. (2001). Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). European Journal of Biochemistry, 268(22), 5851-5856. https://doi.org/10.1046/j.0014-2956.2001.02530.x</Citation></Reference><Reference><Citation>Pesaola, F., Quassollo, G., Venier, A. C., De Paul, A. L., Noher, I., &amp; Bisbal, M. (2021). The neuronal ceroid lipofuscinosis-related protein CLN8 regulates endo-lysosomal dynamics and dendritic morphology. Biology of the Cell, 113(10), 419-437. https://doi.org/10.1111/boc.202000016</Citation></Reference><Reference><Citation>Bach, G., Chen, C. S., &amp; Pagano, R. E. (1999). Elevated lysosomal pH in mucolipidosis type IV cells. Clinica Chimica Acta; International Journal of Clinical Chemistry, 280(1-2), 173-179. https://doi.org/10.1016/s0009-8981(98)00183-1</Citation></Reference><Reference><Citation>Schmid, J. A., Mach, L., Paschke, E., &amp; Glössl, J. (1999). Accumulation of sialic acid in endocytic compartments interferes with the formation of mature lysosomes. Impaired proteolytic processing of cathepsin B in fibroblasts of patients with lysosomal sialic acid storage disease. Journal of Biological Chemistry, 274(27), 19063-19071. https://doi.org/10.1074/jbc.274.27.19063</Citation></Reference><Reference><Citation>Yan, G., Li, D., Zhong, X., Liu, G., Wang, X., Lu, Y., Qin, F., Guo, Y., Duan, S., &amp; Li, D. (2021). Identification of HDAC6 selective inhibitors: Pharmacophore based virtual screening, molecular docking and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics, 39(6), 1928-1939.</Citation></Reference><Reference><Citation>Nong, Y., Hou, Y., Pu, Y., Li, S., &amp; Lan, Y. (2021). Development and validation of high-content analysis for screening HDAC6-selective inhibitors. SLAS Discovery, 26(5), 628-641. https://doi.org/10.1177/24725552211002463</Citation></Reference><Reference><Citation>Malik, B. R., Maddison, D. C., Smith, G. A., &amp; Peters, O. M. (2019). Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. Molecular Brain, 12, 100. https://doi.org/10.1186/s13041-019-0504-x</Citation></Reference><Reference><Citation>Orr, M. E., &amp; Oddo, S. (2013). Autophagic/lysosomal dysfunction in Alzheimer's disease. Alzheimer's Research and Therapy, 5, 53. https://doi.org/10.1186/alzrt217</Citation></Reference><Reference><Citation>Aman, Y., Schmauck-Medina, T., Hansen, M., Morimoto, R. I., Simon, A. K., Bjedov, I., Palikaras, K., Simonsen, A., Johansen, T., Tavernarakis, N., Rubinsztein, D. C., Partridge, L., Kroemer, G., Labbadia, J., &amp; Fang, E. F. (2021). Autophagy in healthy aging and disease. Nature Aging, 1(8), 634-650. https://doi.org/10.1038/s43587-021-00098-4</Citation></Reference><Reference><Citation>Bagh, M. B., Peng, S., Chandra, G., Zhang, Z., Singh, S. P., Pattabiraman, N., Liu, A., &amp; Mukherjee, A. B. (2017). Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in a neurodegenerative lysosomal storage disease model. Nature Communications, 8, 14612. https://doi.org/10.1038/ncomms14612</Citation></Reference><Reference><Citation>Lee, J.-H., Yang, D.-S., Goulbourne, C. N., Im, E., Stavrides, P., Pensalfini, A., Chan, H., Bouchet-Marquis, C., Bleiwas, C., Berg, M. J., Huo, C., Peddy, J., Pawlik, M., Levy, E., Rao, M., Staufenbiel, M., &amp; Nixon, R. A. (2022). Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nature Neuroscience, 25(6), 688-701. https://doi.org/10.1038/s41593-022-01084-8</Citation></Reference><Reference><Citation>Nah, J., Yuan, J., &amp; Jung, Y. K. (2015). Autophagy in neurodegenerative diseases: From mechanism to therapeutic approach. Molecules and Cells, 38(5), 381-389. https://doi.org/10.14348/molcells.2015.0034</Citation></Reference><Reference><Citation>Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., &amp; Jones, D. T. (2021). Alzheimer disease. Nature Reviews Disease Primers, 7, 33. https://doi.org/10.1038/s41572-021-00269-y</Citation></Reference><Reference><Citation>Chen, H., Chen, F., Zhang, M., Chen, Y., Cui, L., &amp; Liang, C. (2021). A review of APOE genotype-dependent autophagic flux regulation in Alzheimer's disease. Journal of Alzheimer's Disease, 84(2), 535-555. https://doi.org/10.3233/jad-210602</Citation></Reference><Reference><Citation>Lai, S. S. M., Ng, K. Y., Koh, R. Y., Chok, K. C., &amp; Chye, S. M. (2021). Endosomal-lysosomal dysfunctions in Alzheimer's disease: Pathogenesis and therapeutic interventions. Metabolic Brain Disease, 36(6), 1087-1100. https://doi.org/10.1007/s11011-021-00737-0</Citation></Reference><Reference><Citation>Avrahami, L., Farfara, D., Shaham-Kol, M., Vassar, R., Frenkel, D., &amp; Eldar-Finkelman, H. (2013). Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: In vivo and in vitro studies. Journal of Biological Chemistry, 288(2), 1295-1306. https://doi.org/10.1074/jbc.M112.409250</Citation></Reference><Reference><Citation>Blumenreich, S., Barav, O. B., Jenkins, B. J., &amp; Futerman, A. H. (2020). Lysosomal storage disorders shed light on lysosomal dysfunction in Parkinson's disease. International Journal of Molecular Sciences, 21(14), 4966. https://doi.org/10.3390/ijms21144966</Citation></Reference><Reference><Citation>Wallings, R. L., Humble, S. W., Ward, M. E., &amp; Wade-Martins, R. (2019). Lysosomal dysfunction at the centre of Parkinson's disease and frontotemporal dementia/amyotrophic lateral sclerosis. Trends in Neurosciences, 42(12), 899-912. https://doi.org/10.1016/j.tins.2019.10.002</Citation></Reference><Reference><Citation>van Veen, S., Martin, S., Van den Haute, C., Benoy, V., Lyons, J., Vanhoutte, R., Kahler, J. P., Decuypere, J. P., Gelders, G., Lambie, E., Zielich, J., Swinnen, J. V., Annaert, W., Agostinis, P., Ghesquière, B., Verhelst, S., Baekelandt, V., Eggermont, J., &amp; Vangheluwe, P. (2020). ATP13A2 deficiency disrupts lysosomal polyamine export. Nature, 578(7795), 419-424. https://doi.org/10.1038/s41586-020-1968-7</Citation></Reference><Reference><Citation>Singh, F., &amp; Ganley, I. G. (2021). Parkinson's disease and mitophagy: An emerging role for LRRK2. Biochemical Society Transactions, 49(2), 551-562. https://doi.org/10.1042/BST20190236</Citation></Reference><Reference><Citation>Wie, J., Liu, Z., Song, H., Tropea, T. F., Yang, L., Wang, H., Liang, Y., Cang, C., Aranda, K., Lohmann, J., Yang, J., Lu, B., Chen-Plotkin, A. S., Luk, K. C., &amp; Ren, D. (2021). A growth-factor-activated lysosomal K+ channel regulates Parkinson's pathology. Nature, 592(7855), E10. https://doi.org/10.1038/s41586-021-03438-x</Citation></Reference><Reference><Citation>Monaco, A., &amp; Fraldi, A. (2020). Protein aggregation and dysfunction of autophagy-lysosomal pathway: A vicious cycle in lysosomal storage diseases. Frontiers in Molecular Neuroscience, 13, 37. https://doi.org/10.3389/fnmol.2020.00037</Citation></Reference><Reference><Citation>Yun, T., Ko, H. R., Jo, D. K., Park, K. W., Cho, S. W., Kim, J., &amp; Ahn, J. Y. (2021). Inhibitor of DNA binding 2 (Id2) mediates microtubule polymerization in the brain by regulating αK40 acetylation of α-tubulin. Cell Death Discovery, 7(1), 257. https://doi.org/10.1038/s41420-021-00652-4</Citation></Reference><Reference><Citation>Shen, S., &amp; Kozikowski, A. P. (2020). A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases. (2014-2019). Expert Opinion on Therapeutic Patents, 30(2), 121-136. https://doi.org/10.1080/13543776.2019.1708901</Citation></Reference><Reference><Citation>Godena, V. K., Brookes-Hocking, N., Moller, A., Shaw, G., Oswald, M., Sancho, R. M., Miller, C. C. J., Whitworth, A. J., &amp; De Vos, K. J. (2014). Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nature Communications, 5, 5245. https://doi.org/10.1038/ncomms6245</Citation></Reference><Reference><Citation>Yan, S., Wei, X., Jian, W., Qin, Y., Liu, J., Zhu, S., Jiang, F., Lou, H., &amp; Zhang, B. (2020). Pharmacological inhibition of HDAC6 attenuates NLRP3 inflammatory response and protects dopaminergic neurons in experimental models of Parkinson's disease. Frontiers in Aging Neuroscience, 12, 78. https://doi.org/10.3389/fnagi.2020.00078</Citation></Reference><Reference><Citation>Onishi, T., Maeda, R., Terada, M., Sato, S., Fujii, T., Ito, M., Hashikami, K., Kawamoto, T., &amp; Tanaka, M. (2021). A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice. Scientific Reports, 11, 15423. https://doi.org/10.1038/s41598-021-94923-w</Citation></Reference><Reference><Citation>Esteves, A. R., Palma, A. M., Gomes, R., Santos, D., Silva, D. F., &amp; Cardoso, S. M. (2019). Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1865(8), 2008-2023. https://doi.org/10.1016/j.bbadis.2018.11.014</Citation></Reference><Reference><Citation>Zhang, Y., Anoopkumar-Dukie, S., Arora, D., &amp; Davey, A. K. (2020). Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases. European Journal of Pharmacology, 867, 172847. https://doi.org/10.1016/j.ejphar.2019.172847</Citation></Reference><Reference><Citation>Picci, C., Wong, V. S. C., Costa, C. J., McKinnon, M. C., Goldberg, D. C., Swift, M., Alam, N. M., Prusky, G. T., Shen, S., Kozikowski, A. P., Willis, D. E., &amp; Langley, B. (2020). HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice. Experimental Neurology, 328, 113281. https://doi.org/10.1016/j.expneurol.2020.113281</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36135933</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-9726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Aging cell</Title><ISOAbbreviation>Aging Cell</ISOAbbreviation></Journal><ArticleTitle>The MK2 cascade mediates transient alteration in mGluR-LTD and spatial learning in a murine model of Alzheimer's disease.</ArticleTitle><Pagination><MedlinePgn>e13717</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acel.13717</ELocationID><Abstract><AbstractText>A key aim of Alzheimer disease research is to develop efficient therapies to prevent and/or delay the irreversible progression of cognitive impairments. Early deficits in long-term potentiation (LTP) are associated with the accumulation of amyloid beta in rodent models of the disease; however, less is known about how mGluR-mediated long-term depression (mGluR-LTD) is affected. In this study, we have found that mGluR-LTD is enhanced in the APP<sub>swe</sub> /PS1dE9 mouse at 7 but returns to wild-type levels at 13 months of age. This transient over-activation of mGluR signalling is coupled with impaired LTP and shifts the dynamic range of synapses towards depression. These alterations in synaptic plasticity are associated with an inability to utilize cues in a spatial learning task. The transient dysregulation of plasticity can be prevented by genetic deletion of the MAP kinase-activated protein kinase 2 (MK2), a substrate of p38 MAPK, demonstrating that manipulating the mGluR-p38 MAPK-MK2 cascade at 7 months can prevent the shift in synapse dynamic range. Our work reveals the MK2 cascade as a potential pharmacological target to correct the over-activation of mGluR signalling.</AbstractText><CopyrightInformation>© 2022 The Authors. Aging Cell published by Anatomical Society and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Privitera</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3280-8026</Identifier><AffiliationInfo><Affiliation>Bradford School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Ninewells Hospital, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barts and the London School of Medicine, Queen Mary University of London Malta Campus, Victoria, Malta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogg</LastName><ForeName>Ellen L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Bradford School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Marcia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bradford School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domingos</LastName><ForeName>Luana B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Bradford School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaestel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-4944-4652</Identifier><AffiliationInfo><Affiliation>Institute of Cell Biochemistry, Hannover Medical University, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Jürgen</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5487-0736</Identifier><AffiliationInfo><Affiliation>Bradford School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wall</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>School of Life Sciences, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corrêa</LastName><ForeName>Sonia A L</ForeName><Initials>SAL</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7434-1073</Identifier><AffiliationInfo><Affiliation>Bradford School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>200646/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aging Cell</MedlineTA><NlmUniqueID>101130839</NlmUniqueID><ISSNLinking>1474-9718</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036881" MajorTopicYN="N">Long-Term Synaptic Depression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065853" MajorTopicYN="N">Spatial Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP/PS1 mouse</Keyword><Keyword MajorTopicYN="N">Arc/Arg3.1</Keyword><Keyword MajorTopicYN="N">hippocampus</Keyword><Keyword MajorTopicYN="N">mGluR5 signalling</Keyword><Keyword MajorTopicYN="N">p38 MAPK signalling</Keyword><Keyword MajorTopicYN="N">synaptic plasticity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>10</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36135933</ArticleId><ArticleId IdType="doi">10.1111/acel.13717</ArticleId><ArticleId IdType="pmc">PMC9577942</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Alzheimers Dis. 2017;57(4):1041-1048</Citation><ArticleIdList><ArticleId IdType="pubmed">27662322</ArticleId></ArticleIdList></Reference><Reference><Citation>J Signal Transduct. 2012;2012:649079</Citation><ArticleIdList><ArticleId IdType="pubmed">22792454</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9707-E9716</Citation><ArticleIdList><ArticleId IdType="pubmed">30242133</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2011 Apr;39(7):2503-18</Citation><ArticleIdList><ArticleId IdType="pubmed">21109534</ArticleId></ArticleIdList></Reference><Reference><Citation>eNeuro. 2016 May 24;3(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">27257628</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Pharmacol Transl Sci. 2020 Mar 12;3(2):334-344</Citation><ArticleIdList><ArticleId IdType="pubmed">32296772</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2016 Jul 05;8:160</Citation><ArticleIdList><ArticleId IdType="pubmed">27458370</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2016 May;41:19-24</Citation><ArticleIdList><ArticleId IdType="pubmed">27103515</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2020 Sep;154(6):583-597</Citation><ArticleIdList><ArticleId IdType="pubmed">32180217</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Clin Cancer Res. 2019 Mar 8;38(1):121</Citation><ArticleIdList><ArticleId IdType="pubmed">30850014</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8631-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24912177</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2018 Jun 27;98(6):1124-1132.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">29861284</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods. 2001 Dec;25(4):402-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 1999 Jun;1(2):94-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10559880</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rep. 2017 Aug;69(4):746-756</Citation><ArticleIdList><ArticleId IdType="pubmed">28582691</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2004 Jan 15;13(2):159-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2008 May 15;586(10):2499-510</Citation><ArticleIdList><ArticleId IdType="pubmed">18356198</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2019 Sep 1;155:121-130</Citation><ArticleIdList><ArticleId IdType="pubmed">31129151</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2000 Nov;3(11):1107-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11036267</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2016 May 31;15(9):1859-65</Citation><ArticleIdList><ArticleId IdType="pubmed">27210751</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2017 Jul;22(7):981-989</Citation><ArticleIdList><ArticleId IdType="pubmed">27777419</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Biochem Sci. 2018 Mar;43(3):170-179</Citation><ArticleIdList><ArticleId IdType="pubmed">29275999</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2019 Nov 1;1722:146357</Citation><ArticleIdList><ArticleId IdType="pubmed">31369731</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2018 Jun 27;98(6):1080-1098</Citation><ArticleIdList><ArticleId IdType="pubmed">29953871</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2013 Dec 02;369(1633):20130288</Citation><ArticleIdList><ArticleId IdType="pubmed">24298167</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2019 Feb;22(2):154-166</Citation><ArticleIdList><ArticleId IdType="pubmed">30664773</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;61(1):195-208</Citation><ArticleIdList><ArticleId IdType="pubmed">29154272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2009 Feb 4;29(5):1525-37</Citation><ArticleIdList><ArticleId IdType="pubmed">19193899</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2010 Jun 10;66(5):739-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Jan 31;493(7434):674-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2011 Jul 06;8:79</Citation><ArticleIdList><ArticleId IdType="pubmed">21733175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Brain. 2018 Apr 10;11(1):19</Citation><ArticleIdList><ArticleId IdType="pubmed">29631635</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2009 Dec;61(4):395-412</Citation><ArticleIdList><ArticleId IdType="pubmed">19926678</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Sep 6;55(5):697-711</Citation><ArticleIdList><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Jul 17;511(7509):348-52</Citation><ArticleIdList><ArticleId IdType="pubmed">24896183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2018 Dec 26;25(13):3647-3660.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">30590039</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2008 Jul 10;59(1):84-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18614031</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Sep 4;79(5):887-902</Citation><ArticleIdList><ArticleId IdType="pubmed">24012003</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 2006 May;95(5):3291-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16452252</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflammopharmacology. 2019 Aug;27(4):663-677</Citation><ArticleIdList><ArticleId IdType="pubmed">30874945</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2014 Aug 19;5:4701</Citation><ArticleIdList><ArticleId IdType="pubmed">25134715</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2013 Sep;16(9):1299-305</Citation><ArticleIdList><ArticleId IdType="pubmed">23933749</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Genet. 2014 Apr 23;5:88</Citation><ArticleIdList><ArticleId IdType="pubmed">24795750</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2013 Dec 3;253:435-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24012839</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Mar 31;24(13):3370-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2009 Dec;6(6):531-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19747158</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2017 Mar 8;93(5):1015-1034</Citation><ArticleIdList><ArticleId IdType="pubmed">28279350</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Cell. 2022 Oct;21(10):e13717</Citation><ArticleIdList><ArticleId IdType="pubmed">36135933</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Jun 18;82(6):1299-316</Citation><ArticleIdList><ArticleId IdType="pubmed">24945773</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2021 Aug;69(8):1852-1881</Citation><ArticleIdList><ArticleId IdType="pubmed">33634529</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36135833</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2076-3271</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>08</Month><Day>31</Day></PubDate></JournalIssue><Title>Medical sciences (Basel, Switzerland)</Title><ISOAbbreviation>Med Sci (Basel)</ISOAbbreviation></Journal><ArticleTitle>Medication-Wide Association Study Plus (MWAS+): A Proof of Concept Study on Drug Repurposing.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">48</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medsci10030048</ELocationID><Abstract><AbstractText>The high cost and time for developing a new drug or repositioning a partially-developed drug has fueled interest in "repurposing" drugs. Drug repurposing is particularly of interest for Alzheimer's disease (AD) or AD-related dementias (ADRD) because there are no unrestricted disease-modifying treatments for ADRD. We have designed and pilot tested a 3-Step Medication-Wide Association Study Plus (MWAS+) approach to rigorously accelerate the identification of drugs with a high potential to be repurposed for delaying and preventing AD/ADRD: Step 1 is a hypothesis-free exploration; Step 2 is mechanistic filtering; And Step 3 is hypothesis testing using observational data and prospective cohort design. Our results demonstrated the feasibility of the MWAS+ approach. The Step 1 analysis identified potential candidate drugs including atorvastatin and GLP1. The literature search in Step 2 found evidence supporting the mechanistic plausibility of the statin-ADRD association. Finally, Step 3 confirmed our hypothesis that statin may lower the risk of incident ADRD, which was statistically significant using a target trial design that emulated randomized controlled trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Research and Leadership, George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Data Science and Outcome Research, Washington DC VA Medical Center, Washington, DC 20422, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamrini</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Research and Leadership, George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Data Science and Outcome Research, Washington DC VA Medical Center, Washington, DC 20422, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Utah Hospital, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Irvine Clinical Research, Irvine, CA 92614, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Ali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6832-6424</Identifier><AffiliationInfo><Affiliation>Department of Clinical Research and Leadership, George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Data Science and Outcome Research, Washington DC VA Medical Center, Washington, DC 20422, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Georgetown University, Washington, DC 20057, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wen-Chih</ForeName><Initials>WC</Initials><Identifier Source="ORCID">0000-0002-2834-2024</Identifier><AffiliationInfo><Affiliation>Providence VA Medical Center, Providence, RI 02908, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Department of Epidemiology, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Yijun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Research and Leadership, George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Data Science and Outcome Research, Washington DC VA Medical Center, Washington, DC 20422, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng-Treitler</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-8353-7473</Identifier><AffiliationInfo><Affiliation>Department of Clinical Research and Leadership, George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Data Science and Outcome Research, Washington DC VA Medical Center, Washington, DC 20422, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG073474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG069121</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Med Sci (Basel)</MedlineTA><NlmUniqueID>101629322</NlmUniqueID><ISSNLinking>2076-3271</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>A0JWA85V8F</RegistryNumber><NameOfSubstance UI="D000069059">Atorvastatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069059" MajorTopicYN="N">Atorvastatin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075082" MajorTopicYN="N">Proof of Concept Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AD</Keyword><Keyword MajorTopicYN="N">ADRD</Keyword><Keyword MajorTopicYN="N">drug repurposing</Keyword><Keyword MajorTopicYN="N">hypothesis generation</Keyword><Keyword MajorTopicYN="N">hypothesis testing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36135833</ArticleId><ArticleId IdType="pii">medsci10030048</ArticleId><ArticleId IdType="doi">10.3390/medsci10030048</ArticleId><ArticleId IdType="pmc">PMC9503040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adv Exp Med Biol. 2017;1031:233-247</Citation><ArticleIdList><ArticleId IdType="pubmed">29214576</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2013 May 7;80(19):1778-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23390181</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Apr 3;348(14):1333-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2019 Feb;44:62-75</Citation><ArticleIdList><ArticleId IdType="pubmed">30795894</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroepidemiology. 2020;54(3):214-226</Citation><ArticleIdList><ArticleId IdType="pubmed">31574510</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2020 Aug 17;12(1):98</Citation><ArticleIdList><ArticleId IdType="pubmed">32807237</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2019 Mar 05;10:103</Citation><ArticleIdList><ArticleId IdType="pubmed">30890971</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Methods Psychiatr Res. 2018 Jun;27(2):e1608</Citation><ArticleIdList><ArticleId IdType="pubmed">29484742</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2016 Apr 15;183(8):758-64</Citation><ArticleIdList><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Regen Res. 2018 Feb;13(2):198-206</Citation><ArticleIdList><ArticleId IdType="pubmed">29557360</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Prev Cardiol. 2022 May 5;29(5):804-814</Citation><ArticleIdList><ArticleId IdType="pubmed">34871380</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2021 Jun 29;77(25):3145-3156</Citation><ArticleIdList><ArticleId IdType="pubmed">34167639</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2020 Sep 8;95(10):e1322-e1332</Citation><ArticleIdList><ArticleId IdType="pubmed">32753444</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutrients. 2016 Dec 20;8(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">27999412</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2011 Aug 9;77(6):556-63</Citation><ArticleIdList><ArticleId IdType="pubmed">21795660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2021 Jul 27;11(1):15280</Citation><ArticleIdList><ArticleId IdType="pubmed">34315986</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 2018 Dec;158:359-375</Citation><ArticleIdList><ArticleId IdType="pubmed">30273553</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2021 Sep;17(9):580-589</Citation><ArticleIdList><ArticleId IdType="pubmed">34239130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1951 Oct 27;2(6687):755-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14874500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2020 Dec;16(12):661-673</Citation><ArticleIdList><ArticleId IdType="pubmed">32939050</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2019 Jul 09;5:272-293</Citation><ArticleIdList><ArticleId IdType="pubmed">31334330</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36134890</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1293</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>HIV medicine</Title><ISOAbbreviation>HIV Med</ISOAbbreviation></Journal><ArticleTitle>Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infection.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/hiv.13411</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">CD4/CD8 ratio is a marker of immune activation in HIV infection and has been associated with neurocognitive performance during chronic infection, but little is known about the early phases. The aim of this study was to examine the relationship between blood CD4/CD8 ratio and central nervous system endpoints in primary HIV infection (PHI) before and after antiretroviral treatment (ART).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective analysis of the Primary Infection Stage CNS Events Study (PISCES) cohort. We longitudinally assessed blood and cerebrospinal fluid (CSF) markers of inflammation, immune activation and neuronal injury, and neuropsychological testing performance (NPZ4, an average of three motor and one processing speed tests, and a summarized total score, NPZ11, including also executive function, learning and memory) in ART-naïve participants enrolled during PHI. Spearman correlation and linear mixed models assessed the relationships between the trajectory of CD4/CD8 ratio over time and neurocognitive performance, blood and CSF markers of immune activation and neuronal injury.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In all, 109 PHI participants were enrolled. The mean CD4/CD8 ratio decreased with longer time from infection to starting treatment (p &lt; 0.001). Every unit increase in NPZ4 score was independently associated with a 0.15 increase in CD4/CD8 ratio (95% CI: 0.002-0.29; p = 0.047), whereas no correlation was found between CD4/CD8 ratio and NPZ11. Among the cognitive domains, only a change in processing speed was correlated with CD4/CD8 ratio over time (p = 0.03). The trajectory of the CD4/CD8 ratio was negatively correlated with change in CSF neurofilament light chain (p = 0.04).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The trajectory of CD4/CD8 ratio was independently associated with motor/psychomotor speed performance, suggesting that immune activation is involved in brain injury during the early stages of the infection.</AbstractText><CopyrightInformation>© 2022 British HIV Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Leah T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, Yale University New Haven, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco School of Medicine, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gisslén</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases at Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Region Västra Götaland, Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry at Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emu</LastName><ForeName>Brinda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Pathology, Yale School of Medicine, Yale University New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabre</LastName><ForeName>Roxane</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Public Health, Nice University Hospital, Université Côte d'Azur, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christian</LastName><ForeName>Pradier</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Public Health, Nice University Hospital, Université Côte d'Azur, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Signe</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Nice University Hospital, Université Côte d'Azur, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spudich</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, Yale University New Haven, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center foor Neuroepidemiology and Clinical Neurological Research, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassallo</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Infectious Diseases, Cannes General Hospital, Cannes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unité de Recherche Clinique Cote d'Azur (UR2CA), URRIS, Centre Hospitalier Universitaire Pasteur 2, Nice, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>ad strategic fund and the alzheimer association</Agency><Country/></Grant><Grant><Agency>Alzheimer's Drug Discovery Foundation</Agency><Country/></Grant><Grant><Agency>erling-persson familiy foundation</Agency><Country/></Grant><Grant><Agency>european union joint programme</Agency><Country/></Grant><Grant><Agency>european union's horizon 2020 research and innovation programme</Agency><Country/></Grant><Grant><Agency>national institue of health</Agency><Country/></Grant><Grant><Agency>olav thon foundation</Agency><Country/></Grant><Grant><GrantID>UKDRI-1003</GrantID><Agency>UK Dementia Research Institute at UCL</Agency><Country/></Grant><Grant><GrantID>JPND2021-00694</GrantID><Agency>European Union Joint Programme-Neurodegenerative Disease Research</Agency><Country/></Grant><Grant><GrantID>(#201809-2016862</GrantID><Agency>Alzheimer Drug Discovery Foundation</Agency><Country/></Grant><Grant><GrantID>(#2018-02532</GrantID><Agency>Swedish Research Council</Agency><Country/></Grant><Grant><GrantID>M01 RR0008336</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI071713</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH074466</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH081772</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>#ADSF-21-831377-C</GrantID><Acronym>ALZ</Acronym><Agency>Alzheimer's Association</Agency><Country>United States</Country></Grant><Grant><GrantID>#ADSF-21-831381-C</GrantID><Acronym>ALZ</Acronym><Agency>Alzheimer's Association</Agency><Country>United States</Country></Grant><Grant><GrantID>(#ADSF-21-831376-C</GrantID><Acronym>ALZ</Acronym><Agency>Alzheimer's Association</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR0008336</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI071713</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH074466</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH081772</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>HIV Med</MedlineTA><NlmUniqueID>100897392</NlmUniqueID><ISSNLinking>1464-2662</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD4/CD8 ratio</Keyword><Keyword MajorTopicYN="N">HIV-associated neurocognitive disorders</Keyword><Keyword MajorTopicYN="N">early HIV infection</Keyword><Keyword MajorTopicYN="N">immune activation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>7</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36134890</ArticleId><ArticleId IdType="doi">10.1111/hiv.13411</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PloS One. 2013;8:e81355.</Citation></Reference><Reference><Citation>van Sighem A, Gras L, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24:1527-1535.</Citation></Reference><Reference><Citation>d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55:320-328.</Citation></Reference><Reference><Citation>Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63:213-221.</Citation></Reference><Reference><Citation>Lescure F-X, Omland LH, Engsig FN, et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis. 2011;52:235-243.</Citation></Reference><Reference><Citation>Vassallo M, Durant J, Biscay V, et al. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIVassociated neurocognitive disorders? Aids. 2014;28:493-501.</Citation></Reference><Reference><Citation>Sadek JR, Vigil O, Grant I, Heaton RK, group H. The impact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. J Clin Exp Neuropsychol. 2007;29:266-276.</Citation></Reference><Reference><Citation>Heaton R, Clifford D, Franklin D, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER study. Neurology. 2010;75:2087-2096.</Citation></Reference><Reference><Citation>Ances BM, Vaida F, Yeh MJ, et al. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis. 2010;201:336-340.</Citation></Reference><Reference><Citation>Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIVassociated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10:317-331.</Citation></Reference><Reference><Citation>Hinkin C, Castellon S, Durvasula R, et al. Medication adherence among HIV+ adults effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59:1944-1950.</Citation></Reference><Reference><Citation>Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25:1747-1751.</Citation></Reference><Reference><Citation>Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses. 2008;24:1301-1307.</Citation></Reference><Reference><Citation>Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265-273.</Citation></Reference><Reference><Citation>Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. Aids. 2007;21:1915-1921.</Citation></Reference><Reference><Citation>Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS. 2013;27:1387-1395.</Citation></Reference><Reference><Citation>Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology. 1991;41:69-74.</Citation></Reference><Reference><Citation>Edén A, Marcotte TD, Heaton RK, et al. Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PloS One. 2016;11:e0157160.</Citation></Reference><Reference><Citation>Jan Jessen Krut JJ, Mellberg T, Price RW, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014;9:e88591.</Citation></Reference><Reference><Citation>Gisslén M, Price RW, Andreasson U, et al. Plasma concentration of the Neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135-140.</Citation></Reference><Reference><Citation>Fuchs D, Chiodi F, Albert J, et al. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. Aids. 1989;3:285-288.</Citation></Reference><Reference><Citation>Sprent J. Fundamental Immunology: T Lymphocytes and the Thymus. Raven Press; 1989.</Citation></Reference><Reference><Citation>Sainz T, Serrano-Villar S, Díaz L, et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIVinfected children and young adults. Aids. 2013;27:1513-1516.</Citation></Reference><Reference><Citation>Buggert M, Frederiksen J, Noyan K, et al. Multiparametric bioinformatics distinguish the CD4/CD8 ratio as a suitable laboratory predictor of combined T cell pathogenesis in HIV infection. J Immunol. 2014;192:2099-2108.</Citation></Reference><Reference><Citation>Serrano-Villar S, Moreno S, Fuentes-Ferrer M, et al. The CD4: CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med. 2014;15:40-49.</Citation></Reference><Reference><Citation>Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120-1126.</Citation></Reference><Reference><Citation>Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10:e1004078.</Citation></Reference><Reference><Citation>Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco general hospital cohort. Br Med J (Clin Res Ed). 1988;296:745-750.</Citation></Reference><Reference><Citation>Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262-270.</Citation></Reference><Reference><Citation>Deeks SG, Phillips AN. Clinical review: HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:288-292.</Citation></Reference><Reference><Citation>Modrich L, Scherzer R, Zolopa A, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 1999;2010(53):102.</Citation></Reference><Reference><Citation>Mussini C, Lorenzini P, Cozzi-Lepri A, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015;2:e98-e106.</Citation></Reference><Reference><Citation>Grauer OM, Reichelt D, Grüneberg U, et al. Neurocognitive decline in HIV patients is associated with ongoing Tcell activation in the cerebrospinal fluid. Ann Clin Transl Neurol. 2015;2:906-919.</Citation></Reference><Reference><Citation>Rawson T, Dubb S, Pozniak A, et al. Assessing the role of peripheral CD8 T cells in neurocognitive impairment in HIV-infected men who have sex with men: data from the MSM Neurocog study. Int J STD AIDS. 2015;26:128-132.</Citation></Reference><Reference><Citation>Vassallo M, Durant J, Lebrun-Frenay C, et al. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation. HIV Med. 2015;16:431-440.</Citation></Reference><Reference><Citation>Vassallo M, Fabre R, Durant J, et al. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. J Neurovirol. 2017;23:216-225.</Citation></Reference><Reference><Citation>Zetola NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infect Dis Clin North Am. 2007;21:19-48.</Citation></Reference><Reference><Citation>Lindbäck S, Thorstensson R, Karlsson AC, et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Aids. 2000;14:2333-2339.</Citation></Reference><Reference><Citation>Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol. 2008;82:5510-5518.</Citation></Reference><Reference><Citation>Yilmaz A, Blennow K, Hagberg L, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn. 2017;17:761-770.</Citation></Reference><Reference><Citation>Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3-16.</Citation></Reference><Reference><Citation>Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206(2):275-282. Published online 2012 May 2. doi:10.1093/infdis/jis326</Citation></Reference><Reference><Citation>Hellmuth J, Fletcher JL, Valcour V, et al. Neurologic signs and symptoms frequently manifest in acute HIV infection. Neurology. 2016;87:148-154.</Citation></Reference><Reference><Citation>Simioni S, Cavassini M, Annoni J-M, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243-1250.</Citation></Reference><Reference><Citation>Hardy DJ, Hinhn CH. Reaction time performance in adults with HIV/AIDS. J Clin Exp Neuropsychol. 2002;24:912-929.</Citation></Reference><Reference><Citation>Peluso MJ, Meyerhoff DJ, Price RW, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis. 2013;207:1703-1712.</Citation></Reference><Reference><Citation>Gisslén M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr. 1999;21:271-276.</Citation></Reference><Reference><Citation>Sailasuta N, Ross W, Ananworanich J, et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PloS One. 2012;7:e49272.</Citation></Reference><Reference><Citation>Young AC, Yiannoutsos CT, Hegde M, et al. Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. Neurology. 2014;83:1592-1600.</Citation></Reference><Reference><Citation>Wright PW, Vaida FF, Fernández RJ, et al. Cerebral white matter integrity during primary HIV infection. AIDS. 2015;29(4):433-442. doi:10.1097/QAD.0000000000000560 PMID: 25513818.</Citation></Reference><Reference><Citation>Ragin AB, Wu Y, Gao Y, et al. Brain alterations within the first 100 days of HIV infection. Ann Clin Transl Neurol. 2015;2(1):12-21. doi:10.1002/acn3.136 Epub 2014 Dec 18. PMID: 25642430.</Citation></Reference><Reference><Citation>Ragin AB, Du H, Ochs R, et al. Structural brain alterations can be detected early in HIV infection. Neurology. 2012;79(24):2328-2334. doi:10.1212/WNL.0b013e318278b5b4 Epub 2012 Nov 28. PMID: 23197750.</Citation></Reference><Reference><Citation>Fahey J, Giorgi J, Martinez-Maza O, Detels R, Mitsuyasu R, Taylor J. Immune pathogenesis of AIDS and related syndromes. Annales de l'Institut Pasteur/Immunologie. Vol 138. Elsevier; 1987:245-252.</Citation></Reference><Reference><Citation>Bouscarat F, Levacher M, Landman R, et al. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS. 1998;12:1267-1273.</Citation></Reference><Reference><Citation>Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003;17:2015-2023.</Citation></Reference><Reference><Citation>Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.</Citation></Reference><Reference><Citation>Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826.</Citation></Reference><Reference><Citation>Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis. 2005;5:98.</Citation></Reference><Reference><Citation>Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206:275-282.</Citation></Reference><Reference><Citation>Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr. 1999;2008(47):168-173.</Citation></Reference><Reference><Citation>Peluso MJ, Spudich S. Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics. Curr HIV/AIDS Rep. 2014;11:353-362.</Citation></Reference><Reference><Citation>Chu C, Selwyn PA. Albert Einstein College of Medicine, Bronx, New York. Diagnosis and initial Management of Acute HIV infection. Am Fam Physician. 2010;81(10):1239-1244.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36134730</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>We are preventing some dementias now-But how? The Potamkin lecture.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12770</ELocationID><Abstract><AbstractText>Most dementias are untreatable and their prevalence is increasing around the world. However, the incidence of dementia is declining in some countries. We need to find out urgently why and how and apply the lessons promptly and widely. Given the multiplicity and variability of environmental, socioeconomic, and individual risk and protective factors, the approach needs to be comprehensive, customized to work in a particular setting, and cost effective, to justify the needed funding. Stroke, heart disease, and dementia share the same major preventable risk and protective factors and pose risks for each other. Preventing them together might result in efficiencies and economies of scale. Prevention can best occur in existing actionable population health units through established leaders in government, non-governmental organizations, and the community, around a positive message of promoting brain health as the key to health, productivity, and well-being.</AbstractText><CopyrightInformation>© 2022 the Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hachinski</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, Robarts Research Institute and University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dementia Prevention/Brain Health Initiative</CollectiveName><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, Robarts Research Institute and University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>7</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36134730</ArticleId><ArticleId IdType="doi">10.1002/alz.12770</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Liu KY, Howard R. Can we learn lessons from the FDA's approval of aducanumab. Nat Rev Neurol. 2021;17(11):715-722. https://doi.org/10.1038/s41582-021-00557-x. Epub 2021 Sep 17. PMID: 34535787.</Citation></Reference><Reference><Citation>The Economist, Editorial.1976:14</Citation></Reference><Reference><Citation>Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32(9):632-637. https://doi.org/10.1001/archneur.1975.00490510088009. PMID: 1164215</Citation></Reference><Reference><Citation>Hachinski VC, Lassen NA, Marshall J, Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet. 1974;2(7874):207-210. https://doi.org/10.1016/s0140-6736(74)91496-2. PMID: 4135618. DOI: 10.1016/s0140-6736(74)91496-2</Citation></Reference><Reference><Citation>Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology. 1997;49(4):1096-1105. https://doi.org/10.1212/wnl.49.4.1096. PMID: 9339696</Citation></Reference><Reference><Citation>Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013;136:2697-2706</Citation></Reference><Reference><Citation>Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. AnnNeurol. 2018;83(1):74-83.</Citation></Reference><Reference><Citation>Hachinski VC, Bowler JV. Vascular dementia. Neurology. 1993;43(10):2159-2161.</Citation></Reference><Reference><Citation>Hachinski V. Vascular dementia: a radical redefinition. Dementia. 1994;5:130-132. PMID: 8087166 DOI: 10.1159/000106709</Citation></Reference><Reference><Citation>Hachinski V, Iadecola C, Petersen RC, et al. National institute of neurological disorders and stroke-Canadian Stroke Network Vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220-2241</Citation></Reference><Reference><Citation>Ngandu T, Lehtisalo J, Solomon A, et al. A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet 2015;385:2255-2263</Citation></Reference><Reference><Citation>Kivipelto M, Mangialasche F, Snyder HM, et al. World-Wide FINGERS network: a global approach to risk reduction and prevention of dementia. Alzheimers Dement. 2020;16:1078-1094.</Citation></Reference><Reference><Citation>Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J. 2018;39:453-460</Citation></Reference><Reference><Citation>The SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia. JAMA. 2019;321(6):553-561.</Citation></Reference><Reference><Citation>Chen V, Hongyan M, Allen M, et al. Lifetime risks for hypertension by contemporary guidelines in african american and white men and women. JAMA Cardiol. 2019;4(5):455-459. https://doi.org/10.1001/jamacardio.2019.0529</Citation></Reference><Reference><Citation>Hachinski V, Østergaard L. The ambibaric brain: pathophysiological and clinical implications. Stroke. 2021;52(6):e259-e262. Epub 2021 May 4.</Citation></Reference><Reference><Citation>Willie CK, Tzeng YC, Fisher JA, Ainslie PN. Integrative regulation of human brain blood flow. J Physiol. 2014;592(5):841-859. Epub 2014 Jan 6. PMID: 24396059. PMCID: PMC3948549. DOI: 10.1113/jphysiol.2013.268953</Citation></Reference><Reference><Citation>Hachinski V, Oveisgharan S, Romney A K, Shankle W R. Optimizing the Hachinski Ischemic Scale. Arch Neurol. 2012;69(2):169-75. Epub 2011 Oct 10. PMID: 21987392.DOI: 10.1001/archneurol.2011.1698</Citation></Reference><Reference><Citation>Avan A, Hachinski V. Implications of the decreasing incidence of dementia in some countries during 1990-2019: A Global Burden of Disease Study. Alzheimers Dement. 2022 (In press)</Citation></Reference><Reference><Citation>Sposato LA, Kapral MK, Wu J, Gill SS, Hackam DG, Cipriano LE, Hachinski V. Declining incidence of stroke and dementia: coincidence or prevention opportunity? JAMA Neurol. 2015;72:1529-1531</Citation></Reference><Reference><Citation>Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and dementia risk: a systematic review and meta-analysis. Alzheimers Dement. 2018 ;14(11):1416-1426. https://doi.org/10.1016/j.jalz.2018.06.3061. Epub 2018 Aug 31.PMID: 30177276</Citation></Reference><Reference><Citation>Hachinski V. Brain health-curbing stroke, heart disease, and dementia: the 2020 Wartenberg lecture. Neurology. 2021;97(6):273-279. https://doi.org/10.1212/WNL.0000000000012103. Epub 2021 Apr 21. PMID: 33883239 DOI: 10.1212/WNL.0000000000012103</Citation></Reference><Reference><Citation>Hachinski V, Dementia prevention initiative. the comprehensive, customized, cost-effective approach (CCCAP) to prevention of dementia Alzheimers Dement. 2022. https://doi.org/10.1002/alz.12586. Online ahead of print. PMID: 35103397. DOI: 10.1002/alz.12586</Citation></Reference><Reference><Citation>Avan A, Hachinski V, Brain Health Learn, Act Group. Brain Health: Key to health, productivity and wellbeing. Alzheimers Dement. 2021. PMID: 34569702. DOI: 10.1002/alz.12478</Citation></Reference><Reference><Citation>Hardy S, Loehr L, Butler K, et al. Reducing the blood pressure - related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control. J Am Heart Assoc. 2015;4:3002276</Citation></Reference><Reference><Citation>Xie J, Sreenivasan S, Korniss G, Zhang W, Lim C, Szymanski B K. Social consensus through the influence of committed minorities. Phys Rev E Stat Nonlin Soft Matter Phys. 2011;84(1 Pt 1). Epub 2011 Jul 22. PMID: 21867136. DOI: 10.1103/PhysRevE.84.011130</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36134540</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Regional Precuneus Cortical Hyperexcitability in Alzheimer's Disease Patients.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26514</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Neuronal excitation/inhibition (E/I) imbalance is a potential cause of neuronal network malfunctioning in Alzheimer's disease (AD), contributing to cognitive dysfunction. Here, we used a novel approach combining transcranial magnetic stimulation (TMS) and electroencephalography (EEG) to probe cortical excitability in different brain areas known to be directly involved in AD pathology.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed TMS-EEG recordings targeting the left dorsolateral prefrontal cortex (l-DLPFC), the left posterior parietal cortex (l-PPC), and the precuneus (PC) in a large sample of patients with mild-to-moderate AD (n = 65) that were compared with a group of age-matched healthy controls (n = 21).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that patients with AD are characterized by a regional cortical hyperexcitability in the PC and, to some extent, in the frontal lobe, as measured by TMS-evoked potentials. Notably, cortical excitability assessed over the l-PPC was comparable between the 2 groups. Furthermore, we found that the individual level of PC excitability was associated with the level of cognitive impairment, as measured with Mini-Mental State Examination, and with corticospinal fluid levels of Aβ<sub>42</sub> .</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our data provide novel evidence that precuneus cortical hyperexcitability is a key feature of synaptic dysfunction in patients with AD. The current results point to the combined approach of TMS and EEG as a novel promising technique to measure hyperexcitability in patients with AD. This index could represent a useful biomarker to stage disease severity and evaluate response to novel therapies. ANN NEUROL 2022.</AbstractText><CopyrightInformation>© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Casula</LastName><ForeName>Elias P</ForeName><Initials>EP</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5039-973X</Identifier><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, La Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borghi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT), Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maiella</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellicciari</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnì</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mencarelli</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assogna</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Acunto</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Lorenzo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spampinato</LastName><ForeName>Danny A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santarnecchi</LastName><ForeName>Emiliano</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martorana</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Clinic, Department of Systems Medicine, University of Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6155-9439</Identifier><AffiliationInfo><Affiliation>Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Alzheimers Drug Discovery Foundation</Agency><Country/></Grant><Grant><Agency>BeforERC</Agency><Country/></Grant><Grant><Agency>BrightFocus Foundation</Agency><Country/></Grant><Grant><Agency>H2020 European Research Council</Agency><Country/></Grant><Grant><Agency>Italian Ministry of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36134540</ArticleId><ArticleId IdType="doi">10.1002/ana.26514</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Maestú F, de Haan W, Busche MA, DeFelipe J. Neuronal excitation/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology. Ageing Res Rev 2021;69:101372. https://doi.org/10.1016/j.arr.2021.101372.</Citation></Reference><Reference><Citation>Ranasinghe KG, Kudo K, Hinkley L, et al. Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer's disease. Brain 2022;145:744-753. https://doi.org/10.1093/brain/awab442.</Citation></Reference><Reference><Citation>Lam AD, Sarkis RA, Pellerin KR, et al. Association of epileptiform abnormalities and seizures in Alzheimer disease. Neurology 2020;95:e2259-e2270. https://doi.org/10.1212/WNL.0000000000010612.</Citation></Reference><Reference><Citation>Babiloni C, Arakaki X, Azami H, et al. Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel. Alzheimers Dement 2021;17:1528-1553. https://doi.org/10.1002/alz.12311.</Citation></Reference><Reference><Citation>Teipel SJ, Grothe M, Lista S, et al. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med Clin 2013;97:399-424. https://doi.org/10.1016/j.mcna.2012.12.013.</Citation></Reference><Reference><Citation>Davatzikos C, Fan Y, Wu X, et al. Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging. Neurobiol Aging 2008;29:514-523. https://doi.org/10.1016/j.neurobiolaging.2006.11.010.</Citation></Reference><Reference><Citation>Alagona G, Ferri R, Pennisi G, et al. Motor cortex excitability in Alzheimer's disease and in subcortical ischemic vascular dementia. Neurosci Lett 2004;362:95-98. https://doi.org/10.1016/j.neulet.2004.03.006.</Citation></Reference><Reference><Citation>de Carvalho M, de Mendonça A, Miranda PC, et al. Magnetic stimulation in Alzheimer's disease. J Neurol 1997;244:304-307. https://doi.org/10.1007/s004150050091.</Citation></Reference><Reference><Citation>Alagona G, Bella R, Ferri R, et al. Transcranial magnetic stimulation in Alzheimer disease: motor cortex excitability and cognitive severity. Neurosci Lett 2001;314:57-60. https://doi.org/10.1016/S0304-3940(01)02288-1.</Citation></Reference><Reference><Citation>Lazzaro VD, Oliviero A, Pilato F, et al. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:555-559. https://doi.org/10.1136/jnnp.2003.018127.</Citation></Reference><Reference><Citation>Martorana A, Stefani A, Palmieri MG, et al. L-dopa modulates motor cortex excitability in Alzheimer's disease patients. J Neural Transm 2008;115:1313-1319. https://doi.org/10.1007/s00702-008-0082-z.</Citation></Reference><Reference><Citation>Khedr EM, Ahmed MA, Darwish ES, Ali AM. The relationship between motor cortex excitability and severity of Alzheimer's disease: a transcranial magnetic stimulation study. Clin Neurophysiol 2011;41:107-113. https://doi.org/10.1016/j.neucli.2011.03.002.</Citation></Reference><Reference><Citation>Casarotto S, Määttä S, Herukka SK, et al. Transcranial magnetic stimulation-evoked EEG/cortical potentials in physiological and pathological aging. Neuroreport 2011;22:592-597. https://doi.org/10.1097/WNR.0b013e328349433a.</Citation></Reference><Reference><Citation>Ferreri F, Vecchio F, Vollero L, et al. Sensorimotor cortex excitability and connectivity in Alzheimer's disease: a TMS-EEG co-registration study. Hum Brain Mapp 2016;37:2083-2096.</Citation></Reference><Reference><Citation>Bagattini C, Mutanen TP, Fracassi C, et al. Predicting Alzheimer's disease severity by means of TMS-EEG coregistration. Neurobiol Aging 2019;80:38-45.</Citation></Reference><Reference><Citation>Tremblay S, Rogasch NC, Premoli I, et al. Clinical utility and prospective of TMS-EEG. Clin Neurophysiol 2019;130:802-844. https://doi.org/10.1016/j.clinph.2019.01.001.</Citation></Reference><Reference><Citation>Casula EP, Pellicciari MC, Bonnì S, et al. Evidence for interhemispheric imbalance in stroke patients as revealed by combining transcranial magnetic stimulation and electroencephalography. Hum Brain Mapp 2021;42:1343-1358. https://doi.org/10.1002/hbm.25297.</Citation></Reference><Reference><Citation>Koch G, Bonnì S, Pellicciari MC, et al. Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease. Neuroimage 2018;169:302-311.</Citation></Reference><Reference><Citation>Koch G, Motta C, Bonnì S, et al. Effect of rotigotine vs placebo on cognitive functions among patients with mild to moderate Alzheimer disease: a randomized clinical trial. JAMA Netw Open 2020;3:e2010372. https://doi.org/10.1001/jamanetworkopen.2020.10372.</Citation></Reference><Reference><Citation>Martorana A, Koch G. Is dopamine involved in Alzheimer's disease? Front Aging Neurosci 2014;6:252. https://doi.org/10.3389/fnagi.2014.00252.</Citation></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717. https://doi.org/10.1523/JNEUROSCI.2177-05.2005.</Citation></Reference><Reference><Citation>Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci 2018;19:687-700. https://doi.org/10.1038/s41583-018-0067-3.</Citation></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-316. https://doi.org/10.1006/nimg.2002.1208.</Citation></Reference><Reference><Citation>Gili T, Cercignani M, Serra L, et al. Regional brain atrophy and functional disconnection across Alzheimer's disease evolution. J Neurol Neurosurg Psychiatry 2011;82:58-66. https://doi.org/10.1136/jnnp.2009.199935.</Citation></Reference><Reference><Citation>Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature 2016;539:187-196. https://doi.org/10.1038/nature20412.</Citation></Reference><Reference><Citation>Karas G, Scheltens P, Rombouts S, et al. Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology 2007;49:967-976. https://doi.org/10.1007/s00234-007-0269-2.</Citation></Reference><Reference><Citation>Lundstrom BN, Ingvar M, Petersson KM. The role of precuneus and left inferior frontal cortex during source memory episodic retrieval. Neuroimage 2005;27:824-834. https://doi.org/10.1016/j.neuroimage.2005.05.008.</Citation></Reference><Reference><Citation>Bonanni L, Moretti D, Benussi A, et al. Hyperconnectivity in dementia is early and focal and wanes with progression. Cereb Cortex 2021;31:97-105. https://doi.org/10.1093/cercor/bhaa209.</Citation></Reference><Reference><Citation>Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016;12:292-323. https://doi.org/10.1016/j.jalz.2016.02.002.</Citation></Reference><Reference><Citation>Rocchi L, Di Santo A, Brown K, et al. Disentangling EEG responses to TMS due to cortical and peripheral activations. Brain Stimul 2021;14:4-18. https://doi.org/10.1016/j.brs.2020.10.011.</Citation></Reference><Reference><Citation>Rosanova M, Casali A, Bellina V, et al. Natural frequencies of human corticothalamic circuits. J Neurosci 2009;29:7679-7685. https://doi.org/10.1523/JNEUROSCI.0445-09.2009.</Citation></Reference><Reference><Citation>Thielscher A, Antunes A, Saturnino GB. Field modeling for transcranial magnetic stimulation: A useful tool to understand the physiological effects of TMS? 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), 2015;222-225. https://doi.org/10.1109/EMBC.2015.7318340.</Citation></Reference><Reference><Citation>Casula EP, Tieri G, Rocchi L, et al. Feeling of ownership over an embodied avatar's hand brings about fast changes of fronto-parietal cortical dynamics. J Neurosci 2022;42:692-701. https://doi.org/10.1523/JNEUROSCI.0636-21.2021.</Citation></Reference><Reference><Citation>Casula EP, Pellicciari MC, Picazio S, et al. Spike-timing-dependent plasticity in the human dorso-lateral prefrontal cortex. Neuroimage 2016;143:204-213. https://doi.org/10.1016/j.neuroimage.2016.08.060.</Citation></Reference><Reference><Citation>Rogasch NC, Fitzgerald PB. Assessing cortical network properties using TMS-EEG. Hum Brain Mapp 2013;34:1652-1669. https://doi.org/10.1002/hbm.22016.</Citation></Reference><Reference><Citation>Maris E, Oostenveld R. Nonparametric statistical testing of EEG- and MEG-data. J Neurosci Methods 2007;164:177-190. https://doi.org/10.1016/j.jneumeth.2007.03.024.</Citation></Reference><Reference><Citation>Zott B, Simon MM, Hong W, et al. A vicious cycle of β amyloid-dependent neuronal hyperactivation. Science 2019;365:559-565. https://doi.org/10.1126/science.aay0198.</Citation></Reference><Reference><Citation>Busche MA, Chen X, Henning HA, et al. Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci 2012;109:8740-8745. https://doi.org/10.1073/pnas.1206171109.</Citation></Reference><Reference><Citation>Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214:170-197. https://doi.org/10.1002/cne.902140206.</Citation></Reference><Reference><Citation>Machado A, Ferreira D, Grothe MJ, et al. The cholinergic system in subtypes of Alzheimer's disease: an in vivo longitudinal MRI study. Alzheimer's Res Ther 2020;12:51. https://doi.org/10.1186/s13195-020-00620-7.</Citation></Reference><Reference><Citation>Geula C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. Neurology 1998;51:S18-S29. https://doi.org/10.1212/WNL.51.1_Suppl_1.S18.</Citation></Reference><Reference><Citation>George AA, Vieira JM, Xavier-Jackson C, et al. Implications of oligomeric amyloid-Beta (oAβ42) signaling through α7β2-nicotinic acetylcholine receptors (nAChRs) on basal forebrain cholinergic neuronal intrinsic excitability and cognitive decline. J Neurosci 2021;41:555-575. https://doi.org/10.1523/JNEUROSCI.0876-20.2020.</Citation></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology 2011;77:39-47. https://doi.org/10.1212/WNL.0b013e3182231419.</Citation></Reference><Reference><Citation>Niskanen E, Könönen M, Määttä S, et al. New insights into Alzheimer's disease progression: a combined TMS and structural MRI study. PLoS One 2011;6:e26113. https://doi.org/10.1371/journal.pone.0026113.</Citation></Reference><Reference><Citation>Bonnì S, Veniero D, Mastropasqua C, et al. TMS evidence for a selective role of the precuneus in source memory retrieval. Behav Brain Res 2015;282:70-75.</Citation></Reference><Reference><Citation>Mancini M, Mastropasqua C, Bonnì S, et al. Theta burst stimulation of the Precuneus modulates resting state connectivity in the left temporal pole. Brain Topogr 2017;30:312-319. https://doi.org/10.1007/s10548-017-0559-x.</Citation></Reference><Reference><Citation>Koch G, Casula EP, Bonnì S, et al. Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. Brain In press.</Citation></Reference><Reference><Citation>Casula EP, Mayer IMS, Desikan M, et al. Motor cortex synchronization influences the rhythm of motor performance in premanifest huntington's disease. Mov Disord 2018;33:440-448. https://doi.org/10.1002/mds.27285.</Citation></Reference><Reference><Citation>Palmqvist S, Schöll M, Strandberg O, et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 2017;8:1214. https://doi.org/10.1038/s41467-017-01150-x.</Citation></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259. https://doi.org/10.1007/BF00308809.</Citation></Reference><Reference><Citation>Casula EP, Pellicciari MC, Bonnì S, et al. Decreased frontal gamma activity in Alzheimer disease patients. Ann Neurol 2022;92:464-475. https://doi.org/10.1002/ana.26444.</Citation></Reference><Reference><Citation>Nikulin VV, Kičić D, Kähkönen S, Ilmoniemi RJ. Modulation of electroencephalographic responses to transcranial magnetic stimulation: evidence for changes in cortical excitability related to movement. Eur J Neurosci 2003;18:1206-1212. https://doi.org/10.1046/j.1460-9568.2003.02858.x.</Citation></Reference><Reference><Citation>Massimini M, Ferrarelli F, Huber R, et al. Breakdown of cortical effective connectivity during sleep. Science 2005;309:2228-2232. https://doi.org/10.1126/science.1117256.</Citation></Reference><Reference><Citation>Kähkönen S, Komssi S, Wilenius J, Ilmoniemi RJ. Prefrontal transcranial magnetic stimulation produces intensity-dependent EEG responses in humans. Neuroimage 2005;24:955-960. https://doi.org/10.1016/j.neuroimage.2004.09.048.</Citation></Reference><Reference><Citation>Belardinelli P, König F, Liang C, et al. TMS-EEG signatures of glutamatergic neurotransmission in human cortex. Sci Rep 2021;11:8159. https://doi.org/10.1038/s41598-021-87533-z.</Citation></Reference><Reference><Citation>Cash RFH, Noda Y, Zomorrodi R, et al. Characterization of glutamatergic and GABAA-mediated neurotransmission in motor and dorsolateral prefrontal cortex using paired-pulse TMS-EEG. Neuropsychopharmacology 2017;42:502-511. https://doi.org/10.1038/npp.2016.133.</Citation></Reference><Reference><Citation>Noda Y, Zomorrodi R, Cash RFH, et al. Characterization of the influence of age on GABAA and glutamatergic mediated functions in the dorsolateral prefrontal cortex using paired-pulse TMS-EEG. Aging 2017;9:556-567. https://doi.org/10.18632/aging.101178.</Citation></Reference><Reference><Citation>Barr MS, Farzan F, Davis KD, et al. Measuring GABAergic inhibitory activity with TMS-EEG and its potential clinical application for chronic pain. J Neuroimmune Pharmacol 2013;8:535-546. https://doi.org/10.1007/s11481-012-9383-y.</Citation></Reference><Reference><Citation>Premoli I, Rivolta D, Espenhahn S, et al. Characterization of GABAB-receptor mediated neurotransmission in the human cortex by paired-pulse TMS-EEG. Neuroimage 2014;103:152-162. https://doi.org/10.1016/j.neuroimage.2014.09.028.</Citation></Reference><Reference><Citation>Conde V, Tomasevic L, Akopian I, et al. The non-transcranial TMS-evoked potential is an inherent source of ambiguity in TMS-EEG studies. Neuroimage 2019;185:300-312. https://doi.org/10.1016/j.neuroimage.2018.10.052.</Citation></Reference><Reference><Citation>Ye Q, Zou F, Dayan M, et al. Individual susceptibility to TMS affirms the precuneal role in meta-memory upon recollection. Brain Struct Funct 2019;224:2407-2419. https://doi.org/10.1007/s00429-019-01909-6.</Citation></Reference><Reference><Citation>Kraft A, Dyrholm M, Kehrer S, et al. TMS over the right precuneus reduces the bilateral field advantage in visual short term memory capacity. Brain Stimul 2015;8:216-223. https://doi.org/10.1016/j.brs.2014.11.004.</Citation></Reference><Reference><Citation>Hebscher M, Meltzer JA, Gilboa A. A causal role for the precuneus in network-wide theta and gamma oscillatory activity during complex memory retrieval. eLife 2019;8:e43114. https://doi.org/10.7554/eLife.43114.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36133075</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-4365</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in aging neuroscience</Title><ISOAbbreviation>Front Aging Neurosci</ISOAbbreviation></Journal><ArticleTitle>Dementia-related genetic variants in an Italian population of early-onset Alzheimer's disease.</ArticleTitle><Pagination><MedlinePgn>969817</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnagi.2022.969817</ELocationID><Abstract><AbstractText>Early-onset Alzheimer's disease (EOAD) is the most common form of early-onset dementia. Although three major genes have been identified as causative, the genetic contribution to the disease remains unsolved in many patients. Recent studies have identified pathogenic variants in genes representing a risk factor for developing Alzheimer's disease (AD) and in causative genes for other degenerative dementias as responsible for EOAD. To study them further, we investigated a panel of candidate genes in 102 Italian EOAD patients, 45.10% of whom had a positive family history and 21.74% with a strong family history of dementia. We found that 10.78% of patients carried pathogenic or likely pathogenic variants, including a novel variant, in <i>PSEN1</i>, <i>PSEN2</i>, or <i>APP</i>, and 7.84% showed homozygosity for the ε4 <i>APOE</i> allele. Additionally, 7.84% of patients had a moderate risk allele in <i>PSEN1</i>, <i>PSEN2</i>, or <i>TREM2</i> genes. Besides, we observed that 12.75% of our patients carried only a variant in genes associated with other neurodegenerative diseases. The combination of these variants contributes to explain 46% of cases with a definite familiarity and 32% of sporadic forms. Our results confirm the importance of extensive genetic screening in EOAD for clinical purposes, to select patients for future treatments and to contribute to the definition of overlapping pathogenic mechanisms between AD and other forms of dementia.</AbstractText><CopyrightInformation>Copyright © 2022 Bartoletti-Stella, Tarozzi, Mengozzi, Asirelli, Brancaleoni, Mometto, Stanzani-Maserati, Baiardi, Linarello, Spallazzi, Pantieri, Ferriani, Caffarra, Liguori, Parchi and Capellari.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bartoletti-Stella</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarozzi</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mengozzi</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asirelli</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Science and Surgery (DIMEC), University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brancaleoni</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologia e Rete Stroke Metropolitana, Ospedale Maggiore, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mometto</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>UOC Neurologia, Ospedale Guglielmo da Saliceto, Piacenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanzani-Maserati</LastName><ForeName>Michelangelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baiardi</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linarello</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Programma Cure Intermedie - Azienda USL di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spallazzi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>U.O. di Neurologia, Azienda Ospedaliero-Universitaria, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pantieri</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferriani</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UOC Psicologia Clinica Ospedaliera, Ospedale Bellaria, Azienda USL di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caffarra</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unità di Neuroscienze, Università di Parma, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liguori</LastName><ForeName>Rocco</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parchi</LastName><ForeName>Piero</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capellari</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Aging Neurosci</MedlineTA><NlmUniqueID>101525824</NlmUniqueID><ISSNLinking>1663-4365</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">early onset Alzheimer disease</Keyword><Keyword MajorTopicYN="N">genetic heterogeneity</Keyword><Keyword MajorTopicYN="N">mutation screening</Keyword><Keyword MajorTopicYN="N">next generation sequencing</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>3</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36133075</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2022.969817</ArticleId><ArticleId IdType="pmc">PMC9484406</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Neuropathol. 2019 Aug;138(2):201-220</Citation><ArticleIdList><ArticleId IdType="pubmed">30903345</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2004 Nov;61(11):1773-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2016 Sep 02;4(1):98</Citation><ArticleIdList><ArticleId IdType="pubmed">27589997</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2021 Feb 24;11(1):142</Citation><ArticleIdList><ArticleId IdType="pubmed">33627629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2019 Jun;113:141-147</Citation><ArticleIdList><ArticleId IdType="pubmed">30954774</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2019 Nov;138(5):729-749</Citation><ArticleIdList><ArticleId IdType="pubmed">31392412</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Med. 2015 May;17(5):405-24</Citation><ArticleIdList><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2012 Jan;69(1):59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">21911656</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2016 Feb 25;4:17</Citation><ArticleIdList><ArticleId IdType="pubmed">26916334</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2018 Jun;66:179.e17-179.e29</Citation><ArticleIdList><ArticleId IdType="pubmed">29544907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2009 Jul 15;25(14):1754-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2019 Jun 10;9(1):8368</Citation><ArticleIdList><ArticleId IdType="pubmed">31182772</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2019 Mar 1;2(3):e191350</Citation><ArticleIdList><ArticleId IdType="pubmed">30924900</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Dec 13;65(11):1817-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16344531</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2019;71(1):227-243</Citation><ArticleIdList><ArticleId IdType="pubmed">31381512</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;66(2):551-563</Citation><ArticleIdList><ArticleId IdType="pubmed">30320576</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2018 Dec 26;20(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">30587772</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2018 Jun;66:180.e23-180.e31</Citation><ArticleIdList><ArticleId IdType="pubmed">29525180</ArticleId></ArticleIdList></Reference><Reference><Citation>Continuum (Minneap Minn). 2019 Feb;25(1):34-51</Citation><ArticleIdList><ArticleId IdType="pubmed">30707186</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neurol Neurosci Rep. 2021 Jan 19;21(2):4</Citation><ArticleIdList><ArticleId IdType="pubmed">33464407</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1994 May;7(1):74-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8075646</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Res. 2010 Sep;20(9):1297-303</Citation><ArticleIdList><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2014 Aug 1;30(15):2114-20</Citation><ArticleIdList><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 May;581(7809):434-443</Citation><ArticleIdList><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2021 Jan;97:145.e7-145.e15</Citation><ArticleIdList><ArticleId IdType="pubmed">32507413</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1997 Jan;48(1):139-47</Citation><ArticleIdList><ArticleId IdType="pubmed">9008509</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2019 Aug;138(2):171-172</Citation><ArticleIdList><ArticleId IdType="pubmed">31300866</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1999 Sep;65(3):664-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10441572</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2017 Aug;25(8):973-981</Citation><ArticleIdList><ArticleId IdType="pubmed">28537274</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2019;67(1):243-256</Citation><ArticleIdList><ArticleId IdType="pubmed">30530974</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2021 Sep;53(9):1276-1282</Citation><ArticleIdList><ArticleId IdType="pubmed">34493870</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2021 Aug 17;144(7):2186-2198</Citation><ArticleIdList><ArticleId IdType="pubmed">33693619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2018 Dec 20;13(1):66</Citation><ArticleIdList><ArticleId IdType="pubmed">30572908</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2016 Apr 21;12(4):e1004873</Citation><ArticleIdList><ArticleId IdType="pubmed">27100738</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2017 Sep;134(3):475-487</Citation><ArticleIdList><ArticleId IdType="pubmed">28447221</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2014 Jun;13(6):614-29</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2020 Apr;61:40-48</Citation><ArticleIdList><ArticleId IdType="pubmed">31863938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1991 May 11;337(8750):1158-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1674030</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (Amst). 2021 Feb 20;13(1):e12155</Citation><ArticleIdList><ArticleId IdType="pubmed">33665345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2015 Oct 2;290(40):24152-65</Citation><ArticleIdList><ArticleId IdType="pubmed">26260791</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Mol Case Stud. 2019 Dec 13;5(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">31836585</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Interv Aging. 2015 Jul 14;10:1163-72</Citation><ArticleIdList><ArticleId IdType="pubmed">26203236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2012 Sep;33(9):1340-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1996 Sep 1;24(17):3439-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8811101</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2016 Jun;12(6):733-48</Citation><ArticleIdList><ArticleId IdType="pubmed">27016693</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2011 Sep;16(9):903-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2020 Jan;85:155.e5-155.e8</Citation><ArticleIdList><ArticleId IdType="pubmed">31217084</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2014 Apr;11(4):361-2</Citation><ArticleIdList><ArticleId IdType="pubmed">24681721</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2014 Mar;46(3):310-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2019 Mar;51(3):414-430</Citation><ArticleIdList><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2018 Aug;15(8):591-594</Citation><ArticleIdList><ArticleId IdType="pubmed">30013048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2003 Jun;21(6):577-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12754702</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2022 Apr;21(4):329-341</Citation><ArticleIdList><ArticleId IdType="pubmed">35305339</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2016 Jun 7;86(23):2134-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27037229</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2010 May;31(5):725-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18667258</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):168-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20</Citation><ArticleIdList><ArticleId IdType="pubmed">23315928</ArticleId></ArticleIdList></Reference><Reference><Citation>NPJ Genom Med. 2021 Sep 28;6(1):80</Citation><ArticleIdList><ArticleId IdType="pubmed">34584092</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2020 Sep;93:69-77</Citation><ArticleIdList><ArticleId IdType="pubmed">32464432</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2006 Sep;63(9):1307-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16966510</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067</Citation><ArticleIdList><ArticleId IdType="pubmed">29165669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2022 Jan 9;17(1):3</Citation><ArticleIdList><ArticleId IdType="pubmed">35000612</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2016 Dec;48(12):1581-1586</Citation><ArticleIdList><ArticleId IdType="pubmed">27776117</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Genomics. 2022 Feb 10;15(1):26</Citation><ArticleIdList><ArticleId IdType="pubmed">35144616</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2017 Nov;59:220.e1-220.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">28789839</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36131689</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1674-8301</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of biomedical research</Title><ISOAbbreviation>J Biomed Res</ISOAbbreviation></Journal><ArticleTitle>Tracers progress for positron emission tomography imaging of glial-related disease.</ArticleTitle><Pagination><MedlinePgn>321-335</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7555/JBR.36.20220017</ELocationID><Abstract><AbstractText>Glial cells play an essential part in the neuron system. They can not only serve as structural blocks in the human brain but also participate in many biological processes. Extensive studies have shown that astrocytes and microglia play an important role in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, as well as glioma, epilepsy, ischemic stroke, and infections. Positron emission tomography is a functional imaging technique providing molecular-level information before anatomic changes are visible and has been widely used in many above-mentioned diseases. In this review, we focus on the positron emission tomography tracers used in pathologies related to glial cells, such as glioma, Alzheimer's disease, and neuroinflammation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Haoran</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Radiation Medicine, Fudan University, Shanghai 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tianwu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Radiation Medicine, Fudan University, Shanghai 200032, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Biomed Res</MedlineTA><NlmUniqueID>101551157</NlmUniqueID><ISSNLinking>1674-8301</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">glia</Keyword><Keyword MajorTopicYN="N">glioma</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">positron emission tomography tracer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36131689</ArticleId><ArticleId IdType="doi">10.7555/JBR.36.20220017</ArticleId><ArticleId IdType="pmc">PMC9548440</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2082-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17763978</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2017 Jun;58(6):975-981</Citation><ArticleIdList><ArticleId IdType="pubmed">28232614</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Radiol. 2011 Dec;84 Spec No 2:S90-106</Citation><ArticleIdList><ArticleId IdType="pubmed">22433833</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):593-601</Citation><ArticleIdList><ArticleId IdType="pubmed">29282517</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):503-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25351507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2022 Aug;63(8):1252-1258</Citation><ArticleIdList><ArticleId IdType="pubmed">35027372</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem. 2004 Jan 15;12(2):423-38</Citation><ArticleIdList><ArticleId IdType="pubmed">14723961</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Regen Res. 2021 Dec;16(12):2494-2498</Citation><ArticleIdList><ArticleId IdType="pubmed">33907039</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2003 May 13;60(9):1495-500</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2016 Aug 30;87(9):920-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27473132</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2178-2189</Citation><ArticleIdList><ArticleId IdType="pubmed">31264169</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2188-93</Citation><ArticleIdList><ArticleId IdType="pubmed">20544193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Endocrinol. 2005 Feb;19(2):540-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15498831</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Radiat Isot. 2021 Dec;178:109954</Citation><ArticleIdList><ArticleId IdType="pubmed">34607293</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2009 Jun;50(6):982-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19443600</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2006 Mar;47(3):393-403</Citation><ArticleIdList><ArticleId IdType="pubmed">16513607</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine (Baltimore). 2018 Jul;97(29):e11556</Citation><ArticleIdList><ArticleId IdType="pubmed">30024551</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2013 Apr 25;56(8):3429-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23521048</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2010 Oct;51(10):1532-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20847166</ArticleId></ArticleIdList></Reference><Reference><Citation>Invest Radiol. 2010 Dec;45(12):755-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20829706</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 1992 Apr;33(4):532-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1552337</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2001 Aug;42(8):1243-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11483687</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11926379</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2013 Nov;9(6):666-76</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2007 Apr;48(4):573-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17401094</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Sep 18;79(6):1094-108</Citation><ArticleIdList><ArticleId IdType="pubmed">24050400</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Cancer. 2019 Aug 5;19(1):767</Citation><ArticleIdList><ArticleId IdType="pubmed">31382920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Imaging. 2018 Jan-Dec;17:1536012118792317</Citation><ArticleIdList><ArticleId IdType="pubmed">30203712</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2265-2275</Citation><ArticleIdList><ArticleId IdType="pubmed">35157105</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Esp Med Nucl Imagen Mol. 2017 Jul - Aug;36(4):227-232</Citation><ArticleIdList><ArticleId IdType="pubmed">28219644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2005 Feb;57(2):168-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15668962</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):394-402</Citation><ArticleIdList><ArticleId IdType="pubmed">23208700</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Radiol. 2011 Dec;84 Spec No 2:S107-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22433821</ArticleId></ArticleIdList></Reference><Reference><Citation>AJR Am J Roentgenol. 2008 Jun;190(6):W365-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18492879</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2077-2089</Citation><ArticleIdList><ArticleId IdType="pubmed">31254035</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomedicines. 2021 Jul 13;9(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">34356874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Nucl Med. 2016 Nov;30(9):608-618</Citation><ArticleIdList><ArticleId IdType="pubmed">27418267</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2006 Jun;110(3):503-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16337685</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Oncol. 2016 Sep;18(9):1199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">27106405</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2018 Dec;59(12):1869-1876</Citation><ArticleIdList><ArticleId IdType="pubmed">29728519</ArticleId></ArticleIdList></Reference><Reference><Citation>EJNMMI Res. 2012 Apr 23;2:15</Citation><ArticleIdList><ArticleId IdType="pubmed">22524272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2013;33 Suppl 1:S67-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22531422</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2009 Mar;108(5):1177-86</Citation><ArticleIdList><ArticleId IdType="pubmed">19141073</ArticleId></ArticleIdList></Reference><Reference><Citation>EJNMMI Res. 2016 Dec;6(1):72</Citation><ArticleIdList><ArticleId IdType="pubmed">27678494</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Neuroimmunol Neuroinflamm. 2021 Apr 1;8(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">33795375</ArticleId></ArticleIdList></Reference><Reference><Citation>EBioMedicine. 2021 Sep;71:103571</Citation><ArticleIdList><ArticleId IdType="pubmed">34530385</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):268-281</Citation><ArticleIdList><ArticleId IdType="pubmed">30245918</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1049-58</Citation><ArticleIdList><ArticleId IdType="pubmed">21570201</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosurg. 2003 Sep;99(3):474-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12959432</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Neuroanat. 2018 Nov;93:2-15</Citation><ArticleIdList><ArticleId IdType="pubmed">28873338</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2005 Oct;23(4):344-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16226499</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2233-2236</Citation><ArticleIdList><ArticleId IdType="pubmed">32088848</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucl Med Biol. 2008 Feb;35(2):171-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18312826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2010 Sep;68(3):319-29</Citation><ArticleIdList><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2019 Sep 27;10:1114</Citation><ArticleIdList><ArticleId IdType="pubmed">31611796</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):283-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24072346</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 May 2;32(18):6391-410</Citation><ArticleIdList><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nucl Med. 2015 Sep;40(9):e429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">26204212</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Res. 2014 Feb;79:1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24144733</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2020 Feb 21;25(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">32098280</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hybrid Imaging. 2021 Apr 13;5(1):7</Citation><ArticleIdList><ArticleId IdType="pubmed">34181107</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):422-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15650870</ArticleId></ArticleIdList></Reference><Reference><Citation>EJNMMI Res. 2017 Oct 16;7(1):84</Citation><ArticleIdList><ArticleId IdType="pubmed">29038960</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hybrid Imaging. 2021 Aug 18;5(1):15</Citation><ArticleIdList><ArticleId IdType="pubmed">34405282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2001 Aug 11;358(9280):461-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11513911</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2017 Feb;58(2):320-325</Citation><ArticleIdList><ArticleId IdType="pubmed">27856631</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cancer. 2008 Jun;8(6):425-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18500244</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun Health. 2021 Aug 24;17:100336</Citation><ArticleIdList><ArticleId IdType="pubmed">34589819</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1859-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19495746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comput Assist Tomogr. 2011 Nov-Dec;35(6):679-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22082535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2016 May;57(5):785-91</Citation><ArticleIdList><ArticleId IdType="pubmed">26823567</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2008 Oct;29(10):1456-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2021 Sep 24;13:737002</Citation><ArticleIdList><ArticleId IdType="pubmed">34630070</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1850-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26062933</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2020 Dec 08;25(24):</Citation><ArticleIdList><ArticleId IdType="pubmed">33302541</ArticleId></ArticleIdList></Reference><Reference><Citation>EClinicalMedicine. 2021 Jun 23;37:100982</Citation><ArticleIdList><ArticleId IdType="pubmed">34195586</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2014;32:367-402</Citation><ArticleIdList><ArticleId IdType="pubmed">24471431</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2016 Oct 15;22(20):5079-5086</Citation><ArticleIdList><ArticleId IdType="pubmed">27185374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Perspect Biol. 2017 May 1;9(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">27940517</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nucl Med. 2012 Sep;37(9):854-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22889774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2020 Aug;61(8):1107-1112</Citation><ArticleIdList><ArticleId IdType="pubmed">32620705</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiology. 2015 Nov;277(2):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">25965900</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vasc Surg. 2012 Sep;56(3):765-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22726755</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Feb 15;49(4):2924-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19948230</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 1989 Feb 28;161(2-3):197-202</Citation><ArticleIdList><ArticleId IdType="pubmed">2542045</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Carcinog. 2017 Nov;56(11):2355-2371</Citation><ArticleIdList><ArticleId IdType="pubmed">28618012</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2010 Aug;114(3):784-94</Citation><ArticleIdList><ArticleId IdType="pubmed">20477945</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Ther. 2017 Jul;6(Suppl 1):5-13</Citation><ArticleIdList><ArticleId IdType="pubmed">28733961</ArticleId></ArticleIdList></Reference><Reference><Citation>Reprod Toxicol. 2003 Jul-Aug;17(4):365-75</Citation><ArticleIdList><ArticleId IdType="pubmed">12849846</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2017 Feb 23;60(4):1272-1291</Citation><ArticleIdList><ArticleId IdType="pubmed">28106992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Dec 18;159(7):1603-14</Citation><ArticleIdList><ArticleId IdType="pubmed">25525878</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2021 May;141(5):697-708</Citation><ArticleIdList><ArticleId IdType="pubmed">33723967</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):146-163</Citation><ArticleIdList><ArticleId IdType="pubmed">33433698</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2011 Jan;58(1):60-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21075154</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2013 Aug;54(8):1420-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23857514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Imaging Biol. 2008 Jan-Feb;10(1):1-18</Citation><ArticleIdList><ArticleId IdType="pubmed">17957408</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2009 Aug;50(8):1276-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19617321</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2014 Oct 15;5(10):963-71</Citation><ArticleIdList><ArticleId IdType="pubmed">25123416</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2017 Feb 13;11:24</Citation><ArticleIdList><ArticleId IdType="pubmed">28243193</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2012 Mar;53(3):415-24</Citation><ArticleIdList><ArticleId IdType="pubmed">22323782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2016 Jan;79(1):110-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2020 Apr;61(4):604-607</Citation><ArticleIdList><ArticleId IdType="pubmed">31562223</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Transl Neurol. 2015 Feb;2(2):131-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25750918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2020 Apr;61(4):498-504</Citation><ArticleIdList><ArticleId IdType="pubmed">31541032</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Dec 21;355(25):2652-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2016 Oct;139 Suppl 2:136-153</Citation><ArticleIdList><ArticleId IdType="pubmed">26990767</ArticleId></ArticleIdList></Reference><Reference><Citation>EJNMMI Phys. 2021 Apr 29;8(1):39</Citation><ArticleIdList><ArticleId IdType="pubmed">33914185</ArticleId></ArticleIdList></Reference><Reference><Citation>Q J Nucl Med Mol Imaging. 2015 Mar;59(1):70-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25517079</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 1987 Jun;28(6):1037-40</Citation><ArticleIdList><ArticleId IdType="pubmed">3585494</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2010 Nov;133(11):3336-48</Citation><ArticleIdList><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>EJNMMI Res. 2018 Jul 25;8(1):67</Citation><ArticleIdList><ArticleId IdType="pubmed">30046944</ArticleId></ArticleIdList></Reference><Reference><Citation>AJNR Am J Neuroradiol. 2008 Jun;29(6):1176-82</Citation><ArticleIdList><ArticleId IdType="pubmed">18388218</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2013 Aug;126(3):305-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23406382</ArticleId></ArticleIdList></Reference><Reference><Citation>J Magn Reson Imaging. 2017 Nov;46(5):1247-1262</Citation><ArticleIdList><ArticleId IdType="pubmed">28370695</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioconjug Chem. 2017 Apr 19;28(4):1016-1023</Citation><ArticleIdList><ArticleId IdType="pubmed">28156095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2009 Apr;109(2):623-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19226369</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2017 May;13(5):279-289</Citation><ArticleIdList><ArticleId IdType="pubmed">28387340</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2016 May 26;59(10):4778-89</Citation><ArticleIdList><ArticleId IdType="pubmed">27088900</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Sens. 2021 Sep 24;6(9):3424-3435</Citation><ArticleIdList><ArticleId IdType="pubmed">34415143</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):420-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16404596</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2012;29(2):319-27</Citation><ArticleIdList><ArticleId IdType="pubmed">22233766</ArticleId></ArticleIdList></Reference><Reference><Citation>Asia Ocean J Nucl Med Biol. 2017 Winter;5(1):10-21</Citation><ArticleIdList><ArticleId IdType="pubmed">28840134</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):584-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15545326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2015 Jan 28;356(2 Pt A):211-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24569091</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nucl Med. 2020 Oct;45(10):747-756</Citation><ArticleIdList><ArticleId IdType="pubmed">32701794</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem. 2005 Nov 15;13(22):6188-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16039131</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Apr 23;9(4):e95830</Citation><ArticleIdList><ArticleId IdType="pubmed">24759867</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1561-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14579097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Nucl Med. 2021 Dec;35(12):1279-1292</Citation><ArticleIdList><ArticleId IdType="pubmed">34406623</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 1991 Jul;11(4):545-56</Citation><ArticleIdList><ArticleId IdType="pubmed">1904879</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucl Med Biol. 2022 May-Jun;108-109:76-84</Citation><ArticleIdList><ArticleId IdType="pubmed">35349913</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2019 Jan;60(1):93-99</Citation><ArticleIdList><ArticleId IdType="pubmed">29777006</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2016 Feb;57(2):208-14</Citation><ArticleIdList><ArticleId IdType="pubmed">26541774</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Oncol. 2014 Mar;16(3):434-40</Citation><ArticleIdList><ArticleId IdType="pubmed">24305717</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Nov 23;25(47):10857-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16306398</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1998 Nov;4(11):1334-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9809561</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Imaging Biol. 2012 Feb;14(1):88-95</Citation><ArticleIdList><ArticleId IdType="pubmed">21400112</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2016 Jun;131(6):803-20</Citation><ArticleIdList><ArticleId IdType="pubmed">27157931</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2022 Jan 15;28(2):327-337</Citation><ArticleIdList><ArticleId IdType="pubmed">34615724</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2006 Nov;5(11):937-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17052661</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuroradiol. 2022 Sep;32(3):735-747</Citation><ArticleIdList><ArticleId IdType="pubmed">35147721</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2021 Jun 22;144(5):1565-1575</Citation><ArticleIdList><ArticleId IdType="pubmed">33824991</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22008728</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucl Med Commun. 2010 Nov;31(11):931-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20827227</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2008 Jan 10;51(1):17-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18067245</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2013 Jun;54(6):880-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23575995</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancers (Basel). 2012 Mar 01;4(1):244-56</Citation><ArticleIdList><ArticleId IdType="pubmed">24213238</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Sci. 2016 Jun 10;88:124-31</Citation><ArticleIdList><ArticleId IdType="pubmed">27094781</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2018 Feb;33(2):273-281</Citation><ArticleIdList><ArticleId IdType="pubmed">29278274</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):615-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23232505</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2009 Sep 8;73(10):754-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19587325</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2011 Apr;134(Pt 4):1089-100</Citation><ArticleIdList><ArticleId IdType="pubmed">21436112</ArticleId></ArticleIdList></Reference><Reference><Citation>Life (Basel). 2021 May 26;11(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">34073557</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosurg Rev. 2019 Jun;42(2):185-195</Citation><ArticleIdList><ArticleId IdType="pubmed">28918564</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2004 Mar;55(3):306-19</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomolecules. 2016 Jan 06;6(1):7</Citation><ArticleIdList><ArticleId IdType="pubmed">26751494</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2014 Sep;62(9):1377-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24807023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36131624</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1475-6374</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of enzyme inhibition and medicinal chemistry</Title><ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation></Journal><ArticleTitle>Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities.</ArticleTitle><Pagination><MedlinePgn>2605-2620</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2122054</ELocationID><Abstract><AbstractText>Twenty-four novel compounds bearing tetrahydroacridine and <i>N</i>-propargyl moieties have been designed, synthesised, and evaluated <i>in vitro</i> for their anti-cholinesterase and anti-monoamine oxidase activities. Propargyltacrine <b>23</b> (IC<sub>50</sub> = 21 nM) was the most potent acetylcholinesterase (AChE) inhibitor, compound <b>20</b> (IC<sub>50</sub> = 78 nM) showed the best inhibitory human butyrylcholinesterase (<i>h</i>BChE) profile, and ligand <b>21</b> afforded equipotent and significant values on both ChEs (human AChE [<i>h</i>AChE]: IC<sub>50</sub> = 0.095 ± 0.001 µM; <i>h</i>BChE: IC<sub>50</sub> = 0.093 ± 0.003 µM). Regarding MAO inhibition, compounds <b>7</b>, <b>15</b>, and <b>25</b> demonstrated the highest inhibitory potential towards <i>h</i>MAO-B (IC<sub>50</sub> = 163, 40, and 170 nM, respectively). In all, compounds <b>7</b>, <b>15</b>, <b>20</b>, <b>21</b>, <b>23</b>, and <b>25</b> exhibiting the most balanced pharmacological profile, were submitted to permeability and cell viability tests. As a result, 7-phenoxy-<i>N</i>-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroacridin-9-amine hydrochloride (<b>15</b>) has been identified as a permeable agent that shows a balanced pharmacological profile [IC<sub>50</sub> (<i>h</i>AChE) = 1.472 ± 0.024 µM; IC<sub>50</sub> (<i>h</i>BChE) = 0.659 ± 0.077 µM; IC<sub>50</sub> (<i>h</i>MAO-B) = 40.39 ± 5.98 nM], and consequently, as a new hit-ligand that deserves further investigation, in particular <i>in vivo</i> analyses, as the preliminary cell viability test results reported here suggest that this is a relatively safe therapeutic agent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chrienova</LastName><ForeName>Zofia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nepovimova</LastName><ForeName>Eugenie</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0281-246X</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrys</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolezal</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9495-3934</Identifier><AffiliationInfo><Affiliation>Biomedical Research Centre and Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janockova</LastName><ForeName>Jana</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2034-1860</Identifier><AffiliationInfo><Affiliation>Biomedical Research Centre and Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muckova</LastName><ForeName>Lubica</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6693-6061</Identifier><AffiliationInfo><Affiliation>Biomedical Research Centre and Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabova</LastName><ForeName>Lenka</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soukup</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Biomedical Research Centre and Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oleksak</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valis</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedical Research Centre and Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korabecny</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biomedical Research Centre and Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marco-Contelles</LastName><ForeName>José</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of General Organic Chemistry (CSIC), Laboratory of Medicinal Chemistry, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuca</LastName><ForeName>Kamil</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9664-1109</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Enzyme Inhib Med Chem</MedlineTA><NlmUniqueID>101150203</NlmUniqueID><ISSNLinking>1475-6366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4VX7YNB537</RegistryNumber><NameOfSubstance UI="D013619">Tacrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.-</RegistryNumber><NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.7</RegistryNumber><NameOfSubstance UI="D000110">Acetylcholinesterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.8</RegistryNumber><NameOfSubstance UI="D002091">Butyrylcholinesterase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000110" MajorTopicYN="N">Acetylcholinesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="N">Amines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002091" MajorTopicYN="Y">Butyrylcholinesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010088" MajorTopicYN="N">Oxidoreductases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013619" MajorTopicYN="N">Tacrine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">Cholinesterase inhibitor</Keyword><Keyword MajorTopicYN="N">monoamine oxidase inhibitor</Keyword><Keyword MajorTopicYN="N">propargyl amines</Keyword><Keyword MajorTopicYN="N">tacrine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36131624</ArticleId><ArticleId IdType="doi">10.1080/14756366.2022.2122054</ArticleId><ArticleId IdType="pmc">PMC9518283</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur J Neurol. 2018 Jan;25(1):59-70</Citation><ArticleIdList><ArticleId IdType="pubmed">28872215</ArticleId></ArticleIdList></Reference><Reference><Citation>F1000Res. 2018 Jul 31;7:</Citation><ArticleIdList><ArticleId IdType="pubmed">30135715</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 3;75:54-62</Citation><ArticleIdList><ArticleId IdType="pubmed">28089695</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Suppl. 2006;(70):457-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17017568</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Med Chem. 2003 Mar;38(3):223-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12667689</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2017 Jun 16;22(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">28621747</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmaco. 1996 Nov;51(11):693-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9035375</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Chem. 2021 Sep;114:105070</Citation><ArticleIdList><ArticleId IdType="pubmed">34126574</ArticleId></ArticleIdList></Reference><Reference><Citation>Biophys J. 2014 Aug 5;107(3):630-641</Citation><ArticleIdList><ArticleId IdType="pubmed">25099802</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Apr 6;271(13):992-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8139084</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2018 Aug 09;61(15):6937-6943</Citation><ArticleIdList><ArticleId IdType="pubmed">29969030</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2020 Feb 1;30(3):126880</Citation><ArticleIdList><ArticleId IdType="pubmed">31864798</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1998 Jun;12(2):93-101</Citation><ArticleIdList><ArticleId IdType="pubmed">9651138</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2016 Aug 1;69:81-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26891670</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2002;14 Suppl 1:77-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12636181</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2015 Apr;148:34-46</Citation><ArticleIdList><ArticleId IdType="pubmed">25448037</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 2021 Apr;186:114460</Citation><ArticleIdList><ArticleId IdType="pubmed">33571502</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2005 Jan 20;288(2):349-59</Citation><ArticleIdList><ArticleId IdType="pubmed">15620875</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2003 Jul;86(2):290-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12871570</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2018 Nov;125(11):1519-1551</Citation><ArticleIdList><ArticleId IdType="pubmed">29637260</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2006 Jun;6(6):887-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16784411</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2013 Feb 20;18(2):2397-418</Citation><ArticleIdList><ArticleId IdType="pubmed">23429378</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2016 Jul 30;8(1):23</Citation><ArticleIdList><ArticleId IdType="pubmed">27473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 2006 May;23(5):873-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16715377</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Res Rev. 2013 Jan;33(1):139-89</Citation><ArticleIdList><ArticleId IdType="pubmed">21793014</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2015 Nov 25;58(22):8985-9003</Citation><ArticleIdList><ArticleId IdType="pubmed">26503905</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Neurobiol. 2011;100:191-215</Citation><ArticleIdList><ArticleId IdType="pubmed">21971009</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):61-2</Citation><ArticleIdList><ArticleId IdType="pubmed">12794380</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Saf. 2014 Jun;13(6):759-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24845946</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2001 Jan;132(2):500-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11159700</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Med Chem. 2011 Aug;46(8):3250-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21570751</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):555-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12787840</ArticleId></ArticleIdList></Reference><Reference><Citation>J Enzyme Inhib Med Chem. 2015 Dec;30(6):995-1001</Citation><ArticleIdList><ArticleId IdType="pubmed">25792506</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Sep 25;288(12):1475-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2018 Feb 1;370:191-206</Citation><ArticleIdList><ArticleId IdType="pubmed">28673719</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotoxicology. 2004 Jan;25(1-2):155-65</Citation><ArticleIdList><ArticleId IdType="pubmed">14697890</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Biol Interact. 2005 Dec 15;157-158:219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16289124</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim Care Companion CNS Disord. 2013;15(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">23930233</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 1961 Jul;7:88-95</Citation><ArticleIdList><ArticleId IdType="pubmed">13726518</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2008;22(7):563-86</Citation><ArticleIdList><ArticleId IdType="pubmed">18547126</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Chem Toxicol. 2019 May;42(3):252-256</Citation><ArticleIdList><ArticleId IdType="pubmed">29421945</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2000 May 18;43(10):2007-18</Citation><ArticleIdList><ArticleId IdType="pubmed">10821713</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Suppl. 2000;(60):157-69</Citation><ArticleIdList><ArticleId IdType="pubmed">11205137</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1996 Apr;16(4):881-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8608006</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Drug Targets. 2012 Apr;13(4):483-94</Citation><ArticleIdList><ArticleId IdType="pubmed">22280345</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2013 Jun;27(6):469-78</Citation><ArticleIdList><ArticleId IdType="pubmed">23733403</ArticleId></ArticleIdList></Reference><Reference><Citation>Angew Chem Int Ed Engl. 2017 Oct 2;56(41):12765-12769</Citation><ArticleIdList><ArticleId IdType="pubmed">28861918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2013 Apr 1;23(7):1916-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23481643</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2013 Oct;10(8):893-906</Citation><ArticleIdList><ArticleId IdType="pubmed">24093535</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36131364</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1747-0285</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Chemical biology &amp; drug design</Title><ISOAbbreviation>Chem Biol Drug Des</ISOAbbreviation></Journal><ArticleTitle>Comprehensive review on natural pharmacophore tethered 1,2,3-triazoles as active pharmaceuticals.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/cbdd.14148</ELocationID><Abstract><AbstractText>The privileged 1,2,3-triazole scaffold is drawing researcher's attention due to its widespread applications in diverse fields such as drug discovery (e.g., carboxyamidotriazole), organic synthesis (click-reaction template), polymeric materials (e.g., triazolamer), supramolecular receptors (e.g., triazolophane), fluorescent materials (e.g., metal-organic frameworks), and agricultural sectors (e.g., fungicides). Various 1,2,3-triazole persuasion modules are also currently available in the market that have multiple assets such as active pharmaceuticals and agricultural purposes. Owed to the highly consistent and firmest synthesis approach, that is, click reaction of various azides and acetylene derivatives by copper (I)-catalyzed 1,3-dipolar cycloaddition (CuAAC), highly functionalized 1,2,3-triazoles are prepared in scalar yields for drug discovery. Given the importance of 1,2,3-triazole chemistry, the present review focuses specifically on the synthesis of structurally diverse 1,2,3-triazoles linked to natural pharmacophores and their biological importance. Furthermore, the dual/multi-pharmacophores assimilated 1,2,3-triazoles have listed interesting biological activities that could be valuable as future drug leads. In addition, this comprehensive review can serve as a template for the development of new diverse scaffolds that will ensure for new therapeutic approaches for the existing myriad diseases and disorders.</AbstractText><CopyrightInformation>© 2022 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rammohan</LastName><ForeName>Aluru</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8624-6209</Identifier><AffiliationInfo><Affiliation>Ural Federal University, Yekaterinburg, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Bhumireddy Chinnachennaiahgari</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Chemtex Environmental Laboratory Inc., Port Aurthur, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basha</LastName><ForeName>Nabhubygari Mahaboob</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>School of Engineering &amp; Technology, Department of Basic Science &amp; Humanities, Sri Padmavati Mahila Visvavidyalayam, Tirupati, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zyryanov</LastName><ForeName>Grigory V</ForeName><Initials>GV</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5982-8983</Identifier><AffiliationInfo><Affiliation>Ural Federal University, Yekaterinburg, Russian Federation.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>I. Ya. Postovskiy Institute of Organic Synthesis, Ural Division of the Russian Academy of Sciences, Yekaterinburg, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nageswararao</LastName><ForeName>Mekala</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chemtex Environmental Laboratory Inc., Port Aurthur, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21-13-00304</GrantID><Agency>Russian Scientific Foundation</Agency><Country/></Grant><Grant><GrantID>NSh-1223.2022.1.3</GrantID><Agency>Council of the President of the Russian Federation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Chem Biol Drug Des</MedlineTA><NlmUniqueID>101262549</NlmUniqueID><ISSNLinking>1747-0277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">1,2,3-triazoles</Keyword><Keyword MajorTopicYN="N">Alzheimer disease (AD)</Keyword><Keyword MajorTopicYN="N">azides</Keyword><Keyword MajorTopicYN="N">chromenone</Keyword><Keyword MajorTopicYN="N">click reaction</Keyword><Keyword MajorTopicYN="N">nucleosides</Keyword><Keyword MajorTopicYN="N">tacrine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>0</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36131364</ArticleId><ArticleId IdType="doi">10.1111/cbdd.14148</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Aggrey, M. O., Li, H. H., Wang, W. Q., Song, W., Wang, Y., &amp; Xuan, L. J. (2018). Isocryptolepine, an indoloquinoline alkaloid from Cryptolepis sanguinolenta promotes LDL uptake in HepG2 cells. Revista Brasileira de Farmacognosia, 28, 654-657.</Citation></Reference><Reference><Citation>Almalki, A. S., Nazreen, S., Malebari, A. M., Ali, N. M., Elhenawy, A. A., Alghamdi, A. A., Ahmad, A., Alfaifi, S. Y., Alsharif, M. A., &amp; Alam, M. M. (2021). Synthesis and biological evaluation of 1, 2, 3-triazole tethered thymol-1, 3, 4-oxadiazole derivatives as anticancer and antimicrobial agents. Pharmaceuticals, 14(9), 866.</Citation></Reference><Reference><Citation>Al-Mulla, A. (2017). A review: Biological importance of heterocyclic compounds. Der Pharma Chemica, 9(13), 141-147.</Citation></Reference><Reference><Citation>Andreeva, O. V., Garifullin, B. F., Zarubaev, V. V., Slita, A. V., Yesaulkova, I. L., Saifina, L. F., Shulaeva, M. M., Belenok, M. G., Semenov, V. E., &amp; Kataev, V. E. (2020). Synthesis of 1,2,3-triazolyl nucleoside analogues and their antiviral activity. Molecular Diversity, 25, 473-490.</Citation></Reference><Reference><Citation>Artyushin, O. I., Moiseeva, A. A., Zarubaev, V. V., Slita, A. V., Galochkina, A. V., Muryleva, A. A., Borisevich, S. S., Yarovaya, O. I., Salakhutdinov, N. F., &amp; Brel, V. K. (2019). Synthesis of camphecene and cytisine conjugates using click chemistry methodology and study of their antiviral activity. Chemistry &amp; Biodiversity, 16(11), 1900340.</Citation></Reference><Reference><Citation>Asgari, M. S., Mohammadi-Khanaposhtani, M., Kiani, M., Ranjbar, P. R., Zabihi, E., Pourbagher, R., Rahimi, R., Faramarzi, M. A., Biglar, M., Larijani, B., &amp; Mahdavi, M. (2019). Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies. Bioorganic Chemistry, 92, 103206-103214.</Citation></Reference><Reference><Citation>Bajracharya, G. B. (2015). Diversity, pharmacology and synthesis of bergenin and its derivatives: Potential materials for therapeutic usages. Fitoterapia, 101, 133-152.</Citation></Reference><Reference><Citation>Bangalore, P. K., Vagolu, S. K., Bollikanda, R. K., Veeragoni, D. K., Choudante, P. C., Misra, S., Sriram, D., Sridhar, B., &amp; Kantevari, S. (2019). Usnic acid enaminone coupled 1,2,3-triazoles as antibacterial and antitubercular agents. Journal of Natural Products, 83(1), 26-35.</Citation></Reference><Reference><Citation>Bebenek, E., Jastrzębska, M., Kadela-Tomanek, M., Chrobak, E., Orzechowska, B., Zwolińska, K., Latocha, M., Mertas, A., Czuba, Z., &amp; Boryczka, S. (2017). Novel triazole hybrids of betulin: Synthesis and biological activity profile. Molecules, 22(11), 1876-1891.</Citation></Reference><Reference><Citation>Beteck, R. M., Smit, F. J., Haynes, R. K., &amp; N'Da, D. D. (2014). Recent progress in the development of anti-malarial quinolones. Malaria Journal, 13(1), 1-10.</Citation></Reference><Reference><Citation>Bozorov, K., Zhao, J., &amp; Aisa, H. A. (2019). 1,2,3-Triazole containing hybrids as leads in medicinal chemistry: A recent overview. Bioorganic &amp; Medicinal Chemistry, 27(16), 3511-3531.</Citation></Reference><Reference><Citation>Brandão, G. C., Missias, F. C., Arantes, L. M., Soares, L. F., Roy, K. K., Doerksen, R. J., de Oliveira, A. B., &amp; Pereira, G. R. (2018). Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapachol-based compounds. European Journal of Medicinal Chemistry, 145, 191-205.</Citation></Reference><Reference><Citation>Bruno, M., Trucchi, B., Burlando, B., Ranzato, E., Martinotti, S., Akkol, E. K., Süntar, I., Keleş, H., &amp; Verotta, L. (2013). (+)-Usnic acid enamines with remarkable cicatrizing properties. Bioorganic &amp; Medicinal Chemistry, 21(7), 1834-1843.</Citation></Reference><Reference><Citation>Burange, A. S., Gadam, K. G., Tugaonkar, P. S., Thakur, S. D., Soni, R. K., Khan, R. R., Tai, M. S., &amp; Gopinath, C. S. (2021). Green synthesis of xanthene and acridine-based heterocycles of pharmaceutical importance: A review. Environmental Chemistry Letters, 19, 3283-3314.</Citation></Reference><Reference><Citation>Carta, A., Paglietti, G., Nikookar, M. E., Sanna, P., Sechi, L., &amp; Zanetti, S. (2002). Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. European Journal of Medicinal Chemistry, 37(5), 355-366.</Citation></Reference><Reference><Citation>Chavan, P. V., Desai, U. V., Wadgaonkar, P. P., Tapase, S. R., Kodam, K. M., Choudhari, A., &amp; Sarkar, D. (2019). Click chemistry based multicomponent approach in the synthesis of spirochromenocarbazole tethered 1,2,3-triazoles as potential anticancer agents. Bioorganic Chemistry, 85, 475-486.</Citation></Reference><Reference><Citation>Chekir, S., Debbabi, M., Regazzetti, A., Dargère, D., Laprévote, O., Jannet, H. B., &amp; Gharbi, R. (2018). Design, synthesis and biological evaluation of novel 1,2,3-triazole linked coumarinopyrazole conjugates as potent anticholin-esterase, anti-5-lipoxygenase, anti-tyrosinase and anti-cancer agents. Bioorganic Chemistry, 80, 189-194.</Citation></Reference><Reference><Citation>Chien, M., Anderson, T. K., Jockusch, S., Tao, C., Li, X., Kumar, S., Russo, J. J., Kirchdoerfer, R. N., &amp; Ju, J. (2020). Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. Journal of Proteome Research, 19(11), 4690-4697.</Citation></Reference><Reference><Citation>Chipoline, I. C., da Fonseca, A. C., da Costa, G. R., de Souza, M. P., Rabelo, V. W., de Queiroz, L. N., de Souza, T. L., de Almeida, E. C., Abreu, P. A., Pontes, B., &amp; Ferreira, V. F. (2020). Molecular mechanism of action of new 1, 4-naphthoquinones tethered to 1,2,3-1H-triazoles with cytotoxic and selective effect against oral squamous cell carcinoma. Bioorganic Chemistry, 101, 103984-103997.</Citation></Reference><Reference><Citation>Dahlström, B., Mellstrand, T., Löfdahl, C. G., &amp; Johansson, M. (1982). Pharmakokinetic properties of noscapine. European Journal of Clinical Pharmacology, 22(6), 535-539.</Citation></Reference><Reference><Citation>Dheer, D., Singh, V., &amp; Shankar, R. (2017). Medicinal attributes of 1,2,3-triazoles: Current developments. Bioorganic Chemistry, 71, 30-54.</Citation></Reference><Reference><Citation>El-Sheref, E. M., Elbastawesy, M. A., Brown, A. B., Shawky, A. M., Gomaa, H. A., Bräse, S., &amp; Youssif, B. G. (2021). Design and synthesis of (2-oxo-1, 2-Dihydroquinolin-4-yl)-1, 2, 3-triazole derivatives via click reaction: Potential apoptotic antiproliferative agents. Molecules, 26(22), 6798.</Citation></Reference><Reference><Citation>Galinis, D. L., Fuller, R. W., McKee, T. C., Cardellina, J. H., Gulakowski, R. J., McMahon, J. B., &amp; Boyd, M. R. (1996). Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide a and (−)-calanolide B. Journal of Medicinal Chemistry, 39(22), 4507-4510.</Citation></Reference><Reference><Citation>Gholampour, M., Ranjbar, S., Edraki, N., Mohabbati, M., Firuzi, O., &amp; Khoshneviszadeh, M. (2019). Click chemistry assisted synthesis of novel aminonaphthoquinone-1,2,3-triazole hybrids and investigation of their cytotoxicity and cancer cell cycle alterations. Bioorganic Chemistry, 88, 102967-102975.</Citation></Reference><Reference><Citation>Głuszyńska, A. (2015). Biological potential of carbazole derivatives. European Journal of Medicinal Chemistry, 94, 405-426.</Citation></Reference><Reference><Citation>Gomtsyan, A. (2012). Heterocycles in drugs and drug discovery. Chemistry of Heterocyclic Compounds, 48(1), 7-10.</Citation></Reference><Reference><Citation>Guillonneau, C., Nault, A., Raimbaud, E., Léonce, S., Kraus-Berthier, L., Pierré, A., &amp; Goldstein, S. (2005). Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues. Bioorganic &amp; Medicinal Chemistry, 13(1), 175-184.</Citation></Reference><Reference><Citation>Hasanpour, Z., Salehi, P., Bararjanian, M., Esmaeili, M. A., Alilou, M., &amp; Mohebbi, M. (2021). Semi-synthesis of new 1, 2, 3-triazole derivatives of 9-Bromonoscapine and their anticancer activities. Iranian Journal of Pharmaceutical Research: IJPR, 20(2), 546.</Citation></Reference><Reference><Citation>Hong, S. W., Lee, S. H., Moon, J. H., Hwang, J. J., Kim, D. E., Ko, E., Kim, H. S., Cho, I. J., Kang, J. S., Kim, D. J., &amp; Kim, J. E. (2003). SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene, 32(12), 1508-1517.</Citation></Reference><Reference><Citation>Hordyjewska, A., Ostapiuk, A., Horecka, A., &amp; Kurzepa, J. (2019). Betulin and betulinic acid: Triterpenoids derivatives with a powerful biological potential. Phytochemistry Reviews, 18(3), 929-951.</Citation></Reference><Reference><Citation>Huang, M., Duan, W. G., Lin, G. S., &amp; Li, B. Y. (2021). Synthesis, antifungal activity, 3D-QSAR, and molecular docking study of novel menthol-derived 1,2,4-triazole-thioether compounds. Molecules, 26(22), 6948.</Citation></Reference><Reference><Citation>Huang, Y., Huang, W., Yang, G., Wang, R., &amp; Ma, L. (2021). Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents. Bioorganic &amp; Medicinal Chemistry Letters, 43, 128092.</Citation></Reference><Reference><Citation>Iqbal, S., Khan, M. A., Javaid, K., Sadiq, R., Fazal-ur-Rehman, S., Choudhary, M. I., &amp; Basha, F. Z. (2017). New carbazole linked 1,2,3-triazoles as highly potent non-sugar α-glucosidase inhibitors. Bioorganic Chemistry, 74, 72-81.</Citation></Reference><Reference><Citation>Jameel, E., Umar, T., Kumar, J., &amp; Hoda, N. (2016). Coumarin: A privileged scaffold for the design and development of antineurodegenerative agents. Chemical Biology &amp; Drug Design, 87(1), 21-38.</Citation></Reference><Reference><Citation>Jana, S., Iram, S., Thomas, J., Hayat, M. Q., Pannecouque, C., &amp; Dehaen, W. (2017). Application of the triazolization reaction to afford dihydroartemisinin derivatives with anti-HIV activity. Molecules, 22(2), 303-315.</Citation></Reference><Reference><Citation>Jesus, M., Martins, A. P., Gallardo, E., &amp; Silvestre, S. (2016). Diosgenin: Recent highlights on pharmacology and analytical methodology. Journal of Analytical Methods in Chemistry, 2016, 1-16. https://doi.org/10.1155/2016/4156293</Citation></Reference><Reference><Citation>Jung, M., Lee, K., Kim, H., &amp; Park, M. (2004). Recent advances in artemisinin and its derivatives as antimalarial and antitumor agents. Current Medicinal Chemistry, 11(10), 1265-1284.</Citation></Reference><Reference><Citation>Keri, R. S., Patil, S. A., Budagumpi, S., &amp; Nagaraja, B. M. (2015). Triazole: A promising antitubercular agent. Chemical Biology &amp; Drug Design, 86(4), 410-423.</Citation></Reference><Reference><Citation>Khan, I., Guru, S. K., Rath, S. K., Chinthakindi, P. K., Singh, B., Koul, S., Bhushan, S., &amp; Sangwan, P. L. (2016). A novel triazole derivative of betulinic acid induces extrinsic and intrinsic apoptosis in human leukemia HL-60 cells. European Journal of Medicinal Chemistry, 108, 104-116.</Citation></Reference><Reference><Citation>Kharb, R., Sharma, P. C., &amp; Yar, M. S. (2011). Pharmacological significance of triazole scaffold. Journal of Enzyme Inhibition and Medicinal Chemistry, 26(1), 1-21.</Citation></Reference><Reference><Citation>Kommera, H., Kaluđerović, G. N., Kalbitz, J., &amp; Paschke, R. (2011). Lupane triterpenoids-betulin and betulinic acid derivatives induce apoptosis in tumor cells. Investigational New Drugs, 29(2), 266-272.</Citation></Reference><Reference><Citation>Koziol, A., Stryjewska, A., Librowski, T., Salat, K., Gawel, M., Moniczewski, A., &amp; Lochynski, S. (2014). An overview of the pharmacological properties and potential applications of natural monoterpenes. Mini Reviews in Medicinal Chemistry, 14(14), 1156-1168.</Citation></Reference><Reference><Citation>Krinochkin, A. P., Shtaitz, Y. K., Rammohan, A., Butorin, I. I., Savchuk, M. I., Khalymbadzha, I. A., Kopchuk, D. S., Slepukhin, P. A., Melekhin, V. V., Shcheglova, A. V., &amp; Zyryanov, G. V. (2022). 1H-Pyrazole-appended pyridines and their 1, 2, 4-triazine precursors: A rational synthesis and in silico and in vitro evaluation of anti-cancer activity. European Journal of Organic Chemistry, 2022(22), e202200227.</Citation></Reference><Reference><Citation>Kumar, D., Narayanam, M. K., Chang, K. H., &amp; Shah, K. (2011). Synthesis of novel Indolyl-1, 2, 4-triazoles as potent and selective anticancer agents. Chemical Biology &amp; Drug Design, 77(3), 182-188.</Citation></Reference><Reference><Citation>Kumar, P. P., Siva, B., Rao, B. V., Kumar, G. D., Nayak, V. L., Jain, S. N., &amp; Babu, K. S. (2019). Synthesis and biological evaluation of bergenin-1,2,3-triazole hybrids as novel class of anti-mitotic agents. Bioorganic Chemistry, 91, 103161-103169.</Citation></Reference><Reference><Citation>Kuntala, N., Telu, J. R., Banothu, V., Nallapati, S. B., Anireddy, J. S., &amp; Pal, S. (2015). Novel benzoxepine-1,2,3-triazole hybrids: Synthesis and pharmacological evaluation as potential antibacterial and anticancer agents. MedChemComm, 6(9), 1612-1619.</Citation></Reference><Reference><Citation>Li, Y., Wu, J. M., Shan, F., Wu, G. S., Ding, J., Xiao, D., Han, J. X., Atassi, G., Leonce, S., Caignard, D. H., &amp; Renard, P. (2003). Synthesis and cytotoxicity of dihydroartemisinin ethers containing cyanoarylmethyl group. Bioorganic &amp; Medicinal Chemistry, 11(6), 977-984.</Citation></Reference><Reference><Citation>Linster, C. L., &amp; Van Schaftingen, E. (2007). Vitamin C: Biosynthesis, recycling and degradation in mammals. The FEBS Journal, 274(1), 1-22.</Citation></Reference><Reference><Citation>Lloyd, D. G., Hughes, R. B., Zisterer, D. M., Williams, D. C., Fattorusso, C., Catalanotti, B., Campiani, G., &amp; Meegan, M. J. (2004). Benzoxepin derived estrogen receptor modulators: A novel molecular scaffold for the estrogen receptor. Journal of Medicinal Chemistry, 47(23), 5612-5615.</Citation></Reference><Reference><Citation>López, Y. C., Viltres, H., Gupta, N. K., Acevedo-Peña, P., Leyva, C., Ghaffari, Y., &amp; Kim, K. S. (2021). Transition metal-based metal-organic frameworks for environmental applications: A review. Environmental Chemistry Letters, 19, 1295-1334.</Citation></Reference><Reference><Citation>Luo, H., Lv, Y. F., Zhang, H., Hu, J. M., Li, H. M., &amp; Liu, S. J. (2021). Synthesis and antitumor activity of 1-substituted 1, 2, 3-triazole-Mollugin derivatives. Molecules, 26(11), 3249.</Citation></Reference><Reference><Citation>Macan, A. M., Harej, A., Cazin, I., Klobučar, M., Stepanić, V., Pavelić, K., Pavelić, S. K., Schols, D., Snoeck, R., Andrei, G., &amp; Raić-Malić, S. (2019). Antitumor and antiviral activities of 4-substituted 1, 2, 3-triazolyl-2, 3-dibenzyl-L-ascorbic acid derivatives. European Journal of Medicinal Chemistry, 184, 111739-111755.</Citation></Reference><Reference><Citation>Marvadi, S. K., Krishna, V. S., Sinegubova, E. O., Volobueva, A. S., Esaulkova, Y. L., Muryleva, A. A., Tentler, D. G., Sriram, D., Zarubaev, V. V., &amp; Kantevari, S. (2019). 5-Chloro-2-thiophenyl-1,2,3-triazolylmethyldihydroquinolines as dual inhibitors of mycobacterium tuberculosis and influenza virus: Synthesis and evaluation. Bioorganic &amp; Medicinal Chemistry Letters, 29(18), 2664-2669.</Citation></Reference><Reference><Citation>Najafi, Z., Mahdavi, M., Saeedi, M., Karimpour-Razkenari, E., Edraki, N., Sharifzadeh, M., Khanavi, M., &amp; Akbarzadeh, T. (2019). Novel tacrine-coumarin hybrids linked to 1,2,3-triazole as anti-Alzheimer's compounds: In vitro and in vivo biological evaluation and docking study. Bioorganic Chemistry, 83, 303-316.</Citation></Reference><Reference><Citation>Noël, S., Léger, B., Ponchel, A., Sadjadi, S., &amp; Monflier, E. (2021). Cyclodextrins as multitask agents for metal nano-heterogeneous catalysis: A review. Environmental Chemistry Letters, 19, 4327-4348.</Citation></Reference><Reference><Citation>Ouahrouch, A., Taourirte, M., Schols, D., Snoeck, R., Andrei, G., Engels, J. W., &amp; Lazrek, H. B. (2016). Design, synthesis, and antiviral activity of novel Ribonucleosides of 1,2,3-Triazolylbenzyl-aminophosphonates. Archiv der Pharmazie, 349(1), 30-41.</Citation></Reference><Reference><Citation>Padayatty, S. J., Katz, A., Wang, Y., Eck, P., Kwon, O., Lee, J. H., Chen, S., Corpe, C., Dutta, A., Dutta, S. K., &amp; Levine, M. (2003). Vitamin C as an antioxidant: Evaluation of its role in disease prevention. Journal of the American College of Nutrition, 22(1), 18-35.</Citation></Reference><Reference><Citation>Pavan Kumar, C., Devi, A., Ashok Yadav, P., Rao Vadaparthi, R., Shankaraiah, G., Sowjanya, P., Jain, N., &amp; Suresh, B. K. (2016). Click reaction mediated synthesis of costunolide and dehydrocostuslactone derivatives and evaluation of their cytotoxic activity. Journal of Asian Natural Products Research, 18(11), 1063-1078.</Citation></Reference><Reference><Citation>Qiu, H. Y., Wang, P. F., Lin, H. Y., Tang, C. Y., Zhu, H. L., &amp; Yang, Y. H. (2018). Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents. Chemical Biology &amp; Drug Design, 91(3), 681-690.</Citation></Reference><Reference><Citation>Quin, L. D., &amp; Tyrell, J. A. (2010). Fundamentals of heterocyclic chemistry: Importance in nature and in the synthesis of pharmaceuticals. John Wiley &amp; Sons.</Citation></Reference><Reference><Citation>Raj, R., Land, K. M., &amp; Kumar, V. (2015). 4-aminoquinoline-hybridization en route towards the development of rationally designed antimalarial agents. RSC Advances, 5(101), 82676-82698.</Citation></Reference><Reference><Citation>Rammohan, A., Mallikarjuna Reddy, G., Raul Garcia, J., Zyryanov, G. V., Sravya, G., Bakthavatchala Reddy, N., &amp; Yuvaraja, G. (2019). Microwave-assisted synthesis of N-substituted maleimide derivatives as exogenous antioxidant agents. Journal of Heterocyclic Chemistry, 56(2), 470-476.</Citation></Reference><Reference><Citation>Rammohan, A., Reddy, J. S., Sravya, G., Rao, C. N., &amp; Zyryanov, G. V. (2020). Chalcone synthesis, properties and medicinal applications: A review. Environmental Chemistry Letters, 18, 433-458.</Citation></Reference><Reference><Citation>Rastegari, A., Nadri, H., Mahdavi, M., Moradi, A., Mirfazli, S. S., Edraki, N., Moghadam, F. H., Larijani, B., Akbarzadeh, T., &amp; Saeedi, M. (2019). Design, synthesis and anti-Alzheimer's activity of novel 1,2,3-triazole-chromenone carboxamide derivatives. Bioorganic Chemistry, 83, 391-401.</Citation></Reference><Reference><Citation>Robinson, A., Kumar, T. V., Sreedhar, E., Naidu, V. G., Krishna, S. R., Babu, K. S., Srinivas, P. V., &amp; Rao, J. M. (2008). A new sesquiterpene lactone from the roots of Saussurea lappa: Structure-anticancer activity study. Bioorganic &amp; Medicinal Chemistry Letters, 18(14), 4015-4017.</Citation></Reference><Reference><Citation>Rodphon, W., Laohapaisan, P., Supantanapong, N., Reamtong, O., Ngiwsara, L., Lirdprapamongkol, K., Thongsornkleeb, C., Khunnawutmanotham, N., Tummatorn, J., Svasti, J., &amp; Ruchirawat, S. (2021). Synthesis of Isocryptolepine-triazole adducts and evaluation of their cytotoxic activity. ChemMedChem, 16(24), 3750-3762.</Citation></Reference><Reference><Citation>Sabat, N., Migianu-Griffoni, E., Tudela, T., Lecouvey, M., Kellouche, S., Carreiras, F., Gallier, F., Uziel, J., &amp; Lubin-Germain, N. (2020). Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin. European Journal of Medicinal Chemistry, 188, 112009-112015.</Citation></Reference><Reference><Citation>Sahoo, S., Sindhu, K. N., &amp; Sreeveena, K. (2019). The significance of 1,2,4-triazoles in agriculture science: A review. Research Journal of Pharmacy and Technology, 12(10), 5091-5097.</Citation></Reference><Reference><Citation>Saini, A., Kumar, S., Raj, R., Chowdhary, S., Gendrot, M., Mosnier, J., Fonta, I., Pradines, B., &amp; Kumar, V. (2021). Synthesis and antiplasmodial evaluation of 1H-1,2,3-triazole grafted 4-aminoquinoline-benzoxaborole hybrids and benzoxaborole analogues. Bioorganic Chemistry, 16, 104733-104745.</Citation></Reference><Reference><Citation>Seenaiah, D., Reddy, P. R., Reddy, G. M., Padmaja, A., &amp; Padmavathi, V. (2014). Synthesis, antimicrobial and cytotoxic activities of pyrimidinyl benzoxazole, benzothiazole and benzimidazole. European Journal of Medicinal Chemistry, 77, 1-7.</Citation></Reference><Reference><Citation>Shtro, A. A., Zarubaev, V. V., Luzina, O. A., Sokolov, D. N., &amp; Salakhutdinov, N. F. (2015). Derivatives of usnic acid inhibit broad range of influenza viruses and protect mice from lethal influenza infection. Antiviral Chemistry &amp; Chemotherapy, 24(3-4), 92-98.</Citation></Reference><Reference><Citation>Tandon, V. K., &amp; Kumar, S. (2013). Recent development on naphthoquinone derivatives and their therapeutic applications as anticancer agents. Expert Opinion on Therapeutic Patents, 23(9), 1087-1108.</Citation></Reference><Reference><Citation>Tandon, V. K., Singh, K. A., Awasthi, A. K., Khanna, J. M., Lal, B., &amp; Anand, N. (2004). Chemo and stereoselective synthesis of benzocycloheptene and 1-benzoxepin derivatives as α-sympathomimetic and anorexigenic agents. Bioorganic &amp; Medicinal Chemistry Letters, 14(11), 2867-2870.</Citation></Reference><Reference><Citation>Tolan, H. E., El-Sayed, W. A., Tawfek, N., Abdel-Megeid, F. M., &amp; Kutkat, O. M. (2020). Synthesis and anti-H5N1 virus activity of triazole and oxadiazole pyrimidine hybrids and their nucleoside analogs. Nucleosides, Nucleotides &amp; Nucleic Acids, 39(5), 649-670.</Citation></Reference><Reference><Citation>Varsha, K., Sharma, A., Kaur, A., Madan, J., Pandey, R. S., Jain, U. K., &amp; Chandra, R. (2017). Natural plant derived anticancer drugs nanotherapeutics: A review on preclinical to clinical success. Nanostructures for Cancer Therapy, 775-809. https://doi.org/10.1016/B978-0-323-46144-3.00028-3</Citation></Reference><Reference><Citation>Vatmurge, N. S., Hazra, B. G., Pore, V. S., Shirazi, F., Chavan, P. S., &amp; Deshpande, M. V. (2008). Synthesis and antimicrobial activity of β-lactam-bile acid conjugates linked via triazole. Bioorganic &amp; Medicinal Chemistry Letters, 18(6), 2043-2047.</Citation></Reference><Reference><Citation>Wang, H., Xu, R., Shi, Y., Si, L., Jiao, P., Fan, Z., Han, X., Wu, X., Zhou, X., Yu, F., &amp; Zhang, Y. (2016). Design, synthesis and biological evaluation of novel L-ascorbic acid-conjugated pentacyclic triterpene derivatives as potential influenza virus entry inhibitors. European Journal of Medicinal Chemistry, 110, 376-388.</Citation></Reference><Reference><Citation>Wang, M., Fang, L., Liu, T., Chen, X., Zheng, Y., Zhang, Y., Chen, S., &amp; Li, Z. (2021). Discovery of 7-O-1, 2, 3-triazole hesperetin derivatives as multi-target-directed ligands against Alzheimer's disease. Chemico-Biological Interactions, 342, 109489.</Citation></Reference><Reference><Citation>Wang, Z., Li, M. Y., Mi, C., Wang, K. S., Ma, J., &amp; Jin, X. (2017). Mollugin has an anti-cancer therapeutic effect by inhibiting TNF-α-induced NF-κB activation. International Journal of Molecular Sciences, 18(8), 1619.</Citation></Reference><Reference><Citation>Wen, Y. N., Zhang, Z. F., Liu, N. N., Xiang, Y. H., Zhang, Z. Y., Andrei, G., Snoeck, R., Schols, D., Zhang, Q. S., &amp; Wu, Q. P. (2016). Synthesis and bioactivity of novel trisubstituted triazole nucleosides. Nucleosides, Nucleotides and Nucleic Acids, 35(3), 147-160.</Citation></Reference><Reference><Citation>Wittine, K., Babić, M. S., Makuc, D., Plavec, J., Pavelić, S. K., Sedić, M., Pavelić, K., Leyssen, P., Neyts, J., Balzarini, J., &amp; Mintas, M. (2012). Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: Synthesis, anti-HCV and antitumor activity evaluations. Bioorganic &amp; Medicinal Chemistry, 20(11), 3675-3685.</Citation></Reference><Reference><Citation>Xu, Z. J., Zhou, Y. J., Wang, J. H., Mao, L. F., Li, W., &amp; Xu, G. Q. (2021). The synthesis and antitumor activity of 1, 8-Naphthalimide derivatives linked 1, 2, 3-triazole. Frontiers in Bioengineering and Biotechnology, 9, 1-7. https://doi.org/10.3389/fbioe.2021.662432</Citation></Reference><Reference><Citation>Yang, Z. S., Zhou, W. L., Sui, Y., Wang, J. X., Wu, J. M., Zhou, Y., Zhang, Y., He, P. L., Han, J. Y., Tang, W., &amp; Li, Y. (2005). Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(β or α)-dihydroartemisin-inoxy]phenoxyl aliphatic acids and esters. Journal of Medicinal Chemistry, 48(14), 4608-4617.</Citation></Reference><Reference><Citation>Yu, X., Guo, Q., Su, G., Yang, A., Hu, Z., Qu, C., Wan, Z., Li, R., Tu, P., &amp; Chai, X. (2016). Usnic acid derivatives with cytotoxic and antifungal activities from the lichen Usnea longissima. Journal of Natural Products, 79(5), 1373-1380.</Citation></Reference><Reference><Citation>Zheng, Y., Zhang, Y. L., Li, Z., Shi, W., Ji, Y. R., Guo, Y. H., Huang, C., Sun, G. P., &amp; Li, J. (2021). Design and synthesis of 7-O-1, 2, 3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice. European Journal of Medicinal Chemistry, 213, 113162.</Citation></Reference><Reference><Citation>Zielińska-Błajet, M., &amp; Feder-Kubis, J. (2020). Monoterpenes and their derivatives-Recent development in biological and medical applications. International Journal of Molecular Sciences, 21(19), 7078.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36131327</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Nanoscale alterations in GABA<sub>B</sub> receptors and GIRK channel organization on the hippocampus of APP/PS1 mice.</ArticleTitle><Pagination><MedlinePgn>136</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-022-01078-5</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by a reorganization of brain activity determining network hyperexcitability and loss of synaptic plasticity. Precisely, a dysfunction in metabotropic GABA<sub>B</sub> receptor signalling through G protein-gated inwardly rectifying K<sup>+</sup> (GIRK or Kir3) channels on the hippocampus has been postulated. Thus, we determined the impact of amyloid-β (Aβ) pathology in GIRK channel density, subcellular distribution, and its association with GABA<sub>B</sub> receptors in hippocampal CA1 pyramidal neurons from the APP/PS1 mouse model using quantitative SDS-digested freeze-fracture replica labelling (SDS-FRL) and proximity ligation in situ assay (P-LISA). In wild type mice, single SDS-FRL detection revealed a similar dendritic gradient for GIRK1 and GIRK2 in CA1 pyramidal cells, with higher densities in spines, and GIRK3 showed a lower and uniform distribution. Double SDS-FRL showed a co-clustering of GIRK2 and GIRK1 in post- and presynaptic compartments, but not for GIRK2 and GIRK3. Likewise, double GABA<sub>B1</sub> and GIRK2 SDS-FRL detection displayed a high degree of co-clustering in nanodomains (40-50 nm) mostly in spines and axon terminals. In APP/PS1 mice, the density of GIRK2 and GIRK1, but not for GIRK3, was significantly reduced along the neuronal surface of CA1 pyramidal cells and in axon terminals contacting them. Importantly, GABA<sub>B1</sub> and GIRK2 co-clustering was not present in APP/PS1 mice. Similarly, P-LISA experiments revealed a significant reduction in GABA<sub>B1</sub> and GIRK2 interaction on the hippocampus of this animal model. Overall, our results provide compelling evidence showing a significant reduction on the cell surface density of pre- and postsynaptic GIRK1 and GIRK2, but not GIRK3, and a decline in GABA<sub>B</sub> receptors and GIRK2 channels co-clustering in hippocampal pyramidal neurons from APP/PS1 mice, thus suggesting that a disruption in the GABA<sub>B</sub> receptor-GIRK channel membrane assembly causes dysregulation in the GABA<sub>B</sub> signalling via GIRK channels in this AD animal model.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martín-Belmonte</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Synaptic Structure Laboratory, Instituto de Investigación en Discapacidades Neurológicas (IDINE), Department Ciencias Médicas, Facultad de Medicina, Universidad Castilla-La Mancha, Campus Biosanitario, C/ Almansa 14, 02008, Albacete, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, 08907, L'Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropharmacology and Pain Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge, IDIBELL, 08907, L'Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguado</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Synaptic Structure Laboratory, Instituto de Investigación en Discapacidades Neurológicas (IDINE), Department Ciencias Médicas, Facultad de Medicina, Universidad Castilla-La Mancha, Campus Biosanitario, C/ Almansa 14, 02008, Albacete, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfaro-Ruiz</LastName><ForeName>Rocío</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Synaptic Structure Laboratory, Instituto de Investigación en Discapacidades Neurológicas (IDINE), Department Ciencias Médicas, Facultad de Medicina, Universidad Castilla-La Mancha, Campus Biosanitario, C/ Almansa 14, 02008, Albacete, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Martínez</LastName><ForeName>Ana Esther</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Synaptic Structure Laboratory, Instituto de Investigación en Discapacidades Neurológicas (IDINE), Department Ciencias Médicas, Facultad de Medicina, Universidad Castilla-La Mancha, Campus Biosanitario, C/ Almansa 14, 02008, Albacete, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Ossa</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Sistemas Informáticos, Escuela Superior de Ingeniería Informática, Universidad de Castilla-La Mancha, 02071, Albacete, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aso</LastName><ForeName>Ester</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, 08907, L'Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropharmacology and Pain Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge, IDIBELL, 08907, L'Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gómez-Acero</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, 08907, L'Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropharmacology and Pain Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge, IDIBELL, 08907, L'Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shigemoto</LastName><ForeName>Ryuichi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology Austria (ISTA), Am Campus 1, A-3400, Klosterneuburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukazawa</LastName><ForeName>Yugo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Brain Structure and Function, Faculty of Medical Science, University of Fukui, Fukui, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Life Science Innovation Center, University of Fukui, Fukui, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciruela</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, 08907, L'Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropharmacology and Pain Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge, IDIBELL, 08907, L'Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luján</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Synaptic Structure Laboratory, Instituto de Investigación en Discapacidades Neurológicas (IDINE), Department Ciencias Médicas, Facultad de Medicina, Universidad Castilla-La Mancha, Campus Biosanitario, C/ Almansa 14, 02008, Albacete, Spain. Rafael.Lujan@uclm.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051676">G Protein-Coupled Inwardly-Rectifying Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018080">Receptors, GABA-B</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051676" MajorTopicYN="Y">G Protein-Coupled Inwardly-Rectifying Potassium Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018080" MajorTopicYN="Y">Receptors, GABA-B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36131327</ArticleId><ArticleId IdType="doi">10.1186/s13195-022-01078-5</ArticleId><ArticleId IdType="pii">10.1186/s13195-022-01078-5</ArticleId><ArticleId IdType="pmc">PMC9490896</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur J Neurosci. 2006 Mar;23(6):1479-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16553611</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2019 Mar 22;10(1):1331</Citation><ArticleIdList><ArticleId IdType="pubmed">30902970</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2019;2040:41-50</Citation><ArticleIdList><ArticleId IdType="pubmed">31432474</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2010 Jan;90(1):291-366</Citation><ArticleIdList><ArticleId IdType="pubmed">20086079</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2010 May;11(5):301-15</Citation><ArticleIdList><ArticleId IdType="pubmed">20389305</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Neurobiol. 2015;123:279-313</Citation><ArticleIdList><ArticleId IdType="pubmed">26422988</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Jul 28;10(7):e0134385</Citation><ArticleIdList><ArticleId IdType="pubmed">26218288</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2009 Aug;110(4):1363-76</Citation><ArticleIdList><ArticleId IdType="pubmed">19558451</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 May 18;50(4):589-601</Citation><ArticleIdList><ArticleId IdType="pubmed">16701209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2013 Dec;23(12):1231-45</Citation><ArticleIdList><ArticleId IdType="pubmed">23804514</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2010 Oct;32(8):1265-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20846323</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2011 Dec;34(11):1724-36</Citation><ArticleIdList><ArticleId IdType="pubmed">22098295</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1996 Nov 15;16(22):7137-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8929423</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2020 May;153(3):362-376</Citation><ArticleIdList><ArticleId IdType="pubmed">31875959</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1997 Sep;19(3):687-95</Citation><ArticleIdList><ArticleId IdType="pubmed">9331358</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2022 Mar;231:107977</Citation><ArticleIdList><ArticleId IdType="pubmed">34480967</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Cell Biol. 2015 Jun 01;67:17.17.1-17.17.16</Citation><ArticleIdList><ArticleId IdType="pubmed">26061241</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2019 Mar 07;20(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">30866445</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Apr 19;26(16):4289-97</Citation><ArticleIdList><ArticleId IdType="pubmed">16624949</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2006 Dec;24(3):516-24</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Apr 13;25(15):3787-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15829630</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2002 Feb 28;33(5):715-29</Citation><ArticleIdList><ArticleId IdType="pubmed">11879649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Signal. 2006 Dec;18(12):2172-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16809021</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomol Eng. 2001 Jun;17(6):157-65</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2021 Oct 14;22(20):</Citation><ArticleIdList><ArticleId IdType="pubmed">34681766</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1999 Feb 1;19(3):1006-17</Citation><ArticleIdList><ArticleId IdType="pubmed">9920664</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2013 Jul 25;7:117</Citation><ArticleIdList><ArticleId IdType="pubmed">23898239</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2021 Jul;223:107808</Citation><ArticleIdList><ArticleId IdType="pubmed">33476640</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Dec 7;25(49):11468-78</Citation><ArticleIdList><ArticleId IdType="pubmed">16339040</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2010 May 5;30(18):6367-74</Citation><ArticleIdList><ArticleId IdType="pubmed">20445063</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Model Mech. 2015 Jan;8(1):57-63</Citation><ArticleIdList><ArticleId IdType="pubmed">25398851</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Synaptic Neurosci. 2015 Mar 23;7:6</Citation><ArticleIdList><ArticleId IdType="pubmed">25852540</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neuropharmacol. 2022;20(6):1035-1045</Citation><ArticleIdList><ArticleId IdType="pubmed">34736381</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2004 Feb;7(2):153-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14745451</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Struct Funct. 2018 Apr;223(3):1565-1587</Citation><ArticleIdList><ArticleId IdType="pubmed">29177691</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Pathol. 2020 May;30(3):554-575</Citation><ArticleIdList><ArticleId IdType="pubmed">31729777</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neuroanat. 2014 May 27;8:38</Citation><ArticleIdList><ArticleId IdType="pubmed">24904307</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2007 Apr 1;580(Pt 1):51-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17185339</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Neurobiol. 2015;123:161-200</Citation><ArticleIdList><ArticleId IdType="pubmed">26422985</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Jan 26;25(4):799-807</Citation><ArticleIdList><ArticleId IdType="pubmed">15673659</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2004 Jul;84(3):835-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15269338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 1993 Apr;463:391-407</Citation><ArticleIdList><ArticleId IdType="pubmed">8246190</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2008 Apr;105(2):497-511</Citation><ArticleIdList><ArticleId IdType="pubmed">18088366</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2019 Jan 11;363(6423):</Citation><ArticleIdList><ArticleId IdType="pubmed">30630900</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2017 Aug 08;11:455</Citation><ArticleIdList><ArticleId IdType="pubmed">28848381</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2014 Aug;20(8):886-96</Citation><ArticleIdList><ArticleId IdType="pubmed">24973918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2004 Jan 15;13(2):159-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36131298</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Letter to the editor on a paper by Kaivola et al. (2020): carriership of two copies of C9orf72 hexanucleotide repeat intermediate-length alleles is not associated with amyotrophic lateral sclerosis or frontotemporal dementia.</ArticleTitle><Pagination><MedlinePgn>141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-022-01438-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Boer</LastName><ForeName>Sterre C M</ForeName><Initials>SCM</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-9595-7221</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands. scm.deboer@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands. scm.deboer@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolley</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MRC Prion Unit at UCL, Institute of Prion Diseases, UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mol</LastName><ForeName>Merel O</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serpente</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reus</LastName><ForeName>Lianne M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Minkelen</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vugt</LastName><ForeName>Joke F A</ForeName><Initials>JFA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seelaar</LastName><ForeName>Harro</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Ruissen</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC Prion Unit at UCL, Institute of Prion Diseases, UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande A L</ForeName><Initials>YAL</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Acta Neuropathol Commun. 2020 Nov 9;8(1):187</RefSource><PMID Version="1">33168078</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="Y">Pick Disease of the Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36131298</ArticleId><ArticleId IdType="doi">10.1186/s40478-022-01438-0</ArticleId><ArticleId IdType="pii">10.1186/s40478-022-01438-0</ArticleId><ArticleId IdType="pmc">PMC9494883</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hum Mutat. 2013 Feb;34(2):363-73</Citation><ArticleIdList><ArticleId IdType="pubmed">23111906</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):257-68</Citation><ArticleIdList><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1165-70</Citation><ArticleIdList><ArticleId IdType="pubmed">21622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2021 Sep 2;11(1):451</Citation><ArticleIdList><ArticleId IdType="pubmed">34475377</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Aug;21(8):1112-24</Citation><ArticleIdList><ArticleId IdType="pubmed">26481318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2021;81(4):1445-1451</Citation><ArticleIdList><ArticleId IdType="pubmed">33935096</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2012 Dec;33(12):2950.e5-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22840558</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2021 Jan;97:148.e9-148.e16</Citation><ArticleIdList><ArticleId IdType="pubmed">32843152</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2017 Sep;54(9):591-597</Citation><ArticleIdList><ArticleId IdType="pubmed">28689190</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2020 Nov 9;8(1):187</Citation><ArticleIdList><ArticleId IdType="pubmed">33168078</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2013 Mar 7;92(3):345-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2012 Dec;69(12):1583-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22964832</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):245-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Genet. 2022 Mar 14;8(2):e665</Citation><ArticleIdList><ArticleId IdType="pubmed">35295181</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36131294</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>09</Month><Day>21</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity.</ArticleTitle><Pagination><MedlinePgn>61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-022-00558-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Alzheimer's Disease (AD) affects millions globally, but therapy development is lagging. New experimental systems that monitor neuronal functions in conditions approximating the AD brain may be beneficial for identifying new therapeutic strategies.</AbstractText><AbstractText Label="METHODS">We expose cultured neurons to aqueous-soluble human brain extract from 43 individuals across a spectrum of AD pathology. Multi-electrode arrays (MEAs) and live-cell imaging were used to assess neuronal firing and neurite integrity (NI), respectively, following treatments of rat cortical neurons (MEA) and human iPSC-derived neurons (iN) with human brain extracts.</AbstractText><AbstractText Label="RESULTS">We observe associations between spontaneous activity and Aβ42:40 levels, between neurite integrity and oligomeric Aβ, and between neurite integrity and tau levels present in the brain extracts. However, these associations with Aβ and tau do not fully account for the effects observed. Proteomic profiling of the brain extracts revealed additional candidates correlated with neuronal structure and activity. Neurotoxicity in MEA and NI assays was associated with proteins implicated in lysosomal storage disorders, while neuroprotection was associated with proteins of the WAVE regulatory complex controlling actin cytoskeleton dynamics. Elevated ganglioside GM2 activator (GM2A) associates with reductions in both NI and MEA activity, and cell-derived GM2A alone is sufficient to induce a loss of neurite integrity and a reduction in neuronal firing.</AbstractText><AbstractText Label="CONCLUSIONS">The techniques and data herein introduce a system for modeling neuronal vulnerability in response to factors in the human brain and provide insights into proteins potentially contributing to AD pathogenesis.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hsieh</LastName><ForeName>Yi-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Rd, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Negri</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Rd, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Rd, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearse</LastName><ForeName>Richard V</ForeName><Initials>RV</Initials><Suffix>2nd</Suffix><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Rd, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Rd, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, 1510 Clifton Rd NE, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, 600 S. Paulina St, Chicago, IL, 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, 1510 Clifton Rd NE, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young-Pearse</LastName><ForeName>Tracy L</ForeName><Initials>TL</Initials><Identifier Source="ORCID">0000-0001-7846-1542</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Rd, Boston, MA, 02115, USA. tpearse@bwh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Harvard University, 7 Divinity Ave, Cambridge, MA, 02138, USA. tpearse@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG055909</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG056011</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005732">Gangliosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>19600-01-2</RegistryNumber><NameOfSubstance UI="D005678">G(M2) Ganglioside</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005678" MajorTopicYN="N">G(M2) Ganglioside</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005732" MajorTopicYN="N">Gangliosides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="Y">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ABI1</Keyword><Keyword MajorTopicYN="N">ABI2</Keyword><Keyword MajorTopicYN="N">Alzheimer’s</Keyword><Keyword MajorTopicYN="N">Aβ</Keyword><Keyword MajorTopicYN="N">GM2A</Keyword><Keyword MajorTopicYN="N">HEXA</Keyword><Keyword MajorTopicYN="N">LOAD</Keyword><Keyword MajorTopicYN="N">MEA</Keyword><Keyword MajorTopicYN="N">Proteomics</Keyword><Keyword MajorTopicYN="N">Sex</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">WAVE</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36131294</ArticleId><ArticleId IdType="doi">10.1186/s13024-022-00558-4</ArticleId><ArticleId IdType="pii">10.1186/s13024-022-00558-4</ArticleId><ArticleId IdType="pmc">PMC9494921</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sci Adv. 2020 Oct 21;6(43):</Citation><ArticleIdList><ArticleId IdType="pubmed">33087358</ArticleId></ArticleIdList></Reference><Reference><Citation>eNeuro. 2020 Jan 24;7(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">31896559</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2014 Jul 03;6(4):37</Citation><ArticleIdList><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2022 Jun 30;611:85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">35483223</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2000 Mar 22-29;283(12):1571-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Genet. 2018 Aug 09;9:294</Citation><ArticleIdList><ArticleId IdType="pubmed">30140277</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2022 Mar 12;:</Citation><ArticleIdList><ArticleId IdType="pubmed">35278341</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2018 Aug;14(8):989-997</Citation><ArticleIdList><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2022 Jun;18(6):1186-1202</Citation><ArticleIdList><ArticleId IdType="pubmed">34550630</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2014 Mar;35(3):492-510</Citation><ArticleIdList><ArticleId IdType="pubmed">24269023</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Proteomics. 2014 Sep;13(9):2513-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24942700</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2011 Aug 19;10(9):698-712</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Syst. 2017 Jan 25;4(1):60-72.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">27989508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1991 Oct;30(4):572-80</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 May;26(5):769-780</Citation><ArticleIdList><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2014 Jul 1;23(13):3523-36</Citation><ArticleIdList><ArticleId IdType="pubmed">24524897</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2006 Apr 15;572(Pt 2):477-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2013 Mar;9(2):99-112</Citation><ArticleIdList><ArticleId IdType="pubmed">23375565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Perspect Biol. 2012 May 01;4(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">22491782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 2012 Apr;363(1-2):109-18</Citation><ArticleIdList><ArticleId IdType="pubmed">22147196</ArticleId></ArticleIdList></Reference><Reference><Citation>Proteomics. 2018 Oct;18(20):e1800108</Citation><ArticleIdList><ArticleId IdType="pubmed">30230243</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2000 Dec 1;304(3):411-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11090283</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2020 May 7;15(1):28</Citation><ArticleIdList><ArticleId IdType="pubmed">32381088</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2002;18 Suppl 1:S96-104</Citation><ArticleIdList><ArticleId IdType="pubmed">12169536</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2022 Feb;25(2):213-225</Citation><ArticleIdList><ArticleId IdType="pubmed">35115731</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Biochem. 2019 Jun 20;88:461-485</Citation><ArticleIdList><ArticleId IdType="pubmed">31220974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2010 Jan;67(1):122-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Brief Bioinform. 2018 Jan 1;19(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">27694351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2018 Jul 11;9(1):2676</Citation><ArticleIdList><ArticleId IdType="pubmed">29992960</ArticleId></ArticleIdList></Reference><Reference><Citation>Membranes (Basel). 2020 Dec 09;10(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">33316913</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2018 Jun;21(6):811-819</Citation><ArticleIdList><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Jun 5;78(5):785-98</Citation><ArticleIdList><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Jul 19;297(5580):353-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2008 Aug;14(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2002 Apr 4;416(6880):535-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Aug 7;11(1):3942</Citation><ArticleIdList><ArticleId IdType="pubmed">32770063</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Alzheimers Dis. 2011 Jan 09;2011:193618</Citation><ArticleIdList><ArticleId IdType="pubmed">21274438</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Nov 25;21(23):</Citation><ArticleIdList><ArticleId IdType="pubmed">33255694</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Data. 2018 Mar 13;5:180036</Citation><ArticleIdList><ArticleId IdType="pubmed">29533394</ArticleId></ArticleIdList></Reference><Reference><Citation>Biophys J. 2017 Sep 19;113(6):1194-1199</Citation><ArticleIdList><ArticleId IdType="pubmed">28410623</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Bioinformatics. 2012;13 Suppl 16:S5</Citation><ArticleIdList><ArticleId IdType="pubmed">23176322</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Mar 14;27(11):2866-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2020 Mar 17;12(1):26</Citation><ArticleIdList><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2021 Nov 3;109(21):3402-3420.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">34473944</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2005 Oct 24;579(25):5501-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16212960</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1979 Feb;76(2):982-5</Citation><ArticleIdList><ArticleId IdType="pubmed">85305</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2009 Jun 25;62(6):788-801</Citation><ArticleIdList><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>J Proteome Res. 2008 Jan;7(1):225-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18173221</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36130946</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>09</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.</ArticleTitle><Pagination><MedlinePgn>5308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-32944-3</ELocationID><Abstract><AbstractText>The endosome-associated GTPase Rab5 is a central player in the molecular mechanisms leading to degeneration of basal forebrain cholinergic neurons (BFCN), a long-standing target for drug development. As p38α is a Rab5 activator, we hypothesized that inhibition of this kinase holds potential as an approach to treat diseases associated with BFCN loss. Herein, we report that neflamapimod (oral small molecule p38α inhibitor) reduces Rab5 activity, reverses endosomal pathology, and restores the numbers and morphology of BFCNs in a mouse model that develops BFCN degeneration. We also report on the results of an exploratory (hypothesis-generating) phase 2a randomized double-blind 16-week placebo-controlled clinical trial (Clinical trial registration: NCT04001517/EudraCT #2019-001566-15) of neflamapimod in mild-to-moderate dementia with Lewy bodies (DLB), a disease in which BFCN degeneration is an important driver of disease expression. A total of 91 participants, all receiving background cholinesterase inhibitor therapy, were randomized 1:1 between neflamapimod 40 mg or matching placebo capsules (taken orally twice-daily if weight &lt;80 kg or thrice-daily if weight &gt;80 kg). Neflamapimod does not show an effect in the clinical study on the primary endpoint, a cognitive-test battery. On two secondary endpoints, a measure of functional mobility and a dementia rating-scale, improvements were seen that are consistent with an effect on BFCN function. Neflamapimod treatment is well-tolerated with no study drug associated treatment discontinuations. The combined preclinical and clinical observations inform on the validity of the Rab5-based pathogenic model of cholinergic degeneration and provide a foundation for confirmatory (hypothesis-testing) clinical evaluation of neflamapimod in DLB.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Alam</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-1285-1115</Identifier><AffiliationInfo><Affiliation>EIP Pharma Inc, 20 Park Plaza, Suite 424, Boston, MA, 02116, USA. jalam@eippharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomperts</LastName><ForeName>Stephen N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Massachusetts Alzheimer's Disease Research Center, 114 16th Street, Massachusetts General Hospital, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6947-9537</Identifier><AffiliationInfo><Affiliation>Cogstate Ltd, Runway East Borough Market, 20 St. Thomas St, London, SE1 9RS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemstra</LastName><ForeName>Afina W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration, Amsterdam UMC at VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Research Center, Cronenburg 2, 1081 GN, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Germann</LastName><ForeName>Ursula A</ForeName><Initials>UA</Initials><AffiliationInfo><Affiliation>EIP Pharma Inc, 20 Park Plaza, Suite 424, Boston, MA, 02116, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavrides</LastName><ForeName>Philip H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darji</LastName><ForeName>Sandipkumar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malampati</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peddy</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleiwas</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlik</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pensalfini</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dun-Sheng</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbanna</LastName><ForeName>Shivakumar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basavarajappa</LastName><ForeName>Balapal S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY, 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, 1051 Riverside Dr., New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smiley</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardner</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>EIP Pharma Inc, 20 Park Plaza, Suite 424, Boston, MA, 02116, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackburn</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>EIP Pharma Inc, 20 Park Plaza, Suite 424, Boston, MA, 02116, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Hui-May</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Anoixis Corporation, 214 N. Main St. #104, Natick, MA, 01760, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prins</LastName><ForeName>Niels D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Brain Research Center, Cronenburg 2, 1081 GN, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration, Amsterdam UMC at VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>John E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-0225-4923</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration, Amsterdam UMC at VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metis Cognition Ltd, Park House, Kilmington Common, Warminster, BA12 6QY, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration, Amsterdam UMC at VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA. ralph.nixon@nki.rfmh.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA. ralph.nixon@nki.rfmh.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA. ralph.nixon@nki.rfmh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04001517</AccessionNumber></AccessionNumberList></DataBank><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>2019-001566-15</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AA019443</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062376</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048308">Mitogen-Activated Protein Kinase 14</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066187" MajorTopicYN="Y">Basal Forebrain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059329" MajorTopicYN="N">Cholinergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020558" MajorTopicYN="N">GTP Phosphohydrolases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048308" MajorTopicYN="N">Mitogen-Activated Protein Kinase 14</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36130946</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-32944-3</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-32944-3</ArticleId><ArticleId IdType="pmc">PMC9492778</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brain. 2020 Mar 1;143(3):993-1009</Citation><ArticleIdList><ArticleId IdType="pubmed">32203580</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2020 Jan 22;105(2):260-275.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">31759806</ArticleId></ArticleIdList></Reference><Reference><Citation>Continuum (Minneap Minn). 2019 Feb;25(1):34-51</Citation><ArticleIdList><ArticleId IdType="pubmed">30707186</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2021 May 27;13(1):106</Citation><ArticleIdList><ArticleId IdType="pubmed">34044875</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2022 Jun 3;145(5):1773-1784</Citation><ArticleIdList><ArticleId IdType="pubmed">34605858</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2021 Mar;36(3):767-771</Citation><ArticleIdList><ArticleId IdType="pubmed">33285015</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2014 Apr 9;34(15):5099-106</Citation><ArticleIdList><ArticleId IdType="pubmed">24719089</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13333-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8917591</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2019 Jul 3;39(27):5255-5268</Citation><ArticleIdList><ArticleId IdType="pubmed">31043483</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2017 Jul 4;89(1):88-100</Citation><ArticleIdList><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2018 May 22;9(6):596</Citation><ArticleIdList><ArticleId IdType="pubmed">29789529</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2022 Jan-Mar 01;36(1):64-72</Citation><ArticleIdList><ArticleId IdType="pubmed">34393189</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2000 Jul;157(1):277-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2021;30:102604</Citation><ArticleIdList><ArticleId IdType="pubmed">33711623</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2003 Jul;8(1):51-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12842428</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2021 Dec;46(13):2320-2329</Citation><ArticleIdList><ArticleId IdType="pubmed">34188186</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2019 Sep;15(9):1133-1148</Citation><ArticleIdList><ArticleId IdType="pubmed">31378574</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1630-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2021 Apr 05;7(1):e12153</Citation><ArticleIdList><ArticleId IdType="pubmed">33842683</ArticleId></ArticleIdList></Reference><Reference><Citation>Anat Rec. 1991 Dec;231(4):482-97</Citation><ArticleIdList><ArticleId IdType="pubmed">1793176</ArticleId></ArticleIdList></Reference><Reference><Citation>Elife. 2021 Apr 06;10:</Citation><ArticleIdList><ArticleId IdType="pubmed">33821790</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Jul 30;23(17):6788-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12890772</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2014 Oct;261(10):1939-48</Citation><ArticleIdList><ArticleId IdType="pubmed">25059393</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2021 Apr 12;144(3):781-788</Citation><ArticleIdList><ArticleId IdType="pubmed">33521808</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2017 Jan 17;88(3):276-283</Citation><ArticleIdList><ArticleId IdType="pubmed">27940650</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Methods. 2009 May;41(2):472-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19363187</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2015;48(1):219-27</Citation><ArticleIdList><ArticleId IdType="pubmed">26401942</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2016 Jan 29;291(5):2067-79</Citation><ArticleIdList><ArticleId IdType="pubmed">26663083</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Commun. 2022 Feb 07;4(2):fcac013</Citation><ArticleIdList><ArticleId IdType="pubmed">35415608</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Feb 15;295(5558):1291-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11847341</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Dis. 2010 Dec;1(3):199-211</Citation><ArticleIdList><ArticleId IdType="pubmed">22720195</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2005 Apr 21;46(2):173-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15848797</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2003;117(4):909-19</Citation><ArticleIdList><ArticleId IdType="pubmed">12654342</ArticleId></ArticleIdList></Reference><Reference><Citation>J Prev Alzheimers Dis. 2019;6(1):2-15</Citation><ArticleIdList><ArticleId IdType="pubmed">30569080</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2015 Jul 28;19(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">26221005</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2004;17 Suppl 1:3-14</Citation><ArticleIdList><ArticleId IdType="pubmed">14676464</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2016 Sep;108:128-35</Citation><ArticleIdList><ArticleId IdType="pubmed">26876309</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 2013 Jan;33(1):127-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23109423</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2017 Jul;31(7):2729-2743</Citation><ArticleIdList><ArticleId IdType="pubmed">28663518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2004;18(1):94-100</Citation><ArticleIdList><ArticleId IdType="pubmed">15087584</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2021 Jul;35(7):e21691</Citation><ArticleIdList><ArticleId IdType="pubmed">34118085</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Mar 31;7:45306</Citation><ArticleIdList><ArticleId IdType="pubmed">28361984</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Mol Neurosci. 2020 Sep 08;13:570586</Citation><ArticleIdList><ArticleId IdType="pubmed">33013322</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2020 Feb 1;77(2):225-233</Citation><ArticleIdList><ArticleId IdType="pubmed">31657834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 May;21(5):707-16</Citation><ArticleIdList><ArticleId IdType="pubmed">26194181</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vis Exp. 2015 Feb 06;(96):e52434</Citation><ArticleIdList><ArticleId IdType="pubmed">25742564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2001 Feb;7(2):421-32</Citation><ArticleIdList><ArticleId IdType="pubmed">11239470</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2002 Jul-Aug;23(4):601-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12009509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2014;40(3):737-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24577458</ArticleId></ArticleIdList></Reference><Reference><Citation>Autophagy. 2016 Dec;12(12):2516-2520</Citation><ArticleIdList><ArticleId IdType="pubmed">27715387</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2016 Nov 04;7:13249</Citation><ArticleIdList><ArticleId IdType="pubmed">27811848</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2020 Nov 24;33(8):108420</Citation><ArticleIdList><ArticleId IdType="pubmed">33238112</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2000 Aug;27(2):279-88</Citation><ArticleIdList><ArticleId IdType="pubmed">10985348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Aug 24;31(34):12059-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21865449</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10439-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11504920</ArticleId></ArticleIdList></Reference><Reference><Citation>J Prev Alzheimers Dis. 2017;4(4):273-278</Citation><ArticleIdList><ArticleId IdType="pubmed">29181493</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2002;13(3):183-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11893841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2013 Feb 14;152(4):924-924.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">23415236</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2004 Oct 1;1022(1-2):101-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15353219</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2017 Jan 13;5(1):7</Citation><ArticleIdList><ArticleId IdType="pubmed">28086964</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2016 Mar;39:90-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26923405</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2020 Dec 4;15(12):e0233073</Citation><ArticleIdList><ArticleId IdType="pubmed">33275615</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2001 Jul 15;21(14):5239-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11438599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Jun 20;7(1):3868</Citation><ArticleIdList><ArticleId IdType="pubmed">28634349</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2020 Fall;32(4):370-375</Citation><ArticleIdList><ArticleId IdType="pubmed">32498602</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2019 May 07;13:446</Citation><ArticleIdList><ArticleId IdType="pubmed">31133787</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2017 Dec 01;4:11-18</Citation><ArticleIdList><ArticleId IdType="pubmed">29296659</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2019 Mar 18;10:237</Citation><ArticleIdList><ArticleId IdType="pubmed">30936831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2021 Mar;36(3):611-621</Citation><ArticleIdList><ArticleId IdType="pubmed">33382126</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2021 Jul 12;13:703876</Citation><ArticleIdList><ArticleId IdType="pubmed">34322015</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2020 Dec;146:105134</Citation><ArticleIdList><ArticleId IdType="pubmed">33045357</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2022 Mar 1;98(9):e947-e957</Citation><ArticleIdList><ArticleId IdType="pubmed">34969939</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2021 Jan;268(1):95-101</Citation><ArticleIdList><ArticleId IdType="pubmed">32725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2008 Aug;173(2):370-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18535180</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36130840</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10.1212/WNL.0000000000201043</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000201043</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">ATN (β-Amyloid, Tau, Neurodegeneration) system categorizes individuals based on their core Alzheimer's disease (AD) biomarkers. An important potential future use for ATN is therapeutic decision-making in clinical practice once disease-modifying treatments, e.g., anti-amyloid, become widely available. In this cross-sectional study, we applied ATN and estimated potential eligibility for anti-amyloid treatment in a real-life memory clinic with biomarker assessments integrated into the routine diagnostic procedure and all specialized resources available for the implementation of novel treatments.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included all consecutive patients at the Karolinska University Hospital Memory clinic in Solna, Stockholm, Sweden, who had their first diagnostic visit in April 2018-February 2021, informed consent for the clinic research database, and available clinical and biomarker (CSF, imaging) data. ATN classification was based on CSF Aβ42 (or Aβ42/40; A), CSF phosphorylated tau (T), and medial temporal lobe atrophy (N). For CSF markers, we applied laboratory cut-offs and data-driven cut-offs for comparison (determined with Gaussian mixture modelling). Anti-amyloid treatment eligibility was assessed following the published recommendations for aducanumab (AD dementia or MCI with no evidence of non-AD etiology, appropriate level of cognition, AD-consistent CSF profile).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Study population consisted of 410 patients (52% subjective cognitive impairment, 23% mild cognitive impairment MCI, 25% any dementia; age 59±7 years, 56% women). Regardless of biomarker cut-offs, most patients were A-T-N- (54-57%). A+ prevalence was 17-30% (higher with data-driven cut-offs). Up to 13% of all patients (27% of those with MCI and 28% of those with dementia) were potentially eligible for anti-amyloid treatment when AD-consistent CSF was defined as any A+ profile. When A+T+ profile was required, treatment was targeted more to the dementia than MCI stage (eligibility up to 14% in MCI, 22% in dementia). The opposite applied to earlier stage intervention (A+T-N-; eligibility up to 12% in MCI, 2% in dementia).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">In a memory clinic setting with all necessary infrastructure and national guidelines in place for dementia diagnostic examination ("best-case scenario"), most patients did not meet the eligibility criteria for anti-amyloid treatment. Continuing the development of disease-modifying treatments with different mechanisms of action is a priority.</AbstractText><CopyrightInformation>© 2022 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; anna.rosenberg@ki.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Öhlund-Wistbacka</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Aging, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Anette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnard</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Unit Aging, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagman</LastName><ForeName>Göran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Unit Aging, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rydén</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Unit Aging, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thunborg</LastName><ForeName>Charlotta</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Aging, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiggenraad</LastName><ForeName>Fleur</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medical Unit Aging, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandebring-Matton</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurogeriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivipelto</LastName><ForeName>Miia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Aging, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36130840</ArticleId><ArticleId IdType="pii">WNL.0000000000201043</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000201043</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36130664</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0953</ISSN><JournalIssue CitedMedium="Internet"><Volume>215</Volume><Issue>Pt 2</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Environmental research</Title><ISOAbbreviation>Environ Res</ISOAbbreviation></Journal><ArticleTitle>Mitigating the impact of air pollution on dementia and brain health: Setting the policy agenda.</ArticleTitle><Pagination><MedlinePgn>114362</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0013-9351(22)01689-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.envres.2022.114362</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Emerging research suggests exposure to high levels of air pollution at critical points in the life-course is detrimental to brain health, including cognitive decline and dementia. Social determinants play a significant role, including socio-economic deprivation, environmental factors and heightened health and social inequalities. Policies have been proposed more generally, but their benefits for brain health have yet to be fully explored.</AbstractText><AbstractText Label="OBJECTIVE AND METHODS" NlmCategory="OBJECTIVE">Over the course of two years, we worked as a consortium of 20+ academics in a participatory and consensus method to develop the first policy agenda for mitigating air pollution's impact on brain health and dementia, including an umbrella review and engaging 11 stakeholder organisations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified three policy domains and 14 priority areas. Research and Funding included: (1) embracing a complexities of place approach that (2) highlights vulnerable populations; (3) details the impact of ambient PM<sub>2.5</sub> on brain health, including current and historical high-resolution exposure models; (4) emphasises the importance of indoor air pollution; (5) catalogues the multiple pathways to disease for brain health and dementia, including those most at risk; (6) embraces a life course perspective; and (7) radically rethinks funding. Education and Awareness included: (8) making this unrecognised public health issue known; (9) developing educational products; (10) attaching air pollution and brain health to existing strategies and campaigns; and (11) providing publicly available monitoring, assessment and screening tools. Policy Evaluation included: (12) conducting complex systems evaluation; (13) engaging in co-production; and (14) evaluating air quality policies for their brain health benefits.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Given the pressing issues of brain health, dementia and air pollution, setting a policy agenda is crucial. Policy needs to be matched by scientific evidence and appropriate guidelines, including bespoke strategies to optimise impact and mitigate unintended consequences. The agenda provided here is the first step toward such a plan.</AbstractText><CopyrightInformation>Crown Copyright © 2022. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castellani</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Durham Research Methods Centre, Durham University, Stockton Road, Durham, DH1 3LE, United Kingdom; Centre for the Evaluation of Complexity Across the Nexus, University of Surrey, Guildford, GU2 7XH, United Kingdom; Wolfson Research Institute for Health and Wellbeing, Durham University, Stockton Road, DH1 3LE, United Kingdom; Department of Sociology, Durham University, Stockton Road, Durham, DH1 3LE, United Kingdom. Electronic address: brian.c.castellani@durham.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartington</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wistow</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wolfson Research Institute for Health and Wellbeing, Durham University, Stockton Road, DH1 3LE, United Kingdom; Department of Sociology, Durham University, Stockton Road, Durham, DH1 3LE, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckels</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Research and Innovation Services, Durham University, Stockton Road, Durham, DH1 3LE, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellison</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wolfson Research Institute for Health and Wellbeing, Durham University, Stockton Road, DH1 3LE, United Kingdom; Department of Psychology, Durham University, Stockton Road, Durham, DH1 3LE, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Tongeren</LastName><ForeName>Martie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Occupational and Environmental Health, School of Health Sciences, University of Manchester, Manchester, M13 9PL, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steve R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>School of Earth &amp; Environment, University of Leeds, Leeds, LS2 9JT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbrook-Johnson</LastName><ForeName>Pete</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Complexity Across the Nexus, University of Surrey, Guildford, GU2 7XH, United Kingdom; Environmental Change Institute, School of Geography and the Environment, University of Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bicket</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Complexity Across the Nexus, University of Surrey, Guildford, GU2 7XH, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pope</LastName><ForeName>Francis D</ForeName><Initials>FD</Initials><AffiliationInfo><Affiliation>School of Geography, Earth and Environmental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russ</LastName><ForeName>Tom C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, United Kingdom; Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Charlotte L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Sociology, Durham University, Stockton Road, Durham, DH1 3LE, United Kingdom; School of Health in Social Science, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirani</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, W2 1PG, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwannauer</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Health in Social Science, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieno</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UK Centre for Ecology &amp; Hydrology, Bush Estate, Penicuik, Midlothian, EH26 0QB, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turnbull</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Academic Health Sciences Network, North East and North Cumbria, Nuns' Moor Road, Newcastle Upon Tyne NE4 5PL, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for the Evaluation of Complexity Across the Nexus, University of Surrey, Guildford, GU2 7XH, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UK Centre for Ecology &amp; Hydrology, Bush Estate, Penicuik, Midlothian, EH26 0QB, United Kingdom; University of Exeter Medical School, European Centre for Environment and Health, Knowledge Spa, Truro, TR1 3HD, United Kingdom; The University of Edinburgh, School of Chemistry, Level 3, Murchison House, 10 Max Born Crescent, The King's Buildings, West Mains Road, Edinburgh, EH9 3BF, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Environ Res</MedlineTA><NlmUniqueID>0147621</NlmUniqueID><ISSNLinking>0013-9351</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000393">Air Pollutants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052638">Particulate Matter</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000393" MajorTopicYN="Y">Air Pollutants</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000397" MajorTopicYN="Y">Air Pollution</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052638" MajorTopicYN="N">Particulate Matter</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057766" MajorTopicYN="N">Policy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Air pollution</Keyword><Keyword MajorTopicYN="N">Brain health</Keyword><Keyword MajorTopicYN="N">Complex systems theory</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Public policy</Keyword><Keyword MajorTopicYN="N">Social and health inequalities</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36130664</ArticleId><ArticleId IdType="pii">S0013-9351(22)01689-9</ArticleId><ArticleId IdType="doi">10.1016/j.envres.2022.114362</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36130492</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>09</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Association of B cell profile and receptor repertoire with the progression of Alzheimer's disease.</ArticleTitle><Pagination><MedlinePgn>111391</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(22)01228-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2022.111391</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most prevalent type of dementia. Reports have revealed that the peripheral immune system is linked to neuropathology; however, little is known about the contribution of B lymphocytes in AD. For this longitudinal study, 133 participants are included at baseline and second-year follow-up. Also, we analyze B cell receptor (BCR) repertoire data generated from a public dataset of three normal and 10 AD samples and perform BCR repertoire profiling and pairwise sharing analysis. As a result, longitudinal increase in B lymphocytes is associated with increased cerebral amyloid deposition and hyperactivates induced pluripotent stem cell-derived microglia with loss-of-function for beta-amyloid clearance. Patients with AD share similar class-switched BCR sequences with identical isotypes, despite the high somatic hypermutation rate. Thus, BCR repertoire profiling can lead to the development of individualized immune-based therapeutics and treatment. We provide evidence of both quantitative and qualitative changes in B lymphocytes during AD pathogenesis.</AbstractText><CopyrightInformation>Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jong-Chan</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Neuroscience Research Institute, Medical Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; SNU Dementia Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noh</LastName><ForeName>Jinsung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea; Bio-MAX Institute, Seoul National University, Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Sukjin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ki Hyun</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hayoung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; SNU Dementia Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dongjoon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; SNU Dementia Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jieun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Junho</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea; Department of Biomedical Science, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Young</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Institute of Human Behavioral Medicine, Medical Research Center, Seoul National University, Seoul 03080, Republic of Korea; Department of Psychiatry, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yonghee</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyunho</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Duck Kyun</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea; Department of Biomedical Science, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Amos Chungwon</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Bio-MAX Institute, Seoul National University, Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byun</LastName><ForeName>Min Soo</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Dahyun</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Sun-Ho</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Neuroscience Research Institute, Medical Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; SNU Dementia Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea. Electronic address: sunho@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Sunghoon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea; Bio-MAX Institute, Seoul National University, Seoul 08826, Republic of Korea; BK21+ Creative Research Engineer Development for IT, Seoul National University, Seoul 08826, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea; Interdisciplinary Program in Bioengineering, Seoul National University, Seoul 08826, Republic of Korea. Electronic address: skwon@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mook-Jung</LastName><ForeName>Inhee</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Neuroscience Research Institute, Medical Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; SNU Dementia Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea. Electronic address: inhee@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011947" MajorTopicYN="N">Receptors, Antigen, B-Cell</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">B cell receptor repertoire</Keyword><Keyword MajorTopicYN="N">B lymphocyte</Keyword><Keyword MajorTopicYN="N">CP: Immunology</Keyword><Keyword MajorTopicYN="N">CP: Neuroscience</Keyword><Keyword MajorTopicYN="N">Pittsburgh compound B</Keyword><Keyword MajorTopicYN="N">cerebral amyloid deposition</Keyword><Keyword MajorTopicYN="N">immunoglobulin G</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cell</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>02</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36130492</ArticleId><ArticleId IdType="pii">S2211-1247(22)01228-1</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.111391</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36130217</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1347-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>20</Day></PubDate></JournalIssue><Title>Bioscience, biotechnology, and biochemistry</Title><ISOAbbreviation>Biosci Biotechnol Biochem</ISOAbbreviation></Journal><ArticleTitle>Black rice bran intake reduces phosphorylated tau levels and enhances insulin signaling in the brain of aged normal mice.</ArticleTitle><Pagination><MedlinePgn>1570-1575</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/bbb/zbac125</ELocationID><Abstract><AbstractText>This study reports that black rice bran (BRB) intake for 50-52 consecutive weeks (∼12 months) reduces tau phosphorylation with a concomitant activation of insulin signaling and subsequent PI3K/AKT pathway in the brain of aged normal mice. BRB holds promise for preventing the formation of neurofibrillary tangles consisting of hyperphosphorylated tau, a pathological hallmark of Alzheimer's disease.</AbstractText><CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of Japan Society for Bioscience, Biotechnology, and Agrochemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Agriculture, Faculty of Agriculture, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toyama</LastName><ForeName>Hanae</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Graduate School of Science and Technology, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohata</LastName><ForeName>Yumi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Graduate School of Science and Technology, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8828-8085</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Sumiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joh</LastName><ForeName>Toshio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Agriculture, Faculty of Agriculture, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohtsubo</LastName><ForeName>Ken'ichi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9354-3087</Identifier><AffiliationInfo><Affiliation>Faculty of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>01026C</GrantID><Agency>NARO</Agency><Country/></Grant><Grant><Agency>Cabinet Office, Government of Japan</Agency><Country/></Grant><Grant><Agency>Cross-ministerial Strategic Innovation Promotion Program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biosci Biotechnol Biochem</MedlineTA><NlmUniqueID>9205717</NlmUniqueID><ISSNLinking>0916-8451</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012275" MajorTopicYN="Y">Oryza</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PI3K/AKT pathway</Keyword><Keyword MajorTopicYN="N">aged normal mice</Keyword><Keyword MajorTopicYN="N">black rice</Keyword><Keyword MajorTopicYN="N">insulin signaling</Keyword><Keyword MajorTopicYN="N">tau phosphorylation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>16</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36130217</ArticleId><ArticleId IdType="pii">6708367</ArticleId><ArticleId IdType="doi">10.1093/bbb/zbac125</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36130084</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Gliovascular alterations in sporadic and familial Alzheimer's disease: APOE3 Christchurch homozygote glioprotection.</ArticleTitle><Pagination><MedlinePgn>e13119</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.13119</ELocationID><Abstract><AbstractText>In response to brain insults, astrocytes become reactive, promoting protection and tissue repair. However, astroglial reactivity is typical of brain pathologies, including Alzheimer's disease (AD). Considering the heterogeneity of the reactive response, the role of astrocytes in the course of different forms of AD has been underestimated. Colombia has the largest human group known to have familial AD (FAD). This group carries the autosomal dominant and fully penetrant mutation E280A in PSEN1, which causes early-onset AD. Recently, our group identified an E280A carrier who did not develop FAD. The individual was homozygous for the Christchurch mutation R136S in APOE3 (APOEch). Remarkably, APOE is the main genetic risk factor for developing sporadic AD (SAD) and most of cerebral ApoE is produced by astroglia. Here, we characterized astrocyte properties related to reactivity, glutamate homeostasis, and structural integrity of the gliovascular unit (GVU), as factors that could underlie the pathogenesis or protection of AD. Specifically, through histological and 3D microscopy analyses of postmortem samples, we briefly describe the histopathology and cytoarchitecture of the frontal cortex of SAD, FAD, and APOEch, and demonstrate that, while astrodegeneration and vascular deterioration are prominent in SAD, FAD is characterized by hyperreactive-like glia, and APOEch displays the mildest astrocytic and vascular alterations despite having the highest burden of Aβ. Notably, astroglial, gliovascular, and vascular disturbances, as well as brain cell death, correlate with the specific astrocytic phenotypes identified in each condition. This study provides new insights into the potential relevance of the gliovasculature in the development and protection of AD. To our knowledge, this is the first study assessing the components of the GVU in human samples of SAD, FAD, and APOEch.</AbstractText><CopyrightInformation>© 2022 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henao-Restrepo</LastName><ForeName>Julián</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-4988-5220</Identifier><AffiliationInfo><Affiliation>Instituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Área de Neurobiología Celular y Molecular, Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Murillo</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Área de Neurobiología Celular y Molecular, Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valderrama-Carmona</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Instituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Área de Neurobiología Celular y Molecular, Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orozco-Santa</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-6911-9021</Identifier><AffiliationInfo><Affiliation>Instituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Área de Neurobiología Celular y Molecular, Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Johana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia, Facultad de Medicina, SIU, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutiérrez-Vargas</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences Faculty, Remington University Corporation, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moraga</LastName><ForeName>Renato</ForeName><Initials>R</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9412-3380</Identifier><AffiliationInfo><Affiliation>Biomedical Neuroscience Institute BNI, Faculty of Medicine, University of Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toledo</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8678-558X</Identifier><AffiliationInfo><Affiliation>Biomedical Neuroscience Institute BNI, Faculty of Medicine, University of Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Littau</LastName><ForeName>Jessica Lisa</ForeName><Initials>JL</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4609-1828</Identifier><AffiliationInfo><Affiliation>Molecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Härtel</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8913-1757</Identifier><AffiliationInfo><Affiliation>Biomedical Neuroscience Institute BNI, Faculty of Medicine, University of Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arboleda-Velásquez</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulveda-Falla</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0176-2042</Identifier><AffiliationInfo><Affiliation>Molecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5238-0231</Identifier><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia, Facultad de Medicina, SIU, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardona-Gómez</LastName><ForeName>Gloria Patricia</ForeName><Initials>GP</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3814-4494</Identifier><AffiliationInfo><Affiliation>Área de Neurobiología Celular y Molecular, Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villegas</LastName><ForeName>Andrés</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1971-4364</Identifier><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia, Facultad de Medicina, SIU, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada-Duque</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-4492-3400</Identifier><AffiliationInfo><Affiliation>Instituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Área de Neurobiología Celular y Molecular, Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>111577757128</GrantID><Agency>Minciencias, the National Government for the management of the National System of Science, Technology, and Innovation (SNCTI) in Colombia</Agency><Country/></Grant><Grant><GrantID>RF1NS110048</GrantID><Agency>US National Institute of Neurological Disorders and Stroke and National Institute on Aging</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOEch</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">familial Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">gliovascular unit</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">sporadic Alzheimer's disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>15</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36130084</ArticleId><ArticleId IdType="doi">10.1111/bpa.13119</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007;10(11):1369-76.</Citation></Reference><Reference><Citation>Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006 Jan;7(1):41-53.</Citation></Reference><Reference><Citation>Muoio V, Persson PB, Sendeski MM. The neurovascular unit-concept review. Acta Physiol. 2014;210(4):790-8.</Citation></Reference><Reference><Citation>Liedtke W, Edelmann W, Bieri PL, Chiu FC, Cowan NJ, Kucherlapati R, et al. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron. 1996;17(4):607-15.</Citation></Reference><Reference><Citation>Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419-34.</Citation></Reference><Reference><Citation>Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163(5):1064-78.</Citation></Reference><Reference><Citation>Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584-96.</Citation></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-38.</Citation></Reference><Reference><Citation>Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133-50.</Citation></Reference><Reference><Citation>Lv J, Hu W, Yang Z, Li T, Jiang S, Ma Z, et al. Focusing on claudin-5: a promising candidate in the regulation of BBB to treat ischemic stroke. Prog Neurobiol. 2018;161:79-96.</Citation></Reference><Reference><Citation>Dave JM, Bayless KJ. Vimentin as an integral regulator of cell adhesion and endothelial sprouting. Microcirculation. 2014;21:333-44.</Citation></Reference><Reference><Citation>Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA, Pozzan T, et al. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci. 2003;6:43-50.</Citation></Reference><Reference><Citation>Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, et al. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci. 2006;9:260-7.</Citation></Reference><Reference><Citation>Metea MR, Newman EA. Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. J Neurosci. 2006;26(11):2862-70.</Citation></Reference><Reference><Citation>Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev. 2018;98(1):239-389.</Citation></Reference><Reference><Citation>Marín-padilla M. Prenatal development of fibrous (white matter), protoplasmic (gray matter), and layer I astrocytes in the human cerebral cortex: a Golgi study. J Comp Neurol. 1995;357(4):554-72.</Citation></Reference><Reference><Citation>Kacem K, Lacombe P, Seylaz J, Bonvento G. Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: a confocal microscopy study. Glia. 1998;23(1):1-10.</Citation></Reference><Reference><Citation>Nedergaard M, Ransom B, Goldman SA. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci. 2003;26(10):523-30.</Citation></Reference><Reference><Citation>Petzold GC, Murthy VN. Role of astrocytes in neurovascular coupling. Neuron. 2011;71(5):782-97.</Citation></Reference><Reference><Citation>Filosa JA, Morrison HW, Iddings JA, Du W, Kim KJ. Beyond neurovascular coupling, role of astrocytes in the regulation of vascular tone. Neuroscience. 2016;323(5):96-109.</Citation></Reference><Reference><Citation>Walls AB, Waagepetersen HS, Bak LK, Schousboe A, Sonnewald U. The glutamine-glutamate/GABA cycle: function, regional differences in glutamate and GABA production and effects of interference with GABA metabolism. Neurochem Res. 2014;40(2):402-9.</Citation></Reference><Reference><Citation>Tapiero H, Mathé G, Couvreur P, Tew KD II. Glutamine and glutamate. Biomed Pharmacother. 2002;56(9):446-57.</Citation></Reference><Reference><Citation>Hakvoort TBM, He Y, Kulik W, Vermeulen JLM, Duijst S, Ruijter JM, et al. Pivotal role of glutamine synthetase in ammonia detoxification. Hepatology. 2017;65(1):281-93.</Citation></Reference><Reference><Citation>Rose CF, Verkhratsky A, Parpura V. Astrocyte glutamine synthetase: pivotal in health and disease. Biochem Soc Trans. 2013;41(6):1518-24.</Citation></Reference><Reference><Citation>Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65(1):1-105.</Citation></Reference><Reference><Citation>Murphy-Royal C, Dupuis JP, Varela JA, Panatier A, Pinson B, Baufreton J, et al. Surface diffusion of astrocytic glutamate transporters shapes synaptic transmission. Nat Neurosci. 2015;18(2):219-26.</Citation></Reference><Reference><Citation>Son H, Kim S, Hyuk JD, Baek JH, Lee DH, Roh GS, et al. Insufficient glutamine synthetase activity during synaptogenesis causes spatial memory impairment in adult mice. Sci Rep. 2019;9(1):1-9.</Citation></Reference><Reference><Citation>Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V, Verkhratsky A. General pathophysiology of astroglia HHS public access. Adv Exp Med Biol. 2019;1175:149-79.</Citation></Reference><Reference><Citation>Albrecht J, Sidoryk-Wȩgrzynowicz M, Zielińska M, Aschner M. Roles of glutamine in neurotransmission. Neuron Glia Biol. 2010;6(4):263-76.</Citation></Reference><Reference><Citation>Roberts RC, Roche JK, McCullumsmith RE. Localization of excitatory amino acid transporters EAAT1 and EAAT2 in human postmortem cortex: a light and electron microscopic study. Neuroscience. 2014;277:522-40.</Citation></Reference><Reference><Citation>Arriza JL, Fairman WA, Amara SG, Kavanaugh P, Wadiche I, Murdoch H. Functional comparisons of three glutamate cloned from human motor cortex transporter. J Neurosci. 1994;14(9):5559-69.</Citation></Reference><Reference><Citation>Banner SJ, Fray AE, Ince PG, Steward M, Cookson MR, Shaw PJ. The expression of the glutamate re-uptake transporter excitatory amino acid transporter 1 (EAAT1) in the normal human CNS and in motor neurone disease: an immunohistochemical study. Neuroscience. 2002;109(1):27-44.</Citation></Reference><Reference><Citation>Armbruster M, Hanson E, Dulla CG. Glutamate clearance is locally modulated by presynaptic neuronal activity in the cerebral cortex. J Neurosci. 2016;36(40):10404-15.</Citation></Reference><Reference><Citation>Chaudhry FA, Lehre KP, van Lookeren Campagne M, Ottersen OP, Danbolt NC, Storm-Mathisen J. Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron. 1995;15(3):711-20.</Citation></Reference><Reference><Citation>Perego C, Vanoni C, Bossi M, Massari S, Basudev H, Longhi R, et al. The GLT-1 and GLAST glutamate transporters are expressed on morphologically distinct astrocytes and regulated by neuronal activity in primary hippocampal cocultures. J Neurochem. 2000;75(3):1076-84.</Citation></Reference><Reference><Citation>Sullivan SM, Lee A, Björkman ST, Miller SM, Sullivan RKP, Poronnik P, et al. Cytoskeletal anchoring of GLAST determines susceptibility to brain damage: an identified role for GFAP. J Biol Chem. 2007;282(40):29414-23.</Citation></Reference><Reference><Citation>Jha MK, Jo M, Kim JH, Suk K. Microglia-astrocyte crosstalk: an intimate molecular conversation. Neuroscientist. 2019;25:227-40.</Citation></Reference><Reference><Citation>Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7-35.</Citation></Reference><Reference><Citation>Hoogland ICM, Houbolt C, Van Westerloo DJ, Van Gool WA, Van De Beek D. Systemic inflammation and microglial activation: systematic review of animal experiments. J Neuroinflammation. 2012;12:114.</Citation></Reference><Reference><Citation>Murugan M, Ling E-A, Kaur C. Glutamate receptors in microglia. CNS Neurol Disord Drug Targets. 2013;12(6):773-84.</Citation></Reference><Reference><Citation>Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging. 2010;31(4):578-90.</Citation></Reference><Reference><Citation>Dossi E, Vasile F, Rouach N. Human astrocytes in the diseased brain. Brain Res Bull. 2018;136:139-56.</Citation></Reference><Reference><Citation>Verkhratsky A, Ho MS, Vardjan N, Zorec R, Parpura V. General pathophysiology of astroglia. Adv Exp Med Biol. 2019;1175:149-79.</Citation></Reference><Reference><Citation>Kamphuis W, Kooijman L, Orre M, Stassen O, Pekny M, Hol EM. GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer's disease. Glia. 2015;63(6):1036-56.</Citation></Reference><Reference><Citation>Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015;32:121-30.</Citation></Reference><Reference><Citation>Lechuga-Sancho AM, Arroba AI, Frago LM, García-Cáceres C, Delgado-Rubín De Célix A, Argente J, et al. Reduction in the number of astrocytes and their projections is associated with increased synaptic protein density in the hypothalamus of poorly controlled diabetic rats. Endocrinology. 2006;147(11):5314-24.</Citation></Reference><Reference><Citation>Verkhratsky A. Astroglial calcium signaling in aging and Alzheimer's disease. Cold Spring Harb Perspect Biol. 2019;11(7):a035188.</Citation></Reference><Reference><Citation>Liu CY, Yang Y, Ju WN, Wang X, Zhang HL. Emerging roles of astrocytes in neuro-vascular unit and the tripartite synapse with emphasis on reactive gliosis in the context of Alzheimer's disease. Front Cell Neurosci. 2018;12:1-12.</Citation></Reference><Reference><Citation>Matias I, Morgado J, Gomes FCA. Astrocyte heterogeneity: impact to brain aging and disease. Front Aging Neurosci. 2019;11:1-18.</Citation></Reference><Reference><Citation>Osipova ED, Semyachkina-Glushkovskaya OV, Morgun AV, Pisareva NV, Malinovskaya NA, Boitsova EB, et al. Gliotransmitters and cytokines in the control of blood-brain barrier permeability. Rev Neurosci. 2018;29(5):567-91.</Citation></Reference><Reference><Citation>Vazana U, Veksler R, Pell GS, Prager O, Fassler M, Chassidim Y, et al. Glutamate-mediated blood-brain barrier opening: implications for neuroprotection and drug delivery. J Neurosci. 2016;36(29):7727-39.</Citation></Reference><Reference><Citation>Clarke LE, Liddelow SA, Chakraborty C, Münch AE, Heiman M, Barres BA. Normal aging induces A1-like astrocyte reactivity. Proc Natl Acad Sci U S A. 2018;115(8):E1896-905.</Citation></Reference><Reference><Citation>Jack CR, Hampel HJ, Universities S, Cu M, Petersen RC. A new classification system for AD, independent of cognition A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):1-10. https://n.neurology.org/content/87/5/539</Citation></Reference><Reference><Citation>Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018;25(1):59-70.</Citation></Reference><Reference><Citation>Mendez MF. Early-onset Alzheimer disease and its variants. Contin Lifelong Learn Neurol. 2019;25(1):34-51.</Citation></Reference><Reference><Citation>Sepulveda-Falla D, Glatzel M, Lopera F. Phenotypic profile of early-onset familial Alzheimer's disease caused by presenilin-1 E280A mutation. J Alzheimers Dis. 2012;32(1):1-12.</Citation></Reference><Reference><Citation>Rabinovici BGD. Late-onset Alzheimer disease. Continuum. 2019;25:14-33.</Citation></Reference><Reference><Citation>Breteler MMB. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging. 2000;21(2):153-60.</Citation></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's Res Ther. 2011;2(6):1-13.</Citation></Reference><Reference><Citation>Lopera F, Giraldo M, Acosta N, Munoz C, Moreno S, Tirado V, et al. O2-03-05: Alzheimer's Prevention Initiative Colombia registry in the PSEN1 E280A mutation kindred. Alzheimers Dement. 2013;9(4):P321.</Citation></Reference><Reference><Citation>Lalli MA, Cox HC, Arcila ML, Cadavid L, Moreno S, Garcia G, et al. Origin of the PSEN1 E280A mutation causing early-onset Alzheimer's disease. Alzheimers Dement. 2014;10(5):S277-S283.e10.</Citation></Reference><Reference><Citation>Arboleda-Velasquez JF, Lopera F, O'Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680-3.</Citation></Reference><Reference><Citation>Yamazaki Y, Shinohara M, Yamazaki A, Ren Y, Asmann YW, Kanekiyo T, et al. ApoE (Apolipoprotein E) in brain pericytes regulates endothelial function in an isoform-dependent manner by modulating basement membrane components. Arterioscler Thromb Vasc Biol. 2020;40(1):128-44.</Citation></Reference><Reference><Citation>Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008;28(45):11445-53.</Citation></Reference><Reference><Citation>Sepulveda-Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta-Uribe J, Vila-Castelar C, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022;1:1-13.</Citation></Reference><Reference><Citation>Littau JL, Velilla L, Hase Y, Villalba-Moreno ND, Hagel C, Drexler D, et al. Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease. Brain Pathol. 2022;e13097.</Citation></Reference><Reference><Citation>González-Molina LA, Villar-Vesga J, Henao-Restrepo J, Villegas A, Lopera F, Cardona-Gómez GP, et al. Extracellular vesicles from 3xTg-AD mouse and Alzheimer's disease patient astrocytes impair neuroglial and vascular components. Front Aging Neurosci. 2021;13:593927.</Citation></Reference><Reference><Citation>De Strooper B, Karran E. The cellular phase of Alzheimer's disease. Cell. 2016;164(4):603-15.</Citation></Reference><Reference><Citation>Ricciarelli R, Fedele E. The amyloid cascade hypothesis in Alzheimer's disease: it's time to change our mind. Curr Neuropharmacol. 2017;15(6):926-35.</Citation></Reference><Reference><Citation>Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011;17(9):1060-5.</Citation></Reference><Reference><Citation>Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation. 2005;2:1-12.</Citation></Reference><Reference><Citation>Villamil-Ortiz JG, Barrera-Ocampo A, Arias-Londoño JD, Villegas A, Lopera F, Cardona-Gómez GP. Differential pattern of phospholipid profile in the temporal cortex from E280A-familiar and sporadic Alzheimer's disease brains. J Alzheimers Dis. 2018;61(1):209-19.</Citation></Reference><Reference><Citation>Villar-Vesga J, Henao-Restrepo J, Voshart DC, Aguillón D, Villegas A, Castaño D, et al. Differential profile of systemic extracellular vesicles from sporadic and familiar Alzheimer's disease leads to neuroglial and endothelial cell degeneration. Front Aging Neurosci. 2020;12:587989.</Citation></Reference><Reference><Citation>Sepulveda-Falla D, Barrera-Ocampo A, Hagel C, Korwitz A, Vinueza-Veloz MF, Zhou K, et al. Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis. J Clin Invest. 2014;124(4):1552-67.</Citation></Reference><Reference><Citation>Sepulveda-Falla D, Matschke J, Bernreuther C, Hagel C, Puig B, Villegas A, et al. Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease. Brain Pathol. 2011;21(4):452-63.</Citation></Reference><Reference><Citation>Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, et al. Qualitative changes in human γ-secretase underlie familial Alzheimer's disease. J Exp Med. 2015;212(12):2003-13.</Citation></Reference><Reference><Citation>Dinkel F, Trujillo-Rodriguez D, Villegas A, Streffer J, Mercken M, Lopera F, et al. Decreased deposition of beta-amyloid 1-38 and increased deposition of beta-amyloid 1-42 in brain tissue of Presenilin-1 E280A familial Alzheimer's disease patients. Front Aging Neurosci. 2020;12:1-13.</Citation></Reference><Reference><Citation>Pera M, Alcolea D, Sánchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, et al. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol. 2013;125(2):201-13.</Citation></Reference><Reference><Citation>Rasmussen J, Mahler J, Beschorner N, Kaeser SA, Häsler LM, Baumann F, et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease. Proc Natl Acad Sci U S A. 2017;114(49):13018-23.</Citation></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676-82.</Citation></Reference><Reference><Citation>Longair MH, Baker DA, Armstrong JD. Simple neurite tracer: open source software for reconstruction, visualization and analysis of neuronal processes. Bioinformatics. 2011;27(17):2453-4.</Citation></Reference><Reference><Citation>Fernández-Arjona MDM, Grondona JM, Granados-Durán P, Fernández-Llebrez P, López-Ávalos MD. Microglia morphological categorization in a rat model of neuroinflammation by hierarchical cluster and principal components analysis. Front Cell Neurosci. 2017;11:1-22.</Citation></Reference><Reference><Citation>Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):1-7.</Citation></Reference><Reference><Citation>Berg S, Kutra D, Kroeger T, Straehle CN, Kausler BX, Haubold C, et al. Ilastik: interactive machine learning for (bio)image analysis. Nat Methods. 2019;16(12):1226-32.</Citation></Reference><Reference><Citation>Ollion J, Cochennec J, Loll F, Escudé C, Boudier T. TANGO: a generic tool for high-throughput 3D image analysis for studying nuclear organization. Bioinformatics. 2013;29(14):1840-1.</Citation></Reference><Reference><Citation>Huang L, Nakamura Y, Lo EH, Hayakawa K. Astrocyte signaling in the neurovascular unit after central nervous system injury. Int J Mol Sci. 2019;20:282.</Citation></Reference><Reference><Citation>Kugler EC, Greenwood J, MacDonald RB. The “neuro-glial-vascular” unit: the role of glia in neurovascular unit formation and dysfunction. Front Cell Dev Biol. 2021;27:9.</Citation></Reference><Reference><Citation>Lau SF, Cao H, Fu AKY, Ip NY. Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer's disease. Proc Natl Acad Sci U S A. 2020;117(41):25800-9.</Citation></Reference><Reference><Citation>Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.</Citation></Reference><Reference><Citation>DeFelipe J, Alonso-Nanclares L, Arellano JI. Microstructure of the neocortex: comparative aspects. J Neurocytol. 2002;31:299-316.</Citation></Reference><Reference><Citation>Hol EM, Capetanaki Y. Type III intermediate filaments desmin, glial fibrillary acidic protein (GFAP), vimentin, and peripherin. Cold Spring Harb Perspect Biol. 2017;9(12):1-18.</Citation></Reference><Reference><Citation>Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421-43.</Citation></Reference><Reference><Citation>Sepulveda-Falla D, Arboleda-Velasquez JF. Distinct autosomal dominant Alzheimer's disease tau pathology distribution and single-cell transcriptome profiles associated with delayed clinical onset in an APOE3 Christchurch homozygote. Nat Med. 2022 (in review).</Citation></Reference><Reference><Citation>Ortinski PI, Dong J, Mungenast A, Yue C, Takano H, Watson DJ, et al. Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat Neurosci. 2010;13(5):584-91.</Citation></Reference><Reference><Citation>Fluteau A, Ince PG, Minett T, Matthews FE, Brayne C, Garwood CJ, et al. The nuclear retention of transcription factor FOXO3a correlates with a DNA damage response and increased glutamine synthetase expression by astrocytes suggesting a neuroprotective role in the ageing brain. Neurosci Lett. 2015;609:11-7.</Citation></Reference><Reference><Citation>Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K. L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: the “collusion” hypothesis for increased extracellular L-glutamate concentration in neuroinflammation. J Neuroinflammation. 2012;9:1-17.</Citation></Reference><Reference><Citation>Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nat Med. 2014;20(8):886-96.</Citation></Reference><Reference><Citation>Bayraktar OA, Bartels T, Holmqvist S, Kleshchevnikov V, Martirosyan A, Polioudakis D, et al. Astrocyte layers in the mammalian cerebral cortex revealed by a single-cell in situ transcriptomic map. Nat Neurosci. 2020;23(4):500-9.</Citation></Reference><Reference><Citation>Morel L, Chiang MSR, Higashimori H, Shoneye T, Iyer LK, Yelick J, et al. Molecular and functional properties of regional astrocytes in the adult brain. J Neurosci. 2017;37(36):8706-17.</Citation></Reference><Reference><Citation>Köhler S, Winkler U, Hirrlinger J. Heterogeneity of astrocytes in grey and white matter. Neurochem Res. 2019;46:3-14.</Citation></Reference><Reference><Citation>Morel L, Men Y, Chiang MSR, Tian Y, Jin S, Yelick J, et al. Intracortical astrocyte subpopulations defined by astrocyte reporter mice in the adult brain. Glia. 2019;67(1):171-81.</Citation></Reference><Reference><Citation>Papageorgiou IE, Valous NA, Lahrmann B, Janova H, Klaft ZJ, Koch A, et al. Astrocytic glutamine synthetase is expressed in the neuronal somatic layers and down-regulated proportionally to neuronal loss in the human epileptic hippocampus. Glia. 2018;66(5):920-33.</Citation></Reference><Reference><Citation>Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17(11):1016-24.</Citation></Reference><Reference><Citation>Zeppenfeld DM, Simon M, Haswell JD, D'Abreo D, Murchison C, Quinn JF, et al. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. JAMA Neurol. 2017;74(1):91-9.</Citation></Reference><Reference><Citation>Greene C, Hanley N, Campbell M. Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS. 2019;16:3.</Citation></Reference><Reference><Citation>Nichols NR, Day JR, Laping NJ, Johnson SA, Finch CE. GFAP mRNA increases with age in rat and human brain. Neurobiol Aging. 1993;14(5):421-9.</Citation></Reference><Reference><Citation>Khakh BS, Sofroniew MV. Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci. 2015;18(7):942-52.</Citation></Reference><Reference><Citation>Oberheim NA, Wang X, Goldman S, Nedergaard M. Astrocytic complexity distinguishes the human brain. Trends Neurosci. 2006;29(10):547-53.</Citation></Reference><Reference><Citation>Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32:638-47.</Citation></Reference><Reference><Citation>Serrano-Pozo A, Gómez-Isla T, Growdon JH, Frosch MP, Hyman BT. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol. 2013;182(6):2332-44.</Citation></Reference><Reference><Citation>Villar-Vesga J. Astrocyte extracellular vesicles from Alzheimer patients damage neurovascular unit cells. Medellín: University of Antioquia; 2020.</Citation></Reference><Reference><Citation>Walton HS, Dodd PR. Glutamate-glutamine cycling in Alzheimer's disease. Neurochem Int. 2007;50(7-8):1052-66.</Citation></Reference><Reference><Citation>Tong H, Zhang X, Meng X, Xu P, Zou X, Qu S. Amyloid-beta peptide decreases expression and function of glutamate transporters in nervous system cells. Int J Biochem Cell Biol. 2017;85:75-84.</Citation></Reference><Reference><Citation>Ugbode C, Hu Y, Whalley B, Peers C, Rattray M, Dallas ML. Astrocytic transporters in Alzheimer's disease. Biochem J. 2017;474(3):333-55.</Citation></Reference><Reference><Citation>Schallier A, Smolders I, Van Dam D, Loyens E, De Deyn PP, Michotte A, et al. Region-and age-specific changes in glutamate transport in the AβPP23 mouse model for alzheimer's disease. J Alzheimers Dis. 2011;24(2):287-300.</Citation></Reference><Reference><Citation>Pelvig DP, Pakkenberg H, Regeur L, Oster S, Pakkenberg B. Neocortical glial cell numbers in Alzheimer's disease: a stereological study. Dement Geriatr Cogn Disord. 2003;16(4):212-9.</Citation></Reference><Reference><Citation>Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto SI, et al. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013;110(27):E2518-27.</Citation></Reference><Reference><Citation>Suzumura A. Neuron-microglia interaction in neuroinflammation. Curr Protein Pept Sci. 2013;14(1):16-20.</Citation></Reference><Reference><Citation>Wu Z, Guo Z, Gearing M, Chen G. Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzhiemer's disease model. Nat Commun. 2014;5:1-12.</Citation></Reference><Reference><Citation>Malik AR, Willnow TE. Excitatory amino acid transporters in physiology and disorders of the central nervous system. Int J Mol Sci. 2019;20(22):1-37.</Citation></Reference><Reference><Citation>Dudvarski Stankovic N, Teodorczyk M, Ploen R, Zipp F, Schmidt MHH. Microglia-blood vessel interactions: a double-edged sword in brain pathologies. Acta Neuropathol. 2016;131:347-63.</Citation></Reference><Reference><Citation>Eelen G, Dubois C, Cantelmo AR, Goveia J, Brüning U, DeRan M, et al. Role of glutamine synthetase in angiogenesis beyond glutamine synthesis. Nature. 2018;561(7721):63-9.</Citation></Reference><Reference><Citation>Bennett RE, Robbins AB, Hu M, Cao X, Betensky RA, Clark T, et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A. 2018;115(6):E1289-98.</Citation></Reference><Reference><Citation>Ashok BS, Ajith TA, Sivanesan S. Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease. Clin Exp Pharmacol Physiol. 2017;44:327-34.</Citation></Reference><Reference><Citation>Wang H, Eckel RH. What are lipoproteins doing in the brain? Trends Endocrinol Metab. 2014;25(1):8-14.</Citation></Reference><Reference><Citation>Vélez JI, Rivera D, Mastronardi CA, Patel HR, Tobón C, Villegas A, et al. A mutation in DAOA modifies the age of onset in PSEN1 E280A Alzheimer's disease. Neural Plast. 2016;2016:9760314.</Citation></Reference><Reference><Citation>Biron KE, Dickstein DL, Gopaul R, Jefferies WA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One. 2011;6(8):23789.</Citation></Reference><Reference><Citation>Dumanis SB, DiBattista AM, Miessau M, Moussa CEH, Rebeck GW. APOE genotype affects the pre-synaptic compartment of glutamatergic nerve terminals. J Neurochem. 2013;124(1):4-14.</Citation></Reference><Reference><Citation>Sepulveda-Falla D, Chavez-Gutierrez L, Portelius E, Vélez JI, Dujardin S, Barrera-Ocampo A, et al. A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. Acta Neuropathol. 2021;141(2):217-33.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36130073</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Inhibition of the dopamine transporter promotes lysosome biogenesis and ameliorates Alzheimer's disease-like symptoms in mice.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12776</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Lysosomes are degradative organelles that maintain cellular homeostasis and protein quality control. Transcription factor EB (TFEB)-mediated lysosome biogenesis enhances lysosome-dependent degradation and alleviates neurodegenerative diseases, but the mechanisms underlying TFEB regulation and modification are still poorly understood.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">By screening novel small-molecule compounds, we identified a group of lysosome-enhancing compounds (LYECs) that promote TFEB activation and lysosome biogenesis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One of these compounds, LH2-051, significantly inhibited the function of the dopamine transporter (DAT) and subsequently promoted lysosome biogenesis. We uncovered cyclin-dependent kinase 9 (CDK9) as a novel regulator of DAT-mediated lysosome biogenesis and identified six novel CDK9-phosphorylated sites on TFEB. We observed that signal transduction by the DAT-CDK9-TFEB axis occurs on lysosomes. Finally, we found that LH2-051 enhanced the degradation of amyloid beta plaques and improved the memory of amyloid precursor protein (APP)/Presenilin 1 (PS1) mice.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">We identified the DAT-CDK9-TFEB signaling axis as a novel regulator of lysosome biogenesis. Our study sheds light on the mechanisms of protein quality control under pathophysiological conditions.</AbstractText><CopyrightInformation>© 2022 The Authors. Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Limin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jianhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tianyou</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinghua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Wenlong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Lingxi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Xinyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7684-2939</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy, University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3685-6268</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy, University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-2845-5739</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022ZD0213000</GrantID><Agency>Ministry of Science and Technology of the People's Republic of China</Agency><Country/></Grant><Grant><GrantID>92057103</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>31872820</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>91953108</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82130105</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82121005</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82173656</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>18ZR1404000</GrantID><Agency>Shanghai Basic Research Program</Agency><Country/></Grant><Grant><GrantID>SIMM2004KF-09</GrantID><Agency>State Key Laboratory of Drug Research</Agency><Country/></Grant><Grant><GrantID>LG202103-01-03</GrantID><Agency>Lingang Laboratory</Agency><Country/></Grant><Grant><GrantID>LG2020103-01-05</GrantID><Agency>Lingang Laboratory</Agency><Country/></Grant><Grant><GrantID>ZDSYS14005</GrantID><Agency>Innovative Research Team of High-Level Local Universities in Shanghai and a Key Laboratory Program of the Education Commission of Shanghai Municipality</Agency><Country/></Grant><Grant><GrantID>2020TQ0070</GrantID><Agency>China Postdoctoral Science Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">CDK9</Keyword><Keyword MajorTopicYN="N">TFEB</Keyword><Keyword MajorTopicYN="N">dopamine transporter</Keyword><Keyword MajorTopicYN="N">lysosome biogenesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>14</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36130073</ArticleId><ArticleId IdType="doi">10.1002/alz.12776</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Xu H, RenD. Lysosomal physiology. Annu Rev Physiol. 2015;77:57-80. doi: 10.1146/annurev-physiol-021014-071649</Citation></Reference><Reference><Citation>Efeyan A, Comb WC, Sabatini DM. Nutrient-sensing mechanisms and pathways. Nature. 2015;517(7534):302-310. doi: 10.1038/nature14190</Citation></Reference><Reference><Citation>Ballabio A, Bonifacino JS. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol. 2020;21(2):101-118. doi: 10.1038/s41580-019-0185-4</Citation></Reference><Reference><Citation>Ferguson SM. Beyond indigestion: emerging roles for lysosome-based signaling in human disease. Curr Opin Cell Biol. 2015;35:59-68. doi: 10.1016/j.ceb.2015.04.014</Citation></Reference><Reference><Citation>Levine B, Kroemer G. Biological Functions of Autophagy Genes: a Disease Perspective. Cell. Jan;176(1-2):11-42. doi: 10.1016/j.cell.2018.09.048</Citation></Reference><Reference><Citation>Liu X, Li Y, Wang X, et al. The BEACH-containing protein WDR81 coordinates p62 and LC3C to promote aggrephagy. J Cell Biol. 2017;216(5):1301-1320. doi: 10.1083/jcb.201608039</Citation></Reference><Reference><Citation>Li Y, Zhang Y, Gan Q, et al. C. elegans-based screen identifies lysosome-damaging alkaloids that induce STAT3-dependent lysosomal cell death. Protein Cell. 2018;9(12):1013-1026. doi: 10.1007/s13238-018-0520-0</Citation></Reference><Reference><Citation>Maxfield FR, Willard JM, Lu S. Lysosomes: Biology, Diseases, and Therapeutics. 1st ed. John Wiley &amp; Sons, Inc.</Citation></Reference><Reference><Citation>Lee J, Yang D, Goulbourne C, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nat Neurosci. 2022;25(6):688-701. doi: 10.1038/s41593-022-01084-8</Citation></Reference><Reference><Citation>Bowles KR, Silva MC, Whitney K, et al. ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids. Cell. 2021;184(17):4547-4563.e17. doi: 10.1016/j.cell.2021.07.003</Citation></Reference><Reference><Citation>Li Y, Xu M, Ding X, et al. Protein kinase C controls lysosome biogenesis independently of mTORC1. Nat Cell Biol. 2016;18(10):1065-1077. doi: 10.1038/ncb3407</Citation></Reference><Reference><Citation>Perera RM, Zoncu R. The lysosome as a regulatory hub. Annu Rev Cell Dev Biol. 2016;32:223-253. doi: 10.1146/annurev-cellbio-111315-125125</Citation></Reference><Reference><Citation>Bonam SR, Wang F, Muller S. Lysosomes as a therapeutic target. Nat Rev Drug Discovery. 2019;18(12):923-948. doi: 10.1038/s41573-019-0036-1</Citation></Reference><Reference><Citation>Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429-1433. doi: 10.1126/science.1204592</Citation></Reference><Reference><Citation>Sardiello M, Palmieri M, di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473-477. doi: 10.1126/science.1174447</Citation></Reference><Reference><Citation>Chauhan S, Goodwin JG, Chauhan S, et al. ZKSCAN3 is a master transcriptional repressor of autophagy. Mol Cell. 2013;50(1):16-28. doi: 10.1016/j.molcel.2013.01.024</Citation></Reference><Reference><Citation>Yang C, Wang X. Lysosome biogenesis: regulation and functions. J Cell Biol. 2021;220(6). doi: 10.1083/jcb.202102001</Citation></Reference><Reference><Citation>Settembre C, Zoncu R, Medina DL, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31(5):1095-1108. doi: 10.1038/emboj.2012.32</Citation></Reference><Reference><Citation>Martina JA, Puertollano R. Rag GTPases mediate amino acid-dependent recruitment of TFEB and MITF to lysosomes. J Cell Biol. 2013;200(4):475-491. doi: 10.1083/jcb.201209135</Citation></Reference><Reference><Citation>Roczniak-Ferguson A, Petit CS, Froehlich F, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5(228):ra42. doi: 10.1126/scisignal.2002790</Citation></Reference><Reference><Citation>Puertollano R, Ferguson S, Brugarolas J, Ballabio A. The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J. 2018;37(11):e98804. doi: 10.15252/embj.201798804</Citation></Reference><Reference><Citation>Iversen SD, Iversen LL, Dopamine: 50 years in perspective. Trends Neurosci. 2007;30(5):188-193. doi: 10.1016/j.tins.2007.03.002</Citation></Reference><Reference><Citation>Efimova EV, Gainetdinov RR, Budygin EA, Sotnikova TD. Dopamine transporter mutant animals: a translational perspective. J Neurogenet. 2016;30(1):5-15. doi: 10.3109/01677063.2016.1144751</Citation></Reference><Reference><Citation>Tian J, Guo L, Sui S, et al. Disrupted hippocampal growth hormone secretagogue receptor 1α interaction with dopamine receptor D1 plays a role in Alzheimer's disease. Sci Transl Med. 2019;11(505):eaav6278. doi: 10.1126/scitranslmed.aav6278</Citation></Reference><Reference><Citation>Burbulla L, Song P, Mazzulli J, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science. 2017;357(6357):1255-1261. doi: 10.1126/science.aam9080</Citation></Reference><Reference><Citation>Iversen LL. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol. 1971;41(4):571-591. doi: 10.1111/j.1476-5381.1971.tb07066.x</Citation></Reference><Reference><Citation>Amenta F, Bronzetti E, Cantalamessa F, et al. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol. 2001;117(1-2):133-142. doi: 10.1016/s0165-5728(01)00317-4</Citation></Reference><Reference><Citation>Mulvihill KG. Presynaptic regulation of dopamine release: role of the DAT and VMAT2 transporters. Neurochem Int. 2019;122:94-105. doi: 10.1016/j.neuint.2018.11.004</Citation></Reference><Reference><Citation>Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357-W364. doi: 10.1093/nar/gkz382</Citation></Reference><Reference><Citation>Awale M, Reymond J-L. Polypharmacology browser PPB2: target prediction combining nearest neighbors with machine learning. J Chem Inf Model. 2019;59(1):10-17. doi: 10.1021/acs.jcim.8b00524</Citation></Reference><Reference><Citation>Gong J, Cai C, Liu X, et al. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method. Bioinformatics. 2013;29(14):1827-1829. doi: 10.1093/bioinformatics/btt270</Citation></Reference><Reference><Citation>Liu X, Jiang H, Li H. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 1. Method and assessment of virtual screening. J Chem Inf Model. 2011;51(9):2372-2385. doi: 10.1021/ci200060s</Citation></Reference><Reference><Citation>Lu W, Liu X, Cao X, et al. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration. J Med Chem. 2011;54(10):3564-3574. doi: 10.1021/jm200139j</Citation></Reference><Reference><Citation>Penmatsa A, Wang KH, Gouaux E. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature. 2013;503(7474):85-90. doi: 10.1038/nature12533</Citation></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11(1):47-60. doi: 10.1016/0165-0270(84)90007-4</Citation></Reference><Reference><Citation>Nagakura A, Shitaka Y, Yarimizu J, Matsuoka N. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. Eur J Pharmacol. 2013;703(1-3):53-61. doi: 10.1016/j.ejphar.2012.12.023</Citation></Reference><Reference><Citation>Yeshurun S, Rogers J, Short AK, Renoir T, Pang TY, Hannan AJ. Elevated paternal glucocorticoid exposure modifies memory retention in female offspring. Psychoneuroendocrinology. 2017;83:9-18. doi: 10.1016/j.psyneuen.2017.05.014</Citation></Reference><Reference><Citation>Jia L, Quan M, Fu Y, et al. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 2020;19(1):81-92. doi: 10.1016/s1474-4422(19)30290-x</Citation></Reference><Reference><Citation>Ding Y, Fei Y, Lu B. Emerging new concepts of degrader technologies. Trends Pharmacol Sci. 2020;41(7):464-474. doi: 10.1016/j.tips.2020.04.005</Citation></Reference><Reference><Citation>Paiva SL, Crews CM. Targeted protein degradation: elements of PROTAC design. Curr Opin Chem Biol. 2019;50:111-119. doi: 10.1016/j.cbpa.2019.02.022</Citation></Reference><Reference><Citation>Li Z, Wang C, Wang Z, et al. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature. 2019;575(7781):203-209. doi: 10.1038/s41586-019-1722-1</Citation></Reference><Reference><Citation>Eriksen J, Bjørn-Yoshimoto WE, Jørgensen TN, Newman AH, Gether U. Postendocytic sorting of constitutively internalized dopamine transporter in cell lines and dopaminergic neurons. J Biol Chem. 2010;285(35):27289-27301. doi: 10.1074/jbc.M110.131003</Citation></Reference><Reference><Citation>Daniels GM, Amara SG. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J Biol Chem. 1999;274(50):35794-35801. doi: 10.1074/jbc.274.50.35794</Citation></Reference><Reference><Citation>Hong WC, Amara SG. Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in dopamine neurons. FASEB J. 2013;27(8):2995-3007. doi: 10.1096/fj.12-218727</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36129947</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Caspase-2 mRNA levels are not elevated in mild cognitive impairment, Alzheimer's disease, Huntington's disease, or Lewy Body dementia.</ArticleTitle><Pagination><MedlinePgn>e0274784</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0274784</ELocationID><Abstract><AbstractText>Caspase-2 is a member of the caspase family that exhibits both apoptotic and non-apoptotic properties, and has been shown to mediate synaptic deficits in models of several neurological conditions, including Alzheimer's disease (AD), Huntington's disease (HD), and Lewy Body dementia (LBD). Our lab previously reported that caspase-2 protein levels are elevated in these diseases, leading us to hypothesize that elevated caspase-2 protein levels are due to increased transcription of caspase-2 mRNA. There are two major isoforms of caspase-2 mRNA, caspase-2L and caspase-2S. We tested our hypothesis by measuring the levels of these mRNA isoforms normalized to levels of RPL13 mRNA, a reference gene that showed no disease-associated changes. Here, we report no increases in caspase-2L mRNA levels in any of the three diseases studied, AD (with mild cognitive impairment (MCI)), HD and LBD, disproving our hypothesis. Caspase-2S mRNA showed a non-significant downward trend in AD. We also analyzed expression levels of SNAP25 and βIII-tubulin mRNA. SNAP25 mRNA was significantly lower in AD and there were downward trends in MCI, LBD, and HD. βIII-tubulin mRNA expression remained unchanged between disease groups and controls. These findings indicate that factors besides transcriptional regulation cause increases in caspase-2 protein levels. The reduction of SNAP25 mRNA expression suggests that presynaptic dysfunction contributes to cognitive deficits in neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hlynialuk</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemper</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leinonen-Wright</LastName><ForeName>Kailee</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Minneapolis VA Medical Center, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8703-9455</Identifier><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059368">RNA Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C085488">RPL13 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012269">Ribosomal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014404">Tubulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C490360">CASP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053143">Caspase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053143" MajorTopicYN="N">Caspase 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059368" MajorTopicYN="N">RNA Isoforms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012269" MajorTopicYN="N">Ribosomal Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014404" MajorTopicYN="N">Tubulin</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36129947</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0274784</ArticleId><ArticleId IdType="pii">PONE-D-22-13921</ArticleId><ArticleId IdType="pmc">PMC9491574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Biol Chem. 2011 Mar 11;286(10):8493-8506</Citation><ArticleIdList><ArticleId IdType="pubmed">21216964</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2011 Aug 19;6:59</Citation><ArticleIdList><ArticleId IdType="pubmed">21854568</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2016 Apr 21;165(3):535-50</Citation><ArticleIdList><ArticleId IdType="pubmed">27104977</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2004 Apr;11(4):424-38</Citation><ArticleIdList><ArticleId IdType="pubmed">14713958</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2009 Feb 6;136(3):508-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19203584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2012 Aug;19(8):1288-98</Citation><ArticleIdList><ArticleId IdType="pubmed">22498700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39</Citation><ArticleIdList><ArticleId IdType="pubmed">16469371</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2002 Apr;9(4):358-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11965488</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2001 Jan 11;20(2):260-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11313953</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1994 Feb 25;263(5150):1146-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8108733</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2019 Jul 30;7(1):124</Citation><ArticleIdList><ArticleId IdType="pubmed">31362787</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Dec 16;123(6):1079-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16360037</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2015 Nov 15;767:61-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26455477</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2010 Dec 22;68(6):1067-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Jul 14;7(1):5435</Citation><ArticleIdList><ArticleId IdType="pubmed">28710439</ArticleId></ArticleIdList></Reference><Reference><Citation>Apoptosis. 2005 Mar;10(2):313-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15843892</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Genomics. 2005 May 11;21(3):389-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15769908</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 2006 Jul 15;312(12):2347-57</Citation><ArticleIdList><ArticleId IdType="pubmed">16701639</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxid Med Cell Longev. 2019 Jun 02;2019:2140427</Citation><ArticleIdList><ArticleId IdType="pubmed">31281568</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1998 Sep 18;273(38):24535-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9733748</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2012 Sep;181(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">22841474</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2016 Nov;12(11):1149-1158</Citation><ArticleIdList><ArticleId IdType="pubmed">27224930</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Jul 01;8(7):e67033</Citation><ArticleIdList><ArticleId IdType="pubmed">23840868</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Nov 17;6:37116</Citation><ArticleIdList><ArticleId IdType="pubmed">27853238</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2003 Feb 13;22(6):935-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12584573</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Nov 9;338(6108):818-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23042294</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotechniques. 2004 Jul;37(1):112-4, 116, 118-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15283208</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2020 Mar 2;10(1):3869</Citation><ArticleIdList><ArticleId IdType="pubmed">32123248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2016 Nov;22(11):1268-1276</Citation><ArticleIdList><ArticleId IdType="pubmed">27723722</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2005 Mar 30;33(6):e56</Citation><ArticleIdList><ArticleId IdType="pubmed">15800207</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorax. 2002 Sep;57(9):765-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12200519</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Cell Mol Biol. 2017;332:155-212</Citation><ArticleIdList><ArticleId IdType="pubmed">28526132</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Mol Brain Res. 2003 Oct 21;118(1-2):60-71</Citation><ArticleIdList><ArticleId IdType="pubmed">14559355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2006 May;65(5):508-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16772874</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2013;4:1939</Citation><ArticleIdList><ArticleId IdType="pubmed">23748737</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2000 Feb 15;20(4):1386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">10662829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2015 Jan;22(1):22-33</Citation><ArticleIdList><ArticleId IdType="pubmed">25190144</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2019 Aug 9;10(1):3622</Citation><ArticleIdList><ArticleId IdType="pubmed">31399584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Physiol Biochem. 2018;50(2):525-537</Citation><ArticleIdList><ArticleId IdType="pubmed">30308514</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2000 Mar 31;470(3):360-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10745097</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2003 Mar;60(3):369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12633148</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1994 Sep 9;78(5):739-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8087842</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2013 Sep;20(9):1133-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23811850</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2019 Jul 30;7(1):111</Citation><ArticleIdList><ArticleId IdType="pubmed">31358058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Res. 2004 Jan;2(1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">14757846</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cancer Res Clin Oncol. 2013 Jul;139(7):1189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">23568547</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2008 May 29;27(24):3393-404</Citation><ArticleIdList><ArticleId IdType="pubmed">18193089</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1999 Mar 16;256(2):381-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10079193</ArticleId></ArticleIdList></Reference><Reference><Citation>Autophagy. 2014 Jun;10(6):1054-70</Citation><ArticleIdList><ArticleId IdType="pubmed">24879153</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Discov. 2016 Feb 15;2:</Citation><ArticleIdList><ArticleId IdType="pubmed">27019748</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2012 Sep 18;220:41-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22732502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36129754</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2561-7605</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>JMIR aging</Title><ISOAbbreviation>JMIR Aging</ISOAbbreviation></Journal><ArticleTitle>Evaluating Web-Based Automatic Transcription for Alzheimer Speech Data: Transcript Comparison and Machine Learning Analysis.</ArticleTitle><Pagination><MedlinePgn>e33460</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2196/33460</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Speech data for medical research can be collected noninvasively and in large volumes. Speech analysis has shown promise in diagnosing neurodegenerative disease. To effectively leverage speech data, transcription is important, as there is valuable information contained in lexical content. Manual transcription, while highly accurate, limits the potential scalability and cost savings associated with language-based screening.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To better understand the use of automatic transcription for classification of neurodegenerative disease, namely, Alzheimer disease (AD), mild cognitive impairment (MCI), or subjective memory complaints (SMC) versus healthy controls, we compared automatically generated transcripts against transcripts that went through manual correction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited individuals from a memory clinic ("patients") with a diagnosis of mild-to-moderate AD, (n=44, 30%), MCI (n=20, 13%), SMC (n=8, 5%), as well as healthy controls (n=77, 52%) living in the community. Participants were asked to describe a standardized picture, read a paragraph, and recall a pleasant life experience. We compared transcripts generated using Google speech-to-text software to manually verified transcripts by examining transcription confidence scores, transcription error rates, and machine learning classification accuracy. For the classification tasks, logistic regression, Gaussian naive Bayes, and random forests were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The transcription software showed higher confidence scores (P&lt;.001) and lower error rates (P&gt;.05) for speech from healthy controls compared with patients. Classification models using human-verified transcripts significantly (P&lt;.001) outperformed automatically generated transcript models for both spontaneous speech tasks. This comparison showed no difference in the reading task. Manually adding pauses to transcripts had no impact on classification performance. However, manually correcting both spontaneous speech tasks led to significantly higher performances in the machine learning models.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found that automatically transcribed speech data could be used to distinguish patients with a diagnosis of AD, MCI, or SMC from controls. We recommend a human verification step to improve the performance of automatic transcripts, especially for spontaneous tasks. Moreover, human verification can focus on correcting errors and adding punctuation to transcripts. However, manual addition of pauses is not needed, which can simplify the human verification step to more efficiently process large volumes of speech data.</AbstractText><CopyrightInformation>©Thomas Soroski, Thiago da Cunha Vasco, Sally Newton-Mason, Saffrin Granby, Caitlin Lewis, Anuj Harisinghani, Matteo Rizzo, Cristina Conati, Gabriel Murray, Giuseppe Carenini, Thalia S Field, Hyeju Jang. Originally published in JMIR Aging (https://aging.jmir.org), 21.09.2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soroski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2847-0990</Identifier><AffiliationInfo><Affiliation>Vancouver Stroke Program and Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Cunha Vasco</LastName><ForeName>Thiago</ForeName><Initials>T</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-6709-0456</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Faculty of Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton-Mason</LastName><ForeName>Sally</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3390-8253</Identifier><AffiliationInfo><Affiliation>Vancouver Stroke Program and Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granby</LastName><ForeName>Saffrin</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9995-6357</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Faculty of Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5886-5002</Identifier><AffiliationInfo><Affiliation>Vancouver Stroke Program and Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harisinghani</LastName><ForeName>Anuj</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7206-4888</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Faculty of Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9723-211X</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Faculty of Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conati</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8434-9335</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Faculty of Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-2233-6288</Identifier><AffiliationInfo><Affiliation>School of Computing, University of the Fraser Valley, Abbotsford, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carenini</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4310-0119</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Faculty of Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Field</LastName><ForeName>Thalia S</ForeName><Initials>TS</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1176-0633</Identifier><AffiliationInfo><Affiliation>Vancouver Stroke Program and Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Hyeju</ForeName><Initials>H</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7652-1158</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Faculty of Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Aging</MedlineTA><NlmUniqueID>101740387</NlmUniqueID><ISSNLinking>2561-7605</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">natural language processing</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">speech</Keyword><Keyword MajorTopicYN="N">speech recognition software</Keyword><Keyword MajorTopicYN="N">transcription software</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>09</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36129754</ArticleId><ArticleId IdType="pii">v5i3e33460</ArticleId><ArticleId IdType="doi">10.2196/33460</ArticleId><ArticleId IdType="pmc">PMC9536526</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>NPJ Digit Med. 2020 Jun 3;3:82</Citation><ArticleIdList><ArticleId IdType="pubmed">32550644</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2020 Nov 1;27(11):1784-1797</Citation><ArticleIdList><ArticleId IdType="pubmed">32929494</ArticleId></ArticleIdList></Reference><Reference><Citation>IEEE J Biomed Health Inform. 2019 Nov;23(6):2294-2301</Citation><ArticleIdList><ArticleId IdType="pubmed">31034426</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2013 Dec;136(Pt 12):3727-37</Citation><ArticleIdList><ArticleId IdType="pubmed">24142144</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2019 Aug 02;11:205</Citation><ArticleIdList><ArticleId IdType="pubmed">31427959</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2015 Nov 24;85(21):1852-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26511452</ArticleId></ArticleIdList></Reference><Reference><Citation>Degener Neurol Neuromuscul Dis. 2019 Dec 24;9:123-130</Citation><ArticleIdList><ArticleId IdType="pubmed">31920420</ArticleId></ArticleIdList></Reference><Reference><Citation>EJIFCC. 2009 Jan 20;19(4):203-11</Citation><ArticleIdList><ArticleId IdType="pubmed">27683318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acoust Soc Am. 2014 Aug;136(2):EL116-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25096134</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Aff (Millwood). 2014 Apr;33(4):574-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24711317</ArticleId></ArticleIdList></Reference><Reference><Citation>Invest Ophthalmol Vis Sci. 2012 Aug 13;53(9):5452-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22661485</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1994 Jun;51(6):585-94</Citation><ArticleIdList><ArticleId IdType="pubmed">8198470</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc IEEE Int Conf Acoust Speech Signal Process. 2014 May;2014:4858-4862</Citation><ArticleIdList><ArticleId IdType="pubmed">27630535</ArticleId></ArticleIdList></Reference><Reference><Citation>EClinicalMedicine. 2020 Oct 22;28:100583</Citation><ArticleIdList><ArticleId IdType="pubmed">33294808</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317520939773</Citation><ArticleIdList><ArticleId IdType="pubmed">32648470</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2015;50(3):687-98</Citation><ArticleIdList><ArticleId IdType="pubmed">26757034</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2017 Jul;24(4):418-434</Citation><ArticleIdList><ArticleId IdType="pubmed">27684109</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2019 Feb 18;124:133-143</Citation><ArticleIdList><ArticleId IdType="pubmed">30593773</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2021 Jun 8;373:n1462</Citation><ArticleIdList><ArticleId IdType="pubmed">34103308</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2015;49(2):407-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26484921</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36129673</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2299-5684</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Pharmacological reports : PR</Title><ISOAbbreviation>Pharmacol Rep</ISOAbbreviation></Journal><ArticleTitle>Effect of tricyclic 1,2-thiazine derivatives in neuroinflammation induced by preincubation with lipopolysaccharide or coculturing with microglia-like cells.</ArticleTitle><Pagination><MedlinePgn>890-908</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s43440-022-00414-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) is considered the most common cause of dementia among the elderly. One of the modifiable causes of AD is neuroinflammation. The current study aimed to investigate the influence of new tricyclic 1,2-thiazine derivatives on in vitro model of neuroinflammation and their ability to cross the blood-brain barrier (BBB).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The potential anti-inflammatory effect of new tricyclic 1,2-thiazine derivatives (TP1, TP4, TP5, TP6, TP7, TP8, TP9, TP10) was assessed in SH-SY5Y cells differentiated to the neuron-like phenotype incubated with bacterial lipopolysaccharide (5 or 50 μg/ml) or THP-1 microglial cell culture supernatant using MTT, DCF-DA, Griess, and fast halo (FHA) assays. Additionally, for cultures preincubated with 50 µg/ml lipopolysaccharide (LPS), a cyclooxygenase (COX) activity assay was performed. Finally, the potential ability of tested compounds to cross the BBB was evaluated by computational studies. Molecular docking was performed with the TLR4/MD-2 complex to assess the possibility of binding the tested compounds in the LPS binding pocket. Prediction of ADMET parameters (absorption, distribution, metabolism, excretion and toxicity) was also conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The unfavorable effect of LPS and co-culture with THP-1 cells on neuronal cell viability was counteracted with TP1 and TP4 in all tested concentrations. Tested compounds reduced the oxidative and nitrosative stress induced by both LPS and microglia activation and also reduced DNA damage. Furthermore, new derivatives inhibited total COX activity. Additionally, new compounds would cross the BBB with high probability and reach concentrations in the brain not lower than in the serum. The binding affinity at the TLR4/MD-2 complex binding site of TP4 and TP8 compounds is similar to that of the drug donepezil used in Alzheimer's disease. The ADMET analysis showed that the tested compounds should not be toxic and should show high intestinal absorption.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">New tricyclic 1,2-thiazine derivatives exert a neuroregenerative effect in the neuroinflammation model, presumably via their inhibitory influence on COX activity and reduction of oxidative and nitrosative stress.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wiatrak</LastName><ForeName>Benita</ForeName><Initials>B</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1404-2274</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, ul. Mikulicza-Radeckiego 2, 50-345, Wroclaw, Poland. benita.wiatrak@umw.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krzyżak</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Inorganic Chemistry, Wroclaw Medical University, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szczęśniak-Sięga</LastName><ForeName>Berenika</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Wroclaw Medical University, Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szandruk-Bender</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, ul. Mikulicza-Radeckiego 2, 50-345, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szeląg</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, ul. Mikulicza-Radeckiego 2, 50-345, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowak</LastName><ForeName>Beata</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, ul. Mikulicza-Radeckiego 2, 50-345, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SUB.A080.21.021</GrantID><Agency>Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmacol Rep</MedlineTA><NlmUniqueID>101234999</NlmUniqueID><ISSNLinking>1734-1140</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D011451">Prostaglandin-Endoperoxide Synthases</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013843">Thiazines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011451" MajorTopicYN="N">Prostaglandin-Endoperoxide Synthases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="Y">Neuroblastoma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013843" MajorTopicYN="Y">Thiazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">In silico studies</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">SH-SY5Y cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36129673</ArticleId><ArticleId IdType="doi">10.1007/s43440-022-00414-8</ArticleId><ArticleId IdType="pii">10.1007/s43440-022-00414-8</ArticleId><ArticleId IdType="pmc">PMC9584986</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurochem. 2019 Jun;149(5):562-581</Citation><ArticleIdList><ArticleId IdType="pubmed">30702751</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2021 May;58(5):2362-2378</Citation><ArticleIdList><ArticleId IdType="pubmed">33417222</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2001 Mar;58(3):487-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11255454</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Graph Model. 2010 Jun;28(8):899-903</Citation><ArticleIdList><ArticleId IdType="pubmed">20427217</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Apr 08;21(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">32276316</ArticleId></ArticleIdList></Reference><Reference><Citation>Mediators Inflamm. 2015;2015:137357</Citation><ArticleIdList><ArticleId IdType="pubmed">26063967</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Discov. 2008 Jun;3(6):677-87</Citation><ArticleIdList><ArticleId IdType="pubmed">23506148</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comput Chem. 2010 Jan 30;31(2):455-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2020 Feb 5;868:172858</Citation><ArticleIdList><ArticleId IdType="pubmed">31837307</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2015 May;36(5):297-309</Citation><ArticleIdList><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Drug Deliv Rev. 2002 Mar 31;54(3):291-313</Citation><ArticleIdList><ArticleId IdType="pubmed">11922949</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Biotechnol. 2021 Jun 5;21(1):38</Citation><ArticleIdList><ArticleId IdType="pubmed">34090414</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2001 Nov 2;313(1-2):41-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11684335</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunol. 2007 Feb;19(1):3-10</Citation><ArticleIdList><ArticleId IdType="pubmed">17275324</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2018 Feb 22;10:42</Citation><ArticleIdList><ArticleId IdType="pubmed">29520228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2007 Sep 7;130(5):906-17</Citation><ArticleIdList><ArticleId IdType="pubmed">17803912</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Immunol. 2014 Jul;34 Suppl 1:S64-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24711006</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Dec 17;21(24):</Citation><ArticleIdList><ArticleId IdType="pubmed">33348757</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2016 Feb;136(3):457-74</Citation><ArticleIdList><ArticleId IdType="pubmed">26509334</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2018 Dec;14(12):1602-1614</Citation><ArticleIdList><ArticleId IdType="pubmed">30314800</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2018 Mar 21;38(12):2911-2919</Citation><ArticleIdList><ArticleId IdType="pubmed">29563239</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Mol Med. 2016 Jun 01;8(6):595-608</Citation><ArticleIdList><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2016 Aug 15;21(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">27537865</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Sep 14;6:32228</Citation><ArticleIdList><ArticleId IdType="pubmed">27624303</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2016 May 25;8(340):340ra72</Citation><ArticleIdList><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Inf Comput Sci. 2001 Jan-Feb;41(1):120-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11206364</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comput Chem. 2009 Dec;30(16):2785-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19399780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2019 Mar;56(3):1841-1851</Citation><ArticleIdList><ArticleId IdType="pubmed">29936690</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2020 Jan 31;25(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">32023919</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Med Chem. 2013;70:393-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24177366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Chem. 2020 Sep;102:104035</Citation><ArticleIdList><ArticleId IdType="pubmed">32721780</ArticleId></ArticleIdList></Reference><Reference><Citation>ChemMedChem. 2018 Oct 22;13(20):2189-2201</Citation><ArticleIdList><ArticleId IdType="pubmed">30110511</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2018 Jun;23(6):1187-1202</Citation><ArticleIdList><ArticleId IdType="pubmed">29330126</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 May 8;109(19):7421-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22532668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2018 Feb 5;217(2):459-472</Citation><ArticleIdList><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2018 Jul;559(7715):S4-S7</Citation><ArticleIdList><ArticleId IdType="pubmed">30046080</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;22(1):295-306</Citation><ArticleIdList><ArticleId IdType="pubmed">20847440</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2018 Apr 25;10:118</Citation><ArticleIdList><ArticleId IdType="pubmed">29922148</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neurosci. 2014 May;124(5):307-21</Citation><ArticleIdList><ArticleId IdType="pubmed">23930978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2016 Jan;53(1):648-661</Citation><ArticleIdList><ArticleId IdType="pubmed">25511446</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2021 Jul 2;49(W1):W5-W14</Citation><ArticleIdList><ArticleId IdType="pubmed">33893803</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;62(4):1495-1506</Citation><ArticleIdList><ArticleId IdType="pubmed">29504537</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2019 May 09;20(9):</Citation><ArticleIdList><ArticleId IdType="pubmed">31075861</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2002 Oct 15;7(20):1056-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12546895</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2020 Jan 23;25(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">31979316</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2021 Jul 22;22(15):</Citation><ArticleIdList><ArticleId IdType="pubmed">34360585</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2010 Jan;56(1):135-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19781587</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2019 Nov 15;11:317</Citation><ArticleIdList><ArticleId IdType="pubmed">31803047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comput Chem. 2011 May;32(7):1466-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21425294</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Pharmacother. 2021 Sep;141:111878</Citation><ArticleIdList><ArticleId IdType="pubmed">34243096</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2016 Nov 29;87(22):2324-2332</Citation><ArticleIdList><ArticleId IdType="pubmed">27784770</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Inf Model. 2012 Nov 26;52(11):3099-105</Citation><ArticleIdList><ArticleId IdType="pubmed">23092397</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2015 Feb 10;7:9</Citation><ArticleIdList><ArticleId IdType="pubmed">25713531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Life Sci. 2015 Feb;72(3):557-581</Citation><ArticleIdList><ArticleId IdType="pubmed">25332099</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010 Mar 03;5(3):e9505</Citation><ArticleIdList><ArticleId IdType="pubmed">20209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2001 Jan;101(1):2-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11194936</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36129176</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4563</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Hypertension (Dallas, Tex. : 1979)</Title><ISOAbbreviation>Hypertension</ISOAbbreviation></Journal><ArticleTitle>Hypertension, Neurovascular Dysfunction, and Cognitive Impairment.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1161/HYPERTENSIONAHA.122.18085</ELocationID><Abstract><AbstractText>Hypertension affects a significant proportion of the adult and aging population and represents an important risk factor for vascular cognitive impairment and late-life dementia. Chronic high blood pressure continuously challenges the structural and functional integrity of the cerebral vasculature, leading to microvascular rarefaction and dysfunction, and neurovascular uncoupling that typically impairs cerebral blood supply. Hypertension disrupts blood-brain barrier integrity, promotes neuroinflammation, and may contribute to amyloid deposition and Alzheimer pathology. The mechanisms underlying these harmful effects are still a focus of investigation, but studies in animal models have provided significant molecular and cellular mechanistic insights. Remaining questions relate to whether adequate treatment of hypertension may prevent deterioration of cognitive function, the threshold for blood pressure treatment, and the most effective antihypertensive drugs. Recent advances in neurovascular biology, advanced brain imaging, and detection of subtle behavioral phenotypes have begun to provide insights into these critical issues. Importantly, a parallel analysis of these parameters in animal models and humans is feasible, making it possible to foster translational advancements. In this review, we provide a critical evaluation of the evidence available in experimental models and humans to examine the progress made and identify remaining gaps in knowledge.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Santisteban</LastName><ForeName>Monica M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-2836-9075</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY (M.M.S., C.I.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iadecola</LastName><ForeName>Costantino</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9797-073X</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY (M.M.S., C.I.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carnevale</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5016-3161</Identifier><AffiliationInfo><Affiliation>epartment of Molecular Medicine, "Sapienza" University of Rome, Italy (D.C.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of Neuro and Cardiovascular Pathophysiology, IRCCS Neuromed, Pozzilli, Italy (D.C.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hypertension</MedlineTA><NlmUniqueID>7906255</NlmUniqueID><ISSNLinking>0194-911X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">blood-brain barrier</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36129176</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.122.18085</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36129098</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Relationship of serum beta-synuclein with blood biomarkers and brain atrophy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12790</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We provide a detailed comparison of serum beta-synuclein immunoprecipitation - mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations.</AbstractText><AbstractText Label="HIGHLIGHTS" NlmCategory="CONCLUSIONS">Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).</AbstractText><CopyrightInformation>© 2022 The Authors. Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oeckl</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE e.V.), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderl-Straub</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-University Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diehl-Schmid</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Technical University of Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fassbender</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fliessbach</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn and DZNE Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halbgebauer</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huppertz</LastName><ForeName>Hans-Jürgen</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Swiss Epilepsy Clinic, Klinik Lengg AG, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahn</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Hospital Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassubek</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE e.V.), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landwehrmeyer</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauer</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudlo</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Rostock, and German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn and DZNE Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeter</LastName><ForeName>Matthias L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Clinic for Cognitive Neurology, University Clinic Leipzig, and Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinacker</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volk</LastName><ForeName>Alexander E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Institute for Human Genetics, University Hospital Hamburg Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Matias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut für Neurogenomik, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkelmann</LastName><ForeName>Juliane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institut für Neurogenomik, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, and DZNE, Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE e.V.), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4273-4267</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>FTLD Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>01GI1007A</GrantID><Agency>German Federal Ministry of Education and Research</Agency><Country/></Grant><Grant><GrantID>EXC2145SyNergy-ID390857198</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">beta-synuclein</Keyword><Keyword MajorTopicYN="N">blood biomarker</Keyword><Keyword MajorTopicYN="N">brain atrophy</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">p-tau181</Keyword><Keyword MajorTopicYN="N">synaptic degeneration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36129098</ArticleId><ArticleId IdType="doi">10.1002/alz.12790</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Oeckl P, Halbgebauer S, Anderl-Straub S, et al. Targeted mass spectrometry suggests Beta-Synuclein as synaptic blood marker in Alzheimer's disease. J Proteome Res. 2020;19:1310-1318. doi:10.1021/acs.jproteome.9b00824</Citation></Reference><Reference><Citation>Halbgebauer S, Oeckl P, Steinacker P, et al. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2021;92:349-356. doi:10.1136/jnnp-2020-324306</Citation></Reference><Reference><Citation>Camporesi E, Nilsson J, Brinkmalm A, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights. 2020;15:1177271920950319. doi:10.1177/1177271920950319</Citation></Reference><Reference><Citation>de Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement. 2016;12:633-644. doi:10.1016/j.jalz.2015.12.005</Citation></Reference><Reference><Citation>Huber N, Korhonen S, Hoffmann D, et al. Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration-Insights into disease mechanisms and current therapeutic approaches. Mol Psychiatry. 2022;27(3):1300-1309. doi:10.1038/s41380-021-01384-8</Citation></Reference><Reference><Citation>Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022;21:66-77. doi:10.1016/S1474-4422(21)00361-6</Citation></Reference><Reference><Citation>Oeckl P, Metzger F, Nagl M, et al. Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer's and creutzfeldt-jakob disease but no alteration in synucleinopathies. Mol Cell Proteomics. 2016;15:3126-3138. doi:10.1074/mcp.M116.059915</Citation></Reference><Reference><Citation>Nilsson J, Gobom J, Sjödin S, et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. Alzheimers Dement (Amst) 2021;13:e12179. doi:10.1002/dad2.12179</Citation></Reference><Reference><Citation>Bergström S, Remnestål J, Yousef J, et al. Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. Ann Clin Transl Neurol. 2021;8:1456-1470. doi:10.1002/acn3.51402</Citation></Reference><Reference><Citation>De Vos A, Jacobs D, Struyfs H, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimers Dement. 2015;11:1461-1469. doi:10.1016/j.jalz.2015.05.012</Citation></Reference><Reference><Citation>Oeckl P, Wagemann O, Halbgebauer S, et al. Serum Beta-Synuclein is higher in Down syndrome and precedes rise of pTau181. Ann Neurol. 2022;92(1):6-10. doi:10.1002/ANA.26360</Citation></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269. doi:10.1016/j.jalz.2011.03.005</Citation></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456-2477.</Citation></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006-1014.</Citation></Reference><Reference><Citation>Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1-9.</Citation></Reference><Reference><Citation>Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496-503.</Citation></Reference><Reference><Citation>O'Bryant SE, Lacritz LH, Hall J, et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the National Alzheimer's Coordinating Center Database. Arch Neurol. 2010;67:746-749. doi:10.1001/archneurol.2010.115</Citation></Reference><Reference><Citation>Wagner M, Lorenz G, Volk AE, et al. Clinico-genetic findings in 509 frontotemporal dementia patients. Mol Psychiatry. 2021;26;(10):5824-5832. doi:10.1038/S41380-021-01271-2</Citation></Reference><Reference><Citation>Lombardi J, Mayer B, Semler E, et al. Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimers Dement. 2021;17:1595-1609. doi:10.1002/alz.12323</Citation></Reference><Reference><Citation>Huppertz HJ, Kröll-Seger J, Klöppel S, Ganz RE, Kassubek J. Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. Neuroimage. 2010;49:2216-2224. doi:10.1016/J.NEUROIMAGE.2009.10.066</Citation></Reference><Reference><Citation>Shattuck DW, Mirza M, Adisetiyo V, et al. Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage. 2008;39:1064-1080. doi:10.1016/j.neuroimage.2007.09.031</Citation></Reference><Reference><Citation>Marinescu RV, Eshaghi A, Alexander DC, Golland P. BrainPainter: A software for the visualisation of brain structures, biomarkers and associated pathological processes. Multimodal Brain Image Anal Math Found Comput Anat 4th Int Work MBIA 2019, 7th Int Work MFCA 2019, Held Conjunction with MICCAI 2019, Shenzhen, China, Oct 17. 2019;11846:112-20. doi:10.1007/978-3-030-33226-6_13</Citation></Reference><Reference><Citation>Halbgebauer S, Steinacker P, Verde F, et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol Neurosurg Psychiatry. 2022;93(1):68-74. doi:10.1136/jnnp-2021-327129</Citation></Reference><Reference><Citation>Ossenkoppele R, Reimand J, Smith R, et al. Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med. 2021;13:e14398. doi:10.15252/emmm.202114398</Citation></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90;(2):157-164. doi:10.1136/jnnp-2018-318704</Citation></Reference><Reference><Citation>Portelius E, Olsson B, Höglund K, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136:363-376. doi:10.1007/s00401-018-1851-x</Citation></Reference><Reference><Citation>Sandelius Å, Portelius E, Källén Å, et al. Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimers Dement. 2019;15:55-64. doi:10.1016/j.jalz.2018.08.006</Citation></Reference><Reference><Citation>Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-1800. doi:10.1212/WNL.58.12.1791</Citation></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389-404. doi:10.1007/S00401-006-0127-Z</Citation></Reference><Reference><Citation>Xu L, Sun H, Zhang Y, et al. Proteomic analysis of human frontal and temporal cortex using iTRAQ-based 2D LC-MS/MS. Chinese Neurosurg J. 2021;7:27. doi:10.1186/s41016-021-00241-5</Citation></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387-397. doi:10.1038/s41591-020-0762-2</Citation></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422-433. doi:10.1016/S1474-4422(20)30071-5</Citation></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26:379-386. doi:10.1038/s41591-020-0755-1</Citation></Reference><Reference><Citation>Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12;(1):3400. doi:10.1038/S41467-021-23620-Z</Citation></Reference><Reference><Citation>Benussi A, Karikari TK, Ashton N, et al. Diagnostic and prognostic value of serum NfL and p-Tau 181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91:960-967. doi:10.1136/JNNP-2020-323487</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36129041</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>19</Issue><PubDate><Year>2022</Year><Month>10</Month><Day>04</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Gait in Cerebral Amyloid Angiopathy.</ArticleTitle><Pagination><MedlinePgn>e025886</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.121.025886</ELocationID><Abstract><AbstractText>Background Gait is a complex task requiring coordinated efforts of multiple brain networks. To date, there is little evidence on whether gait is altered in cerebral amyloid angiopathy (CAA). We aimed to identify impairments in gait performance and associations between gait impairment and neuroimaging markers of CAA, cognition, and falls. Methods and Results Gait was assessed using the Zeno Walkway during preferred pace and dual task walks, and grouped into gait domains (Rhythm, Pace, Postural Control, and Variability). Participants underwent neuropsychological testing and neuroimaging. Falls and fear of falling were assessed through self-report questionnaires. Gait domain scores were standardized and analyzed using linear regression adjusting for age, sex, height, and other covariates. Participants were patients with CAA (n=29), Alzheimer disease with mild dementia (n=16), mild cognitive impairment (n=24), and normal elderly controls (n=47). CAA and Alzheimer disease had similarly impaired Rhythm, Pace, and Variability, and higher dual task cost than normal controls or mild cognitive impairment. Higher Pace score was associated with better global cognition, processing speed, and memory. Gait measures were not correlated with microbleed count or white matter hyperintensity volume. Number of falls was not associated with gait domain scores, but participants with low fear of falling had higher Pace (odds ratio [OR], 2.61 [95% CI, 1.59-4.29]) and lower Variability (OR, 1.64 [95% CI, 1.10-2.44]). Conclusions CAA is associated with slower walking, abnormal rhythm, and greater gait variability than in healthy controls. Future research is needed to identify the mechanisms underlying gait impairments in CAA, and whether they predict future falls.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Breni</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8560-9664</Identifier><AffiliationInfo><Affiliation>Cumming School of Medicine University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute University of Calgary Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gee</LastName><ForeName>Myrlene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine (Neurology) University of Alberta Edmonton Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelles</LastName><ForeName>Krista</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4491-5758</Identifier><AffiliationInfo><Affiliation>Department of Medicine (Neurology) University of Alberta Edmonton Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hotchkiss Brain Institute University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences University of Calgary Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hotchkiss Brain Institute University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences University of Calgary Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Feryal</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-8038-8495</Identifier><AffiliationInfo><Affiliation>Hotchkiss Brain Institute University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Seaman Family MR Research Centre University of Calgary Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Jerald</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Dentistry University of Alberta Edmonton Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCreary</LastName><ForeName>Cheryl R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Hotchkiss Brain Institute University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Seaman Family MR Research Centre University of Calgary Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Zahinoor</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-5529-3731</Identifier><AffiliationInfo><Affiliation>Cumming School of Medicine University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Seaman Family MR Research Centre University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Psychiatry and Community Health Sciences University of Calgary Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camicioli</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine (Neurology) University of Alberta Edmonton Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Mental Health Institute University of Alberta Edmonton Alberta Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Eric E</ForeName><Initials>EE</Initials><Identifier Source="ORCID">0000-0003-3956-1668</Identifier><AffiliationInfo><Affiliation>Cumming School of Medicine University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences University of Calgary Alberta Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Seaman Family MR Research Centre University of Calgary Alberta Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-142175</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>FDN-154317</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="Y">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">accidental falls</Keyword><Keyword MajorTopicYN="N">cerebral amyloid angiopathy</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">gait</Keyword><Keyword MajorTopicYN="N">neuroimaging</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36129041</ArticleId><ArticleId IdType="doi">10.1161/JAHA.121.025886</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36128968</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2384-8553</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>3</Issue><PubDate><MedlineDate>2022 Jul-Sep</MedlineDate></PubDate></JournalIssue><Title>Annali dell'Istituto superiore di sanita</Title><ISOAbbreviation>Ann Ist Super Sanita</ISOAbbreviation></Journal><ArticleTitle>The Italian fund for Alzheimer's and other dementias: strategies and objectives to face the dementia challenge.</ArticleTitle><Pagination><MedlinePgn>192-196</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4415/ANN_22_03_08</ELocationID><Abstract><AbstractText>The Italian Fund for Alzheimer's and other dementias was approved and signed in December 2021. The Fund is financed with 15 million euros in three years. The main goal is to provide new strategies in the field of dementia with a Public Health perspective. The Fund includes eight main activities that will be monitored and supervised by the Italian National Institute of Health: 1) development of a guideline for the assessment, management and support for people with dementia and their families/carers; 2) updating of the Dementia National Plan (DNP); 3) implementation of the documents of the DNP; 4) conducting surveys dedicated to the Italian Dementia Services; 5) promotion of dementia prevention strategies; 6) training strategies for healthcare professionals, families and caregivers; 7) creation of a National Electronic Record for Dementia; 8) evaluation and monitoring of activities promoted by Regions and Autonomous Provinces in the field of dementia, together with the dementia National Permanent Table. These activities are outlined in detail in the present paper.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ancidoni</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy - Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sciancalepore</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacigalupo</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellomo</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canevelli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy - Dipartimento di Neuroscienze Umane, Sapienza Università di Roma, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacorte</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardo</LastName><ForeName>Flavia L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorenzini</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palazzesi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piscopo</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento di Neuroscienze, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvi</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Ricerca e la Valutazione dei Farmaci, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Caterina B N A</ForeName><Initials>CBNA</Initials><AffiliationInfo><Affiliation>Direzione Generale della Prevenzione Sanitaria, Ministero della Salute, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landoni</LastName><ForeName>Fiammetta</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Direzione Generale della Prevenzione Sanitaria, Ministero della Salute, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Sala</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Direzione Generale della Prevenzione Sanitaria, Ministero della Salute, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Fiandra</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Scientific consultant of the Istituto Superiore di Sanità.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanacore</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Permanent Table of the National Dementia Plan Study Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Istituto Superiore di Sanità FONDEM Study Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Istituto Superiore di Sanità FONDEM StudyGroup</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Ann Ist Super Sanita</MedlineTA><NlmUniqueID>7502520</NlmUniqueID><ISSNLinking>0021-2571</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005376" MajorTopicYN="Y">Financial Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Basso</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Veneto.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bonino</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Valle D'Aosta.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bruni</LastName><ForeName>Amalia Cecilia</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Calabria.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Caci</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Valle D'Aosta.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fabbo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Emilia-Romagna.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Giordano</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Sicilia.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Greco</LastName><ForeName>Annarita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Campania.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lidonnici</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Liguria.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione PA Trento.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lovaldi</LastName><ForeName>Franca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Piemonte.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>March</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione PA Bolzano.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Madrigali</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Toscana.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Palummeri</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Liguria.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Perratone</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Valle D'Aosta.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Scalmana</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regional Representative, Regione Lazio.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Caffarra</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>SINdem.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mazzoleni</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>SIMG.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Pirani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>SIMG.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Trabucchi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AIP.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Belardinelli</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer Uniti Italia Onlus.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Possenti</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Federazione Alzheimer Italia.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Spadin</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Associazione Italiana Malati di Alzheimer.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bargagli</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Expert, Regione Lazio.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bartorelli</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Expert, Regione Lazio.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Biagini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Expert, Regione Lazio.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Capasso</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Expert, Regione Campania.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Cozzari</LastName><ForeName>Maria Pia</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Expert, Cooperativa Sociale Anthropos.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Gainotti</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Expert, Unità Bioetica - ISS.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Di Palma</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Expert, Regione Campania.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Di Fiandra</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Expert, former executive of the Ministry of Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Gabelli</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Expert, Regione Veneto.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Gambina</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Expert, Regione Veneto.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Gasparini</LastName><ForeName>Marina Michela</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Expert, Regione Lazio.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Guaita</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Expert, Regione Lombardia.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Izzicupo</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Expert, Regione Marche.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Notarelli</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Expert, Regione Toscana.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Petrini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Expert, Unità Bioetica - ISS.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Riva</LastName><ForeName>Luciana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Expert, Unità Bioetica - ISS.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Secreto</LastName><ForeName>Piero</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Expert, Regione Piemonte.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Stracciari</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Expert, Regione Emilia-Romagna.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Losito</LastName><ForeName>Gilda</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Guarantor for the Rights of Persons Deprived of Liberty, Regione Lazio.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ciampa</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Representative of Italian Ministry of Labour and Social Policies, Regione Lazio.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bacigalupo</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Administrative Secretarial and Support Activities, on behalf of the Italian National Institute of Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Canevelli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Administrative Secretarial and Support Activities, on behalf of the Italian National Institute of Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Remoli</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Administrative Secretarial and Support Activities, on behalf of the Italian National Institute of Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Salvi</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Administrative Secretarial and Support Activities, on behalf of the Italian National Institute of Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Vanacore</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Administrative Secretarial and Support Activities, on behalf of the Italian National Institute of Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Caterina B N A</ForeName><Initials>CBNA</Initials><AffiliationInfo><Affiliation>Representative of Italian Ministry of Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Landoni</LastName><ForeName>Fiammetta</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Representative of Italian Ministry of Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>La Sala</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Representative of Italian Ministry of Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ancidoni</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bacigalupo</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bellomo</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Caffarra</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Parma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Camilli</LastName><ForeName>Flaminia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Canevelli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Carnevale</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Coclite</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Crestini</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Della Gatta</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Di Fiandra</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Distaso</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bari.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Druda</LastName><ForeName>Ylenia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Bologna.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Esposito</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Napoli.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fabrizi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fauci</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Milano.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Gainotti</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Gasparini</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Giaquinto</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Lecce.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Guaita</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Milano.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lacorte</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Locuratolo</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lombardo</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lorenzini</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Martelli</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Matascioli</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Napoli.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mennini</LastName><ForeName>Saverio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Milanese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Milano.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Morelli</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Napoletano</LastName><ForeName>Antonello</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Palazzesi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Petrini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Piscopo</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Porrello</LastName><ForeName>Maria Cristina</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Remoli</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Milano.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Riva</LastName><ForeName>Luciana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Rivabene</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Sagliocca</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Salerno.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Salvi</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Secreto</LastName><ForeName>Piero</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Torino.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Sciancalepore</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Sciattella</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Stracciari</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bologna.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Vaccaro</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Milano.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Valletta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Vanacore</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Veronese</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Messina.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Vignatelli</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Bologna.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Zaccaria</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Roma.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36128968</ArticleId><ArticleId IdType="doi">10.4415/ANN_22_03_08</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36128778</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Associations of sleep timing and time in bed with dementia and cognitive decline among Chinese older adults: A cohort study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/jgs.18042</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The longitudinal associations of sleep timing and time in bed (TIB) with dementia and cognitive decline in older adults are unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This population-based cohort study used data from 1982 participants who were aged ≥60 years, free of dementia, and living in rural communities in western Shandong, China. At the baseline (2014) and follow-up (2018) examinations, sleep parameters were assessed using standard questionnaires. Cognitive function was measured using the Mini-Mental State Examination (MMSE). Dementia was diagnosed following the DSM-IV criteria, and the NIA-AA criteria for Alzheimer disease (AD). Data were analyzed using restricted cubic splines, Cox proportional-hazards models, and general linear models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the mean follow-up of 3.7 years, dementia was diagnosed in 97 participants (68 with AD). Restricted cubic spline curves showed J-shaped associations of sleep duration, TIB, and rise time with dementia risk, and a reverse J-shaped association with mid-sleep time. When sleep parameters were categorized into tertiles, the multivariable-adjusted hazard ratio (HR) of incident dementia was 1.69 (95%CI 1.01-2.83) for baseline sleep duration &gt;8 hours (vs. 7-8 h), 2.17 (1.22-3.87) for bedtime before 9 p.m. (vs. 10 p.m. or later), and 2.00 (1.23-3.24) for mid-sleep time before 1 a.m. (vs. 1-1.5 a.m.). Early bedtime and mid-sleep time were significantly associated with incident AD (HR range: 2.25-2.51; p &lt; 0.05). Among individuals who were free of dementia at follow-up, baseline long TIB, early bedtime and mid-sleep time, early and late rise time, and prolonged TIB and advanced bedtime and mid-sleep time from baseline to follow-up were associated with a greater decline in MMSE score (p &lt; 0.05). These associations with cognitive decline were statistically evident mainly among men or participants who were aged 60-74 years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long TIB and early sleep timing are associated with an increased risk of dementia, and the associations with greater cognitive decline are evident only among older people aged 60-74 years and men.</AbstractText><CopyrightInformation>© 2022 The American Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7998-0034</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Yifei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Provincial Clinical Research Center for Neurological Diseases, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yongxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Provincial Clinical Research Center for Neurological Diseases, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cong</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Provincial Clinical Research Center for Neurological Diseases, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Provincial Clinical Research Center for Neurological Diseases, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sindi</LastName><ForeName>Shireen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Aging Research Center and Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Shi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Provincial Clinical Research Center for Neurological Diseases, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yifeng</ForeName><Initials>Y</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-4672-6654</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Provincial Clinical Research Center for Neurological Diseases, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Chengxuan</ForeName><Initials>C</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1922-4912</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aging Research Center and Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2019QL020</GrantID><Agency>Academic Promotion Program of Shandong First Medical University</Agency><Country/></Grant><Grant><Agency>Alzheimerfonden, Demensförbundet, Karolinska Institutet Foundation and Funds</Agency><Country/></Grant><Grant><GrantID>2021ZD0201801</GrantID><Agency>Brain Science and Brain-like Intelligence Technology Research Projects of China</Agency><Country/></Grant><Grant><GrantID>2021ZD0201808</GrantID><Agency>Brain Science and Brain-like Intelligence Technology Research Projects of China</Agency><Country/></Grant><Grant><GrantID>YXH2019ZXY008</GrantID><Agency>Integrated Traditional Chinese and Western Medicine Program in Shandong Province</Agency><Country/></Grant><Grant><GrantID>202019187</GrantID><Agency>Jinan Science and Technology Bureau</Agency><Country/></Grant><Grant><Agency>Loo and Hans Osterman Foundation for Medical Research, Stockholm, Sweden</Agency><Country/></Grant><Grant><GrantID>2017YFC1310100</GrantID><Agency>National Key Research and Development Program of China</Agency><Country/></Grant><Grant><GrantID>81861138008</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82001397</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82011530139</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><Agency>Postdoctoral Innovation Project of Shandong Province</Agency><Country/></Grant><Grant><Agency>Qilu Health and Hygiene Outstanding Young Talent Training Project</Agency><Country/></Grant><Grant><GrantID>2013kjhm180405</GrantID><Agency>Science and Technology Program for Public Wellbeing of Shandong Province, China</Agency><Country/></Grant><Grant><GrantID>2021LCZX03</GrantID><Agency>Shandong Provincial Key Research and Development Program</Agency><Country/></Grant><Grant><GrantID>CH2019-8320</GrantID><Agency>Swedish Foundation for International Cooperation in Research and Higher Education for the Joint China-Sweden Mobility Program</Agency><Country/></Grant><Grant><GrantID>2017-05819</GrantID><Agency>Swedish Research Council</Agency><Country/></Grant><Grant><GrantID>2020-01574</GrantID><Agency>Swedish Research Council</Agency><Country/></Grant><Grant><Agency>Taishan Scholar Program of Shandong Province, China</Agency><Country/></Grant><Grant><Agency>Youth Talent Promotion Project of China Association for Science and Technology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">cognitive function</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">population-based cohort study</Keyword><Keyword MajorTopicYN="N">sleep</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36128778</ArticleId><ArticleId IdType="doi">10.1111/jgs.18042</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Jia L, Quan M, Fu Y, et al. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 2020;19(1):81-92.</Citation></Reference><Reference><Citation>Mander BA, Winer JR, Walker MP. Sleep and human aging. Neuron. 2017;94(1):19-36.</Citation></Reference><Reference><Citation>Ma Y, Liang L, Zheng F, Shi L, Zhong B, Xie W. Association between sleep duration and cognitive decline. JAMA Netw Open. 2020;3(9):e2013573.</Citation></Reference><Reference><Citation>Sindi S, Kåreholt I, Johansson L, et al. Sleep disturbances and dementia risk: a multicenter study. Alzheimers Dement. 2018;14(10):1235-1242.</Citation></Reference><Reference><Citation>McSorley VE, Bin YS, Lauderdale DS. Associations of sleep characteristics with cognitive function and decline among older adults. Am J Epidemiol. 2019;188(6):1066-1075.</Citation></Reference><Reference><Citation>Ohara T, Honda T, Hata J, et al. Association between daily sleep duration and risk of dementia and mortality in a Japanese community. J Am Geriatr Soc. 2018;66(10):1911-1918.</Citation></Reference><Reference><Citation>Xu W, Tan CC, Zou JJ, Cao XP, Tan L. Sleep problems and risk of all-cause cognitive decline or dementia: an updated systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91(3):236-244.</Citation></Reference><Reference><Citation>Jones SE, Lane JM, Wood AR, et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nat Commun. 2019;10(1):343.</Citation></Reference><Reference><Citation>Didikoglu A, Maharani A, Payton A, Pendleton N, Canal MM. Longitudinal change of sleep timing: association between chronotype and longevity in older adults. Chronobiol Int. 2019;36(9):1285-1300.</Citation></Reference><Reference><Citation>Larcher S, Benhamou PY, Pépin JL, Borel AL. Sleep habits and diabetes. Diabetes Metab. 2015;41(4):263-271.</Citation></Reference><Reference><Citation>Mooldijk SS, Licher S, Wolters FJ. Characterizing demographic, racial, and geographic diversity in dementia research: a systematic review. JAMA Neurol. 2021;78(10):1255-1261.</Citation></Reference><Reference><Citation>Ohayon MM, Vecchierini MF. Normative sleep data, cognitive function and daily living activities in older adults in the community. Sleep. 2005;28(8):981-989.</Citation></Reference><Reference><Citation>Zhang Y-S, Jin Y, Rao W-W, et al. Prevalence and socio-demographic correlates of poor sleep quality among older adults in Hebei province, China. Sci Rep. 2020;10(1):12266.</Citation></Reference><Reference><Citation>Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-1590.</Citation></Reference><Reference><Citation>Cunningham TJ, Ford ES, Chapman DP, Liu Y, Croft JB. Independent and joint associations of race/ethnicity and educational attainment with sleep-related symptoms in a population-based US sample. Prev Med. 2015;77:99-105.</Citation></Reference><Reference><Citation>Spira AP, An Y, Peng Y, et al. APOE genotype and nonrespiratory sleep parameters in cognitively intact older adults. Sleep. 2017;40(8):zsx076.</Citation></Reference><Reference><Citation>Ren Y, Dong Y, Hou T, et al. Prevalence, incidence, and progression of cognitive impairment, no dementia among rural-dwelling Chinese older adults. J Alzheimers Dis. 2022;85(4):1583-1592.</Citation></Reference><Reference><Citation>Wang Y, Han X, Zhang X, et al. Health status and risk profiles for brain aging of rural-dwelling older adults: data from the interdisciplinary baseline assessments in MIND-China. Alzheimers Dement. 2022;8(1):e12254.</Citation></Reference><Reference><Citation>Liu R, Tang S, Wang Y, et al. Self-reported sleep characteristics associated with dementia among rural-dwelling Chinese older adults: a population-based study. BMC Neurol. 2022;22(1):5.</Citation></Reference><Reference><Citation>Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.</Citation></Reference><Reference><Citation>Johns MW. A new method for measuring daytime sleepiness: the epworth sleepiness scale. Sleep. 1991;14(6):540-545.</Citation></Reference><Reference><Citation>Tsai PS, Wang SY, Wang MY, et al. Psychometric evaluation of the Chinese version of the Pittsburgh sleep quality index (CPSQI) in primary insomnia and control subjects. Qual Life Res. 2005;14(8):1943-1952.</Citation></Reference><Reference><Citation>Gabelle A, Gutierrez LA, Jaussent I, et al. Excessive sleepiness andlonger nighttime in bed increase the risk of cognitive decline in frail elderly subjects: the MAPT-sleep study. Front Aging Neurosci. 2017;9:312.</Citation></Reference><Reference><Citation>Sabia S, Fayosse A, Dumurgier J, et al. Association of sleep duration in middle and old age with incidence of dementia. Nat Commun. 2021;12(1):2289.</Citation></Reference><Reference><Citation>Lysen TS, Luik AI, Ikram MK, Tiemeier H, Ikram MA. Actigraphy-estimated sleep and 24-hour activity rhythms and the risk of dementia. Alzheimers Dement. 2020;16(9):1259-1267.</Citation></Reference><Reference><Citation>Suh SW, Han JW, Lee JR, et al. Sleep and cognitive decline: a prospective nondemented elderly cohort study. Ann Neurol. 2018;83(3):472-482.</Citation></Reference><Reference><Citation>Li X, Ding D, Zhao Q, et al. Sleep timing and risk of dementia among the Chinese elderly in an urban community: the Shanghai aging study. Front Neurol. 2021;12:629507.</Citation></Reference><Reference><Citation>Simoes Maria M, Büla C, Santos-Eggimann B, Krief H, Heinzer R, Seematter-Bagnoud L. Sleep characteristics and self-rated health in older persons. Eur Geriatr Med. 2020;11(1):131-138.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth ed. (DSM-IV) American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>Jia Y, Liu R, Tang S, et al. Associations of the glycaemic control of diabetes with dementia and physical function in rural-dwelling older Chinese adults: a population-based study. Clin Interv Aging. 2021;16:1503-1513.</Citation></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.</Citation></Reference><Reference><Citation>Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology. 1993;43(2):250-260.</Citation></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.</Citation></Reference><Reference><Citation>Whinnery J, Jackson N, Rattanaumpawan P, Grandner MA. Short and long sleep duration associated with race/ethnicity, sociodemographics, and socioeconomic position. Sleep. 2014;37(3):601-611.</Citation></Reference><Reference><Citation>Nakakubo S, Doi T, Makizako H, et al. Sleep condition and cognitive decline in Japanese community-dwelling older people: data from a 4-year longitudinal study. J Sleep Res. 2018;28:e12803.</Citation></Reference><Reference><Citation>Wu L, He Y, Jiang B, et al. Association between sleep duration and the prevalence of hypertension in an elderly rural population of China. Sleep Med. 2016;27-28:92-98.</Citation></Reference><Reference><Citation>Brooks A, Lack L. A brief afternoon nap following nocturnal sleep restriction: which nap duration is most recuperative? Sleep. 2006;29(6):831-840.</Citation></Reference><Reference><Citation>Westwood AJ, Beiser A, Jain N, et al. Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia. Neurology. 2017;88(12):1172-1179.</Citation></Reference><Reference><Citation>Ramos AR, Dong C, Rundek T, et al. Sleep duration is associated with white matter hyperintensity volume in older adults: the northern Manhattan study. J Sleep Res. 2014;23(5):524-530.</Citation></Reference><Reference><Citation>Grandner MA, Sands-Lincoln MR, Pak VM, Garland SN. Sleep duration, cardiovascular disease, and proinflammatory biomarkers. Nat Sci Sleep. 2013;5:93-107.</Citation></Reference><Reference><Citation>Park JE, Lee YJ, Byun MS, et al. Differential associations of age and Alzheimer's disease with sleep and rest-activity rhythms across the adult lifespan. Neurobiol Aging. 2021;101:141-149.</Citation></Reference><Reference><Citation>Van Someren EJW, Oosterman JM, Van Harten B, et al. Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk. Neurobiol Learn Mem. 2019;160:132-138.</Citation></Reference><Reference><Citation>Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases. Lancet Neurol. 2019;18(3):307-318.</Citation></Reference><Reference><Citation>Wallace ML, Buysse DJ, Redline S, et al. Multidimensional sleep and mortality in older adults: a machine-learning comparison with other risk factors. J Gerontol A Biol Sci Med Sci. 2019;74(12):1903-1909.</Citation></Reference><Reference><Citation>Jackowska M, Cadar D. The mediating role of low-grade inflammation on the prospective association between sleep and cognitive function in older men and women: 8-year follow-up from the english longitudinal study of ageing. Arch Gerontol Geriatr. 2020;87:103967.</Citation></Reference><Reference><Citation>Rodriguez JC, Dzierzewski JM, Alessi CA. Sleep problems in the elderly. Med Clin North Am. 2015;99(2):431-439.</Citation></Reference><Reference><Citation>Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology. 2020;45(1):104-120.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36128654</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-5949</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>CNS neuroscience &amp; therapeutics</Title><ISOAbbreviation>CNS Neurosci Ther</ISOAbbreviation></Journal><ArticleTitle>Perivascular macrophages in the CNS: From health to neurovascular diseases.</ArticleTitle><Pagination><MedlinePgn>1908-1920</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cns.13954</ELocationID><Abstract><AbstractText>Brain perivascular macrophages (PVMs) are attracting increasing attention as this emerging cell population in the brain has multifaced roles in supporting the central nervous system structure, brain development, and maintaining physiological functions. They also widely participate in neurological diseases such as neurodegeneration and ischemic stroke. Moreover, PVMs have been reported to have both beneficial and detrimental effects under different pathological contexts. Advanced research technologies allowed the further in-depth study of PVMs and revealed novel concepts in their origins, differentiation, and regulatory mechanisms. Deepened understanding of the roles of PVMs in different brain pathological conditions can reveal novel phenotypic changes and regulatory signaling, which might pave the way for the development of novel treatment strategies targeting PVMs.</AbstractText><CopyrightInformation>© 2022 The Authors. CNS Neuroscience &amp; Therapeutics published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yunlu</ForeName><Initials>Y</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6073-5947</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Xiaozhu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yueman</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weijie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ziyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xuan</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Peiying</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5721-9914</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SHDC12019102</GrantID><Agency>Shanghai Shenkang Hospital Development Center</Agency><Country/></Grant><Grant><GrantID>NAF\R11\1010</GrantID><Agency>UK Academy of Medical Sciences</Agency><Country/></Grant><Grant><GrantID>20181805</GrantID><Agency>Shanghai Municipal Education Commission-Gaofeng Clinical Medical Grant Support</Agency><Country/></Grant><Grant><GrantID>shslczdzk03601</GrantID><Agency>Shanghai Municipal Key Clinical Specialty</Agency><Country/></Grant><Grant><GrantID>20SG17</GrantID><Agency>Shanghai Municipal Education Commission</Agency><Country/></Grant><Grant><GrantID>20XD1422400</GrantID><Agency>Shanghai Outstanding Academic Leaders' Program from Shanghai Municipal Science and Technology Committee</Agency><Country/></Grant><Grant><GrantID>PWZxq2017-06</GrantID><Agency>Shanghai Pudong New Area Municipal Commission of Health and Family Planning Funding</Agency><Country/></Grant><Grant><GrantID>SHSMU-ZLCX20211602</GrantID><Agency>Innovative Research Team of High-Level Local Universities in Shanghai</Agency><Country/></Grant><Grant><Agency>Shanghai Education Development Foundation</Agency><Country/></Grant><Grant><GrantID>81901985</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82061130224</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81971096</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>91957111</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81722017</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>CNS Neurosci Ther</MedlineTA><NlmUniqueID>101473265</NlmUniqueID><ISSNLinking>1755-5930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="Y">Central Nervous System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">neurological disease</Keyword><Keyword MajorTopicYN="N">perivascular macrophages</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>2</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36128654</ArticleId><ArticleId IdType="doi">10.1111/cns.13954</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Wang X, Xuan W, Zhu ZY, et al. The evolving role of neuro-immune interaction in brain repair after cerebral ischemic stroke. CNS Neurosci Ther. 2018;24(12):1100-1114.</Citation></Reference><Reference><Citation>Prinz M, Erny D, Hagemeyer N. Ontogeny and homeostasis of CNS myeloid cells. Nat Immunol. 2017;18(4):385-392.</Citation></Reference><Reference><Citation>Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18(2):123-131.</Citation></Reference><Reference><Citation>Herz J, Filiano AJ, Smith A, Yogev N, Kipnis J. Myeloid cells in the central nervous system. Immunity. 2017;46(6):943-956.</Citation></Reference><Reference><Citation>Goldmann T, Wieghofer P, Jordão MJC, et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat Immunol. 2016;17(7):797-805.</Citation></Reference><Reference><Citation>Mato M, Ookawara S, Kurihara K. Uptake of exogenous substances and marked infoldings of the fluorescent granular pericyte in cerebral fine vessels. Am J Anat. 1980;157(3):329-332.</Citation></Reference><Reference><Citation>Mato M, Aikawa E, Mato TK, Kurihara K. Tridimensional observation of fluorescent granular perithelial (FGP) cells in rat cerebral blood vessels. Anat Rec. 1986;215(4):413-419.</Citation></Reference><Reference><Citation>Mato M, Ookawara S, Sakamoto A, et al. Involvement of specific macrophage-lineage cells surrounding arterioles in barrier and scavenger function in brain cortex. Proc Natl Acad Sci USA. 1996;93(8):3269-3274.</Citation></Reference><Reference><Citation>Ookawara S, Mitsuhashi U, Suminaga Y, Mato M. Study on distribution of pericyte and fluorescent granular perithelial (FGP) cell in the transitional region between arteriole and capillary in rat cerebral cortex. Anat Rec. 1996;244(2):257-264.</Citation></Reference><Reference><Citation>Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988;239(4837):290-292.</Citation></Reference><Reference><Citation>Graeber MB, Streit WJ, Kreutzberg GW. Identity of ED2-positive perivascular cells in rat brain. J Neurosci Res. 1989;22(1):103-106.</Citation></Reference><Reference><Citation>Koizumi T, Kerkhofs D, Mizuno T, Steinbusch HWM, Foulquier S. Vessel-associated immune cells in cerebrovascular diseases: from perivascular macrophages to vessel-associated microglia. Front Neurosci. 2019;13:1291.</Citation></Reference><Reference><Citation>Esiri MM, Gay D. Immunological and neuropathological significance of the Virchow-Robin space. J Neurol Sci. 1990;100(1-2):3-8.</Citation></Reference><Reference><Citation>Hutchings M, Weller RO. Anatomical relationships of the pia mater to cerebral blood vessels in man. J Neurosurg. 1986;65(3):316-325.</Citation></Reference><Reference><Citation>Yang T, Guo R, Zhang F. Brain perivascular macrophages: recent advances and implications in health and diseases. CNS Neurosci Ther. 2019;25(12):1318-1328.</Citation></Reference><Reference><Citation>Park L, Uekawa K, Garcia-Bonilla L, et al. Brain perivascular macrophages initiate the neurovascular dysfunction of Alzheimer Aβ peptides. Circ Res. 2017;121(3):258-269.</Citation></Reference><Reference><Citation>Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci USA. 2009;106(4):1261-1266.</Citation></Reference><Reference><Citation>Sun BL, Wang LH, Yang T, et al. Lymphatic drainage system of the brain: a novel target for intervention of neurological diseases. Prog Neurobiol. 2018;163-164:118-143.</Citation></Reference><Reference><Citation>Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4(147):147ra111.</Citation></Reference><Reference><Citation>Goehler LE, Erisir A, Gaykema RP. Neural-immune interface in the rat area postrema. Neuroscience. 2006;140(4):1415-1434.</Citation></Reference><Reference><Citation>Galea I, Bernardes-Silva M, Forse PA, van Rooijen N, Liblau RS, Perry VH. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med. 2007;204(9):2023-2030.</Citation></Reference><Reference><Citation>McGavern DB, Kang SS. Illuminating viral infections in the nervous system. Nat Rev Immunol. 2011;11(5):318-329.</Citation></Reference><Reference><Citation>Sallusto F, Impellizzieri D, Basso C, et al. T-cell trafficking in the central nervous system. Immunol Rev. 2012;248(1):216-227.</Citation></Reference><Reference><Citation>Barkauskas DS, Evans TA, Myers J, Petrosiute A, Silver J, Huang AY. Extravascular CX3CR1+ cells extend intravascular dendritic processes into intact central nervous system vessel lumen. Microsc Microanal. 2013;19(4):778-790.</Citation></Reference><Reference><Citation>Kierdorf K, Erny D, Goldmann T, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16(3):273-280.</Citation></Reference><Reference><Citation>Schulz C, Perdiguero EG, Chorro L, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336(6077):86-90.</Citation></Reference><Reference><Citation>Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841-845.</Citation></Reference><Reference><Citation>Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci. 2014;15(5):300-312.</Citation></Reference><Reference><Citation>Hickey WF, Vass K, Lassmann H. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J Neuropathol Exp Neurol. 1992;51(3):246-256.</Citation></Reference><Reference><Citation>Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339(6116):156-161.</Citation></Reference><Reference><Citation>Lee E, Eo JC, Lee C, Yu JW. Distinct features of brain-resident macrophages: microglia and non-parenchymal brain macrophages. Mol Cells. 2021;44(5):281-291.</Citation></Reference><Reference><Citation>Utz SG, See P, Mildenberger W, et al. Early fate defines microglia and non-parenchymal brain macrophage development. Cell. 2020;181(3):557-573 e18.</Citation></Reference><Reference><Citation>Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90(2):489-519.</Citation></Reference><Reference><Citation>Waddell LA, Lefevre L, Bush SJ, et al. ADGRE1 (EMR1, F4/80) is a rapidly-evolving gene expressed in mammalian monocyte-macrophages. Front Immunol. 2018;9:2246.</Citation></Reference><Reference><Citation>Buxade M, Huerga Encabo H, Riera-Borrull M, et al. Macrophage-specific MHCII expression is regulated by a remote Ciita enhancer controlled by NFAT5. J Exp Med. 2018;215(11):2901-2918.</Citation></Reference><Reference><Citation>Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437-3446.</Citation></Reference><Reference><Citation>Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, Singh H. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity. 1997;6(4):437-447.</Citation></Reference><Reference><Citation>Dakic A, Metcalf D, di Rago L, Mifsud S, Wu L, Nutt SL. PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med. 2005;201(9):1487-1502.</Citation></Reference><Reference><Citation>Moura Silva H, Kitoko JZ, Queiroz CP, et al. c-MAF-dependent perivascular macrophages regulate diet-induced metabolic syndrome. Sci Immunol. 2021;6(64):eabg7506.</Citation></Reference><Reference><Citation>Bottcher C, Schlickeiser S, Sneeboer MA, et al. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat Neurosci. 2019;22(1):78-90.</Citation></Reference><Reference><Citation>Jordao MJC, Sankowski R, Brendecke SM, et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science. 2019;363(6425):eaat7554.</Citation></Reference><Reference><Citation>Sarrazin S, Mossadegh-Keller N, Fukao T, et al. MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells. Cell. 2009;138(2):300-313.</Citation></Reference><Reference><Citation>Hagemeyer N, Kierdorf K, Frenzel K, et al. Transcriptome-based profiling of yolk sac-derived macrophages reveals a role for Irf8 in macrophage maturation. EMBO J. 2016;35(16):1730-1744.</Citation></Reference><Reference><Citation>Tamura T, Kurotaki D, Koizumi S. Regulation of myelopoiesis by the transcription factor IRF8. Int J Hematol. 2015;101(4):342-351.</Citation></Reference><Reference><Citation>Hamilton JA, Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 2013;34(2):81-89.</Citation></Reference><Reference><Citation>Mossadegh-Keller N, Sarrazin S, Kandalla PK, et al. M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. Nature. 2013;497(7448):239-243.</Citation></Reference><Reference><Citation>Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA. 1990;87(12):4828-4832.</Citation></Reference><Reference><Citation>McKercher SR, Torbett BE, Anderson KL, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 1996;15(20):5647-5658.</Citation></Reference><Reference><Citation>Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265(5178):1573-1577.</Citation></Reference><Reference><Citation>Mahe D, Fisson S, Montoni A, Morel A, Couez D. Identification and IFNgamma-regulation of differentially expressed mRNAs in murine microglial and CNS-associated macrophage subpopulations. Mol Cell Neurosci. 2001;18(4):363-380.</Citation></Reference><Reference><Citation>Faraco G, Sugiyama Y, Lane D, et al. Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. J Clin Invest. 2016;126(12):4674-4689.</Citation></Reference><Reference><Citation>Steel CD, Kim WK, Sanford LD, et al. Distinct macrophage subpopulations regulate viral encephalitis but not viral clearance in the CNS. J Neuroimmunol. 2010;226(1-2):81-92.</Citation></Reference><Reference><Citation>Thanopoulou K, Fragkouli A, Stylianopoulou F, Georgopoulos S. Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc Natl Acad Sci USA. 2010;107(48):20816-20821.</Citation></Reference><Reference><Citation>Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol. 2018;18(4):225-242.</Citation></Reference><Reference><Citation>Jung S, Aliberti J, Graemmel P, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20(11):4106-4114.</Citation></Reference><Reference><Citation>Zhang Z, Li Z, Ma Z, et al. Annexin A3 as a marker protein for microglia in the central nervous system of rats. Neural Plast. 2021;2021:5575090.</Citation></Reference><Reference><Citation>Konishi H, Kobayashi M, Kunisawa T, et al. Siglec-H is a microglia-specific marker that discriminates microglia from CNS-associated macrophages and CNS-infiltrating monocytes. Glia. 2017;65(12):1927-1943.</Citation></Reference><Reference><Citation>Buttgereit A, Lelios I, Yu X, et al. Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol. 2016;17(12):1397-1406.</Citation></Reference><Reference><Citation>Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat Rev Neurosci. 2018;19(10):622-635.</Citation></Reference><Reference><Citation>Bennett ML, Bennett FC, Liddelow SA, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci USA. 2016;113(12):E1738-E1746.</Citation></Reference><Reference><Citation>Kim WK, Alvarez X, Fisher J, et al. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am J Pathol. 2006;168(3):822-834.</Citation></Reference><Reference><Citation>Fabriek BO, van Haastert ES, Galea I, et al. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia. 2005;51(4):297-305.</Citation></Reference><Reference><Citation>Wang G, Zhang J, Hu X, et al. Microglia/macrophage polarization dynamics in white matter after traumatic brain injury. J Cereb Blood Flow Metab. 2013;33(12):1864-1874.</Citation></Reference><Reference><Citation>Hu X, Li P, Guo Y, et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012;43(11):3063-3070.</Citation></Reference><Reference><Citation>Galea I, Palin K, Newman TA, van Rooijen N, Perry VH, Boche D. Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. Glia. 2005;49(3):375-384.</Citation></Reference><Reference><Citation>Martin E, el-Behi M, Fontaine B, Delarasse C. Analysis of microglia and monocyte-derived macrophages from the central nervous system by flow cytometry. J Vis Exp. 2017;(124):55781.</Citation></Reference><Reference><Citation>Robinson AP, White TM, Mason DW. Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. Immunology. 1986;57(2):239-247.</Citation></Reference><Reference><Citation>Hammond TR, Dufort C, Dissing-Olesen L, et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity. 2019;50(1):253-271 e6.</Citation></Reference><Reference><Citation>Raivich G, Haas S, Werner A, Klein MA, Kloss C, Kreutzberg GW. Regulation of MCSF receptors on microglia in the normal and injured mouse central nervous system: a quantitative immunofluorescence study using confocal laser microscopy. J Comp Neurol. 1998;395(3):342-358.</Citation></Reference><Reference><Citation>Akiyama H, Nishimura T, Kondo H, Ikeda K, Hayashi Y, McGeer PL. Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer's disease and amyotrophic lateral sclerosis. Brain Res. 1994;639(1):171-174.</Citation></Reference><Reference><Citation>Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res. 1998;57(1):1-9.</Citation></Reference><Reference><Citation>Lin HH, Faunce DE, Stacey M, et al. The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med. 2005;201(10):1615-1625.</Citation></Reference><Reference><Citation>Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 1993;81(6):1607-1613.</Citation></Reference><Reference><Citation>Pey P, Pearce RKB, Kalaitzakis ME, Griffin WST, Gentleman SM. Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease. Acta Neuropathol Commun. 2014;2:21.</Citation></Reference><Reference><Citation>Lim HY, Lim SY, Tan CK, et al. Hyaluronan receptor LYVE-1-expressing macrophages maintain arterial tone through hyaluronan-mediated regulation of smooth muscle cell collagen. Immunity. 2018;49(2):326-341 e7.</Citation></Reference><Reference><Citation>Furube E, Kawai S, Inagaki H, Takagi S, Miyata S. Brain region-dependent heterogeneity and dose-dependent difference in transient microglia population increase during lipopolysaccharide-induced inflammation. Sci Rep. 2018;8(1):2203.</Citation></Reference><Reference><Citation>Mildner A, Huang H, Radke J, Stenzel W, Priller J. P2Y12 receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases. Glia. 2017;65(2):375-387.</Citation></Reference><Reference><Citation>Rajan WD, Wojtas B, Gielniewski B, et al. Defining molecular identity and fates of CNS-border associated macrophages after ischemic stroke in rodents and humans. Neurobiol Dis. 2020;137:104722.</Citation></Reference><Reference><Citation>Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21-78.</Citation></Reference><Reference><Citation>Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002;200(6):629-638.</Citation></Reference><Reference><Citation>Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 1969;40(3):648-677.</Citation></Reference><Reference><Citation>Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 1967;34(1):207-217.</Citation></Reference><Reference><Citation>Ben-Zvi A, Lacoste B, Kur E, et al. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature. 2014;509(7501):507-511.</Citation></Reference><Reference><Citation>Andreone BJ, Chow BW, Tata A, et al. Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. Neuron. 2017;94(3):581-594 e5.</Citation></Reference><Reference><Citation>Nguyen LN, Ma D, Shui G, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 2014;509(7501):503-506.</Citation></Reference><Reference><Citation>Willis CL, Garwood CJ, Ray DE. A size selective vascular barrier in the rat area postrema formed by perivascular macrophages and the extracellular matrix. Neuroscience. 2007;150(2):498-509.</Citation></Reference><Reference><Citation>Prior MJ, Brown AM, Mavroudis G, Lister T, Ray DE, et al. MRI characterisation of a novel rat model of focal astrocyte loss. MAGMA. 2004;17(3-6):125-132.</Citation></Reference><Reference><Citation>Willis CL, Leach L, Clarke GJ, Nolan CC, Ray DE. Reversible disruption of tight junction complexes in the rat blood-brain barrier, following transitory focal astrocyte loss. Glia. 2004;48(1):1-13.</Citation></Reference><Reference><Citation>Zenker D, Begley D, Bratzke H, Rubsamen-Waigmann H, von Briesen H. Human blood-derived macrophages enhance barrier function of cultured primary bovine and human brain capillary endothelial cells. J Physiol. 2003;551(Pt 3):1023-1032.</Citation></Reference><Reference><Citation>Qin J, Lovelace MD, Mitchell AJ, de Koning-Ward T, Grau GE, Pai S. Perivascular macrophages create an intravascular niche for CD8(+) T cell localisation prior to the onset of fatal experimental cerebral malaria. Clin Transl Immunol. 2021;10(4):e1273.</Citation></Reference><Reference><Citation>Kurz C, Walker L, Rauchmann B-S, Perneczky R. Dysfunction of the blood-brain barrier in Alzheimer's disease: evidence from human studies. Neuropathol Appl Neurobiol. 2021;48(3):e12782.</Citation></Reference><Reference><Citation>Bedussi B, Almasian M, de Vos J, VanBavel E, Bakker ENTP. Paravascular spaces at the brain surface: low resistance pathways for cerebrospinal fluid flow. J Cereb Blood Flow Metab. 2018;38(4):719-726.</Citation></Reference><Reference><Citation>Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol. 2015;15(4):203-216.</Citation></Reference><Reference><Citation>Henning EC, Ruetzler CA, Gaudinski MR, et al. Feridex preloading permits tracking of CNS-resident macrophages after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 2009;29(7):1229-1239.</Citation></Reference><Reference><Citation>Wan H, Brathwaite S, Ai J, Hynynen K, Macdonald RL. Role of perivascular and meningeal macrophages in outcome following experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2021;41(8):1842-1857.</Citation></Reference><Reference><Citation>Kierdorf K, Masuda T, Jordão MJC, Prinz M. Macrophages at CNS interfaces: ontogeny and function in health and disease. Nat Rev Neurosci. 2019;20(9):547-562.</Citation></Reference><Reference><Citation>Ji R, Ma L, Chen X, et al. Characterizing the distributions of IDO-1 expressing macrophages/microglia in human and murine brains and evaluating the immunological and physiological roles of IDO-1 in RAW264.7/BV-2 cells. PLoS One. 2021;16(11):e0258204.</Citation></Reference><Reference><Citation>Clapham R, O'Sullivan E, Weller RO, Carare RO. Cervical lymph nodes are found in direct relationship with the internal carotid artery: significance for the lymphatic drainage of the brain. Clin Anat. 2010;23(1):43-47.</Citation></Reference><Reference><Citation>Dissing-Olesen L, Hong S, Stevens B. New brain lymphatic vessels drain old concepts. EBioMedicine. 2015;2(8):776-777.</Citation></Reference><Reference><Citation>Carare RO, Bernardes-Silva M, Newman TA, et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol. 2008;34(2):131-144.</Citation></Reference><Reference><Citation>Foldi M, Gellert A, Kozma M, Poberai M, Zoltán ÖT, Csanda E. New contributions to the anatomical connections of the brain and the lymphatic system. Acta Anat (Basel). 1966;64(4):498-505.</Citation></Reference><Reference><Citation>Louveau A, Da Mesquita S, Kipnis J. Lymphatics in neurological disorders: a neuro-lympho-vascular component of multiple sclerosis and Alzheimer's disease? Neuron. 2016;91(5):957-973.</Citation></Reference><Reference><Citation>Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015;212(7):991-999.</Citation></Reference><Reference><Citation>Expression of concern: blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation. J Biol Chem. 2020;295(26):8886.</Citation></Reference><Reference><Citation>Kaminski M, Bechmann I, Pohland M, Kiwit J, Nitsch R, Glumm J. Migration of monocytes after intracerebral injection at entorhinal cortex lesion site. J Leukoc Biol. 2012;92(1):31-39.</Citation></Reference><Reference><Citation>Kaminski M, Bechmann I, Kiwit J, Glumm J. Migration of monocytes after intracerebral injection. Cell Adh Migr. 2012;6(3):164-167.</Citation></Reference><Reference><Citation>Albargothy NJ, Johnston DA, MacGregor-Sharp M, et al. Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. Acta Neuropathol. 2018;136(1):139-152.</Citation></Reference><Reference><Citation>Drieu A, Lanquetin A, Levard D, et al. Alcohol exposure-induced neurovascular inflammatory priming impacts ischemic stroke and is linked with brain perivascular macrophages. JCI Insight. 2020;5(4):e129226.</Citation></Reference><Reference><Citation>Schwab JM, Nguyen TD, Postler E, Meyermann R, Schluesener HJ. Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia. Acta Neuropathol. 2000;99(6):609-614.</Citation></Reference><Reference><Citation>Pedragosa J, Salas-Perdomo A, Gallizioli M, et al. CNS-border associated macrophages respond to acute ischemic stroke attracting granulocytes and promoting vascular leakage. Acta Neuropathol Commun. 2018;6(1):76.</Citation></Reference><Reference><Citation>Inagaki T, Fujiwara K, Shinohara Y, et al. Perivascular macrophages produce type I collagen around cerebral small vessels under prolonged hypertension in rats. Histochem Cell Biol. 2021;155(4):503-512.</Citation></Reference><Reference><Citation>Iyonaga T, Shinohara K, Mastuura T, Hirooka Y, Tsutsui H. Brain perivascular macrophages contribute to the development of hypertension in stroke-prone spontaneously hypertensive rats via sympathetic activation. Hypertens Res. 2020;43(2):99-110.</Citation></Reference><Reference><Citation>Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci. 1997;17(20):7655-7661.</Citation></Reference><Reference><Citation>Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol. 2002;283(1):H315-H323.</Citation></Reference><Reference><Citation>Niwa K, Younkin L, Ebeling C, et al. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci USA. 2000;97(17):9735-9740.</Citation></Reference><Reference><Citation>Iadecola C, Zhang F, Niwa K, et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 1999;2(2):157-161.</Citation></Reference><Reference><Citation>Han BH, Zhou ML, Abousaleh F, et al. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci. 2008;28(50):13542-13550.</Citation></Reference><Reference><Citation>Koizumi K, Wang G, Park L. Endothelial dysfunction and amyloid-beta-induced neurovascular alterations. Cell Mol Neurobiol. 2016;36(2):155-165.</Citation></Reference><Reference><Citation>Katusic ZS, Austin SA. Endothelial nitric oxide: protector of a healthy mind. Eur Heart J. 2014;35(14):888-894.</Citation></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-738.</Citation></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913-922.</Citation></Reference><Reference><Citation>Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623-635.</Citation></Reference><Reference><Citation>Adlimoghaddam A, Neuendorff M, Roy B, Albensi BC. A review of clinical treatment considerations of donepezil in severe Alzheimer's disease. CNS Neurosci Ther. 2018;24(10):876-888.</Citation></Reference><Reference><Citation>Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844-866.</Citation></Reference><Reference><Citation>Kazama K, Anrather J, Zhou P, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res. 2004;95(10):1019-1026.</Citation></Reference><Reference><Citation>Capone C, Faraco G, Peterson JR, et al. Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension. J Neurosci. 2012;32(14):4878-4886.</Citation></Reference><Reference><Citation>Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension. 2013;62(5):810-817.</Citation></Reference><Reference><Citation>Kerkhofs D, van Hagen BT, Milanova IV, et al. Pharmacological depletion of microglia and perivascular macrophages prevents Vascular Cognitive Impairment in Ang II-induced hypertension. Theranostics. 2020;10(21):9512-9527.</Citation></Reference><Reference><Citation>Schiltz JC, Sawchenko PE. Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J Neurosci. 2002;22(13):5606-5618.</Citation></Reference><Reference><Citation>Nagano T, Tsuda N, Fujimura K, Ikezawa Y, Higashi Y, Kimura SH. Prostaglandin E2 increases the expression of cyclooxygenase-2 in cultured rat microglia. J Neuroimmunol. 2021;361:577724.</Citation></Reference><Reference><Citation>GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795-820.</Citation></Reference><Reference><Citation>Lee JY, Keep RF, He Y, Sagher O, Hua Y, Xi G. Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. J Cereb Blood Flow Metab. 2010;30(11):1793-1803.</Citation></Reference><Reference><Citation>Clark JF, Sharp FR. Bilirubin oxidation products (BOXes) and their role in cerebral vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2006;26(10):1223-1233.</Citation></Reference><Reference><Citation>Joerk A, Ritter M, Langguth N, et al. Propentdyopents as heme degradation intermediates constrict mouse cerebral arterioles and are present in the cerebrospinal fluid of patients with subarachnoid hemorrhage. Circ Res. 2019;124(12):e101-e114.</Citation></Reference><Reference><Citation>Rowland MJ, Hadjipavlou G, Kelly M, Westbrook J, Pattinson KTS. Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm. Br J Anaesth. 2012;109(3):315-329.</Citation></Reference><Reference><Citation>Villa A, Vegeto E, Poletti A, Maggi A. Estrogens, neuroinflammation, and neurodegeneration. Endocr Rev. 2016;37(4):372-402.</Citation></Reference><Reference><Citation>Thion MS, Low D, Silvin A, et al. Microbiome influences prenatal and adult microglia in a sex-specific manner. Cell. 2018;172(3):500-516 e16.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36127711</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>09</Month><Day>20</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Effects and mechanism of Aβ<sub>1-42</sub> on EV-A71 replication.</ArticleTitle><Pagination><MedlinePgn>151</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-022-01882-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">β-Amyloid (Aβ) protein is a pivotal pathogenetic factor in Alzheimer's disease (AD). However, increasing evidence suggests that the brain has to continuously produce excessive Aβ to efficaciously prevent pathogenic micro-organism infections, which induces and accelerates the disease process of AD. Meanwhile, Aβ exhibits activity against herpes simplex virus type 1 (HSV-1) and influenza A virus (IAV) replication, but not against other neurotropic viruses. Enterovirus A71 (EV-A71) is the most important neurotropic enterovirus in the post-polio era. Given the limitation of existing research on the relationship between Aβ and other virus infections, this study aimed to investigate the potent activity of Aβ on EV-A71 infection and extended the potential function of Aβ in other unenveloped viruses may be linked to Alzheimer's disease or infectious neurological diseases.</AbstractText><AbstractText Label="METHODS">Aβ peptides 1-42 are a major pathological factor of senile plaques in Alzheimer's disease (AD). Thus, we utilized Aβ<sub>1-42</sub> as a test subject to perform our study. The production of monomer Aβ<sub>1-42</sub> and their high-molecular oligomer accumulations in neural cells were detected by immunofluorescence assay, ELISA, or Western blot assay. The inhibitory activity of Aβ<sub>1-42</sub> peptides against EV-A71 in vitro was detected by Western blot analysis or qRT-PCR. The mechanism of Aβ<sub>1-42</sub> against EV-A71 replication was analyzed by time-of-addition assay, attachment inhibition assay, pre-attachment inhibition analysis, viral-penetration inhibition assay, TEM analysis of virus agglutination, and pull-down assay.</AbstractText><AbstractText Label="RESULTS">We found that EV-A71 infection induced Aβ production and accumulation in SH-SY5Y cells. We also revealed for the first time that Aβ<sub>1-42</sub> efficiently inhibited the RNA level of EV-A71 VP1, and the protein levels of VP1, VP2, and nonstructural protein 3AB in SH-SY5Y, Vero, and human rhabdomyosarcoma (RD) cells. Mechanistically, we demonstrated that Aβ<sub>1-42</sub> primarily targeted the early stage of EV-A71 entry to inhibit virus replication by binding virus capsid protein VP1 or scavenger receptor class B member 2. Moreover, Aβ<sub>1-42</sub> formed non-enveloped EV-A71 particle aggregates within a certain period and bound to the capsid protein VP1, which partially caused Aβ<sub>1-42</sub> to prevent viruses from infecting cells.</AbstractText><AbstractText Label="CONCLUSIONS">Our findings unveiled that Aβ<sub>1-42</sub> effectively inhibited nonenveloped EV-A71 by targeting the early phase of an EV-A71 life cycle, thereby extending the potential function of Aβ in other non-envelope viruses linked to infectious neurological diseases.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tiantan xili, Beijing, 100050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiqiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tiantan xili, Beijing, 100050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tiantan xili, Beijing, 100050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tiantan xili, Beijing, 100050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tiantan xili, Beijing, 100050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tiantan xili, Beijing, 100050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Boming</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tiantan xili, Beijing, 100050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Mengyuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tiantan xili, Beijing, 100050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuhuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tiantan xili, Beijing, 100050, China. yuhuanlibj@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. yuhuanlibj@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051116">Receptors, Scavenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="Y">Neuroblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051116" MajorTopicYN="N">Receptors, Scavenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Capsid protein VP1</Keyword><Keyword MajorTopicYN="N">Enterovirus A 71</Keyword><Keyword MajorTopicYN="N">Scavenger receptor class B member 2</Keyword><Keyword MajorTopicYN="N">β-Amyloid protein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36127711</ArticleId><ArticleId IdType="doi">10.1186/s12985-022-01882-3</ArticleId><ArticleId IdType="pii">10.1186/s12985-022-01882-3</ArticleId><ArticleId IdType="pmc">PMC9485788</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Alzheimers Dis. 2016 Oct 4;54(3):859-878</Citation><ArticleIdList><ArticleId IdType="pubmed">27392871</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2019 Jan;25(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">30560775</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2021 Jan 13;11:610568</Citation><ArticleIdList><ArticleId IdType="pubmed">33519765</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2010 Nov;10(11):778-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol Sin. 2021 Oct;36(5):1154-1164</Citation><ArticleIdList><ArticleId IdType="pubmed">34046815</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2018 Jul;24(7):1386-1387</Citation><ArticleIdList><ArticleId IdType="pubmed">29912701</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2021 Jul 30;22(15):</Citation><ArticleIdList><ArticleId IdType="pubmed">34360989</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2016 Oct 18;54(4):1273-1281</Citation><ArticleIdList><ArticleId IdType="pubmed">27497484</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Sci. 2020 Jan 10;27(1):23</Citation><ArticleIdList><ArticleId IdType="pubmed">31924205</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2019 Feb 20;16(1):21</Citation><ArticleIdList><ArticleId IdType="pubmed">30786886</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2016;50(4):1227-41</Citation><ArticleIdList><ArticleId IdType="pubmed">26836158</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Genomics. 2017 Jan 25;18(Suppl 1):933</Citation><ArticleIdList><ArticleId IdType="pubmed">28198671</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Biol Ther. 2019 Jan;19(1):73-78</Citation><ArticleIdList><ArticleId IdType="pubmed">30526133</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2012 Mar 27;3:105</Citation><ArticleIdList><ArticleId IdType="pubmed">22470371</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharm Sin B. 2022 Apr;12(4):1542-1566</Citation><ArticleIdList><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2019 Oct 20;20(20):</Citation><ArticleIdList><ArticleId IdType="pubmed">31635198</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2016 Jan;233(1):137-52</Citation><ArticleIdList><ArticleId IdType="pubmed">26446867</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Jul 02;9(7):e101364</Citation><ArticleIdList><ArticleId IdType="pubmed">24988208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2020 Apr 16;94(9):</Citation><ArticleIdList><ArticleId IdType="pubmed">32075924</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2016 May 25;8(340):340ra72</Citation><ArticleIdList><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Cell. 2014 Sep;5(9):692-703</Citation><ArticleIdList><ArticleId IdType="pubmed">24986489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2019 May 27;10(1):2331</Citation><ArticleIdList><ArticleId IdType="pubmed">31133680</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2018 Jul 11;99(1):56-63.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">30001512</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1992 Jan;36(1):100-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1317142</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;62(4):1495-1506</Citation><ArticleIdList><ArticleId IdType="pubmed">29504537</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2020 Apr;16(4):193-197</Citation><ArticleIdList><ArticleId IdType="pubmed">32152461</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2006 Aug 15;575(Pt 1):5-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16809372</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2021 May;71(5):953-962</Citation><ArticleIdList><ArticleId IdType="pubmed">33098544</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2019 Dec 12;11(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">31842425</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2019 Aug;38(8):1443-1447</Citation><ArticleIdList><ArticleId IdType="pubmed">31093802</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Microbes Infect. 2014 Jul;3(7):e53</Citation><ArticleIdList><ArticleId IdType="pubmed">26038749</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2018 Mar 16;13(3):e0194001</Citation><ArticleIdList><ArticleId IdType="pubmed">29547627</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2017 Sep 08;18(9):</Citation><ArticleIdList><ArticleId IdType="pubmed">28885544</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Anti Infect Ther. 2021 Jun;19(6):733-747</Citation><ArticleIdList><ArticleId IdType="pubmed">33183118</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36126456</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders.</ArticleTitle><Pagination><MedlinePgn>113709</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(22)01098-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2022.113709</ELocationID><Abstract><AbstractText>Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct negative regulator of several receptor and receptor-associated tyrosine kinases. This widely localized enzyme has been involved in the pathophysiology of several diseases. More recently, PTP1B has attracted attention in the field of neuroscience, since its activation in brain cells can lead to schizophrenia-like behaviour deficits, anxiety-like effects, neurodegeneration, neuroinflammation and depression. Conversely, PTP1B inhibition has been shown to prevent microglial activation, thus exerting a potent anti-inflammatory effect and has also shown potential to increase the cognitive process through the stimulation of hippocampal insulin, leptin and BDNF/TrkB receptors. Notwithstanding, most research on the clinical efficacy of targeting PTP1B has been developed in the field of obesity and type 2 diabetes mellitus (TD2M). However, despite the link existing between these metabolic alterations and neurodegeneration, no clinical trials assessing the neurological advantages of PTP1B inhibition have been performed yet. Preclinical studies, though, have provided strong evidence that targeting PTP1B could allow to reach different pathophysiological mechanisms at once. herefore, specific interventions or trials should be designed to modulate PTP1B activity in brain, since it is a promising strategy to decelerate or prevent neurodegeneration in aged individuals, among other neurological diseases. The present paper fails to include all neurological conditions in which PTP1B could have a role; instead, it focuses on those which have been related to metabolic alterations and neurodegenerative processes. Moreover, only preclinical data is discussed, since clinical studies on the potential of PTP1B inhibition for treating neurological diseases are still required.</AbstractText><CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olloquequi</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institute of Biomedical Sciences, Faculty of Health Sciences, Universidad Autónoma de Chile, Talca, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cano</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Ace Alzheimer Center Barcelona - International University of Catalunya (UIC), Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), Universitat de Barcelona, Barcelona, Spain. Electronic address: acano@fundacioace.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-López</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), Universitat de Barcelona, Barcelona, Spain; Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, 08034 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrasco</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain; Department of Biochemistry and Biotechnology, Rovira i Virgili University, Spain Unit of Biochemistry and Pharmacology, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, 43201 Reus, Tarragona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verdaguer</LastName><ForeName>Ester</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain; Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, Universitat de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortuna</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal; CIBIT/ICNAS - Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folch</LastName><ForeName>Jaume</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Biochemistry and Biotechnology, Rovira i Virgili University, Spain Unit of Biochemistry and Pharmacology, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, 43201 Reus, Tarragona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulló</LastName><ForeName>Mònica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biotechnology, Rovira i Virgili University, Spain Unit of Biochemistry and Pharmacology, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, 43201 Reus, Tarragona, Spain; Institute of Health Pere Virgili-IISPV, Nutrition and Metabolic Disorders Research Group, 43204 Reus, Spain; CIBER Physiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auladell</LastName><ForeName>Carme</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain; Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, Universitat de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camins</LastName><ForeName>Antoni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain. Electronic address: camins@ub.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ettcheto</LastName><ForeName>Miren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain. Electronic address: camins@ub.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D054562">Protein Tyrosine Phosphatase, Non-Receptor Type 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020738">Leptin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054562" MajorTopicYN="N">Protein Tyrosine Phosphatase, Non-Receptor Type 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020738" MajorTopicYN="N">Leptin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">Insulin receptor</Keyword><Keyword MajorTopicYN="N">Neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Neurological disorders</Keyword><Keyword MajorTopicYN="N">PTP1B</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword></KeywordList><CoiStatement>Conflict of interest statement The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36126456</ArticleId><ArticleId IdType="pii">S0753-3322(22)01098-8</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2022.113709</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36126422</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-6750</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><PubDate><Year>2022</Year><Month>11</Month></PubDate></JournalIssue><Title>Environment international</Title><ISOAbbreviation>Environ Int</ISOAbbreviation></Journal><ArticleTitle>Life-course exposure to air pollution and biological ageing in the Lothian Birth Cohort 1936.</ArticleTitle><Pagination><MedlinePgn>107501</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0160-4120(22)00428-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.envint.2022.107501</ELocationID><Abstract><AbstractText Label="BACKGROUND">Exposure to air pollution is associated with a range of diseases. Biomarkers derived from DNA methylation (DNAm) offer potential mechanistic insights into human health differences, connecting disease pathogenesis and biological ageing. However, little is known about sensitive periods during the life course where air pollution might have a stronger impact on DNAm, or whether effects accumulate over time. We examined associations between air pollution exposure across the life course and DNAm-based markers of biological ageing.</AbstractText><AbstractText Label="METHODS">Data were derived from the Scotland-based Lothian Birth Cohort 1936. Participants' residential history was linked to annual levels of fine particle (PM<sub>2.5</sub>), sulphur dioxide (SO<sub>2</sub>), nitrogen dioxide (NO<sub>2</sub>), and ozone (O<sub>3</sub>) around 1935, 1950, 1970, 1980, 1990, and 2001; pollutant concentrations were estimated using the EMEP4UK atmospheric chemistry transport model. Blood samples were obtained between ages of 70 and 80 years, and Horvath DNAmAge, Hannum DNAmAge, DNAmPhenoAge, DNAmGrimAge, and DNAm telomere length (DNAmTL) were computed. We applied the structured life-course modelling approach: least angle regression identified best-fit life-course models for a composite measure of air pollution (air quality index [AQI]), and mixed-effects regression estimated selected models for AQI and single pollutants.</AbstractText><AbstractText Label="RESULTS">We included 525 individuals with 1782 observations. In the total sample, increased air pollution around 1970 was associated with higher epigenetic age (AQI: b = 0.322 year, 95 %CI: 0.088, 0.555) measured with Horvath DNAmAge in late adulthood. We found shorter DNAmTL among males with higher air pollution around 1980 (AQI: b = -0.015 kilobase, 95 %CI: -0.027, -0.004) and among females with higher exposure around 1935 (AQI: b = -0.017 kilobase, 95 %CI: -0.028, -0.006). Findings were more consistent for the pollutants PM<sub>2.5</sub>, SO<sub>2</sub> and NO<sub>2</sub>.</AbstractText><AbstractText Label="DISCUSSION">We tested the life-course relationship between air pollution and DNAm-based biomarkers. Air pollution around birth and in young-to-middle adulthood is linked to accelerated epigenetic ageing and telomere-associated ageing in later life.</AbstractText><CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baranyi</LastName><ForeName>Gergő</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Research on Environment, Society and Health, School of GeoSciences, The University of Edinburgh, Edinburgh, UK. Electronic address: gergo.baranyi@ed.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deary</LastName><ForeName>Ian J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Lothian Birth Cohorts, Department of Psychology, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCartney</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Lothian Birth Cohorts, Department of Psychology, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shortt</LastName><ForeName>Niamh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Research on Environment, Society and Health, School of GeoSciences, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UK Centre for Ecology &amp; Hydrology (UKCEH), Bush Estate, Penicuik, UK; University of Exeter Medical School, Knowledge Spa, Truro TR1 3HD, UK; The University of Edinburgh, School of Chemistry, Edinburgh EH9 3BF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russ</LastName><ForeName>Tom C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Alzheimer Scotland Dementia Research Centre, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward Thompson</LastName><ForeName>Catharine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>OPENspace Research Centre, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieno</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UK Centre for Ecology &amp; Hydrology (UKCEH), Bush Estate, Penicuik, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Simon R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Lothian Birth Cohorts, Department of Psychology, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearce</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Research on Environment, Society and Health, School of GeoSciences, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG054628</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>221890/Z/20/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Environ Int</MedlineTA><NlmUniqueID>7807270</NlmUniqueID><ISSNLinking>0160-4120</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000393">Air Pollutants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052638">Particulate Matter</NameOfSubstance></Chemical><Chemical><RegistryNumber>0UZA3422Q4</RegistryNumber><NameOfSubstance UI="D013458">Sulfur Dioxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>66H7ZZK23N</RegistryNumber><NameOfSubstance UI="D010126">Ozone</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7G510RUBH</RegistryNumber><NameOfSubstance UI="D009585">Nitrogen Dioxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000393" MajorTopicYN="Y">Air Pollutants</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000397" MajorTopicYN="Y">Air Pollution</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089822" MajorTopicYN="N">Birth Cohort</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004781" MajorTopicYN="N">Environmental Exposure</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009585" MajorTopicYN="N">Nitrogen Dioxide</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010126" MajorTopicYN="Y">Ozone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052638" MajorTopicYN="N">Particulate Matter</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013458" MajorTopicYN="N">Sulfur Dioxide</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Air pollution</Keyword><Keyword MajorTopicYN="N">Biological ageing</Keyword><Keyword MajorTopicYN="N">DNA methylation</Keyword><Keyword MajorTopicYN="N">Epigenetic clock</Keyword><Keyword MajorTopicYN="N">Life course</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>18</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36126422</ArticleId><ArticleId IdType="pii">S0160-4120(22)00428-7</ArticleId><ArticleId IdType="doi">10.1016/j.envint.2022.107501</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36125835</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-5828</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>09</Month><Day>20</Day></PubDate></JournalIssue><Title>Current Alzheimer research</Title><ISOAbbreviation>Curr Alzheimer Res</ISOAbbreviation></Journal><ArticleTitle>High frequency repetitive transcranial magnetic stimulation improves cognitive performance parameters in patients with Alzheimer's disease - an exploratory pilot study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1567205019666220920090919</ELocationID><Abstract><AbstractText Label="BACKGROUND">Currently available medication for Alzheimer's disease (AD) may slows cognitive decline only transitory, but has failed to bring about long term positive effects. For this slowly progressive neurodegenerative disease so far no disease modifying therapy exists.</AbstractText><AbstractText Label="OBJECTIVE">To find out if non-pharmacologic non-ivasive neuromodulatory repetitive transcranial magnetic stimulation (rTMS) may offer a new alternative or an add on therapeutic strategy against loss of cognitive functions.</AbstractText><AbstractText Label="METHODS">In this exploratory intervention study safety and symptom development before and after frontopolar cortex stimulation (FPC) using intermittent theta burst stimulation (iTBS) at 10 subsequent working days was monitored as add-on treatment in 28 consecutive patients with AD. Out of these, 10 randomly selected patients received sham stimulation as a control. In addition, ​serum concentrations of neurotransmitter precursor amino acids, of immune activation and inflammation markers, of brain derived neurotrophic factor (BDNF) as well as of nitrite were measured.</AbstractText><AbstractText Label="RESULTS">Treatment was well tolerated, no serious adverse effects were observed. Improvement of cognition was detected by an increase of Mini Mental State Examination score (MMSE; p&lt;0.01, paired rank test) and also by an increase in a modified repeat address phrase test, part of the 6-item cognitive ​impairment test (p &lt; 0.01). A trend to an increase in the clock drawing test (CDT; p = 0.08) was also found in the verum treated group. Furtheron, in 10 of the AD patients with additional symptoms of depression treated with iTBS, a significant decrease in the HAMD-7 scale (p &lt;0.01) and a trend to lower serum phenylalanine concentrations (p = 0.08) was seen. No changes of the parameters tested were found in the sham treated patients.</AbstractText><AbstractText Label="CONCLUSION">Our preliminary results may indicate that iTBS is effective in the treatment of AD. Also a slight influence of iTBS on the metabolism of phenylalanine was found after 10 iTBS sessions. An impact of iTBS to influence the enzyme phenylalanine hydroxylase (PAH), as found in previous series of treatment resistant depression, could not be seen in this our first observational trial in 10 AD patients with comorbidity of depression. Longer treatment periods for several weeks in a higher number of AD patients with depression could cause more intense and disease modifying effects visible in different neurotransmitter concentrations important in the pathogenesis of AD.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leblhuber</LastName><ForeName>Friedrich</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Gerontology, Kepler University Clinic, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geisler</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehrlich</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gerontology, Kepler University Clinic, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Kostja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gerontology, Kepler University Clinic, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuchs</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Alzheimer Res</MedlineTA><NlmUniqueID>101208441</NlmUniqueID><ISSNLinking>1567-2050</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">cognitive performance</Keyword><Keyword MajorTopicYN="N">concomitant depression</Keyword><Keyword MajorTopicYN="N">intermittent theta burst stimulation</Keyword><Keyword MajorTopicYN="N">memory impairment</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">non-invasive brain stimulation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>05</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36125835</ArticleId><ArticleId IdType="pii">CAR-EPUB-126419</ArticleId><ArticleId IdType="doi">10.2174/1567205019666220920090919</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36125588</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">0948-5023</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of molecular modeling</Title><ISOAbbreviation>J Mol Model</ISOAbbreviation></Journal><ArticleTitle>Recognition of Aβ oligomer by LilrB2 acceptor: a tetracoordinated zipper mechanism.</ArticleTitle><Pagination><MedlinePgn>322</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00894-022-05315-4</ELocationID><Abstract><AbstractText>Leukocyte immunoglobulin-like receptor B2 (LilrB2) is one of discovered cell surface β-amyloid (Aβ) receptors and taken as a promising therapeutic target for the treatment of Alzheimer's disease (AD). Aβ42 oligomer rather than monomer is toxic to neuronal cells and can directly bind to LilrB2, resulting in synaptic loss and cognitive impairment in the development of AD. Therefore, uncovering the mechanism of interaction between Aβ42 oligomer and LilrB2 becomes the first step to obtain a clear drug target and specific binding sites. Herein, a tetracoordinated mechanism for the Aβ oligomer-LilrB2 binding was first put forward by employing Aβ42 dimer mimic-antiparallel copies of Aβ42 core fragment <sup>16</sup>KLVFFA<sup>21</sup>, to bind LilrB2 as models, in which four key residues (F5/F6/L12/F14) in the Aβ42 mimic are bound strongly with LilrB2 residue(s) or accommodated by four hydrophobic cavities in LilrB2 to generate a stable complex. Bi-dentate binding, however, cannot keep the complex Aβ42 mimic-LilrB2 stable. The inhibitor fluspirilene can disturb the binding of four key residues of Aβ42 to LilrB2, justifying the tetracoordinated zipper mechanism on the other hand.</AbstractText><CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, University of Jinan, Jinan, 250022, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Jinfei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, University of Jinan, Jinan, 250022, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Wenqi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, University of Jinan, Jinan, 250022, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, University of Jinan, Jinan, 250022, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Sajjad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, University of Jinan, Jinan, 250022, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ai</LastName><ForeName>Hongqi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, University of Jinan, Jinan, 250022, People's Republic of China. chm_aihq@ujn.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZR2017MB008</GrantID><Agency>Natural Science Foundation of Shandong Province</Agency><Country/></Grant><Grant><GrantID>2018GSF118005</GrantID><Agency>Shandong Provincial Key Research &amp; Development Plan (Public Welfare Special Project) of China.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Mol Model</MedlineTA><NlmUniqueID>9806569</NlmUniqueID><ISSNLinking>0948-5023</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491341">LILRB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>C5QA4GLR9M</RegistryNumber><NameOfSubstance UI="D005484">Fluspirilene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005484" MajorTopicYN="Y">Fluspirilene</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">16KLVFFA21</Keyword><Keyword MajorTopicYN="N">Aβ oligomer</Keyword><Keyword MajorTopicYN="N">Fluspirilene</Keyword><Keyword MajorTopicYN="N">LilrB2</Keyword><Keyword MajorTopicYN="N">Tetracoordinated zipper mechanism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36125588</ArticleId><ArticleId IdType="doi">10.1007/s00894-022-05315-4</ArticleId><ArticleId IdType="pii">10.1007/s00894-022-05315-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Higgins A (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256(5054):184–184</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng MS (2012) [Molecular Pathology] Synapses and Alzheimer’s disease. Cold Spring Harb Perspect Biol 4(5):747–749</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a005777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell MA, Robertson JD, Teesdale WJ (1998) Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 158(1):47–52</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00092-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Sleegers K (2010) Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 19(R1):4–11</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq142</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L (2005) Twenty Years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120(4):545–555</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.02.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci 13(7):812–818</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2583</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T (2011) Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 31(18):6627–6638</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0203-11.2011</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Shin WS, Chan H (2018) Inhibiting amyloid-beta cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design. Nat Chem 10(12):1213–1221</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41557-018-0147-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LM, Kostylev MA, Lee S, Strittmatter SM (2019) Systematic and standardized comparison of reported Amyloid-β receptors for sufficiency, affinity, and Alzheimer’s disease relevance. J Biol Chem 294(15):6042–6053</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.006252</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Vidal GS, Djurisic M (2013) Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer’s model. Science 341(6152):1399–1404</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1242077</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarosz-Griffiths HH, Noble E, Rushworth JV (2016) Amyloid-β receptors: the good, the bad, and the prion protein. J Biol Chem 291(7):3174–3183</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R115.702704</ArticleId></ArticleIdList></Reference><Reference><Citation>Colletier J, Laganowsky A, Landau M (2011) Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci U S A 108(41):16938–16943</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1112600108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lührs T, Ritter C, Adrian M, Riek-Loher D, Riek R (2005) 3D structure of Alzheimer’s amyloid-β(1–42) fibrils. Proc Natl Acad Sci USA 102(48):17342–17347</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506723102</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen P, Cummings J, Doody R, Kramer L, Salloway S, Selkoe D, Sims J, Sperling R, Vellas B (2020) The future of anti-amyloid trials. J Prev Alz Dis 7:146–151</Citation></Reference><Reference><Citation>Linse S, Scheidt T, Bernfur K, Vendruscolo M, Dobson CM, Cohen SIA, Sileikis E, Lundqvist M, Qian F, O’Malley T, Bussiere T, Weinreb PH, Xu CK, Meisl G, Devenish SRA, Knowles TPJ, Hansson O (2020) Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies. Nat Struct Mol Biol 27(12):1125–1133</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-0505-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Arndt JW, Qian F, Smith BA (2018) Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep 8(1):6412</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24501-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Nir L, Barak R, Eyal C, Guy F, Ora SF (2011) Rosetta FlexPepDock web server—high resolution modeling of peptide–protein interactions. Nucleic Acids Res 39(suppl_2):W249–W253</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr431</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G, Huey R (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 48(16):443–453</Citation></Reference><Reference><Citation>Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (2015) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19(14):1639–1662</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-987X(19981115)19:14&lt;1639::AID-JCC10&gt;3.0.CO;2-B</ArticleId></ArticleIdList></Reference><Reference><Citation>Zsoldos Z, Reid D, Simon A, Sadjad BS, Johnson AP (2006) eHiTS: an innovative approach to the docking and scoring function problems. Curr Protein Peptide Sci 7(5):421–435</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920306778559412</ArticleId></ArticleIdList></Reference><Reference><Citation>Masman MF, Eisel U, Csizmadia IG, Penke B, Luiten P (2009) In silico study of full-length amyloid beta 1–42 tri- and penta-oligomers in solution. J Phys Chem B 113(34):11710–11719</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jp901057w</ArticleId></ArticleIdList></Reference><Reference><Citation>Berendsen HJC, van der Spoel D, van Drunen R (1995) GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Communal 91:43–56</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0010-4655(95)00042-E</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham MJ, Murtola T, Schulz R (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2:19–25</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.softx.2015.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Cheng X, Jo S, Mackerell AD, Klauda JB, Im W (2016) CHARMM-GUI input generator for NAMD, Gromacs, Amber, Openmm, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. Biophys J 110(3):405–413</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2015.11.3431</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Karplus M (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30(10):1545–1614</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21287</ArticleId></ArticleIdList></Reference><Reference><Citation>Darden T, York D, Lee P (1993) Particle mesh Ewald: an N·log(N) method for Ewald sums in large systems. J Chem Phys 98(12):10089–10092</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.464397</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess B, Bekker H, Fraaije H (1997) LINCS: a linear constraint solver for molecular simulations. J Comput Chem 18(12):1463–1472</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-987X(199709)18:12&lt;1463::AID-JCC4&gt;3.0.CO;2-H</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity rescaling. J Chem Phys 126(1):014101</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.2408420</ArticleId></ArticleIdList></Reference><Reference><Citation>Berendsen HJC, Postma J, Gunsteren WF (1984) Molecular-dynamics with coupling to an external bath. J Chem Phys 81(8):3684–3690</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.448118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakamura K, Orita K, Hirokawa K (1996) Observation of characteristic phonon spectra for cage and mobile ions in the layered superionic conductor AgCrS2. J Phys Chem Solids 57(1):147–157</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3697(95)00116-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22(12):2577–2637</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bip.360221211</ArticleId></ArticleIdList></Reference><Reference><Citation>Viet MH, Nguyen PH, Derreumaux P, Li MS (2014) Effect of the English familial disease mutation (H6R) on the monomers and dimers of Aβ40 and Aβ42. ACS Chem Neurosci 5(8):646–657</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn500007j</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph Model 14(1):33–38</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0263-7855(96)00018-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker NA, Sept D, Joseph S, Holst MJ, Mccammon JA (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 98(18):10037–10041</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.181342398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari R, Kumar R, Lynn A (2014) g_mmpbsa–a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54(7):1951–1962</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci500020m</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong M, Li H, Hu D, Zhao W, Zhu X (2016) Molecular dynamics study on the inhibition mechanisms of drugs CQ1–3 for Alzheimer amyloid-β40 aggregation induced by Cu2+. Acs Chem Neurosci 7(5):599–614</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.5b00343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng YJ, Yin YW, Ma YQ, Ding HM (2021) Improving the performance of MM/PBSA in protein-protein interactions via the screening electrostatic energy. J Chem Inf Model 61(5):2454–2462</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c00410</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36125124</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1948-7193</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>ACS chemical neuroscience</Title><ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation></Journal><ArticleTitle>Could Amyloid-β 1-42 or α-Synuclein Interact Directly with Mitochondrial DNA? A Hypothesis.</ArticleTitle><Pagination><MedlinePgn>2803-2812</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acschemneuro.2c00512</ELocationID><Abstract><AbstractText>The amyloid β (Aβ) and the α-synuclein (α-syn) are shown to be translocated into mitochondria. Even though their roles are widely investigated in pathological conditions, information on the presence and functions of Aβ and α-syn in mitochondria in endogenous levels is somewhat limited. We hypothesized that endogenous Aβ fragments or α-syn could interact with mitochondrial DNA (mtDNA) directly or influence RNAs or transcription factors in mitochondria and change the mtDNA transcription profile. In this review, we summarized clues of these possible interactions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gezen-Ak</LastName><ForeName>Duygu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yurttaş</LastName><ForeName>Zuhal</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Çamoǧlu</LastName><ForeName>Tugay</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dursun</LastName><ForeName>Erdinç</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3701-6674</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Chem Neurosci</MedlineTA><NlmUniqueID>101525337</NlmUniqueID><ISSNLinking>1948-7193</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="Y">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">Mitochondrial DNA</Keyword><Keyword MajorTopicYN="N">Parkinson disease</Keyword><Keyword MajorTopicYN="N">amyloid β</Keyword><Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">mtDNA transcription</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">α-synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36125124</ArticleId><ArticleId IdType="doi">10.1021/acschemneuro.2c00512</ArticleId><ArticleId IdType="pmc">PMC9542719</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Genes Dev. 2009 Nov 15;23(22):2639-49</Citation><ArticleIdList><ArticleId IdType="pubmed">19933153</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2008 Apr 4;283(14):9089-100</Citation><ArticleIdList><ArticleId IdType="pubmed">18245082</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2001 Dec 4;12(17):3839-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11726805</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2017 Feb 2;5(1):13</Citation><ArticleIdList><ArticleId IdType="pubmed">28153046</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2006 May;38(5):515-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16604074</ArticleId></ArticleIdList></Reference><Reference><Citation>RNA. 2013 Feb;19(2):129-40</Citation><ArticleIdList><ArticleId IdType="pubmed">23264567</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2020 Aug;330:113321</Citation><ArticleIdList><ArticleId IdType="pubmed">32339611</ArticleId></ArticleIdList></Reference><Reference><Citation>Przegl Lek. 2014;71(1):26-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24712265</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromolecular Med. 2018 Sep;20(3):363-375</Citation><ArticleIdList><ArticleId IdType="pubmed">29948923</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Jan 10;299(5604):256-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12446870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hormones (Athens). 2019 Mar;18(1):17-21</Citation><ArticleIdList><ArticleId IdType="pubmed">30484097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2013 Nov;74(5):655-68</Citation><ArticleIdList><ArticleId IdType="pubmed">23794434</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1995 Jan 27;80(2):225-36</Citation><ArticleIdList><ArticleId IdType="pubmed">7834742</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Oct;20(10):1299-309</Citation><ArticleIdList><ArticleId IdType="pubmed">15966006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cells. 2017 Sep 30;40(9):613-620</Citation><ArticleIdList><ArticleId IdType="pubmed">28927263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2019 Jul 29;9(1):10919</Citation><ArticleIdList><ArticleId IdType="pubmed">31358782</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Nov 27;12(11):e0188605</Citation><ArticleIdList><ArticleId IdType="pubmed">29176823</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2008 Dec 9;1244:40-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18817762</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Neurobiol. 2014 May;34(4):603-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24659023</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2021 Jan;58(1):184-203</Citation><ArticleIdList><ArticleId IdType="pubmed">32914394</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 2010 Jun 1;21(11):1850-63</Citation><ArticleIdList><ArticleId IdType="pubmed">20392839</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2017 Jul 19;8(7):1435-1437</Citation><ArticleIdList><ArticleId IdType="pubmed">28586203</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2016 Apr;131(4):539-48</Citation><ArticleIdList><ArticleId IdType="pubmed">26820848</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2007 Oct 8;18(15):1543-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17885598</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2016 Nov 22;7:13548</Citation><ArticleIdList><ArticleId IdType="pubmed">27874000</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2009 Aug;218(2):286-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19358844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2016 Oct 20;167(3):722-738.e23</Citation><ArticleIdList><ArticleId IdType="pubmed">27768893</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene. 2011 Nov 15;488(1-2):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">21699964</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutat Res. 2011 Nov-Dec;728(3):98-106</Citation><ArticleIdList><ArticleId IdType="pubmed">21763451</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Bioallied Sci. 2012 Apr;4(2):112-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22557921</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10726-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15247418</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2014 Aug;1842(8):1198-207</Citation><ArticleIdList><ArticleId IdType="pubmed">24252612</ArticleId></ArticleIdList></Reference><Reference><Citation>J Invest Dermatol. 2014 Jul;134(7):1971-1980</Citation><ArticleIdList><ArticleId IdType="pubmed">24496235</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1992 Apr 10;256(5054):184-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2001 Apr 21;357(9264):1265-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11418155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitochondrion. 2006 Jun;6(3):143-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16730242</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2018 Sep 18;19(9):</Citation><ArticleIdList><ArticleId IdType="pubmed">30231582</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2015 Jan;12(1):79-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25402006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2014 May 02;9:16</Citation><ArticleIdList><ArticleId IdType="pubmed">24885175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2013 Dec;41(22):9987-98</Citation><ArticleIdList><ArticleId IdType="pubmed">24003031</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Sep 27;8(9):e70681</Citation><ArticleIdList><ArticleId IdType="pubmed">24086248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Aug 28;388(6645):839-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromolecular Med. 2004;5(2):147-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15075441</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Mol Neurosci. 2017 Jul 13;10:224</Citation><ArticleIdList><ArticleId IdType="pubmed">28751856</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2022;85(1):381-394</Citation><ArticleIdList><ArticleId IdType="pubmed">34806611</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Genet. 2007 Feb;120(6):821-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17066297</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2016 Sep 6;54(2):809-19</Citation><ArticleIdList><ArticleId IdType="pubmed">27567853</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2014;40(2):319-30</Citation><ArticleIdList><ArticleId IdType="pubmed">24448779</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol Evol. 2014 Sep 22;6(10):2634-46</Citation><ArticleIdList><ArticleId IdType="pubmed">25245407</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Jul 21;313(5785):324-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Genet. 2018 Sep;34(9):682-692</Citation><ArticleIdList><ArticleId IdType="pubmed">29945721</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2006 May 1;15(9):1437-49</Citation><ArticleIdList><ArticleId IdType="pubmed">16551656</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2005 Feb;19(2):255-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15548589</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Nov 27;7(1):16386</Citation><ArticleIdList><ArticleId IdType="pubmed">29180624</ArticleId></ArticleIdList></Reference><Reference><Citation>BMB Rep. 2019 Jan;52(1):13-23</Citation><ArticleIdList><ArticleId IdType="pubmed">30545443</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2008 Feb;27(4):947-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18333965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2015 Dec;78(6):1000-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26343811</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2009 Jul;132(Pt 7):1795-809</Citation><ArticleIdList><ArticleId IdType="pubmed">19052140</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Res. 2018 Jan;40(1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">29057715</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2010 Jan 14;65(1):66-79</Citation><ArticleIdList><ArticleId IdType="pubmed">20152114</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Mol Biosci. 2018 Jun 11;5:53</Citation><ArticleIdList><ArticleId IdType="pubmed">29942805</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2003 Jul 22;42(28):8465-71</Citation><ArticleIdList><ArticleId IdType="pubmed">12859192</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2011 Aug 15;71(16):5588-97</Citation><ArticleIdList><ArticleId IdType="pubmed">21742773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene. 2011 Nov 15;488(1-2):13-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21708232</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Apr 23;8(4):e62277</Citation><ArticleIdList><ArticleId IdType="pubmed">23626796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2016 Aug;80(2):301-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27315116</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Biosci (Landmark Ed). 2017 Jan 1;22(5):835-853</Citation><ArticleIdList><ArticleId IdType="pubmed">27814650</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2010 Oct 20;29(20):3571-89</Citation><ArticleIdList><ArticleId IdType="pubmed">20842103</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2013;36(3):459-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23624519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Syst. 2017 Feb 22;4(2):242-250.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">28131823</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2001 Apr;77(1):239-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11279280</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 May 1;454(3):187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19429081</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2013 Sep;62:90-101</Citation><ArticleIdList><ArticleId IdType="pubmed">23200807</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Model Mech. 2017 Sep 1;10(9):1075-1087</Citation><ArticleIdList><ArticleId IdType="pubmed">28883016</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2011 Nov;1812(11):1359-70</Citation><ArticleIdList><ArticleId IdType="pubmed">21871956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2002 Mar;51(3):296-301</Citation><ArticleIdList><ArticleId IdType="pubmed">11891824</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging (Albany NY). 2011 Aug;3(8):803-12</Citation><ArticleIdList><ArticleId IdType="pubmed">21869458</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2020;74(1):287-307</Citation><ArticleIdList><ArticleId IdType="pubmed">32007957</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1998 Apr 9;392(6676):605-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Rev. 2021 Feb 24;121(4):2545-2647</Citation><ArticleIdList><ArticleId IdType="pubmed">33543942</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2011 Oct;1813(10):1814-21</Citation><ArticleIdList><ArticleId IdType="pubmed">21664385</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2014 Jul 18;289(29):20182-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24878959</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2018 Jan 4;46(D1):D380-D386</Citation><ArticleIdList><ArticleId IdType="pubmed">29087512</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurosci. 2014 Jun 04;15:69</Citation><ArticleIdList><ArticleId IdType="pubmed">24898419</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2012;942:269-86</Citation><ArticleIdList><ArticleId IdType="pubmed">22399427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2018 Mar;83(3):522-531</Citation><ArticleIdList><ArticleId IdType="pubmed">29405350</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1986 Jan 29;134(2):743-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2868716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2012 Oct;72(4):517-24</Citation><ArticleIdList><ArticleId IdType="pubmed">23109146</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2011 Aug 19;146(4):645-58</Citation><ArticleIdList><ArticleId IdType="pubmed">21854988</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 May 21;304(5674):1158-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2016 Feb;38:216.e7-216.e10</Citation><ArticleIdList><ArticleId IdType="pubmed">26639155</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1983 Feb 25;219(4587):979-80</Citation><ArticleIdList><ArticleId IdType="pubmed">6823561</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Apr 15;6:24475</Citation><ArticleIdList><ArticleId IdType="pubmed">27080380</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 2008 Jun 10;314(10):2076-89</Citation><ArticleIdList><ArticleId IdType="pubmed">18440504</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Alzheimers Dis. 2011 Mar 15;2011:925050</Citation><ArticleIdList><ArticleId IdType="pubmed">21461357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol (Mosk). 2016 Nov-Dec;50(6):1049-1052</Citation><ArticleIdList><ArticleId IdType="pubmed">28064322</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2010 Jun 18;1338:67-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20226177</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biosyst. 2017 Jul 25;13(8):1545-1551</Citation><ArticleIdList><ArticleId IdType="pubmed">28642958</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1988 Aug;8(8):2804-15</Citation><ArticleIdList><ArticleId IdType="pubmed">3411354</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Biochem Biophys. 2007 Aug 1;464(1):57-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17537399</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2011;23(2):207-19</Citation><ArticleIdList><ArticleId IdType="pubmed">20966550</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2016 Mar;79(3):366-78</Citation><ArticleIdList><ArticleId IdType="pubmed">26605748</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2017 Oct 18;8(10):2335-2346</Citation><ArticleIdList><ArticleId IdType="pubmed">28707894</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Sci. 2013 Aug;34(8):1453-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23250517</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol. 2010;11(7):215</Citation><ArticleIdList><ArticleId IdType="pubmed">20670382</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2013;3:2540</Citation><ArticleIdList><ArticleId IdType="pubmed">23985836</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2004 Dec;111(12):1543-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15455214</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem Cell Biol. 2015 Jul;64:212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25952151</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2013;36(1-2):76-86</Citation><ArticleIdList><ArticleId IdType="pubmed">23752060</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1997 Oct;49(4):918-25</Citation><ArticleIdList><ArticleId IdType="pubmed">9339668</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2016 Apr;131(4):525-37</Citation><ArticleIdList><ArticleId IdType="pubmed">26898910</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 6;72(1):57-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Transl Neurol. 2014 Apr;1(4):284-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25590040</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Biophys Biomol Struct. 1993;22:199-232</Citation><ArticleIdList><ArticleId IdType="pubmed">8347989</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2009 Aug;14(8 Suppl 7):8-13; discussion 16-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19890241</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2016 Jun 8;8(342):342ra78</Citation><ArticleIdList><ArticleId IdType="pubmed">27280685</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2021 Apr;595(8):976-1002</Citation><ArticleIdList><ArticleId IdType="pubmed">33314045</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2017 May;53:36-47</Citation><ArticleIdList><ArticleId IdType="pubmed">28208064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36124862</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-7518</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>39</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of materials chemistry. B</Title><ISOAbbreviation>J Mater Chem B</ISOAbbreviation></Journal><ArticleTitle>Superhydrophilic nanocomposite adsorbents modified <i>via</i> nitrogen-rich phosphonate-functionalized ionic liquid linkers: enhanced phosphopeptide enrichment and phosphoproteome analysis of tau phosphorylation in the hippocampal lysate of Alzheimer's transgenic mice.</ArticleTitle><Pagination><MedlinePgn>7967-7978</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2tb01508k</ELocationID><Abstract><AbstractText>In this study, new graphene-based IMAC nanocomposites for phosphopeptide enrichment were prepared according to the guideline of our new design strategy. Superhydrophilic polyethyleneimine (PEI) was introduced, to which a phosphonate-functionalized ionic liquid (PFIL) was covalently bound, to form superhydrophilic and cationic surface layers with high densities of nitrogen atoms, phosphonate functional groups, and high-loading metal ions. Due to the combined features of superhydrophilicity, flexibility, highly dense metal binding sites, large surface area and excellent size-exclusion effect, the fabricated nanocomposite G@mSiO<sub>2</sub>@PEI-PFIL-Ti<sup>4+</sup> exhibits superior detection sensitivity to enrich phosphopeptides (tryptic β-casein digest, 0.1 fmol), and extraordinary enrichment specificity to enrich phosphopeptides from a digest mixture of β-casein and bovine serum albumin (BSA) (molar ratio, 1 : 12 000). The excellent size-exclusion effect was also observed, and 27 endogenous phosphopeptides were identified in human saliva. All these results could be attributed to the unique superhydrophilic nanocomposite structure with a high density of a cationic linker modified with phosphonate functionality. Moreover, G@mSiO<sub>2</sub>@PEI-PFIL-Ti<sup>4+</sup> adsorbents were used to extract phosphopeptides from the tryptic digests of hippocampal lysates for quantitative phosphoproteome analysis. The preliminary results indicate that 1649 phosphoproteins, 3286 phosphopeptides and 4075 phosphorylation sites were identified. A total of 13 Alzheimer's disease (AD)-related phosphopeptides within tau proteins were detected with a wide coverage from p-Thr111 to p-Ser404, in which the amounts of some phoshopeptides at certain sites in AD transgenic mice were found statistically higher than those in wild type littermates. Besides, phosphorylated neurofilament heavy chains, a potential biomarker for amyotrophic lateral sclerosis and traumatic brain injury, were also identified. Finally, the adsorbent was applied to human cerebrospinal fluid (CSF) and blood samples. 5 unique phosphopeptides of neuroendocrine specific VGF were identified in the CSF, while many phosphopeptides originated from the nervous system were found in the blood sample. All these results suggest that our new IMAC materials exhibit unbiased enrichment ability with superior detection sensitivity and specificity, allowing the global phosphoproteome analysis of complicated biological samples more convincible and indicating the potential use in disease diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Chenglong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China. lianghongze@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qiyao</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Ningbo Key Laboratory of Behavior Neuroscience, Zhejiang Province Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo 315211, China. cuiwei@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Weida</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China. lianghongze@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Binbin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China. lianghongze@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Quanshou</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China. lianghongze@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Chenyang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China. lianghongze@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yishan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China. lianghongze@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yinghua</ForeName><Initials>Y</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0569-2881</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China. lianghongze@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lingling</ForeName><Initials>L</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-2577-3363</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China. lianghongze@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-5647-6890</Identifier><AffiliationInfo><Affiliation>CAS Key Laboratory of Separation Science for Analytical Chemistry, National Chromatographic Research and Analysis Center, Dalian Institute of Chemical Physics, Chinese Academy of Science, Dalian, Liaoning, 116023, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Ningbo Key Laboratory of Behavior Neuroscience, Zhejiang Province Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo 315211, China. cuiwei@nbu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Hongze</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8278-2258</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China. lianghongze@nbu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Mater Chem B</MedlineTA><NlmUniqueID>101598493</NlmUniqueID><ISSNLinking>2050-750X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002364">Caseins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007202">Indicators and Reagents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052578">Ionic Liquids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007477">Ions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063065">Organophosphonates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010748">Phosphopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>27432CM55Q</RegistryNumber><NameOfSubstance UI="D012710">Serum Albumin, Bovine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7782-42-5</RegistryNumber><NameOfSubstance UI="D006108">Graphite</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-98-6</RegistryNumber><NameOfSubstance UI="D011094">Polyethyleneimine</NameOfSubstance></Chemical><Chemical><RegistryNumber>D1JT611TNE</RegistryNumber><NameOfSubstance UI="D014025">Titanium</NameOfSubstance></Chemical><Chemical><RegistryNumber>N762921K75</RegistryNumber><NameOfSubstance UI="D009584">Nitrogen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002364" MajorTopicYN="N">Caseins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006108" MajorTopicYN="Y">Graphite</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007202" MajorTopicYN="N">Indicators and Reagents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052578" MajorTopicYN="Y">Ionic Liquids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007477" MajorTopicYN="N">Ions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053761" MajorTopicYN="Y">Nanocomposites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009584" MajorTopicYN="N">Nitrogen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063065" MajorTopicYN="Y">Organophosphonates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010748" MajorTopicYN="N">Phosphopeptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011094" MajorTopicYN="N">Polyethyleneimine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012710" MajorTopicYN="N">Serum Albumin, Bovine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014025" MajorTopicYN="N">Titanium</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36124862</ArticleId><ArticleId IdType="doi">10.1039/d2tb01508k</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36124351</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0376-2491</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>35</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Zhonghua yi xue za zhi</Title><ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Correlation of muscle strength with cognitive function and medial temporal lobe atrophy in patients with mild to moderate Alzheimer's disease].</ArticleTitle><Pagination><MedlinePgn>2786-2792</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112137-20220406-00715</ELocationID><Abstract><AbstractText><b>Objective:</b> To analyze the correlation of muscle strength with cognitive function and medial temporal lobe atrophy (MTA) in patients with mild to moderate Alzheimer's disease (AD). <b>Methods:</b> General information, sarcopenia-related indicators, neuropsychological tests and MTA score were collected in 80 confirmed AD patients (41 mild and 39 moderate patients) and 43 normal controls (NC) from the Memory Disorders Clinic of Department Of Neurology in the Second Affiliated Hospital of Soochow University between January and December 2021. Appendicular skeletal muscle mass index (ASMI), grip strength and 5-times sit-to-stand time and 6-m gait speed were used for assessing muscle mass, muscle strength and physical function, respectively. Cognitive function was assessed by Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment scale (MoCA), Memory and Executive Screening Scale (MES), Digit Symbol Substitution Test (DSST), Digital Span Test (DST) and Verbal Fluency Task (VFT), respectively. DST included Forward Digit Span Test (FDST) and Backward Digit Span Test (BDST). All the subjects underwent 3.0T coronal three-dimensional gradient echo sequence MRI. MTA scale was performed to evaluate the degree of medial temporal lobe atrophy. The differences in the sarcopenia-related indicators, cognitive score and MTA score were analyzed among the three groups, and the partial correlation analysis was performed between the inter-groups. <b>Results:</b> Eighty AD patients (24 males and 56 females) were included, aged (72±7) years old, with 41 mild and 39 moderate patients. Meanwhile, 43 NC included 19 males and 24 females, with a mean age of (70±6) years old. The disease duration in moderate AD patients was longer than that of mild AD patients [34.0 (25.0, 43.5) months vs 24.0 (11.0, 34.0) months, <i>P</i>&lt;0.001]. The differences of sarcopenia-related indicators and MTA score among the three groups were statistically significant (all <i>P</i>&lt;0.001), including 5-times sit-to-stand time [(13.6±1.8) s vs (11.5±1.7) s vs (10.3±1.9) s, <i>P</i>&lt;0.001] and MTA score [2.0 (2.0, 3.0) vs 1.0 (1.0, 2.0) vs 0 (0, 0), <i>P</i>&lt;0.001]. In neuropsychological tests, compared to the NC group, MMSE, MoCA, MES and VFT scores in mild and moderate AD groups were lower (all <i>P</i>&lt;0.001); meanwhile, compared to the mild AD group, the moderate group had lower MMSE, MoCA, MES, DSST and VFT scores (all <i>P</i>&lt;0.001). In sarcopenia-related indicators, muscle strength in particular was correlated with widespread cognitive functioning domains and MTA score in AD patients. Grip strength was positively correlated with MMSE, MoCA , MES, FDST (<i>r</i>=0.387, 0.418, 0.522 and 0.484, respectively, all <i>P</i>&lt;0.001), DSST (<i>r</i>=0.327, <i>P</i>=0.006) and VFT score (<i>r</i>=0.354, <i>P</i>=0.003), and negatively correlated with MTA score (<i>r</i>=-0.631, <i>P</i>&lt;0.001). 5-times sit-to-stand time was negatively correlated with MMSE, MoCA, MES, DSST, FDST, VFT score (<i>r</i>=-0.583, -0.587, -0.814, -0.591, -0.552 and -0.485, respectively, all <i>P</i>&lt;0.001), and BDST (<i>r</i>=-0.355, <i>P</i>=0.003) strongly positively correlated with MTA score (<i>r</i>=0.836, <i>P</i>&lt;0.001). ASMI was positively correlated with MMSE, MoCA, MES, DSST, FDST score (<i>r</i>=0.257, 0.238, 0.428, 0.282 and 0.364, respectively, all <i>P</i>&lt;0.05), and negatively correlated with MTA score (<i>r</i>=-0.377, <i>P</i>=0.001). 6-m gait speed was positively correlated with MMSE, MoCA, MES, DSST, FDST score (<i>r</i>=0.419, 0.486, 0.699, 0.559 and 0.500, respectively, all <i>P</i>&lt;0.001), BDST and VFT score (<i>r</i>=0.384、0.377, respectively, both <i>P</i>=0.001), and strongly negatively correlated with MTA score (<i>r</i>=-0.803, <i>P</i>&lt;0.001). <b>Conclusions:</b> Patients with mild to moderate AD have widespread cognitive impairment. Muscle mass, muscle strength and physical function are all significantly impaired. Compared to muscle mass and physical function, decreased muscle strength is significantly associated with widespread cognitive decline and increased degree of medial temporal lobe atrophy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>S W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Imaging, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>J T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Imaging, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y C</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Ultrasound, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Y H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Suzhou Municipal Hospital affiliated to Nanjing Medical University, Suzhou 215002, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>C F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Neurology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>LD2021031</GrantID><Agency>Elderly Health Research Project in Jiangsu Province</Agency><Country/></Grant><Grant><GrantID>SYSD2019109</GrantID><Agency>Suzhou Science and Technology Development Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7511141</NlmUniqueID><ISSNLinking>0376-2491</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>04Q9AIZ7NO</RegistryNumber><NameOfSubstance UI="D000068437">Pemetrexed</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="N">Muscle Strength</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068437" MajorTopicYN="N">Pemetrexed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055948" MajorTopicYN="Y">Sarcopenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>目的：</b> 分析轻中度阿尔茨海默病（AD）患者肌肉力量与认知功能、内侧颞叶萎缩（MTA）间的相关性。 <b>方法：</b> 选取2021年1—12月在苏州大学附属第二医院神经内科记忆障碍门诊确诊的80例AD患者（轻度41例，中度39例）和同期体检中心体检的43名对照者（NC），收集一般资料、肌少症相关指标、神经心理学测试与MTA评分。肌少症相关指标中四肢骨骼肌量指数（ASMI）评估肌肉量，握力与5次起坐时间评估肌肉力量，6 m步速评估躯体功能。认知功能量表为简易精神状态量表（MMSE）、蒙特利尔认知评估量表（MoCA）、记忆与执行功能筛查量表（MES）、数字符号转换测验（DSST）、数字广度测试（DST）、词语流畅性试验（VFT），DST包括顺序（FDST）和倒序（BDST）。受试者均行3.0 T颅脑冠状位三维梯度回波序列磁共振检查，MTA量表评估内侧颞叶萎缩程度。分析三组肌少症相关指标、认知评分、MTA评分间的差异，并且两两之间进行偏相关分析。 <b>结果：</b> 80例AD患者，男24例、女56例，年龄（72±7）岁，其中轻度AD患者41例，中度AD患者39例；43名NC，男19名、女24名，年龄（70±6）岁。中度AD组病程长于轻度AD组［34.0（25.0，43.5）个月比24.0（11.0，34.0）个月，<i>P</i>&lt;0.001］。三组肌少症相关指标及MTA评分比较，组间差异均有统计学意义（均<i>P</i>&lt;0.001），如5次起坐时间［（13.6±1.8）s比（11.5±1.7）s比（10.3±1.9）s，<i>P</i>&lt;0.001］，MTA评分［2.0（2.0，3.0）分比1.0（1.0，2.0）分比0（0，0）分，<i>P</i>&lt;0.001］。神经心理学测试中，轻、中度AD组MMSE、MoCA、MES、VFT得分均低于NC组，且中度AD组低于轻度AD组（均<i>P</i>&lt;0.001）。AD组肌少症相关指标中，尤其是肌肉力量，与多个认知功能领域和MTA评分相关。握力与MMSE、MoCA、MES、FDST（<i>r</i>=0.387、0.418、0.522、0.484，均<i>P</i>&lt;0.001）、DSST（<i>r</i>=0.327，<i>P</i>=0.006）、VFT得分（<i>r</i>=0.354，<i>P</i>=0.003）呈正相关，与MTA评分（<i>r</i>=-0.631，<i>P</i>&lt;0.001）呈负相关；5次起坐时间与MMSE、MoCA、MES、DSST、FDST、VFT（<i>r</i>=-0.583、-0.587、-0.814、-0.591、-0.552、-0.485，均<i>P</i>&lt;0.001）、BDST（<i>r</i>=-0.355，<i>P</i>=0.003）得分呈负相关，与MTA评分（<i>r</i>=0.836，<i>P</i>&lt;0.001）呈正相关；ASMI与MMSE、MoCA、MES、DSST、FDST得分（<i>r</i>=0.257、0.238、0.428、0.282、0.364，均<i>P</i>&lt;0.05）呈正相关，与MTA评分（<i>r</i>=-0. 377，<i>P</i>=0.001）呈负相关；6 m步速与MMSE、MoCA、MES、DSST、FDST（<i>r</i>=0.419、0.486、0.699、0.559、0.500，均<i>P</i>&lt;0.001）、BDST和VFT得分（<i>r</i>=0.384、0.377，均<i>P</i>=0.001）呈正相关，与MTA评分（<i>r</i>=-0.803，<i>P</i>&lt;0.001）呈负相关。 <b>结论：</b> 轻中度AD患者认知功能广泛性受损，肌肉量、肌肉力量、躯体功能均明显减退。相较肌肉量与躯体功能，肌肉力量下降与广泛性认知功能减退和MTA程度增加显著相关。.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36124351</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112137-20220406-00715</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36124291</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1687-5443</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Neural plasticity</Title><ISOAbbreviation>Neural Plast</ISOAbbreviation></Journal><ArticleTitle>Aerobic Exercise Regulates Apoptosis through the PI3K/Akt/GSK-3<i>β</i> Signaling Pathway to Improve Cognitive Impairment in Alzheimer's Disease Mice.</ArticleTitle><Pagination><MedlinePgn>1500710</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/1500710</ELocationID><Abstract><AbstractText>Neuronal apoptosis is an important factor in the etiology of Alzheimer's disease (AD). Aerobic exercise (AE) enhances learning and memory, improves cognitive impairment, increases telomere binding protein expression, and decreases apoptosis regulators, but it remains unclear whether it can improve cognitive impairment caused by neuronal apoptosis in AD. Therefore, this study investigated whether an 8-week running table exercise intervention could reduce apoptosis and improve cognitive function in the hippocampal neurons of AD model mice. After the exercise intervention, we evaluated the learning memory ability (positioning, navigation, and spatial search) of mice using a Morris water labyrinth, Nissl staining, immunohistochemistry, and protein application to detect hippocampal PI3K/Akt/GSK-3<i>β</i> signaling pathway protein and hippocampal neuronal cell apoptosis protein B cell lymphoma 2 (Bcl-2) and apoptosis-promoting protein bcl-2-related X (Bax) protein expression. The results showed that aerobic exercise improved the location and spatial exploration ability of mice, increased the number of PI3K- and p-Akt-positive cells, increased the expression of PI3K, p-Akt, and bcl-2 proteins, decreased the expression of GSK-3<i>β</i> and Bax proteins, and increased the bcl-2/Bax ratio of mice. The results suggest that aerobic exercise can reduce apoptosis and improve cognitive function in AD mice. The molecular mechanism may involve activation of the PI3K/Akt/GSK-3<i>β</i> signaling pathway.</AbstractText><CopyrightInformation>Copyright © 2022 Yan Peng et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0787-7158</Identifier><AffiliationInfo><Affiliation>College of Kinesiology, Shenyang Sport University, Shenyang, 110102 Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Rui</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7411-8920</Identifier><AffiliationInfo><Affiliation>College of Kinesiology, Shenyang Sport University, Shenyang, 110102 Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Gang</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6803-9521</Identifier><AffiliationInfo><Affiliation>College of Kinesiology, Shenyang Sport University, Shenyang, 110102 Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Weijie</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-7237-4154</Identifier><AffiliationInfo><Affiliation>College of Kinesiology, Shenyang Sport University, Shenyang, 110102 Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6209-1807</Identifier><AffiliationInfo><Affiliation>College of Kinesiology, Shenyang Sport University, Shenyang, 110102 Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rihui</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6803-9786</Identifier><AffiliationInfo><Affiliation>College of Kinesiology, Shenyang Sport University, Shenyang, 110102 Liaoning, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neural Plast</MedlineTA><NlmUniqueID>100883417</NlmUniqueID><ISSNLinking>1687-5443</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034501">Telomere-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>059QF0KO0R</RegistryNumber><NameOfSubstance UI="D014867">Water</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034501" MajorTopicYN="N">Telomere-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors of this paper declare that they have no conflict of interest in this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>2</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36124291</ArticleId><ArticleId IdType="doi">10.1155/2022/1500710</ArticleId><ArticleId IdType="pmc">PMC9482542</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Neurobiol. 2022 Jan;59(1):354-385</Citation><ArticleIdList><ArticleId IdType="pubmed">34699027</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Biochem Biophys. 2021 May 15;702:108698</Citation><ArticleIdList><ArticleId IdType="pubmed">33259796</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Sci. 2020 Dec;40(6):1022-1030</Citation><ArticleIdList><ArticleId IdType="pubmed">33428129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2009 Oct;19(10):1030-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19123237</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Ther Med. 2014 Mar;7(3):587-593</Citation><ArticleIdList><ArticleId IdType="pubmed">24520250</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2017 Oct 06;9(10):</Citation><ArticleIdList><ArticleId IdType="pubmed">28984827</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Nutr. 2020 Jul 28;7:94</Citation><ArticleIdList><ArticleId IdType="pubmed">32850930</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2016 Mar 16;52(1):333-43</Citation><ArticleIdList><ArticleId IdType="pubmed">27003207</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Plast. 2020 Dec 14;2020:8856621</Citation><ArticleIdList><ArticleId IdType="pubmed">33414823</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurosci. 2021 Feb 15;32(6):615-629</Citation><ArticleIdList><ArticleId IdType="pubmed">33583156</ArticleId></ArticleIdList></Reference><Reference><Citation>Metab Brain Dis. 2019 Feb;34(1):21-37</Citation><ArticleIdList><ArticleId IdType="pubmed">30443769</ArticleId></ArticleIdList></Reference><Reference><Citation>Rejuvenation Res. 2015 Feb;18(1):57-89</Citation><ArticleIdList><ArticleId IdType="pubmed">25431878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">33275682</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2020 Dec;57(12):5026-5043</Citation><ArticleIdList><ArticleId IdType="pubmed">32829453</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2015 Jul 9;298:357-66</Citation><ArticleIdList><ArticleId IdType="pubmed">25917310</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2020 Dec;155(6):602-611</Citation><ArticleIdList><ArticleId IdType="pubmed">32396989</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Biochem Funct. 2020 Mar;38(2):213-221</Citation><ArticleIdList><ArticleId IdType="pubmed">31978253</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2019 Jan 15;217:16-24</Citation><ArticleIdList><ArticleId IdType="pubmed">30471283</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Plast. 2012;2012:272374</Citation><ArticleIdList><ArticleId IdType="pubmed">22792491</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Plast. 2021 Aug 26;2021:9960304</Citation><ArticleIdList><ArticleId IdType="pubmed">34484327</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Plast. 2018 Dec 12;4(1):17-52</Citation><ArticleIdList><ArticleId IdType="pubmed">30564545</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Res Rev. 2021 Mar;41(2):770-784</Citation><ArticleIdList><ArticleId IdType="pubmed">32656815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2020 Apr 27;11(4):290</Citation><ArticleIdList><ArticleId IdType="pubmed">32341353</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatriki. 2019 Apr-Jun;30(2):142-155</Citation><ArticleIdList><ArticleId IdType="pubmed">31425142</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Plast. 2020 Sep 1;2020:2960343</Citation><ArticleIdList><ArticleId IdType="pubmed">32952546</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta Mol Cell Res. 2020 May;1867(5):118664</Citation><ArticleIdList><ArticleId IdType="pubmed">32006534</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2019;71(3):715-732</Citation><ArticleIdList><ArticleId IdType="pubmed">31476157</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2018 Aug;43(8):1561-1574</Citation><ArticleIdList><ArticleId IdType="pubmed">29948724</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Prolif. 2020 Apr;53(4):e12787</Citation><ArticleIdList><ArticleId IdType="pubmed">32162733</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2020 Dec 08;25(24):</Citation><ArticleIdList><ArticleId IdType="pubmed">33302541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Physiol Biochem. 2017;44(4):1445-1459</Citation><ArticleIdList><ArticleId IdType="pubmed">29190615</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Med Sci. 2020 Aug 25;17(2):406-416</Citation><ArticleIdList><ArticleId IdType="pubmed">33747277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Immunol. 2021 Mar;131:171-179</Citation><ArticleIdList><ArticleId IdType="pubmed">33461764</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2017 Apr;16(4):273-284</Citation><ArticleIdList><ArticleId IdType="pubmed">28209992</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2020 Oct 1;139:111056</Citation><ArticleIdList><ArticleId IdType="pubmed">32791334</ArticleId></ArticleIdList></Reference><Reference><Citation>P R Health Sci J. 2020 Sep;39(3):264-269</Citation><ArticleIdList><ArticleId IdType="pubmed">33031695</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2020;1228:439-451</Citation><ArticleIdList><ArticleId IdType="pubmed">32342476</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2020 Dec;141:104852</Citation><ArticleIdList><ArticleId IdType="pubmed">33010393</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">33431651</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2011 Apr 15;218(2):308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">21192984</ArticleId></ArticleIdList></Reference><Reference><Citation>Geriatr Gerontol Int. 2017 May;17(5):765-772</Citation><ArticleIdList><ArticleId IdType="pubmed">27396580</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biol Macromol. 2021 Jan 15;167:382-394</Citation><ArticleIdList><ArticleId IdType="pubmed">33278431</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Aug 16;21(16):</Citation><ArticleIdList><ArticleId IdType="pubmed">32824367</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2017;56(4):1469-1484</Citation><ArticleIdList><ArticleId IdType="pubmed">28157094</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr Health Aging. 2018;22(8):944-951</Citation><ArticleIdList><ArticleId IdType="pubmed">30272098</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromolecular Med. 2018 Sep;20(3):386-400</Citation><ArticleIdList><ArticleId IdType="pubmed">29971668</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36123648</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>The presence and co-incidence of geriatric syndromes in older patients with mild-moderate Lewy body dementia.</ArticleTitle><Pagination><MedlinePgn>355</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-022-02897-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Geriatric symptoms are common in dementia cases, while few studies have focused on these symptoms in Lewy body dementia (LBD). The purpose of this study is to investigate the distributions of Apolipoprotein E (APOE) ε4 and geriatric symptoms, and explore their associaitons in Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective study with 185 mild-moderate probable DLB (n = 93) and PDD (n = 92) patients was assigned. Demographic and clinical characteristics, neuropsychological assessments, and APOE genotypes were recorded. Description, correlation and logistic regression models were used to analyze the presence of geriatric symptom complaints and their associations with APOE ε4.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DLB patients displayed more frequency of fluctuating cognition, visual hallucination, rapid eye movement sleep behavior disorder, delusion, depression, anxiety, apathy, and loss of appetite, whereas the PDD cases had constipation, fear of falling, and insomnia more frequently. The APOE ε4 allele was more common in DLB than PDD (29.9% vs. 7.0%, p &lt; 0.001), and the patients with DLB + APOE ε4 (+) were presented more delusions (p = 0.005) and apathy (p = 0.007) than patients with PDD + APOE ε4 (+). We also found that the APOE ε4 allele was significantly associated with hyperhidrosis (OR = 3.472, 95%CI: 1.082-11.144, p = 0.036) and depression (OR = 3.002, 95%CI: 1.079-8.353, p = 0.035) in DLB patients, while there were no significant associations between APOE ε4 allele and the age at visit, the age at onset, scores of MDS-UPDRS III, H&amp;Y stage, ADL, MMSE, MOCA and NPI, as well as the presences of fluctuating cognition, VH, parkinsonism and RBD in both groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The presence and co-incidence of geriatric symptoms are common in patients with mild-moderate LBD. The presence of APOE ε4 allele is associated with hyperhidrosis and depression, but not global cognition, activitives of daily life, motor function and other neuropsychitric symptoms in DLB. These findings improve the awareness of geriatric symptoms, and contribute to the healthcare management of mild-moderate DLB and PDD.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gan</LastName><ForeName>Jinghuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, 119 Nansihuan West Road, Fengtai District, Beijing, 100070, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Zhichao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shuai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebrovascular and of Neurodegenerative Diseases, Tianjin Dementia Institute, 6 Jizhao Road, Jinnan District, Tianjin, 300350, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Zhihong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebrovascular and of Neurodegenerative Diseases, Tianjin Dementia Institute, 6 Jizhao Road, Jinnan District, Tianjin, 300350, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yiming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Qilu hospital, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiao-Dan</ForeName><Initials>XD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebrovascular and of Neurodegenerative Diseases, Tianjin Dementia Institute, 6 Jizhao Road, Jinnan District, Tianjin, 300350, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chunyan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Aviation General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, 119 Nansihuan West Road, Fengtai District, Beijing, 100070, China. jiyongusa@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebrovascular and of Neurodegenerative Diseases, Tianjin Dementia Institute, 6 Jizhao Road, Jinnan District, Tianjin, 300350, China. jiyongusa@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006945" MajorTopicYN="Y">Hyperhidrosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE ε4 carriers</Keyword><Keyword MajorTopicYN="N">Dementia with Lewy bodies</Keyword><Keyword MajorTopicYN="N">Fall</Keyword><Keyword MajorTopicYN="N">Neuropsychiatric symptom</Keyword><Keyword MajorTopicYN="N">Parkinson’s disease dementia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36123648</ArticleId><ArticleId IdType="doi">10.1186/s12883-022-02897-7</ArticleId><ArticleId IdType="pii">10.1186/s12883-022-02897-7</ArticleId><ArticleId IdType="pmc">PMC9484208</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurology. 2017 Jul 4;89(1):88-100</Citation><ArticleIdList><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2021 Nov;92:13-14</Citation><ArticleIdList><ArticleId IdType="pubmed">34653875</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2018 Jul;25(7):917-e69</Citation><ArticleIdList><ArticleId IdType="pubmed">29520899</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 Jan 27;62(2):181-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14745051</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2018 Apr;125(4):615-650</Citation><ArticleIdList><ArticleId IdType="pubmed">29222591</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Neurol Sci. 2020 Jan;47(1):30-43</Citation><ArticleIdList><ArticleId IdType="pubmed">31452470</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Mar 2;12(3):e0171802</Citation><ArticleIdList><ArticleId IdType="pubmed">28253276</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2009 Jul 28;73(4):256-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19535769</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2022 Jan-Mar 01;36(1):36-43</Citation><ArticleIdList><ArticleId IdType="pubmed">35001031</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38</Citation><ArticleIdList><ArticleId IdType="pubmed">23147521</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Geriatr Med. 2002 May;18(2):141-58</Citation><ArticleIdList><ArticleId IdType="pubmed">12180240</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2013 Feb;70(2):223-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23407718</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Aug 14;57(3):456-62</Citation><ArticleIdList><ArticleId IdType="pubmed">11502913</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2021 Apr 9;11(1):7819</Citation><ArticleIdList><ArticleId IdType="pubmed">33837234</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 May 15;455(2):116-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19368858</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Stroke. 2018 Aug;13(6):612-632</Citation><ArticleIdList><ArticleId IdType="pubmed">29786478</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2016 Feb 02;6:e728</Citation><ArticleIdList><ArticleId IdType="pubmed">26836416</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2016 Aug;29:72-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27264344</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2020 May;35(5):436-448</Citation><ArticleIdList><ArticleId IdType="pubmed">31898332</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Geriatr. 2020 Sep 9;20(1):337</Citation><ArticleIdList><ArticleId IdType="pubmed">32907545</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1995 Apr;43(4):378-83</Citation><ArticleIdList><ArticleId IdType="pubmed">7706627</ArticleId></ArticleIdList></Reference><Reference><Citation>NPJ Parkinsons Dis. 2019 Jul 26;5:15</Citation><ArticleIdList><ArticleId IdType="pubmed">31372495</ArticleId></ArticleIdList></Reference><Reference><Citation>J Parkinsons Dis. 2019;9(s2):S313-S322</Citation><ArticleIdList><ArticleId IdType="pubmed">31594249</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurol. 2021 Mar 31;21(1):144</Citation><ArticleIdList><ArticleId IdType="pubmed">33789600</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2019 Sep;124:110628</Citation><ArticleIdList><ArticleId IdType="pubmed">31173842</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2021 Feb 26;13(1):53</Citation><ArticleIdList><ArticleId IdType="pubmed">33637117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;63(1):383-394</Citation><ArticleIdList><ArticleId IdType="pubmed">29578483</ArticleId></ArticleIdList></Reference><Reference><Citation>BJPsych Open. 2020 May 08;6(3):e47</Citation><ArticleIdList><ArticleId IdType="pubmed">32381152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):673-685</Citation><ArticleIdList><ArticleId IdType="pubmed">32737460</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2008 Nov 15;23(15):2129-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19025984</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neurol Neurosurg. 2020 Jul;194:105832</Citation><ArticleIdList><ArticleId IdType="pubmed">32311617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2020 Feb 5;12(529):</Citation><ArticleIdList><ArticleId IdType="pubmed">32024799</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Clin Exp Res. 2021 Sep;33(9):2599-2603</Citation><ArticleIdList><ArticleId IdType="pubmed">33506311</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2021 Jan 23;13(1):31</Citation><ArticleIdList><ArticleId IdType="pubmed">33485373</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2012 Jun;18(5):433-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22209346</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2005 Apr;53(4):695-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Urol. 2020 Apr;30(5):267-272</Citation><ArticleIdList><ArticleId IdType="pubmed">32224094</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2018 Jul 1;141(7):2181-2193</Citation><ArticleIdList><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2019 Nov 5;93(19):e1807-e1819</Citation><ArticleIdList><ArticleId IdType="pubmed">31575706</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):641-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17507447</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2018 Feb 15;10(1):19</Citation><ArticleIdList><ArticleId IdType="pubmed">29448953</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2014 Nov;146(5):1387-1394</Citation><ArticleIdList><ArticleId IdType="pubmed">25367475</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2022 Jun 14;1(-1):1037-1048</Citation><ArticleIdList><ArticleId IdType="pubmed">35723094</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2014 May;20(5):503-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24582705</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2015 Mar 10;3:12</Citation><ArticleIdList><ArticleId IdType="pubmed">25775153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2021 Feb;36(2):424-433</Citation><ArticleIdList><ArticleId IdType="pubmed">33111402</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Dec;22(16):2386-93</Citation><ArticleIdList><ArticleId IdType="pubmed">17894337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837</Citation><ArticleIdList><ArticleId IdType="pubmed">17542011</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(5):e5521</Citation><ArticleIdList><ArticleId IdType="pubmed">19436724</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Dir Assoc. 2019 Dec;20(12):1540-1547</Citation><ArticleIdList><ArticleId IdType="pubmed">31351857</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2012 Mar;33(3):629.e5-629.e18</Citation><ArticleIdList><ArticleId IdType="pubmed">22118943</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2017;55(4):1529-1536</Citation><ArticleIdList><ArticleId IdType="pubmed">27886007</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Neurosci. 2020 Dec;82(Pt A):186-191</Citation><ArticleIdList><ArticleId IdType="pubmed">33317730</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2018 Oct;55:8-14</Citation><ArticleIdList><ArticleId IdType="pubmed">30146185</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gerontol Geriatr. 2021 Jan - Feb;92:104268</Citation><ArticleIdList><ArticleId IdType="pubmed">33011431</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2004 Oct;251 Suppl 7:vII18-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15505750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2020 Feb;19(2):157-169</Citation><ArticleIdList><ArticleId IdType="pubmed">31519472</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2021 Apr;146:111248</Citation><ArticleIdList><ArticleId IdType="pubmed">33486068</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2017 Jan;49:218.e13-218.e15</Citation><ArticleIdList><ArticleId IdType="pubmed">27814994</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2011 Oct;26(10):1054-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21905099</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36123123</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10.1212/WNL.0000000000200947</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000200947</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Although Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) represent two different pathologies, they have clinical overlap, and there is a significant degree of co-occurrence of their neuropathological findings. Many studies have examined imaging characteristics in clinically diagnosed patients; however, there is a relative lack of longitudinal studies that have studied patients with pathological confirmation. We examined whether there were differences in longitudinal patterns of cortical atrophy between patients with both AD and DLB (AD/DLB) vs. those with AD alone.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We collected and analyzed clinical and neuroimaging data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database for patients who underwent autopsy. The rates of change in various neuropsychological assessments were not significantly different between AD/DLB and AD patients, and each group had neuropsychological outcomes consistent with disease progression. For our neuroimaging analysis, we used a linear mixed effects model to examine if there were longitudinal differences in cortical rates of atrophy between AD/DLB and AD patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Autopsies and serial neuroimaging was available on 48 patients (24 AD, 24 AD/DLB). Patients with AD alone had significantly higher atrophy rates in the left cuneus, lateral occipital, and parahippocampal regions over time when compared to patients with concomitant DLB, after covarying for interval from imaging to autopsy, gender, and total estimated intracranial volume (eTIV). Site ID was included as a random effect to account for site differences. For these regions, the rate of decline over time in the AD/DLB group were less steep by a difference of 0.1887, 0.395, and 0.0989, respectively (<i>p =.022, .006, and .006</i>). The lattermost left cuneus volume measurement also positively correlated to Braak Lewy score <i>(</i>Pearson's product-moment correlation 0.37, <i>p=.009)</i>, while the lattermost left parahippocampal volume measurement negatively correlated to Braak NFT score <i>(</i>Pearson's product-moment correlation -0.327, <i>p=.02)</i>.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">AD patients had more significant atrophy in the left cuneus, lateral occipital, and parahippocampal regions when compared to AD/DLB patients. These regions are known to distinguish DLB and AD pathology cross-sectionally, but here are shown to distinguish longitudinal disease progression.</AbstractText><CopyrightInformation>© 2022 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Constant</LastName><ForeName>Allison Beers</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Columbia University Vagelos College of Physicians &amp; Surgeons, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basavaraju</LastName><ForeName>Rakshathi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, N.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>France</LastName><ForeName>Jeanelle</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8023-4576</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, N.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9703-2265</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, N.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Getrude H. Sergievsky Center, Department of Neurology, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marder</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, N.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Getrude H. Sergievsky Center, Department of Neurology, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Provenzano</LastName><ForeName>Frank Anthony</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, N fap2005@cumc.columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>21</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36123123</ArticleId><ArticleId IdType="pii">WNL.0000000000200947</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000200947</ArticleId><ArticleId IdType="pmc">PMC9620811</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimers Res Ther. 2018 Mar 1;10(1):27</Citation><ArticleIdList><ArticleId IdType="pubmed">29490691</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1991;82(4):239-59</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2017 Jun 27;9(1):47</Citation><ArticleIdList><ArticleId IdType="pubmed">28655337</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Jul 16;61(4):1402-18</Citation><ArticleIdList><ArticleId IdType="pubmed">22430496</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2015 Jan;36(1):452-61</Citation><ArticleIdList><ArticleId IdType="pubmed">25128280</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2003 Mar-Apr;24(2):197-211</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2015 Feb 07;7:456-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25685712</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2020 Jan 21;94(3):e282-e291</Citation><ArticleIdList><ArticleId IdType="pubmed">31862783</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2007 Mar;130(Pt 3):708-19</Citation><ArticleIdList><ArticleId IdType="pubmed">17267521</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2004 Sep;23(1):325-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15325380</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;66(1):115-126</Citation><ArticleIdList><ArticleId IdType="pubmed">30223398</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Nov 12;59(9):1476</Citation><ArticleIdList><ArticleId IdType="pubmed">12427918</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2014 May;20(5):525-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24637124</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 Jul 1;57(1):19-21</Citation><ArticleIdList><ArticleId IdType="pubmed">21376812</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2009 Jan;132(Pt 1):195-203</Citation><ArticleIdList><ArticleId IdType="pubmed">19022858</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2017 Jul 4;89(1):88-100</Citation><ArticleIdList><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Dec 11;57(11):2117-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11739838</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):908-916</Citation><ArticleIdList><ArticleId IdType="pubmed">28473626</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Biochem. 2019 Nov;73:26-31</Citation><ArticleIdList><ArticleId IdType="pubmed">31400306</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Feb 7;27(6):1405-10</Citation><ArticleIdList><ArticleId IdType="pubmed">17287515</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1997 Oct 10;235(1-2):49-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9389593</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2010 Mar;257(3):359-66</Citation><ArticleIdList><ArticleId IdType="pubmed">19795154</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2015 Apr;36(4):1743-1750</Citation><ArticleIdList><ArticleId IdType="pubmed">25649023</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2013 Apr;260(4):1104-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23224109</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2014 Feb;17(2):304-11</Citation><ArticleIdList><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2013 Feb 1;66:249-60</Citation><ArticleIdList><ArticleId IdType="pubmed">23123680</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychol Rev. 2017 Mar;27(1):1-17</Citation><ArticleIdList><ArticleId IdType="pubmed">27878426</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2015 Jan;23(1):38-46</Citation><ArticleIdList><ArticleId IdType="pubmed">25218360</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2003 Jul 8;42(26):7871-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12834338</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2013 Nov;70(11):1396-402</Citation><ArticleIdList><ArticleId IdType="pubmed">24042491</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Dec;53(4):1181-96</Citation><ArticleIdList><ArticleId IdType="pubmed">20637289</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2006 Jul;65(7):685-97</Citation><ArticleIdList><ArticleId IdType="pubmed">16825955</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2016 Apr;28(4):529-36</Citation><ArticleIdList><ArticleId IdType="pubmed">26572170</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1999;249(6):288-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10653284</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2013 Oct 09;1:65</Citation><ArticleIdList><ArticleId IdType="pubmed">24252435</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Jun 25;58(12):1791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2014 Aug 26;83(9):801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25056580</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36123122</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10.1212/WNL.0000000000201300</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000201300</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">The glymphatic system is a whole-brain perivascular network, which promotes CSF/interstitial fluid exchange. Alterations to this system may play a pivotal role in amyloid β (Aβ) accumulation. However, its involvement in Alzheimer's disease (AD) pathogenesis is not fully understood. Here, we investigated the changes in noninvasive MRI measurements related to the perivascular network in patients with mild cognitive impairment (MCI) and AD. Additionally, we explored the associations of MRI measures with neuropsychological score, PET standardized uptake value ratio (SUVR), and Aβ deposition.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MRI measures, including perivascular space (PVS) volume fraction (PVSVF), fractional volume of free water in white matter (FW-WM), and index of diffusivity along the perivascular space (ALPS index) of patients with MCI, those with AD, and healthy controls from the Alzheimer's Disease Neuroimaging Initiative database were compared. MRI measures were also correlated with the levels of CSF biomarkers, PET SUVR, and cognitive score in the combined subcohort of patients with MCI and AD. Statistical analyses were performed with age, sex, years of education, and <i>APOE</i> status as confounding factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 36 patients with AD, 44 patients with MCI, and 31 healthy controls were analyzed. Patients with AD had significantly higher total, WM, and basal ganglia PVSVF (Cohen's <i>d</i> = 1.15-1.48; <i>p</i> &lt; 0.001), and FW-WM (Cohen's <i>d</i> = 0.73; <i>p</i> &lt; 0.05) and a lower ALPS index (Cohen's <i>d</i> = 0.63; <i>p</i> &lt; 0.05) than healthy controls. Meanwhile, the MCI group only showed significantly higher total (Cohen's <i>d</i> = 0.99; <i>p</i> &lt; 0.05) and WM (Cohen's <i>d</i> = 0.91; <i>p</i> &lt; 0.05) PVSVF. Low ALPS index was associated with lower CSF Aβ42 (<i>r</i> <sub><i>s</i></sub> = 0.41, <i>p</i> <sub><i>fdr</i></sub> = 0.026), FDG-PET uptake (<i>r</i> <sub><i>s</i></sub> = 0.54, <i>p</i> <sub><i>fdr</i></sub> &lt; 0.001), and worse multiple cognitive domain deficits. High FW-WM was also associated with lower CSF Aβ42 (<i>r</i> <sub><i>s</i></sub> = -0.47, <i>p</i> <sub><i>fdr</i></sub> = 0.021) and worse cognitive performances.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study indicates that changes in PVS-related MRI parameters occur in MCI and AD, possibly due to impairment of the glymphatic system. We also report the associations between MRI parameters and Aβ deposition, neuronal change, and cognitive impairment in AD.</AbstractText><CopyrightInformation>Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamagata</LastName><ForeName>Koji</ForeName><Initials>K</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5028-218X</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan kkamagat@juntendo.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andica</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takabayashi</LastName><ForeName>Kaito</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taoka</LastName><ForeName>Toshiaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Innovative Biomedical Visualization (iBMV), Nagoya University Graduate School of Medicine, Shouwa-ku, Nagoya 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nozaki</LastName><ForeName>Hayato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikuta</LastName><ForeName>Junko</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1324-8614</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Shohei</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4276-6226</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagiwara</LastName><ForeName>Akifumi</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5277-3249</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamiya</LastName><ForeName>Kouhei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Toho University Omori Medical Center, Ota-ku, Tokyo 143-8541, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wada</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3432-0267</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akashi</LastName><ForeName>Toshiaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Katsuhiro</ForeName><Initials>K</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8388-3827</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishizawa</LastName><ForeName>Mitsuo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hori</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1791-8032</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Toho University Omori Medical Center, Ota-ku, Tokyo 143-8541, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naganawa</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Nagoya University Graduate School of Medicine, Shouwa-ku, Nagoya 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Shigeki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>for the Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>02</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>21</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36123122</ArticleId><ArticleId IdType="pii">WNL.0000000000201300</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000201300</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36122553</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Bidirectional communication between brain and visceral white adipose tissue: Its potential impact on Alzheimer's disease.</ArticleTitle><Pagination><MedlinePgn>104263</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(22)00445-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2022.104263</ELocationID><Abstract><AbstractText>A variety of axes between brain and abdominal organs have been reported, but the interaction between brain and visceral white adipose tissue (vWAT) remains unclear. In this review, we summarized human studies on the association between brain and vWAT, and generalized their interaction and the underlying mechanisms according to animal and cell experiments. On that basis, we come up with the concept of the brain-vWAT axis (BVA). Furthermore, we analyzed the potential mechanisms of involvement of BVA in the pathogenesis of Alzheimer's disease (AD), including vWAT-derived fatty acids, immunological properties of vWAT, vWAT-derived retinoic acid and vWAT-regulated insulin resistance. The proposal of BVA may expand our understanding to some extent of how the vWAT impacts on brain health and diseases, and provide a novel approach to study the pathogenesis and treatment strategies of neurodegenerative disorders.</AbstractText><CopyrightInformation>Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan-Jiang</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing 400042, China; Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing 400042, China. Electronic address: yanjiang_wang@tmmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China.. Electronic address: xiangyangttt@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>5688UTC01R</RegistryNumber><NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050152" MajorTopicYN="N">Intra-Abdominal Fat</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056128" MajorTopicYN="N">Obesity, Abdominal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’ disease</Keyword><Keyword MajorTopicYN="N">Brain</Keyword><Keyword MajorTopicYN="N">Fatty acid</Keyword><Keyword MajorTopicYN="N">Retinoic acid</Keyword><Keyword MajorTopicYN="N">Visceral white adipose tissue</Keyword></KeywordList><CoiStatement>Declaration of interests The authors confirm that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36122553</ArticleId><ArticleId IdType="pii">S2352-3964(22)00445-5</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.104263</ArticleId><ArticleId IdType="pmc">PMC9490488</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36121878</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6882</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>39</Issue><PubDate><Year>2022</Year><Month>10</Month><Day>04</Day></PubDate></JournalIssue><Title>Analytical chemistry</Title><ISOAbbreviation>Anal Chem</ISOAbbreviation></Journal><ArticleTitle>Diagnosis of Alzheimer's Disease and <i>In Situ</i> Biological Imaging via an Activatable Near-Infrared Fluorescence Probe.</ArticleTitle><Pagination><MedlinePgn>13498-13506</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.analchem.2c02627</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a common neurodegenerative disease that makes the brain nervous system degenerate rapidly and is accompanied by some special cognitive and behavioral dysfunction. Recently, butyrylcholinesterase (<b>BChE</b>) was reported as an important enzyme, whose activity can provide predictive value for timely discovery and diagnosis of AD. Therefore, it is indispensable to design a detection tool for selective and rapid response toward <b>BChE</b>. In this study, we developed a novel near-infrared fluorescent probe (<b><i>Chy-1</i></b>) for the detection of <b>BChE</b> activity. An excellent sensitivity, good biocompatibility, and lower limit of detection (LOD) of 0.12 ng/mL made the probe extremely specific for <b>BChE</b>, which was successfully used in biological imaging. What is more, <b><i>Chy-1</i></b> can not only clearly distinguish tumor from normal cells but also forms a clear boundary between the normal and cancer tissues due to the obvious difference in fluorescence intensity produced via <i>in situ</i> spraying. Most important of all, <b><i>Chy-1</i></b> was also successfully applied to track the <b>BChE</b> activity in AD mouse models. Based on this research, the novel probe may be a powerful tool for clinical diagnosis and therapy of tumor and neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yuexia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, State Key Laboratory of Applied Organic Chemistry and Key Laboratory of Special Function Materials and Structure Design (MOE), College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou730000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, Xinqiao Hospital, Army Medical University, Chongqing400037, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jiemin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, State Key Laboratory of Applied Organic Chemistry and Key Laboratory of Special Function Materials and Structure Design (MOE), College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou730000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yuping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, State Key Laboratory of Applied Organic Chemistry and Key Laboratory of Special Function Materials and Structure Design (MOE), College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou730000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuyan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, State Key Laboratory of Applied Organic Chemistry and Key Laboratory of Special Function Materials and Structure Design (MOE), College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou730000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Wenwu</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-9782-6647</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, State Key Laboratory of Applied Organic Chemistry and Key Laboratory of Special Function Materials and Structure Design (MOE), College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou730000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Second Affiliated Hospital of Chongqing Medical University, No. 74 Linjiang Rd, Yuzhong District, Chongqing400010, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anal Chem</MedlineTA><NlmUniqueID>0370536</NlmUniqueID><ISSNLinking>0003-2700</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.8</RegistryNumber><NameOfSubstance UI="D002091">Butyrylcholinesterase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002091" MajorTopicYN="N">Butyrylcholinesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>13</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36121878</ArticleId><ArticleId IdType="doi">10.1021/acs.analchem.2c02627</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36121669</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.2909</ELocationID><Abstract><AbstractText Label="Importance" NlmCategory="UNASSIGNED">Alzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid plaques and τ tangles in the brain, represents an unmet medical need with no fully approved therapeutics to modify disease progression.</AbstractText><AbstractText Label="Objective" NlmCategory="UNASSIGNED">To investigate the safety and efficacy of crenezumab, a humanized monoclonal immunoglobulin G4 antibody targeting β-amyloid oligomers, in participants with prodromal to mild (early) AD.</AbstractText><AbstractText Label="Design, Setting, and Participants" NlmCategory="UNASSIGNED">Two phase 3 multicenter randomized double-blind placebo-controlled parallel-group efficacy and safety studies of crenezumab in participants with early AD, CREAD and CREAD2, were initiated in 2016 and 2017, respectively, and were designed to evaluate the efficacy and safety of crenezumab in participants with early AD. CREAD (194 sites in 30 countries) and CREAD2 (209 sites in 27 countries) were global multicenter studies. A total of 3736 and 3664 participants were screened in CREAD and CREAD2, respectively. A total of 3736 and 3664 participants were screened in CREAD and CREAD2, respectively. Both trials enrolled individuals aged 50 to 85 years with early AD. Participants with some comorbidities and evidence of cerebral infarction or more than 4 microbleeds or areas of leptomeningeal hemosiderosis on magnetic resonance imaging were excluded. After 2923 and 2858 were excluded, respectively, 813 participants in CREAD and 806 in CREAD2 were randomly assigned in a 1:1 ratio to either placebo or crenezumab. In the final analysis, there were 409 participants in the placebo group and 404 in the crenezumab group in CREAD and 399 in the placebo group and 407 in the crenezumab group in CREAD2. Data were analyzed up until January 2019 and August 2019, respectively.</AbstractText><AbstractText Label="Interventions" NlmCategory="UNASSIGNED">Participants received placebo or 60 mg/kg crenezumab intravenously every 4 weeks for up to 100 weeks.</AbstractText><AbstractText Label="Main Outcomes and Measures" NlmCategory="UNASSIGNED">The primary outcome was change from baseline to week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) score.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">There were 813 participants in CREAD (mean [SD] age, 70.7 [8.2] years; 483 female and 330 male) and 806 in CREAD2 (mean [SD] age, 70.9 [7.7] years; 456 female and 350 male). Baseline characteristics were balanced between both groups. The between-group difference in mean change from baseline in CDR-SB score (placebo minus crenezumab) was -0.17 (95% CI, -0.86 to 0.53; P = .63) at week 105 in the CREAD study (88 placebo; 86 crenezumab). Compared with previous trials, no new safety signals were identified, and amyloid-related imaging abnormalities with edema were rare, mild, and transient. No meaningful changes in AD biomarkers were observed. Both studies were discontinued following a preplanned interim analysis indicating that CREAD was unlikely to meet the primary end point.</AbstractText><AbstractText Label="Conclusions and Relevance" NlmCategory="UNASSIGNED">Crenezumab was well tolerated but did not reduce clinical decline in participants with early AD.</AbstractText><AbstractText Label="Trial Registration" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifiers: CREAD, NCT02670083; CREAD2, NCT03114657.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostrowitzki</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackey</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabe</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassetta</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fatebenefratelli Foundation, Associazione Fatebenefratelli Per la Ricerca Division, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Austin Health Continuing Care Clinical Service Unit, Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Mercè</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blondeau</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quartino</LastName><ForeName>Angelica</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolton</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Roche Products Australia Pty Ltd, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanofi Genzyme, Waltham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostaszewski</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanabria-Bohórquez</LastName><ForeName>Sandra M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabbia</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Balazs</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichenlaub</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Jillian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Roche Products Ltd, Welwyn Garden City, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honigberg</LastName><ForeName>Lee A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03114657</AccessionNumber><AccessionNumber>NCT02670083</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36121669</ArticleId><ArticleId IdType="pii">2796551</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.2909</ArticleId><ArticleId IdType="pmc">PMC9486635</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Neurol. 2008 Aug;65(8):1091-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18695059</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Dec;168(12):1266-77</Citation><ArticleIdList><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2021 Oct 1;181(10):1276-1278</Citation><ArticleIdList><ArticleId IdType="pubmed">34254984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2019 Aug;86(2):215-224</Citation><ArticleIdList><ArticleId IdType="pubmed">31168802</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2020 Nov;16(11):1483-1492</Citation><ArticleIdList><ArticleId IdType="pubmed">33049114</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2020 Jan 22;12(1):16</Citation><ArticleIdList><ArticleId IdType="pubmed">31969177</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmune Pharmacol. 2017 Mar;12(1):194-203</Citation><ArticleIdList><ArticleId IdType="pubmed">28025724</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2020;76(3):967-979</Citation><ArticleIdList><ArticleId IdType="pubmed">32568196</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2018 Sep 19;10(1):96</Citation><ArticleIdList><ArticleId IdType="pubmed">30231896</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Dec 20;6:39374</Citation><ArticleIdList><ArticleId IdType="pubmed">27996029</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2021 May 6;384(18):1691-1704</Citation><ArticleIdList><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):270-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2019 Dec 1;11(1):97</Citation><ArticleIdList><ArticleId IdType="pubmed">31787113</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2020;17(4):393-406</Citation><ArticleIdList><ArticleId IdType="pubmed">32116192</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1982 Jun;140:566-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2018 May 22;90(21):e1889-e1897</Citation><ArticleIdList><ArticleId IdType="pubmed">29695589</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2011 Dec;20(10):1727-36</Citation><ArticleIdList><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2019 Feb;15(2):73-88</Citation><ArticleIdList><ArticleId IdType="pubmed">30610216</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1984 Nov;141(11):1356-64</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36121640</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1720-8319</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Aging clinical and experimental research</Title><ISOAbbreviation>Aging Clin Exp Res</ISOAbbreviation></Journal><ArticleTitle>Correlation between parameters related to sarcopenia and gray matter volume in patients with mild to moderate Alzheimer's disease.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40520-022-02244-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) is a neurodegenerative disease characterized by brain atrophy and closely correlated with sarcopenia. Mounting studies indicate that parameters related to sarcopenia are associated with AD, but some results show inconsistent. Furthermore, the association between the parameters related to sarcopenia and gray matter volume (GMV) has rarely been explored.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the correlation between parameters related to sarcopenia and cerebral GMV in AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Demographics, neuropsychological tests, parameters related to sarcopenia, and magnetic resonance imaging (MRI) scans were collected from 42 patients with AD and 40 normal controls (NC). Parameters related to sarcopenia include appendicular skeletal muscle mass index (ASMI), grip strength, 5-times sit-to-stand (5-STS) time and 6-m gait speed. The GMV of each cerebral region of interest (ROI) and the intracranial volume were calculated by computing the numbers of the voxels in the specific region based on MRI data. Partial correlation and multivariate stepwise linear regression analysis explored the correlation between different inter-group GMV ratios in ROIs and parameters related to sarcopenia, adjusting for covariates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 82 participants included 40 NC aged 70.13 ± 5.94 years, 24 mild AD patients aged 73.54 ± 8.27 years and 18 moderate AD patients aged 71.67 ± 9.39 years. Multivariate stepwise linear regression showed that 5-STS time and gait speed were correlated with bilateral hippocampus volume ratios in total AD. Grip strength was associated with the GMV ratio of the left middle frontal gyrus in mild AD and the GMV ratios of the right superior temporal gyrus and right hippocampus in moderate AD. However, ASMI did not have a relationship to any cerebral GMV ratio.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among parameters related to sarcopenia, 5-STS time and gait speed were associated with bilateral hippocampus volume ratios at different clinical stages of patients with AD. Five-STS time provide an objective basis for early screening and can help diagnose patients with AD.</AbstractText><CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shanwen</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8407-6947</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Technology, Changchun University of Science and Technology, Changchun, 130012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Chunying</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Technology, Changchun University of Science and Technology, Changchun, 130012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Imaging, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jiangtao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Imaging, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chun-Feng</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7994-7827</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China. sz_huhua@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SYSD2019109</GrantID><Agency>Application of Science and Technology of Minsheng Technology in Suzhou</Agency><Country/></Grant><Grant><GrantID>LD2021031</GrantID><Agency>Application of Clinical Technology in Elderly Health Research Project in Jiangsu Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Aging Clin Exp Res</MedlineTA><NlmUniqueID>101132995</NlmUniqueID><ISSNLinking>1594-0667</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Appendicular skeletal muscle mass index</Keyword><Keyword MajorTopicYN="N">Gray matter volume</Keyword><Keyword MajorTopicYN="N">Muscle strength</Keyword><Keyword MajorTopicYN="N">Physical function</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36121640</ArticleId><ArticleId IdType="doi">10.1007/s40520-022-02244-3</ArticleId><ArticleId IdType="pii">10.1007/s40520-022-02244-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beaudart C, Zaaria M, Pasleau F et al (2017) Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS ONE 12:e0169548. https://doi.org/10.1371/journal.pone.0169548</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0169548</ArticleId><ArticleId IdType="pubmed">28095426</ArticleId><ArticleId IdType="pmcid">5240970</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon Y, Choi YJ, Kim JO et al (2018) Muscle profile and cognition in patients with Alzheimer’s disease dementia. Neurol Sci 39:1861–1866. https://doi.org/10.1007/s10072-018-3505-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3505-0</ArticleId><ArticleId IdType="pubmed">30084072</ArticleId></ArticleIdList></Reference><Reference><Citation>Dercon Q, Nicholas JM, James SN et al (2021) Grip strength from midlife as an indicator of later-life brain health and cognition: evidence from a British birth cohort. BMC Geriatr 21:475. https://doi.org/10.1186/s12877-021-02411-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-021-02411-7</ArticleId><ArticleId IdType="pubmed">34465287</ArticleId><ArticleId IdType="pmcid">8406895</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper R, Kuh D, Cooper C et al (2011) Objective measures of physical capability and subsequent health: a systematic review. Age Ageing 40:14–23. https://doi.org/10.1093/ageing/afq117</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afq117</ArticleId><ArticleId IdType="pubmed">20843964</ArticleId></ArticleIdList></Reference><Reference><Citation>Camargo EC, Weinstein G, Beiser AS et al (2016) Association of Physical Function with Clinical and Subclinical Brain Disease: The Framingham Offspring Study. J Alzheimers Dis 53:1597–1608. https://doi.org/10.3233/JAD-160229</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160229</ArticleId><ArticleId IdType="pubmed">27540965</ArticleId></ArticleIdList></Reference><Reference><Citation>Taekema DG, Ling CH, Kurrle SE et al (2012) Temporal relationship between handgrip strength and cognitive performance in oldest old people. Age Ageing 41:506–512. https://doi.org/10.1093/ageing/afs013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afs013</ArticleId><ArticleId IdType="pubmed">22374646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WL, Peng TC, Sun YS et al (2015) Examining the association between quadriceps strength and cognitive performance in the elderly. Medicine (Baltimore) 94:e1335. https://doi.org/10.1097/MD.0000000000001335</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000001335</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui SX, Holloway-Kew KL, Hyde NK et al (2020) Muscle strength and gait speed rather than lean mass are better indicators for poor cognitive function in older men. Sci Rep 10:10367. https://doi.org/10.1038/s41598-020-67251-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-67251-8</ArticleId><ArticleId IdType="pubmed">32587294</ArticleId><ArticleId IdType="pmcid">7316855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim GM, Kim BK, Kim DR et al (2021) An association between lower extremity function and cognitive frailty: a sample population from the KFACS study. Int J Environ Res Public Health 18:1007. https://doi.org/10.3390/ijerph18031007</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18031007</ArticleId><ArticleId IdType="pubmed">33498760</ArticleId><ArticleId IdType="pmcid">7908491</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid MH, Zahid MF, Zain S et al (2020) The neuroprotective effects of exercise on cognitive decline: a preventive approach to alzheimer disease. Cureus 12:e6958. https://doi.org/10.7759/cureus.6958</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.6958</ArticleId><ArticleId IdType="pubmed">32190507</ArticleId><ArticleId IdType="pmcid">7067577</ArticleId></ArticleIdList></Reference><Reference><Citation>Burtscher J, Millet GP, Place N et al (2021) The muscle-brain axis and neurodegenerative diseases: the key role of mitochondria in exercise-induced neuroprotection. Int J Mol Sci. https://doi.org/10.3390/ijms22126479</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126479</ArticleId><ArticleId IdType="pubmed">34204228</ArticleId><ArticleId IdType="pmcid">8235687</ArticleId></ArticleIdList></Reference><Reference><Citation>Osawa Y, Tian Q, An Y et al (2021) Longitudinal associations between brain volume and knee extension peak torque. J Gerontol A Biol Sci Med Sci 76:286–290. https://doi.org/10.1093/gerona/glaa095</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glaa095</ArticleId><ArticleId IdType="pubmed">32333769</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino E, Palmer K, Della Pieta C et al (2020) Association between gait, cognition, and gray matter volumes in mild cognitive impairment and healthy controls. Alzheimer Dis Assoc Disord 34:231–237. https://doi.org/10.1097/WAD.0000000000000371</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0000000000000371</ArticleId><ArticleId IdType="pubmed">31977569</ArticleId></ArticleIdList></Reference><Reference><Citation>Allali G, Montembeault M, Saj A et al (2019) Structural brain volume covariance associated with gait speed in patients with amnestic and non-amnestic mild cognitive impairment: a double dissociation. J Alzheimers Dis 71:S29–S39. https://doi.org/10.3233/JAD-190038</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-190038</ArticleId><ArticleId IdType="pubmed">31127784</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuskova V, Ismail Z, Nikolai T et al (2021) Mild behavioral impairment is associated with atrophy of entorhinal cortex and hippocampus in a memory clinic cohort. Front Aging Neurosci 13:643271. https://doi.org/10.3389/fnagi.2021.643271</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.643271</ArticleId><ArticleId IdType="pubmed">34108874</ArticleId><ArticleId IdType="pmcid">8180573</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnellbacher GJ, Hoffstaedter F, Eickhoff SB et al (2020) Functional characterization of atrophy patterns related to cognitive impairment. Front Neurol 11:18. https://doi.org/10.3389/fneur.2020.00018</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00018</ArticleId><ArticleId IdType="pubmed">32038473</ArticleId><ArticleId IdType="pmcid">6993791</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon Y, Moon WJ, Kim JO et al (2019) Muscle strength is independently related to brain atrophy in patients with alzheimer’s disease. Dement Geriatr Cogn Disord 47:306–314. https://doi.org/10.1159/000500718</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000500718</ArticleId><ArticleId IdType="pubmed">31311027</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Johnson DK, Watts A et al (2010) Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol 67:428–433. https://doi.org/10.1001/archneurol.2010.38</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.38</ArticleId><ArticleId IdType="pubmed">20385908</ArticleId><ArticleId IdType="pmcid">2855150</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId><ArticleId IdType="pmcid">3312024</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198. https://doi.org/10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazekas F, Chawluk JB, Alavi A et al (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 149:351–356. https://doi.org/10.2214/ajr.149.2.351</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/ajr.149.2.351</ArticleId><ArticleId IdType="pubmed">3496763</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Jiao J, Zhu M et al (2022) Nutritional Status According to the Short-Form Mini Nutritional Assessment (MNA-SF) and clinical characteristics as predictors of length of stay, mortality, and readmissions among older inpatients in china: a national study. Front Nutr 9:815578. https://doi.org/10.3389/fnut.2022.815578</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.815578</ArticleId><ArticleId IdType="pubmed">35145987</ArticleId><ArticleId IdType="pmcid">8822231</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LK, Woo J, Assantachai P et al (2020) Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 21:e302. https://doi.org/10.1016/j.jamda.2019.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2019.12.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Nie J, Yap PT et al (2014) Knowledge-guided robust MRI brain extraction for diverse large-scale neuroimaging studies on humans and non-human primates. PLoS ONE 9:e77810. https://doi.org/10.1371/journal.pone.0077810</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0077810</ArticleId><ArticleId IdType="pubmed">24489639</ArticleId><ArticleId IdType="pmcid">3906014</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumurgier J, Artaud F, Touraine C et al (2017) Gait speed and decline in gait speed as predictors of incident dementia. J Gerontol A Biol Sci Med Sci 72:655–661. https://doi.org/10.1093/gerona/glw110</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glw110</ArticleId><ArticleId IdType="pubmed">27302701</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso AL, Studenski SA, Chen WG et al (2013) Aging, the central nervous system, and mobility. J Gerontol A Biol Sci Med Sci 68:1379–1386. https://doi.org/10.1093/gerona/glt089</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glt089</ArticleId><ArticleId IdType="pubmed">23843270</ArticleId><ArticleId IdType="pmcid">3805295</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso AL, Verghese J, Metti AL et al (2017) Slowing gait and risk for cognitive impairment: the hippocampus as a shared neural substrate. Neurology 89:336–342. https://doi.org/10.1212/WNL.0000000000004153</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004153</ArticleId><ArticleId IdType="pubmed">28659421</ArticleId><ArticleId IdType="pmcid">5574674</ArticleId></ArticleIdList></Reference><Reference><Citation>Piekema C, Kessels RP, Mars RB et al (2006) The right hippocampus participates in short-term memory maintenance of object-location associations. Neuroimage 33:374–382. https://doi.org/10.1016/j.neuroimage.2006.06.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.06.035</ArticleId><ArticleId IdType="pubmed">16904344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland BH, Oddie SD (2001) Theta band oscillation and synchrony in the hippocampal formation and associated structures: the case for its role in sensorimotor integration. Behav Brain Res 127:119–136. https://doi.org/10.1016/s0166-4328(01)00358-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0166-4328(01)00358-8</ArticleId><ArticleId IdType="pubmed">11718888</ArticleId></ArticleIdList></Reference><Reference><Citation>Allali G, van der Meulen M, Beauchet O et al (2014) The neural basis of age-related changes in motor imagery of gait: an fMRI study. J Gerontol A Biol Sci Med Sci 69:1389–1398. https://doi.org/10.1093/gerona/glt207</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glt207</ArticleId><ArticleId IdType="pubmed">24368777</ArticleId></ArticleIdList></Reference><Reference><Citation>Malouin F, Richards CL, Jackson PL et al (2003) Brain activations during motor imagery of locomotor-related tasks: a PET study. Hum Brain Mapp 19:47–62. https://doi.org/10.1002/hbm.10103</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.10103</ArticleId><ArticleId IdType="pubmed">12731103</ArticleId><ArticleId IdType="pmcid">6872050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ide R, Ota M, Hada Y et al (2022) Dynamic balance deficit and the neural network in Alzheimer’s disease and mild cognitive impairment. Gait Posture 93:252–258. https://doi.org/10.1016/j.gaitpost.2022.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gaitpost.2022.01.018</ArticleId><ArticleId IdType="pubmed">35227962</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso AL, Olson Hunt MJ, Yang M et al (2014) Higher step length variability indicates lower gray matter integrity of selected regions in older adults. Gait Posture 40:225–230. https://doi.org/10.1016/j.gaitpost.2014.03.192</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gaitpost.2014.03.192</ArticleId><ArticleId IdType="pubmed">24792638</ArticleId><ArticleId IdType="pmcid">4071448</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesari M, Kritchevsky SB, Newman AB et al (2009) Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc 57:251–259. https://doi.org/10.1111/j.1532-5415.2008.02126.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2008.02126.x</ArticleId><ArticleId IdType="pubmed">19207142</ArticleId><ArticleId IdType="pmcid">2695653</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31. https://doi.org/10.1093/ageing/afy169</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afy169</ArticleId><ArticleId IdType="pubmed">30312372</ArticleId></ArticleIdList></Reference><Reference><Citation>Landi F, Calvani R, Martone AM et al (2020) Normative values of muscle strength across ages in a “real world” population: results from the longevity check-up 7+ project. J Cachexia Sarcopenia Muscle 11:1562–1569. https://doi.org/10.1002/jcsm.12610</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12610</ArticleId><ArticleId IdType="pubmed">33147374</ArticleId><ArticleId IdType="pmcid">7749608</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Bermejo L, Adsuar JC, Mendoza-Munoz M et al (2021) Test-retest reliability of five times sit to stand test (FTSST) in adults: a systematic review and meta-analysis. Biology (Basel). https://doi.org/10.3390/biology10060510</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology10060510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohannon RW, Bubela DJ, Magasi SR et al (2010) Sit-to-stand test: performance and determinants across the age-span. Isokinet Exerc Sci 18:235–240. https://doi.org/10.3233/IES-2010-0389</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/IES-2010-0389</ArticleId><ArticleId IdType="pubmed">25598584</ArticleId><ArticleId IdType="pmcid">4293702</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson RG (2018) Get a grip: individual variations in grip strength are a marker of brain health. Neurobiol Aging 71:189–222. https://doi.org/10.1016/j.neurobiolaging.2018.07.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.07.023</ArticleId><ArticleId IdType="pubmed">30172220</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold F, Labott BK, Grassler B et al (2022) A link between handgrip strength and executive functioning: a cross-sectional study in older adults with mild cognitive impairment and healthy controls. Healthcare (Basel). https://doi.org/10.3390/healthcare10020230</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10020230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilintari M, Raos V, Savaki HE (2014) Involvement of the superior temporal cortex in action execution and action observation. J Neurosci 34:8999–9011. https://doi.org/10.1523/JNEUROSCI.0736-14.2014</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0736-14.2014</ArticleId><ArticleId IdType="pubmed">24990920</ArticleId><ArticleId IdType="pmcid">6608254</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Liu C, Qiu A (2021) Alzheimer’s Disease Neuroimaging I. Spatial correlation maps of the hippocampus with cerebrospinal fluid biomarkers and cognition in Alzheimer’s disease: A longitudinal study. Hum Brain Mapp 42:2931–2940. https://doi.org/10.1002/hbm.25414</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.25414</ArticleId><ArticleId IdType="pubmed">33739550</ArticleId><ArticleId IdType="pmcid">8127150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisman J, Buzsaki G, Eichenbaum H et al (2017) Viewpoints: how the hippocampus contributes to memory, navigation and cognition. Nat Neurosci 20:1434–1447. https://doi.org/10.1038/nn.4661</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4661</ArticleId><ArticleId IdType="pubmed">29073641</ArticleId><ArticleId IdType="pmcid">5943637</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilgour AH, Todd OM, Starr JM (2014) A systematic review of the evidence that brain structure is related to muscle structure and their relationship to brain and muscle function in humans over the lifecourse. BMC Geriatr 14:85. https://doi.org/10.1186/1471-2318-14-85</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2318-14-85</ArticleId><ArticleId IdType="pubmed">25011478</ArticleId><ArticleId IdType="pmcid">4105796</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sayes J, Harasym D, Turco CV et al (2019) Exercise-induced neuroplasticity: a mechanistic model and prospects for promoting plasticity. Neuroscientist 25:65–85. https://doi.org/10.1177/1073858418771538</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858418771538</ArticleId><ArticleId IdType="pubmed">29683026</ArticleId></ArticleIdList></Reference><Reference><Citation>Westwood AJ, Beiser A, Decarli C et al (2014) Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology 82:1613–1619. https://doi.org/10.1212/WNL.0000000000000382</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000382</ArticleId><ArticleId IdType="pubmed">24706014</ArticleId><ArticleId IdType="pmcid">4013812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimoto A, Kasanuki K, Kumagai R et al (2016) Serum insulin-like growth factor-I and amyloid beta protein in Alzheimer’s disease: relationship with cognitive function. Psychogeriatrics 16:247–254. https://doi.org/10.1111/psyg.12149</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/psyg.12149</ArticleId><ArticleId IdType="pubmed">26439951</ArticleId></ArticleIdList></Reference><Reference><Citation>van Nieuwpoort IC, Vlot MC, Schaap LA et al (2018) The relationship between serum IGF-1, handgrip strength, physical performance and falls in elderly men and women. Eur J Endocrinol 179:73–84. https://doi.org/10.1530/EJE-18-0076</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-18-0076</ArticleId><ArticleId IdType="pubmed">29789408</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaeffer E, Roeben B, Granert O et al (2022) Effects of exergaming on hippocampal volume and brain-derived neurotrophic factor levels in Parkinson’s disease. Eur J Neurol 29:441–449. https://doi.org/10.1111/ene.15165</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15165</ArticleId><ArticleId IdType="pubmed">34724287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Caram LM, Faganello MM et al (2015) Relation between systemic inflammatory markers, peripheral muscle mass, and strength in limb muscles in stable COPD patients. Int J Chron Obstruct Pulmon Dis 10:1553–1558. https://doi.org/10.2147/COPD.S85954</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S85954</ArticleId><ArticleId IdType="pubmed">26345641</ArticleId><ArticleId IdType="pmcid">4531022</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont J, Antonio L, Dedeyne L et al (2021) Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years). J Cachexia Sarcopenia Muscle 12:1818–1831. https://doi.org/10.1002/jcsm.12785</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12785</ArticleId><ArticleId IdType="pubmed">34523822</ArticleId><ArticleId IdType="pmcid">8718046</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu JH, Kim REY, Jung JM et al (2021) Sarcopenia is associated with decreased gray matter volume in the parietal lobe: a longitudinal cohort study. BMC Geriatr 21:622. https://doi.org/10.1186/s12877-021-02581-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-021-02581-4</ArticleId><ArticleId IdType="pubmed">34727885</ArticleId><ArticleId IdType="pmcid">8565062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36121408</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-5207</ISSN><JournalIssue CitedMedium="Internet"><Volume>126</Volume><Issue>38</Issue><PubDate><Year>2022</Year><Month>09</Month><Day>29</Day></PubDate></JournalIssue><Title>The journal of physical chemistry. B</Title><ISOAbbreviation>J Phys Chem B</ISOAbbreviation></Journal><ArticleTitle>Impact of the Flavonoid Quercetin on β-Amyloid Aggregation Revealed by Intrinsic Fluorescence.</ArticleTitle><Pagination><MedlinePgn>7229-7237</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jpcb.2c02763</ELocationID><Abstract><AbstractText>We report the effects of quercetin, a flavonoid present in the human diet, on early stage beta-amyloid (Aβ) aggregation, a seminal event in Alzheimer's disease. Molecular level changes in Aβ arrangements are monitored by time-resolved emission spectral (TRES) measurements of the fluorescence of Aβ's single tyrosine intrinsic fluorophore (Tyr). The results suggest that quercetin binds β-amyloid oligomers at early stages of their aggregation, which leads to the formation of modified oligomers and hinders the creation of β-sheet structures, potentially preventing the onset of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alghamdi</LastName><ForeName>Abeer</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Photophysics Group, Centre for Molecular Nanometrology, Department of Physics, Scottish Universities Physics Alliance, University of Strathclyde, 107 Rottenrow East, Glasgow G4 0NG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birch</LastName><ForeName>David J S</ForeName><Initials>DJS</Initials><AffiliationInfo><Affiliation>Photophysics Group, Centre for Molecular Nanometrology, Department of Physics, Scottish Universities Physics Alliance, University of Strathclyde, 107 Rottenrow East, Glasgow G4 0NG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vyshemirsky</LastName><ForeName>Vladislav</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Mathematics and Statistics, University of Glasgow, Glasgow G12 8QQ, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolinski</LastName><ForeName>Olaf J</ForeName><Initials>OJ</Initials><Identifier Source="ORCID">0000-0002-7838-779X</Identifier><AffiliationInfo><Affiliation>Photophysics Group, Centre for Molecular Nanometrology, Department of Physics, Scottish Universities Physics Alliance, University of Strathclyde, 107 Rottenrow East, Glasgow G4 0NG, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Phys Chem B</MedlineTA><NlmUniqueID>101157530</NlmUniqueID><ISSNLinking>1520-5207</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9IKM0I5T1E</RegistryNumber><NameOfSubstance UI="D011794">Quercetin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011794" MajorTopicYN="N">Quercetin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>10</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36121408</ArticleId><ArticleId IdType="doi">10.1021/acs.jpcb.2c02763</ArticleId><ArticleId IdType="pmc">PMC9527748</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Biol Chem. 2003 Mar 28;278(13):11612-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Physiol Biochem. 2008 Mar;46(3):356-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18272377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemistry. 2010 Aug 9;16(30):9257-63</Citation><ArticleIdList><ArticleId IdType="pubmed">20583044</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharmacol Sin. 2017 Sep;38(9):1205-1235</Citation><ArticleIdList><ArticleId IdType="pubmed">28713158</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2017 Jun;13(6):701-709</Citation><ArticleIdList><ArticleId IdType="pubmed">27750032</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Jan 25;482(7384):216-20</Citation><ArticleIdList><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Pharm Bull. 2003 Oct;26(10):1398-402</Citation><ArticleIdList><ArticleId IdType="pubmed">14519943</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2015 Jul 21;54(28):4297-306</Citation><ArticleIdList><ArticleId IdType="pubmed">26087242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2019 Aug 2;14(1):32</Citation><ArticleIdList><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Jul 31;39(3):409-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2017 Apr 28;18(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">28452954</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Appl Fluoresc. 2016 Mar 30;4(2):024001</Citation><ArticleIdList><ArticleId IdType="pubmed">28809166</ArticleId></ArticleIdList></Reference><Reference><Citation>J Agric Food Chem. 2005 Nov 2;53(22):8537-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16248550</ArticleId></ArticleIdList></Reference><Reference><Citation>J Phys Chem Lett. 2015 Aug 6;6(15):3116-20</Citation><ArticleIdList><ArticleId IdType="pubmed">26267211</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2011 Dec 2;415(4):675-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22079288</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Nov 13;515(7526):274-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>J Phys Chem B. 2008 Dec 11;112(49):15893-902</Citation><ArticleIdList><ArticleId IdType="pubmed">19367903</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2013 Apr;1830(4):2872-81</Citation><ArticleIdList><ArticleId IdType="pubmed">23295967</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Eng Des Sel. 2011 Sep;24(9):743-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21565831</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Appl Fluoresc. 2018 Jan 22;6(2):024002</Citation><ArticleIdList><ArticleId IdType="pubmed">29210673</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2011 Dec 19;89(25-26):939-45</Citation><ArticleIdList><ArticleId IdType="pubmed">22008478</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2016 Sep 29;11(9):e0163072</Citation><ArticleIdList><ArticleId IdType="pubmed">27684569</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2019 May 1;224:109-119</Citation><ArticleIdList><ArticleId IdType="pubmed">30914316</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2013 Jul 17;5(194):194re2</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Biol Drug Des. 2006 Jan;67(1):27-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16492146</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Res. 2002 May;36(5):575-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12150545</ArticleId></ArticleIdList></Reference><Reference><Citation>J Agric Food Chem. 2006 Aug 23;54(17):6343-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16910729</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36121183</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4209</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Medical physics</Title><ISOAbbreviation>Med Phys</ISOAbbreviation></Journal><ArticleTitle>Ensemble of convolutional neural networks and multilayer perceptron for the diagnosis of mild cognitive impairment and Alzheimer's disease.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/mp.15985</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Structural magnetic resonance imaging (sMRI) can provide morphological information about the structure and function of the brain in the same scanning process. It has been widely used in the diagnosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI).</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To capture the anatomical changes in the brain caused by AD/MCI, deep learning-based MRI image analysis methods have been proposed in recent years. However, it is observed that the performance of most existing methods is limited as they only construct a single type of deep network and ignore the significance of other clinical information.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To make up for these defects, an ensemble framework that incorporates three types of dedicatedly-designed convolutional neural networks (CNNs) and a multilayer perceptron (MLP) network is proposed, where three CNNs with entropy-based multi-instance learning pooling layers have more reliable feature selection abilities. The dedicatedly-designed base classifiers can make use of the heterogeneous data, and empower the framework with enhanced diversity and robustness. In particular, to consider the interactions among the base classifiers, a novel multi-head self-attention voting scheme is designed. Moreover, considering the chance that MCI can be transformed to AD, the proposed framework is designed to diagnose AD and predict MCI conversion simultaneously, with the aid of the transfer learning technique.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For performance evaluation and comparison, extensive experiments are conducted on the public dataset of the Alzheimer's Disease Neuroimaging Initiative (ADNI). The results show that the proposed ensemble framework provides superior performance under most of the evaluation metrics. Especially, the proposed framework achieves state-of-the-art diagnostic accuracy (98.61% for the AD diagnosis task, and 84.49% for the MCI conversion prediction task).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These promising results demonstrate the proposed ensemble framework can accurately diagnose AD patients and predict the conversion of MCI patients, which has the potential of clinical practice for diagnosing AD and MCI.</AbstractText><CopyrightInformation>© 2022 American Association of Physicists in Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Minglei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Control Science and Engineering, Harbin Institute of Technology, Harbin, Heilongjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Control Science and Engineering, Harbin Institute of Technology, Harbin, Heilongjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Control Science and Engineering, Harbin Institute of Technology, Harbin, Heilongjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Shen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Mechanical and Industrial Engineering, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Control Science and Engineering, Harbin Institute of Technology, Harbin, Heilongjiang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Young Scientist Studio of Harbin Institute of Technology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Phys</MedlineTA><NlmUniqueID>0425746</NlmUniqueID><ISSNLinking>0094-2405</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">computer-aided diagnosis</Keyword><Keyword MajorTopicYN="N">ensemble learning</Keyword><Keyword MajorTopicYN="N">magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">multiple instance learning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>8</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36121183</ArticleId><ArticleId IdType="doi">10.1002/mp.15985</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10:819-828.</Citation></Reference><Reference><Citation>Wang R, Liu H, Toyonaga T, et al. Generation of synthetic pet images of synaptic density and amyloid from 18f-fdg images using deep learning. Med Phys. 2021;48:5115-5129.</Citation></Reference><Reference><Citation>Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59-66.</Citation></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: Ten years later. Arch Neurol. 2009;66:1447-1455.</Citation></Reference><Reference><Citation>Bradfield NI, Ames D. Mild cognitive impairment: Narrative review of taxonomies and systematic review of their prediction of incident Alzheimer's disease dementia. BJPsych Bull. 2020;44:67-74.</Citation></Reference><Reference><Citation>Nordberg A. Pet imaging of amyloid in Alzheimer's disease. Lancet Neurol. 2004;3:519-527.</Citation></Reference><Reference><Citation>Lehéricy S, Marjanska M, Mesrob L, Sarazin M, Kinkingnehun S. Magnetic resonance imaging of Alzheimer's disease. Eur Radiol. 2007;17:347-362.</Citation></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2:605-613.</Citation></Reference><Reference><Citation>Jack Jr CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119-128.</Citation></Reference><Reference><Citation>Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67-77.</Citation></Reference><Reference><Citation>Arevalo-Rodriguez I, Smailagic N, i Figuls MR, et al. Mini-mental state examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015.</Citation></Reference><Reference><Citation>O'Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using clinical dementia rating scale sum of boxes scores: A Texas Alzheimer's research consortium study. Arch Neurol. 2008;65:1091-1095.</Citation></Reference><Reference><Citation>Doraiswamy P, Bieber F, Kaiser L, Krishnan K, Reuning-Scherer J, Gulanski B. The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology. 1997;48:1511-1517.</Citation></Reference><Reference><Citation>Estévez-González A, Kulisevsky J, Boltes A, Otermín P, García-Sánchez C. Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: Comparison with mild cognitive impairment and normal aging. Int J Geriatr Psychiatry. 2003;18:1021-1028.</Citation></Reference><Reference><Citation>Lin M, Momin S, Lei Y, et al. Fully automated segmentation of brain tumor from multiparametric MRI using 3D context deep supervised U-net. Med Phys. 2021;48:4365-4374.</Citation></Reference><Reference><Citation>Haweel R, Shalaby A, Mahmoud A, et al. A robust DWT-CNN-based CAD system for early diagnosis of autism using task-based FMRI. Med Phys. 2021;48:2315-2326.</Citation></Reference><Reference><Citation>Jo M, Oh SH. A preliminary attempt to visualize nigrosome 1 in the substantia nigra for Parkinson's disease at 3t: An efficient susceptibility map-weighted imaging (SMWI) with quantitative susceptibility mapping using deep neural network (QSMNET). Med Phys. 2020;47:1151-1160.</Citation></Reference><Reference><Citation>Suk HI, Lee SW, Shen D, Initiative ADN, et al. Hierarchical feature representation and multimodal fusion with deep learning for AD/MCI diagnosis. NeuroImage. 2014;101:569-582.</Citation></Reference><Reference><Citation>Hwang EJ, Kim HG, Kim D, et al. Texture analyses of quantitative susceptibility maps to differentiate Alzheimer's disease from cognitive normal and mild cognitive impairment. Med Phys. 2016;43(8Part1):4718-4728.</Citation></Reference><Reference><Citation>Moradi E, Pepe A, Gaser C, et al. Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects. Neuroimage. 2015;104:398-412.</Citation></Reference><Reference><Citation>Beheshti I, Demirel H, Matsuda H, et al. Classification of Alzheimer's disease and prediction of mild cognitive impairment-to-Alzheimer's conversion from structural magnetic resource imaging using feature ranking and a genetic algorithm. Comput Biol Med. 2017;83:109-119.</Citation></Reference><Reference><Citation>Basaia S, Agosta F, Wagner L, et al. Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks. NeuroImage. 2019;21:101645.</Citation></Reference><Reference><Citation>Calvini P, Chincarini A, Gemme G, et al. Automatic analysis of medial temporal lobe atrophy from structural MRIS for the early assessment of Alzheimer disease. Med Phys. 2009;36:3737-3747.</Citation></Reference><Reference><Citation>Koikkalainen J, Lötjönen J, Thurfjell L, et al. Multi-template tensor-based morphometry: Application to analysis of Alzheimer's disease. NeuroImage. 2011;56:1134-1144.</Citation></Reference><Reference><Citation>Liu M, Zhang D, Shen D. Relationship induced multi-template learning for diagnosis of Alzheimer's disease and mild cognitive impairment. IEEE Trans Med Imaging. 2016;35:1463-1474.</Citation></Reference><Reference><Citation>Shi Y, Suk HI, Gao Y, Lee SW, Shen D. Leveraging coupled interaction for multimodal Alzheimer's disease diagnosis. IEEE Trans Neural Netw Learn Syst. 2019;31:186-200.</Citation></Reference><Reference><Citation>Tong T, Wolz R, Gao Q, et al. Multiple instance learning for classification of dementia in brain MRI. Med Image Anal. 2014;18:808-818.</Citation></Reference><Reference><Citation>Coupé P, Eskildsen SF, Manjón JV, et al. Scoring by nonlocal image patch estimator for early detection of Alzheimer's disease. NeuroImage. 2012;1:141-152.</Citation></Reference><Reference><Citation>Liu M, Zhang J, Adeli E, Shen D. Landmark-based deep multi-instance learning for brain disease diagnosis. Med Image Anal. 2018;43:157-168.</Citation></Reference><Reference><Citation>Wang SH, Phillips P, Sui Y, Liu B, Yang M, Cheng H. Classification of Alzheimer's disease based on eight-layer convolutional neural network with leaky rectified linear unit and max pooling. J Med Syst. 2018;42:1-11.</Citation></Reference><Reference><Citation>Wu C, Guo S, Hong Y, et al. Discrimination and conversion prediction of mild cognitive impairment using convolutional neural networks. Quant Imaging Med Surg. 2018;8:992.</Citation></Reference><Reference><Citation>Cao Y, Geddes TA, Yang JYH, Yang P. Ensemble deep learning in bioinformatics. Nat Mach Intell. 2020;2:500-508.</Citation></Reference><Reference><Citation>Loddo A, Buttau S, Di Ruberto C. Deep learning based pipelines for Alzheimer's disease diagnosis: A comparative study and a novel deep-ensemble method. Comput Biol Med. 2022;141:105032.</Citation></Reference><Reference><Citation>Kang W, Lin L, Zhang B, et al. Multi-model and multi-slice ensemble learning architecture based on 2d convolutional neural networks for Alzheimer's disease diagnosis. Comput Biol Med. 2021;136:104678.</Citation></Reference><Reference><Citation>Choi JY, Lee B. Combining of multiple deep networks via ensemble generalization loss, based on MRI images, for Alzheimer's disease classification. IEEE Signal Process Lett. 2020;27:206-210.</Citation></Reference><Reference><Citation>Wang H, Shen Y, Wang S, et al. Ensemble of 3D densely connected convolutional network for diagnosis of mild cognitive impairment and Alzheimer's disease. Neurocomputing. 2019;333:145-156.</Citation></Reference><Reference><Citation>Dietterich TG. Ensemble methods in machine learning. International Workshop on Multiple Classifier Systems. Springer; 2000:1-15.</Citation></Reference><Reference><Citation>Jack Jr CR, Bernstein MA, Fox NC, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685-691.</Citation></Reference><Reference><Citation>Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17:87-97.</Citation></Reference><Reference><Citation>Fonov V, Evans A, McKinstry R, Almli C, Collins D. Unbiased nonlinear average age-appropriate brain templates from birth to adulthood. NeuroImage. 2009;47:S102.</Citation></Reference><Reference><Citation>Holland D, Brewer JB, Hagler DJ, et al. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci. 2009;106:20 954-20 959.</Citation></Reference><Reference><Citation>He K, Zhang X, Ren S, Sun J. Deep residual learning for image recognition. Proc IEEE Comput Soc Conf Comput Vis Pattern Recognit. 2016;770-778.</Citation></Reference><Reference><Citation>Shi J, Zheng X, Li Y, Zhang Q, Ying S. Multimodal neuroimaging feature learning with multimodal stacked deep polynomial networks for diagnosis of Alzheimer's disease. IEEE J Biomed Health Inform. 2017;22:173-183.</Citation></Reference><Reference><Citation>Liu S, Liu S, Cai W, et al. Multimodal neuroimaging feature learning for multiclass diagnosis of Alzheimer's disease. IEEE Trans Biomed Eng. 2014;62:1132-1140.</Citation></Reference><Reference><Citation>Cui R, Liu M. Hippocampus analysis by combination of 3D densenet and shapes for Alzheimer's disease diagnosis. IEEE J Biomed Health Inform. 2018;23:2099-2107.</Citation></Reference><Reference><Citation>Lian C, Liu M, Zhang J, Shen D. Hierarchical fully convolutional network for joint atrophy localization and Alzheimer's disease diagnosis using structural MRI. IEEE Trans Pattern Anal Mach Intell. 2020;42:880-893.</Citation></Reference><Reference><Citation>Chen Y, Xia Y. Iterative sparse and deep learning for accurate diagnosis of Alzheimer's disease. Pattern Recognit. 2021;116:107944.</Citation></Reference><Reference><Citation>Zhang J, Zheng B, Gao A, Feng X, Liang D, Long X. A 3D densely connected convolution neural network with connection-wise attention mechanism for Alzheimer's disease classification. Magn Reson Imaging. 2021;78:119-126.</Citation></Reference><Reference><Citation>Ju C, Bibaut A, van der Laan M. The relative performance of ensemble methods with deep convolutional neural networks for image classification. J Appl Statist. 2018;45:2800-2818.</Citation></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, et al. Development and assessment of a composite score for memory in the Alzheimer's disease neuroimaging initiative (ADNI). Brain Imaging Behav. 2012;6:502-516.</Citation></Reference><Reference><Citation>Petersen RC, Aisen P, Beckett LA, et al. Alzheimer's disease neuroimaging initiative (ADNI): Clinical characterization. Neurology. 2010;74:201-209.</Citation></Reference><Reference><Citation>Tjoa E, Guan C. A survey on explainable artificial intelligence (xai): Toward medical xai. IEEE Trans Neural Netw Learn Syst. 2020;32:4793-4813.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36121025</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>21</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Enzyme-substrate interface targeting by imidazole-based γ-secretase modulators activates γ-secretase and stabilizes its interaction with APP.</ArticleTitle><Pagination><MedlinePgn>e111084</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/embj.2022111084</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) pathogenesis has been linked to the accumulation of longer, aggregation-prone amyloid β (Aβ) peptides in the brain. Γ-secretases generate Aβ peptides from the amyloid precursor protein (APP). Γ-secretase modulators (GSMs) promote the generation of shorter, less-amyloidogenic Aβs and have therapeutic potential. However, poorly defined drug-target interactions and mechanisms of action have hampered their therapeutic development. Here, we investigate the interactions between the imidazole-based GSM and its target γ-secretase-APP using experimental and in silico approaches. We map the GSM binding site to the enzyme-substrate interface, define a drug-binding mode that is consistent with functional and structural data, and provide molecular insights into the underlying mechanisms of action. In this respect, our analyses show that occupancy of a γ-secretase (sub)pocket, mediating binding of the modulator's imidazole moiety, is sufficient to trigger allosteric rearrangements in γ-secretase as well as stabilize enzyme-substrate interactions. Together, these findings may facilitate the rational design of new modulators of γ-secretase with improved pharmacological properties.</AbstractText><CopyrightInformation>© 2022 The Authors. Published under the terms of the CC BY NC ND 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Petit</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5721-8041</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hitzenberger</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9726-2370</Identifier><AffiliationInfo><Affiliation>Center for Functional Protein Assemblies, Theoretical Biophysics (T38), Technical University of Munich, Garching, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1015-1577</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lismont</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoltowska</LastName><ForeName>Katarzyna Marta</ForeName><Initials>KM</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5853-3465</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enzlein</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1789-4090</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hopf</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0802-6451</Identifier><AffiliationInfo><Affiliation>Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Mannheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Faculty, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zacharias</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5163-2663</Identifier><AffiliationInfo><Affiliation>Center for Functional Protein Assemblies, Theoretical Biophysics (T38), Technical University of Munich, Garching, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chávez-Gutiérrez</LastName><ForeName>Lucía</ForeName><Initials>L</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8239-559X</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0B2519N</GrantID><Agency>Fonds Wetenschappelijk Onderzoek (FWO)</Agency><Country/></Grant><Grant><GrantID>1S47020N</GrantID><Agency>Fonds Wetenschappelijk Onderzoek (FWO)</Agency><Country/></Grant><Grant><GrantID>SB/1S23819N</GrantID><Agency>Fonds Wetenschappelijk Onderzoek (FWO)</Agency><Country/></Grant><Grant><GrantID>03FH8I01IA</GrantID><Agency>German Federal Ministry of Research (BMBF)</Agency><Country/></Grant><Grant><GrantID>S16013</GrantID><Agency>Stichting Alzheimer Onderzoek (SAO)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091062">Gamma Secretase Inhibitors and Modulators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="Y">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091062" MajorTopicYN="N">Gamma Secretase Inhibitors and Modulators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">amyloid β</Keyword><Keyword MajorTopicYN="N">preselinin</Keyword><Keyword MajorTopicYN="N">γ-secretase</Keyword><Keyword MajorTopicYN="N">γ-secretase modulators</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36121025</ArticleId><ArticleId IdType="doi">10.15252/embj.2022111084</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Acx H, Chávez-Gutiérrez L, Serneels L, Lismont S, Benurwar M, Elad N, De Strooper B (2014) Signature amyloid β profiles are produced by different γ-secretase complexes. J Biol Chem 289: 4346-4355</Citation></Reference><Reference><Citation>Alexander GC, Emerson S, Kesselheim, AS (2021) Evaluation of aducanumab for Alzheimer disease scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA 324: 1717-1718</Citation></Reference><Reference><Citation>Andersen HC (1983) Rattle: a “velocity” version of the shake algorithm for molecular dynamics calculations. J Comput Phys 52: 24-34</Citation></Reference><Reference><Citation>Berendsen HJC, Postma JPM, Van Gunsteren WF, Dinola A, Haak JR (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684-3690</Citation></Reference><Reference><Citation>Case D, Ben-Shalom I, Brozell S, Cerutti D, Cheatham T III, Cruzeiro V, Darden T, Duke R, Ghoreishi D, Gilson M et al (2018) AMBER 2018. San Francisco, CA: University of California</Citation></Reference><Reference><Citation>Chávez-Gutiérrez L, Szaruga M (2020) Mechanisms of neurodegeneration - insights from familial Alzheimer's disease. Semin Cell Dev Biol 105: 75-85</Citation></Reference><Reference><Citation>Chávez-Gutiérrez L, Tolia A, Maes E, Li T, Wong PC, De Strooper B (2008) Glu332 in the nicastrin ectodomain is essential for γ-secretase complex maturation but not for its activity. J Biol Chem 283: 20096-20105</Citation></Reference><Reference><Citation>Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H et al (2012) The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J 31: 2261-2274</Citation></Reference><Reference><Citation>Cullen N, Shorena S, Palmqvist S, Stomrud E, Mattsson-Carlgren N, Hansson O, Alzheimer's Disease Neuroimaging Initiative (2022) Association of CSF Aβ38 levels with risk of Alzheimer disease related decline. Neurology 98: e958-e967</Citation></Reference><Reference><Citation>De Strooper B, Chávez Gutiérrez L (2015) Learning by failing: Ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. Annu Rev Pharmacol Toxicol 55: 419-437</Citation></Reference><Reference><Citation>Dickson CJ, Madej BD, Skjevik ÅA, Betz RM, Teigen K, Gould IR, Walker RC (2014) Lipid14: the amber lipid force field. J Chem Theory Comput 10: 865-879</Citation></Reference><Reference><Citation>Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA (2004) PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res 32: 665-667</Citation></Reference><Reference><Citation>Escamilla-Ayala A, Wouters R, Sannerud R, Annaert W (2020) Contribution of the presenilins in the cell biology, structure and function of γ-secretase. Semin Cell Dev Biol 105: 12-26</Citation></Reference><Reference><Citation>Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, Näslund J (2003) Partial purification and characterization of γ-secretase from post-mortem human brain. J Biol Chem 278: 24277-24284</Citation></Reference><Reference><Citation>Fernandez MA, Klutkowski JA, Freret T, Wolfe MS (2014) Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid β-peptides (Aβ) by γ-secretase to increase 42-to-40-residue Aβ. J Biol Chem 289: 31043-31052</Citation></Reference><Reference><Citation>Fox T, Kollman PA (1998) Application of the RESP methodology in the parametrization of organic solvents. J Phys Chem B 102: 8070-8079</Citation></Reference><Reference><Citation>Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA et al (2009) Gaussian 09 revision A.1. Wallingford, CT: Gaussian Inc.</Citation></Reference><Reference><Citation>Goga N, Rzepiela AJ, De Vries AH, Marrink SJ, Berendsen HJC (2012) Efficient algorithms for langevin and DPD dynamics. J Chem Theory Comput 8: 3637-3649</Citation></Reference><Reference><Citation>Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L (2013) γ-Secretase inhibitors and modulators. Biochim Biophys Acta 1828: 2898-2907</Citation></Reference><Reference><Citation>Güner G, Lichtenthaler SF, Dzne D (2020) The substrate repertoire of γ-secretase/presenilin. Semin Cell Dev Biol 105: 27-42</Citation></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B (2000) Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2: 461-462</Citation></Reference><Reference><Citation>Hopkins CW, Le Grand S, Walker RC, Roitberg AE (2015) Long-time-step molecular dynamics through hydrogen mass repartitioning. J Chem Theory Comput 11: 1864-1874</Citation></Reference><Reference><Citation>Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 7855: 33-38</Citation></Reference><Reference><Citation>Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem 29: 1859-1865</Citation></Reference><Reference><Citation>Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935</Citation></Reference><Reference><Citation>Jurisch-Yaksi N, Sannerud R, Annaert W (2013) A fast growing spectrum of biological functions of gamma-secretase in development and disease. Biochim Biophys Acta 1828: 2815-2827</Citation></Reference><Reference><Citation>Kopan R (2012) Notch signaling. Cold Spring Harb Perspect Biol 4: a011213</Citation></Reference><Reference><Citation>Kretner B, Trambauer J, Fukumori A, Mielke J, Kuhn P, Kremmer E, Giese A, Lichtenthaler SF, Haass C, Arzberger T et al (2016) Generation and deposition of Aβ43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease. EMBO Mol Med 8: 458-465</Citation></Reference><Reference><Citation>Lauritzen I, Checler F, Afram E (2021) Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99? J Biol Chem 296: 100489</Citation></Reference><Reference><Citation>Le Guilloux V, Schmidtke P, Tuffery P (2009) Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics 10: 1-11</Citation></Reference><Reference><Citation>Lee J, Hitzenberger M, Rieger M, Kern NR, Zacharias M, Im W (2020) CHARMM-GUI supports the Amber force fields. J Chem Phys 153: 035103</Citation></Reference><Reference><Citation>Liu L, Lauro BM, Wolfe MS, Selkoe DJ (2021) Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate γ -secretase function in generating Alzheimer-causing A β peptides. J Biol Chem 296: 100393</Citation></Reference><Reference><Citation>Liu L, Lauro BM, He A, Wolfe MS, Bennett DA, Lee H, Bhattarai S, Karch CM, Young-pearse T, Selkoe DJ et al (2022) Identification of the Aβ37/ 42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease. Alzheimers Dement https://doi.org/10.1002/alz.12646</Citation></Reference><Reference><Citation>Luo JE, Li YM (2022) Turning the tide on Alzheimer's disease: modulation of γ - secretase. Cell Biosci 12: 1-12</Citation></Reference><Reference><Citation>Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C (2015) ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 11: 3696-3713</Citation></Reference><Reference><Citation>Mehra R, Kepp KP (2021) Understanding familial Alzheimer's disease: the fit-stay-trim mechanism of γ-secretase. Comput Mol Sci 12: e1556</Citation></Reference><Reference><Citation>Mekala S, Nelson G, Li Y (2020) Recent developments of small molecule γ-secretase modulators for Alzheimer's disease. RSC Med Chem 11: 1003-1022</Citation></Reference><Reference><Citation>Moore BD, Martin J, de Mena L, Sanchez J, Cruz PE, Ceballos-Diaz C, Ladd TB, Ran Y, Levites Y, Kukar TL et al (2018) Short Aβ peptides attenuate Aβ42 toxicity in vivo. J Exp Med 215: 283-301</Citation></Reference><Reference><Citation>Oehlrich D, Berthelot DJ, Gijsen HJM (2011) γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem 54: 669-698</Citation></Reference><Reference><Citation>Okochi M, Tagami S, Yanagida K, Takami M, Kodama TS, Mori K, Nakayama T, Ihara Y, Takeda M (2013) γ-Secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43. Cell Rep 3: 42-51</Citation></Reference><Reference><Citation>Petit D, Hitzenberger M, Lismont S, Zoltowska KM, Ryan NS, Mercken M, Bischoff F, Zacharias M, Chávez-Gutiérrez L (2019) Extracellular interface between APP and Nicastrin regulates Aβ length and response to γ-secretase modulators. EMBO J 38: e101494</Citation></Reference><Reference><Citation>Petit D, Fernández SG, Zoltowska KM, Enzlein T, Ryan NS, Connor AO, Szaruga M, Hill E, Vandenberghe R, Fox NC et al (2022) Aβ profiles generated by Alzheimer's disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Mol Psychiatry 27: 2821-2832</Citation></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE (2021) UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci 30: 70-82</Citation></Reference><Reference><Citation>Pozdnyakov N, Murrey HE, Crump CJ, Pettersson M, Ballard TE, Am Ende CW, Ahn K, Li YM, Bales KR, Johnson DS (2013) γ-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem 288: 9710-9720</Citation></Reference><Reference><Citation>Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R et al (2005) Longer forms of amyloid-β protein: implications for the mechanism of intramembrane cleavage by γ-secretase. J Neurosci 25: 436-445</Citation></Reference><Reference><Citation>Roe DR, Cheatham TE (2013) PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9: 3084-3095</Citation></Reference><Reference><Citation>Salomon-Ferrer R, Götz AW, Poole D, Le Grand S, Walker RC (2013) Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh ewald. J Chem Theory Comput 9: 3878-3888</Citation></Reference><Reference><Citation>Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8: 1-14</Citation></Reference><Reference><Citation>Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, Ryan NS, Lashley T, Fox NC, Murayama S et al (2015) Qualitative changes in human gamma-secretase underlie familial Alzheimer's disease. J Exp Med 212: 2003-2013</Citation></Reference><Reference><Citation>Szaruga M, Munteanu B, Lismont S, Veugelen S, Horré K, Mercken M, Saido TC, Ryan NS, De Vos T, Savvides SN et al (2017) Alzheimer's-causing mutations shift Aβ length by destabilizing γ-secretase-Aβn interactions. Cell 170: 443-456</Citation></Reference><Reference><Citation>Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y (2009) Gamma-secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29: 13042-13052</Citation></Reference><Reference><Citation>Takeo K, Tanimura S, Shinoda T, Osawa S, Zahariev IK, Takegami N, Ishizuka-Katsura Y, Shinya N, Takagi-Niidome S, Tominaga A et al (2014) Allosteric regulation of γ-secretase activity by a phenylimidazole-type γ-secretase modulator. Proc Natl Acad Sci USA 111: 10544-10549</Citation></Reference><Reference><Citation>Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461</Citation></Reference><Reference><Citation>Uemura K, Farner KC, Hashimoto T, Nasser-Ghodsi N, Wolfe MS, Koo EH, Hyman BT, Berezovska O (2010) Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site. Nat Commun 1: 130</Citation></Reference><Reference><Citation>Velter AI, Bischoff FP, Berthelot D, De Cleyn M, Oehlrich D, Jaroskova L, Macdonald G, Minne G, Pieters S, Rombouts F et al (2014) Anilinotriazoles as potent gamma secretase modulators. Bioorg Med Chem Lett 24: 5805-5813</Citation></Reference><Reference><Citation>Veugelen S, Saito T, Saido TCTC, Chávez-Gutiérrez L, De Strooper B (2016) Familial Alzheimer's disease mutations in presenilin generate amyloidogenic Aβ peptide seeds. Neuron 90: 410-416</Citation></Reference><Reference><Citation>Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions the LIGPLOT program automatically generates schematic 2-D representations of protein-ligand complexes from standard protein data Bank file input. Protein Eng 8: 127-134</Citation></Reference><Reference><Citation>Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a General Amber force field. J Comput Chem 56531: 1157-1174</Citation></Reference><Reference><Citation>Wang J, Wang W, Kollman PA, Case DA (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 25: 247-260</Citation></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T et al (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212-216</Citation></Reference><Reference><Citation>Wu EL, Cheng X, Jo S, Rui H, Song KC, Dávila-Contreras EM, Qi Y, Lee J, Monje-Galvan V, Venable RM et al (2014) CHARMM-GUI membrane builder toward realistic biological membrane simulations. J Comput Chem 35: 1997-2004</Citation></Reference><Reference><Citation>Yagishita S, Morishima-Kawashima M, Ishiura S, Ihara Y (2008) Abeta46 is processed to Abeta40 and Abeta43, but not to Abeta42, in the low density membrane domains. J Biol Chem 283: 733-738</Citation></Reference><Reference><Citation>Yang G, Zhou R, Zhou Q, Guo X, Yan C, Ke M, Lei J, Shi Y (2019) Structural basis of notch recognition by human γ-secretase. Nature 565: 192-197</Citation></Reference><Reference><Citation>Yang G, Zhou R, Guo X, Yan C, Lei J, Shi Y (2021) Structural basis of γ-secretase inhibition and modulation by small molecule drugs. Cell 184: 521-533.e14</Citation></Reference><Reference><Citation>Zhou R, Yang G, Guo X, Zhou Q, Lei J, Shi Y (2019) Recognition of the amyloid precursor protein by human γ-secretase. Science 363: eaaw0930</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36120786</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations.</ArticleTitle><Pagination><MedlinePgn>333-348</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220808</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In amyloid-positive individuals at risk for Alzheimer's disease (AD), high soluble 42-amino acid amyloid-β (Aβ42) levels are associated with normal cognition. It is unknown if this relationship applies longitudinally in a genetic cohort.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the hypothesis that high Aβ42 preserves normal cognition in amyloid-positive individuals with Alzheimer's disease (AD)-causing mutations (APP, PSEN1, or PSEN2) to a greater extent than lower levels of brain amyloid, cerebrospinal fluid (CSF) phosphorylated tau (p-tau), or total tau (t-tau).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cognitive progression was defined as any increase in Clinical Dementia Rating (CDR = 0, normal cognition; 0.5, very mild dementia; 1, mild dementia) over 3 years. Amyloid-positivity was defined as a standard uptake value ratio (SUVR) ≥1.42 by Pittsburgh compound-B positron emission tomography (PiB-PET). We used modified Poisson regression models to estimate relative risk (RR), adjusted for age at onset, sex, education, APOE4 status, and duration of follow-up. The results were confirmed with multiple sensitivity analyses, including Cox regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 232 mutation carriers, 108 were PiB-PET-positive at baseline, with 43 (39.8%) meeting criteria for progression after 3.3±2.0 years. Soluble Aβ42 levels were higher among CDR non-progressors than CDR progressors. Higher Aβ42 predicted a lower risk of progression (adjusted RR, 0.36; 95% confidence interval [CI], 0.19-0.67; p = 0.002) better than lower SUVR (RR, 0.81; 95% CI, 0.68-0.96; p = 0.018). CSF Aβ42 levels predicting lower risk of progression increased with higher SUVR levels.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">High CSF Aβ42 levels predict normal cognition in amyloid-positive individuals with AD-causing genetic mutations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sturchio</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Neuro Svenningsson, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dwivedi</LastName><ForeName>Alok K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Molecular and Translational Medicine, Division of Biostatistics &amp; Epidemiology, Texas Tech University Health Sciences Center, El Paso, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malm</LastName><ForeName>Tarja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Matthew J A</ForeName><Initials>MJA</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cilia</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Parkinson and Movement Disorders Unit, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Emily J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>University of Southern California Keck School of Medicine, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Medical School, Osaka City University, Sutoku University, Abenoku, Osaka, Nagaoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nübling</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Site Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians University Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Andaloussi</LastName><ForeName>Samir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenningsson</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Neuro Svenningsson, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezzat</LastName><ForeName>Kariem</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espay</LastName><ForeName>Alberto J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Consortia (DIAN)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">FDG-PET</Keyword><Keyword MajorTopicYN="N">amyloid-β
</Keyword><Keyword MajorTopicYN="N">atrophy</Keyword><Keyword MajorTopicYN="N">cognition</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120786</ArticleId><ArticleId IdType="pii">JAD220808</ArticleId><ArticleId IdType="doi">10.3233/JAD-220808</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36120785</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Cognitive Heterogeneity and Risk of Progression in Data-Driven Subtle Cognitive Decline Phenotypes.</ArticleTitle><Pagination><MedlinePgn>323-331</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220684</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is increasing recognition of cognitive and pathological heterogeneity in early-stage Alzheimer's disease and other dementias. Data-driven approaches have demonstrated cognitive heterogeneity in those with mild cognitive impairment (MCI), but few studies have examined this heterogeneity and its association with progression to MCI/dementia in cognitively unimpaired (CU) older adults.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We identified cluster-derived subgroups of CU participants based on comprehensive neuropsychological data and compared baseline characteristics and rates of progression to MCI/dementia or a Dementia Rating Scale (DRS) of ≤129 across subgroups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Hierarchical cluster analysis was conducted on individual baseline neuropsychological test scores from 365 CU participants in the UCSD Shiley-Marcos Alzheimer's Disease Research Center longitudinal cohort. Cox regressions examined the risk of progression to consensus diagnosis of MCI or dementia, or to DRS score ≤129, by cluster group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cluster analysis identified 5 groups: All-Average (n = 139), Low-Visuospatial (n = 46), Low-Executive (n = 51), Low-Memory/Language (n = 83), and Low-All Domains (n = 46). Subgroups had unique demographic and clinical characteristics. Rates of progression to MCI/dementia or to DRS ≤129 were faster for all subgroups (Low-All Domains progressed the fastest &gt; Low Memory/Language≥Low-Visuospatial and Low-Executive) relative to the All-Average subgroup.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Faster progression in the Low-Visuospatial, Low-Executive, and Low-Memory/Language groups compared to the All-Average group suggests that there are multiple pathways and/or unique subtle cognitive decline profiles that ultimately lead to a diagnosis of MCI/dementia. Use of comprehensive neuropsychological test batteries that assess several domains may be a key first step toward an individualized approach to early detection and fewer missed opportunities for early intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Kelsey R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Research Service, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bangen</LastName><ForeName>Katherine J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Research Service, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weigand</LastName><ForeName>Alexandra J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Gema</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Service, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Kayla S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Research Service, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>San Diego State University, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bondi</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychology Service, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmonds</LastName><ForeName>Emily C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Tucson, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">cognitive phenotypes</Keyword><Keyword MajorTopicYN="N">heterogeneity</Keyword><Keyword MajorTopicYN="N">subtle cognitive decline</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120785</ArticleId><ArticleId IdType="pii">JAD220684</ArticleId><ArticleId IdType="doi">10.3233/JAD-220684</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36120784</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers.</ArticleTitle><Pagination><MedlinePgn>419-432</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220587</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The ATN scheme was proposed as an unbiased biological characterization of the Alzheimer's disease (AD) spectrum, grouping biomarkers into three categories: brain Amyloidosis-A, Tauopathy-T, Neurodegeneration-N. Although this scheme was mainly recommended for research, it is relevant for diagnosis.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the ATN scheme performance in real-life cohorts reflecting the inflow of patients with cognitive complaints and different underlying disorders in general neurological centers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included patients (n = 1,128) from six centers with their core cerebrospinal fluid-AD biomarkers analyzed centrally. A was assessed through Aβ42/Aβ40, T through pTau-181, and N through tTau. Association between demographic features, clinical diagnosis at baseline/follow-up and ATN profiles was assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of ATN categories was: A-T-N-: 28.3%; AD continuum (A + T-/+N-/+): 47.8%; non-AD (A- plus T or/and N+): 23.9%. ATN profiles prevalence was strongly influenced by age, showing differences according to gender, APOE genotype, and cognitive status. At baseline, 74.6% of patients classified as AD fell in the AD continuum, decreasing to 47.4% in mild cognitive impairment and 42.3% in other neurodegenerative conditions. At follow-up, 41% of patients changed diagnosis, and 92% of patients that changed to AD were classified within the AD continuum. A + was the best individual marker for predicting a final AD diagnosis, and the combinations A + T+ (irrespective of N) and A + T+N+ had the highest overall accuracy (83%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ATN scheme is useful to guide AD diagnosis in real-life neurological centers settings. However, it shows a lack of accuracy for patients with other types of dementia. In such cases, the inclusion of other markers specific for non-AD proteinopathies could be an important aid to the differential diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baldeiras</LastName><ForeName>Inês</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva-Spínola</LastName><ForeName>Anuschka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Research in Neuropsychology and Cognitive Behavioral Intervention, Faculty of Psychology and Educational Sciences, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leitão</LastName><ForeName>Maria João</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durães</LastName><ForeName>João</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tábuas-Pereira</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Vitor Tedim</ForeName><Initials>VT</Initials><AffiliationInfo><Affiliation>ULSM Unidade Local de Sáude de Matosinhos, Matosinhos, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ULSM Unidade Local de Sáude de Matosinhos, Matosinhos, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Álvaro</ForeName><Initials>Á</Initials><AffiliationInfo><Affiliation>Hospital de Braga, Braga, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milheiro</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital de Faro, Faro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santiago</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centro Hospitalar Baixo Vouga, Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058227">Amyloidogenic Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058227" MajorTopicYN="N">Amyloidogenic Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATN scheme</Keyword><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid biomarkers</Keyword><Keyword MajorTopicYN="N">cognitive complaints</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120784</ArticleId><ArticleId IdType="pii">JAD220587</ArticleId><ArticleId IdType="doi">10.3233/JAD-220587</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36120783</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Association between Subclinical Epileptiform Discharge and the Severity of Cognitive Decline in Alzheimer's Disease: A Longitudinal Cohort Study.</ArticleTitle><Pagination><MedlinePgn>305-312</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220567</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) is the most common type of dementia. Aging is a risk factor for both AD and seizures. Subclinical epileptiform discharge (SED) has no evident clinical manifestation in patients with AD. Therefore, SED is liable to be overlooked in these patients since electroencephalography is not routinely performed in clinical settings. Previous studies about the association between SED and AD have yielded inconsistent results.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The current study aimed to evaluate the prevalence of SED and its effect on AD severity and clinical outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with AD from Kaohsiung Municipal Ta-tung Hospital were included in this study. International 10-20 system scalp electroencephalography for 13 minutes was performed to detect SED. Clinical outcomes of patients with and without SED were assessed by neuropsychological tests [Cognitive Abilities Screening Instrument (CASI), Mini-Mental State Examination (MMSE), and Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)].</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">288 patients (mean age 80.5 years, 60.4% female) were enrolled in this study. Fifty-seven (19.8%) out of 288 patients with AD had SED. The prevalence of SED increased with the severity of cognitive impairment. Compared with patients without SED, those with SED showed significantly greater decline in CASI (-9.32 versus -3.52 points, p = 0.0001) and MMSE (-2.52 versus -1.12 points, p = 0.0042) scores in one year.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">SED may play a significant role in AD progression and is a potential therapeutic target.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Wei-Chih</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Chung-Yao</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kuan-Ying</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chien</LastName><ForeName>Ching-Fang</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ling-Chun</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yuan-Han</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Post-baccalaureate Medicine, Kaohsiung Medical, University, Kaohsiung City, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">cognitive dysfunction</Keyword><Keyword MajorTopicYN="N">electroencephalography</Keyword><Keyword MajorTopicYN="N">mental status and dementia tests</Keyword><Keyword MajorTopicYN="N">neuropsychological tests</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120783</ArticleId><ArticleId IdType="pii">JAD220567</ArticleId><ArticleId IdType="doi">10.3233/JAD-220567</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36120782</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Relationships Between the Deposition of Amyloid-β and Tau Protein and Glymphatic System Activity in Alzheimer's Disease: Diffusion Tensor Image Study.</ArticleTitle><Pagination><MedlinePgn>295-303</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220534</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyloid-β (Aβ) and tau protein accumulation in the brain is thought to be one of the causes of Alzheimer's disease (AD). Recent study found that the glymphatic system was waste drainage system in the brain and promoting the elimination of Aβ and tau protein.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We evaluated the relationships between the glymphatic system activity and the Aβ and tau protein deposition.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subjects were 21 patients with AD and 36 healthy subjects who underwent diffusion tensor imaging (DTI) scan and the positron emission tomography (PET) using with the Aβ tracer: 11C-PiB and the tau/inflammatory tracer: 18F-THK5351. We computed diffusion tensor image analysis along the perivascular space (DTI-ALPS) index as the proxy of glymphatic system activity, and estimated the relationships between the DTI-ALPS index and Aβ and tau protein/inflammatory deposition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found significant negative correlations between DTI-ALPS index and the standard uptake value ratio (SUVR) of 11C-PiB in the bilateral temporal and left parietal cortices and left posterior cingulate gyrus in all subjects. Further, we detected significant negative correlations between DTI-ALPS index and the SUVR of 18F-THK5351 in the bilateral temporal cortices and right parietal cortex in all participants, too.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data suggested that DTI-ALPS index was a good biomarker for the evaluation of Aβ and tau deposition and neuroinflammation, and this marker might be effective to estimate the glymphatic system activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ota</LastName><ForeName>Miho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuropsychiatry, University of Tsukuba, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakaya</LastName><ForeName>Moto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Graduate School of Medicine, University of Tokyo Bunkyo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shigemoto</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiba</LastName><ForeName>Emiko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoi</LastName><ForeName>Yuma</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Educational Promotion, Clinical Research &amp; Education Promotion Division, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukamoto</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biofunctional Imaging, Fukushima Medical University, Fukushima City, Fukushima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000608225">THK5351</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077502" MajorTopicYN="Y">Glymphatic System</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">11C-PiB</Keyword><Keyword MajorTopicYN="N">18F-THK5351
</Keyword><Keyword MajorTopicYN="N">Diffusion tensor image analysis along the perivascular space (DTI-ALPS)</Keyword><Keyword MajorTopicYN="N">positron 
emission tomography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120782</ArticleId><ArticleId IdType="pii">JAD220534</ArticleId><ArticleId IdType="doi">10.3233/JAD-220534</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36120781</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil.</ArticleTitle><Pagination><MedlinePgn>161-172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220530</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Donepezil is approved for treatment of dementia of the Alzheimer type and is currently available only in tablet forms in the United States.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare steady-state pharmacokinetics of once-weekly 10-mg/d and 5-mg/d Corplex™ donepezil transdermal delivery systems (TDS) with once-daily 10-mg oral donepezil.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Open-label, randomized, crossover study (NCT04617782) enrolled healthy participants aged 18-55 years. All participants received 5-mg/d donepezil TDS during the 5-week Period 1, followed by 10-mg/d TDS or 10-mg/d oral donepezil in the 5-week Period 2; treatments were switched in Period 3. Bioequivalence was assessed at steady state on Week 5.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All 60 enrolled participants received 5-mg/d TDS, 55 received 10-mg/d TDS, and 56 received oral donepezil. Adjusted geometric mean ratio (% [90% CI]) for maximum plasma concentration and area under the plasma concentration versus time curve (0-168 h) were 88.7 (81.7-96.2) and 108.6 (100.5-117.4) for 10-mg/d and 86.1 (79.8-92.9) and 105.3 (97.6-113.6) for dose-normalized 5-mg/d TDS and were generally within the 80% -125% range for establishing bioequivalence with oral donepezil. Skin adhesion was similar for both TDSs (&gt;80% of patches remaining ≥75% adhered throughout the wear period). Overall incidence of adverse events (AEs) was similar across treatments. Compared with 10-mg/d TDS, oral donepezil was associated with higher incidence of gastrointestinal and nervous system AEs (14.5% versus 53.6% and 14.5% versus 30.4%, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Donepezil TDSs are bioequivalent to oral donepezil at steady state and have a safety profile that supports their use in treating dementia of the Alzheimer type.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braeckman</LastName><ForeName>Rene</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>KemPharm, Inc., Celebration, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Corium Inc., Grand Rapids, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C076628">tyramine-deoxysorbitol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="Y">Donepezil</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer type dementia</Keyword><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">bioequivalence</Keyword><Keyword MajorTopicYN="N">donepezil</Keyword><Keyword MajorTopicYN="N">transdermal patch</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120781</ArticleId><ArticleId IdType="pii">JAD220530</ArticleId><ArticleId IdType="doi">10.3233/JAD-220530</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36120780</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Digital Technologies to Prevent Social Isolation and Loneliness in Dementia: A Systematic Review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220438</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dementia poses significant and sustained challenges to global society. Diagnosis can lead to increased feelings of loneliness and social isolation. People with dementia living alone are particularly at risk. Considering the growing number of technologies proposed to aid people with dementia address social isolation and loneliness, we reviewed the existing literature.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To collate and summarize current evidence for digital technologies to prevent social isolation and loneliness for people with dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following the PRISMA guidelines, we systematically searched five databases to identify studies of digital technologies designed to support or prevent social isolation or loneliness for people with dementia. Pre-specified outcomes included social isolation, loneliness, and quality of life. We used deductive thematic analysis to synthesize the major themes emerging from the studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ten studies met our inclusion criteria where all studies reported improvements in quality of life and seven reported benefits regarding social inclusion or a reduction in loneliness. Technologies were varied across purpose, delivery format, theoretical models, and levels of personalization. Two studies clearly described the involvement of people with dementia in the study design and five technologies were available outside the research context.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is limited- but increasing- evidence that technologies hold potential to improve quality of life and reduce isolation/loneliness for people with dementia. Results presented are largely based in small-scale research studies. Involvement of people with dementia was limited and few research concepts are reaching implementation. Closer collaboration with people with dementia to provide affordable, inclusive, and person-centered solutions is urgently required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rai</LastName><ForeName>Harleen Kaur</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Digital Health and Wellness Research Group (DHaWG), Department of Computer and Information Sciences, University of Strathclyde, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kernaghan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Digital Health and Wellness Research Group (DHaWG), Department of Computer and Information Sciences, University of Strathclyde, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoonmade</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Library, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egan</LastName><ForeName>Kieren</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Digital Health and Wellness Research Group (DHaWG), Department of Computer and Information Sciences, University of Strathclyde, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pot</LastName><ForeName>Anne Margriet</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Erasmus School of Health Policy &amp; Management, Erasmus University, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Optentia, North-West University, Vanderbijlpark, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">digital technology</Keyword><Keyword MajorTopicYN="N">loneliness</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">social isolation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120780</ArticleId><ArticleId IdType="pii">JAD220438</ArticleId><ArticleId IdType="doi">10.3233/JAD-220438</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36120779</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Circulating Amyloid-β and Methionine-Related Metabolites to Predict the Risk of Mild Cognitive Impairment: A Nested Case-Control Study.</ArticleTitle><Pagination><MedlinePgn>389-404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220373</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The high cost, limited availability, and perceived invasiveness of amyloid PET and cerebrospinal fluid biomarkers limit their use for the diagnosis of Alzheimer's disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The present study aimed to assess the associations of mild cognitive impairment (MCI) with circulating amyloid-β (Aβ), methionine circulating metabolites (MCMs), and their downstream products, and to develop a nomogram based on these easily accessible blood indexes for the individualized prediction of MCI risk in older adults.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this nested case-control study, we recruited 74 MCI patients and, for each, 3 matched controls (n = 222) within the context of the Tianjin Elderly Nutrition and Cognition (TENC) cohort, a population-based prospective study in China. Concentrations of Aβ, MCMs, and their circulating downstream factors (i.e., leukocyte telomere length and inflammatory cytokines) were evaluated in fasting blood sample using standard procedures. We constructed a nomogram for MCI harnessed multivariable logistic models incorporating variables selected in the Lasso regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the many biomarkers examined, the final prediction nomogram retained only 3 factors: Aβ42/Aβ40 ratio, Hcy, and SAM/SAH ratio. The model achieved favorable discrimination, with a C-statistic of 0.75 (95% confidence interval 0.69-0.81) in internal validation after adjustment of optimism. The calibration accuracy was satisfactory; the Brier score of the model was 0.161 in internal validation after adjustment of optimism.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">his study presents an individualized prediction nomogram incorporating only three blood biomarkers (i.e., Aβ42/Aβ40 ratio, Hcy, and SAM/SAH ratio), which can be conveniently utilized to facilitate early identification and the development of high-risk prevention strategies for MCI in older adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Jingzhu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Huilian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Dezheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zehao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhenshu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Social Medicine and Health Management, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yongjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Changqing</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurosurgical Department of Baodi Clinical College of Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guangshun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Tumor, Baodi Clinical College of Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Guowei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nutrition &amp; Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>AE28F7PNPL</RegistryNumber><NameOfSubstance UI="D008715">Methionine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008715" MajorTopicYN="N">Methionine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflammatory factor</Keyword><Keyword MajorTopicYN="N">leukocyte telomere length</Keyword><Keyword MajorTopicYN="N">methionine circulating metabolites</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">nested case-control study</Keyword><Keyword MajorTopicYN="N">older adult</Keyword><Keyword MajorTopicYN="N">plasma amyloid-β</Keyword><Keyword MajorTopicYN="N">predictive model</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120779</ArticleId><ArticleId IdType="pii">JAD220373</ArticleId><ArticleId IdType="doi">10.3233/JAD-220373</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36120778</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Brain Deep Medullary Veins on 7T MRI in Dutch-Type Hereditary Cerebral Amyloid Angiopathy.</ArticleTitle><Pagination><MedlinePgn>381-388</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220354</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Deep medullary vein (DMV) changes occur in cerebral small vessel diseases (SVD) and in Alzheimer's disease. Cerebral amyloid angiopathy (CAA) is a common SVD that has a high co-morbidity with Alzheimer's disease. So far, DMVs have not been evaluated in CAA.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate DMVs in Dutch-type hereditary CAA (D-CAA) mutation carriers and controls, in relation to MRI markers associated with D-CAA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Quantitative DMV parameters length, tortuosity, inhomogeneity, and density were quantified on 7 Tesla 3D susceptibility weighted MRI in pre-symptomatic D-CAA mutation carriers (n = 8), symptomatic D-CAA mutation carriers (n = 8), and controls (n = 25). Hemorrhagic MRI markers (cerebral microbleeds, intracerebral hemorrhages, cortical superficial siderosis, convexity subarachnoid hemorrhage), non-hemorrhagic MRI markers (white matter hyperintensities, enlarged perivascular spaces, lacunar infarcts, cortical microinfarcts), cortical grey matter perfusion, and diffusion tensor imaging parameters were assessed in D-CAA mutation carriers. Univariate general linear analysis was used to determine associations between DMV parameters and MRI markers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Quantitative DMV parameters length, tortuosity, inhomogeneity, and density did not differ between pre-symptomatic D-CAA mutation carriers, symptomatic D-CAA mutation carriers, and controls. No associations were found between DMV parameters and MRI markers associated with D-CAA.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study indicates that vascular amyloid-β deposition does not affect DMV parameters. In patients with CAA, DMVs do not seem to play a role in the pathogenesis of MRI markers associated with CAA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Harten</LastName><ForeName>Thijs W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>C.J. Gorter Center for High Field MRI, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heijmans</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rooden</LastName><ForeName>Sanneke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wermer</LastName><ForeName>Marieke J H</ForeName><Initials>MJH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Osch</LastName><ForeName>Matthias J P</ForeName><Initials>MJP</Initials><AffiliationInfo><Affiliation>C.J. Gorter Center for High Field MRI, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuijf</LastName><ForeName>Hugo J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Image Science Institute, University Medical Center Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Veluw</LastName><ForeName>Susanne J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, J.P.K. Stroke Research Center, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, J.P.K. Stroke Research Center, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Buchem</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Grond</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Walderveen</LastName><ForeName>Marianne A A</ForeName><Initials>MAA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C537944">Amyloidosis, Cerebroarterial, App-Related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028243" MajorTopicYN="Y">Cerebral Amyloid Angiopathy, Familial</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="Y">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cerebral small vessel disease</Keyword><Keyword MajorTopicYN="N">cerebral veins</Keyword><Keyword MajorTopicYN="N">hereditary cerebral amyloid angiopathy</Keyword><Keyword MajorTopicYN="N">magnetic resonance imaging</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120778</ArticleId><ArticleId IdType="pii">JAD220354</ArticleId><ArticleId IdType="doi">10.3233/JAD-220354</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36120777</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Tea Consumption Is Associated with Reduced Cognitive Decline and Interacts with Iron Intake: A Population-Based Longitudinal Study on 4,820 Old Adults.</ArticleTitle><Pagination><MedlinePgn>271-282</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220344</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies suggest a positive effect of tea intake on cognition. Additional micronutrients that may moderate this association was not previously examined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the association between tea consumption and cognition and explore the interaction between tea consumption and iron intake.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from the China Health and Nutrition Survey between 1997 and 2011 was used. 4,820 individuals (≥55 years) were included in the analyses. Measurement of cognitive function was conducted in 1997, 2000, 2004, and 2006. Tea consumption was self-reported. Food intake was assessed by 24-hour dietary recalls of three consecutive days during home visits between 1997 and 2011. Multivariable mixed linear regression and logistic regression was used to assess the association.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Tea consumption was associated with reduced global cognitive function decline. In fully adjusted models, regression coefficients (95% CIs) for those who consumed 0 cups/day,&lt;2 cups/day, 2-3.9 cups/day, and≥4 cups/day of tea were 0, -0.09 (-0.55-0.37), 0.05 (-0.34-0.45), and 0.87 (0.46-1.29), respectively. This effect was stronger in adults &gt; 60 years. Tea consumption of≥4 cups/day was inversely associated with self-reported poor memory (OR 0.70 (95% CI 0.56-0.86)) and memory decline (OR, 0.73 (95% CI 0.62-0.87)). There was a significant interaction between tea consumption and iron intake in relation to cognition. High iron intake was inversely associated with cognition in non-consumers of tea but not in tea consumers.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Higher tea intake is associated with reduced cognitive decline in adults and inhibits the adverse effect of high iron intake.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sukik</LastName><ForeName>Layan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Human Nutrition, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianghong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Pennsylvania School of Nursing, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Zumin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Human Nutrition, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013662">Tea</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003069">Coffee</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009752" MajorTopicYN="Y">Nutritional Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013662" MajorTopicYN="N">Tea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003069" MajorTopicYN="N">Coffee</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adults</Keyword><Keyword MajorTopicYN="N">Chinese</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">iron intake</Keyword><Keyword MajorTopicYN="N">tea consumption</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120777</ArticleId><ArticleId IdType="pii">JAD220344</ArticleId><ArticleId IdType="doi">10.3233/JAD-220344</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36120776</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.</ArticleTitle><Pagination><MedlinePgn>363-380</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220318</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The differential diagnosis of frontotemporal dementia (FTD) is still a challenging task due to its symptomatic overlap with other neurological diseases and the lack of biofluid-based biomarkers.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the diagnostic potential of a combination of novel biomarkers in cerebrospinal fluid (CSF) and blood.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included 135 patients from the Center for Memory Disturbances, University of Perugia, with the diagnoses FTD (n = 37), mild cognitive impairment due to Alzheimer's disease (MCI-AD, n = 47), Lewy body dementia (PDD/DLB, n = 22), and cognitively unimpaired patients as controls (OND, n = 29). Biomarker levels of neuronal pentraxin-2 (NPTX2), neuronal pentraxin receptor, neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) were measured in CSF, as well as NfL and GFAP in serum. We assessed biomarker differences by analysis of covariance and generalized linear models (GLM). We performed receiver operating characteristics analyses and Spearman correlation to determine biomarker associations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CSF NPTX2 and serum GFAP levels varied most between diagnostic groups. The combination of CSF NPTX2, serum NfL and serum GFAP differentiated FTD from the other groups with good accuracy (FTD versus MCI-AD: area under the curve (AUC) [95% CI] = 0.89 [0.81-0.96]; FTD versus PDD/DLB: AUC = 0.82 [0.71-0.93]; FTD versus OND: AUC = 0.80 [0.70-0.91]). CSF NPTX2 and serum GFAP correlated positively only in PDD/DLB (ρ= 0.56, p &lt; 0.05). NPTX2 and serum NfL did not correlate in any of the diagnostic groups. Serum GFAP and serum NfL correlated positively in all groups (ρ= 0.47-0.74, p &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We show the combined potential of CSF NPTX2, serum NfL, and serum GFAP to differentiate FTD from other neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bolsewig</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Neuro chemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam UMC, VU University, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hok-A-Hin</LastName><ForeName>Yanaika S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Neuro chemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam UMC, VU University, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepe</LastName><ForeName>Federica N</ForeName><Initials>FN</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Neuro chemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam UMC, VU University, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Laboratory of Clinical Neuro chemistry, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boonkamp</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Neuro chemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam UMC, VU University, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ADx Neuro Sciences, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellomo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Laboratory of Clinical Neuro chemistry, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paoletti</LastName><ForeName>Federico Paolini</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Laboratory of Clinical Neuro chemistry, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanmechelen</LastName><ForeName>Eugeen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>ADx Neuro Sciences, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Neuro chemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam UMC, VU University, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parnetti</LastName><ForeName>Lucilla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Laboratory of Clinical Neuro chemistry, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willemse</LastName><ForeName>Eline A J</ForeName><Initials>EAJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Neuro chemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam UMC, VU University, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092775">neuronal pentraxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000628670">GFAP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">NPTX2</Keyword><Keyword MajorTopicYN="N">NPTXR</Keyword><Keyword MajorTopicYN="N">differential diagnosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">glial fibrillary acidic protein</Keyword><Keyword MajorTopicYN="N">neurofilament light</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120776</ArticleId><ArticleId IdType="pii">JAD220318</ArticleId><ArticleId IdType="doi">10.3233/JAD-220318</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36120775</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.</ArticleTitle><Pagination><MedlinePgn>349-362</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-220240</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Abnormal blood lipids are associated with cognitive impairment and amyloid-β (Aβ) deposition in the brain. However, the effects of statins on Alzheimer's disease (AD) have not been determined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Considering that plasma Aβ are related to Aβ deposition in the brain, we investigated the effects of simvastatin on plasma Aβ transport.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a randomized, double-blind, placebo-controlled trial. One hundred and twenty patients with hyperlipidemia were randomly assigned to receive 40 mg of simvastatin per day or matching placebo for 12 weeks (sixty patients per group). Plasma Aβ, sLRP1, sRAGE, and lipid levels were measured at baseline and at the 6-week and 12-week visits.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The ITT database ultimately included 108 participants (placebo group: n = 53; simvastatin group: n = 55) and 64 (59.3%) were women, ranging in age from 45 to 75 years (mean 57.2±6.9 years). Multiple linear regression analysis showed that, after 12 weeks of follow-up, compared with the placebo group, ΔAβ42 levels (the change of Aβ42 levels from baseline at week 12) increased more and ΔsRAGE levels decreased more in the simvastatin group (Aβ42: β= 5.823, p = 0.040; sRAGE: β= -72.012, p = 0.031), and a significant negative association was found between ΔAβ42 and ΔsRAGE levels (β= -0.115, p = 0.045). In addition, generalized estimation equation analysis showed that triglycerides levels were negatively correlated with Aβ40 (β= -16.79, p = 0.023), Aβ42 (β= -6.10, p = 0.001), and sRAGE (β= -51.16, p = 0.003).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Daily oral simvastatin (40 mg/day) in patients with hyperlipidemia for 12 weeks can significantly increase plasma Aβ42 levels compared with placebo, which was associated with reduced triglycerides and sRAGE levels, indicating that statins may affect plasma Aβ transport.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Liangjun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical research center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Huyi Hospital of Traditional Chinese Medicine, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Qiumin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Science, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>AGG2FN16EV</RegistryNumber><NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006949" MajorTopicYN="Y">Hyperlipidemias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">hyperlipidemia</Keyword><Keyword MajorTopicYN="N">plasma amyloid-β</Keyword><Keyword MajorTopicYN="N">simvastatin</Keyword><Keyword MajorTopicYN="N">soluble low-density lipoprotein receptor-related protein-1</Keyword><Keyword MajorTopicYN="N">soluble receptor of advanced glycation end products</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120775</ArticleId><ArticleId IdType="pii">JAD220240</ArticleId><ArticleId IdType="doi">10.3233/JAD-220240</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36120397</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1875-8584</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Behavioural neurology</Title><ISOAbbreviation>Behav Neurol</ISOAbbreviation></Journal><ArticleTitle>Comorbid Neurodegeneration in Primary Progressive Aphasia: Clinicopathological Correlations in a Single-Center Study.</ArticleTitle><Pagination><MedlinePgn>6075511</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/6075511</ELocationID><Abstract><AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Primary progressive aphasia (PPA) is a clinically variable syndrome manifesting as slow progressive loss of speech and language with multiple underlying neurodegenerative pathologies.</AbstractText><AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">We included data from nine PPA patients with available autopsies. We then retrospectively reviewed all available medical records, neuropsychology, and MRI results to confirm the corresponding subtypes of PPA and compared them with postmortem neuropathological results.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Clinical presentations corresponded to the nonfluent/agrammatic variant in six cases, the semantic variant in one case, the logopenic variant in one case, and the mixed variant (concomitant nonfluent/agrammatic plus semantic variant) in one case. Patients with a broader clinical presentation, i.e., combining manifestations of one PPA subtype and symptoms of another PPA variant, had autopsy comorbidities showing multiple neurodegenerative disorders. Of the nine subjects enrolled in the study, Alzheimer's disease (AD) was found in eight cases; however, in only one case, AD was detected as an isolated neuropathological substrate of PPA. In eight brain samples, different comorbid neuropathologies were detected: three cases with comorbid AD and dementia with Lewy bodies, two cases with comorbid AD and TDP-43 pathology, one case with comorbid AD and complex tauopathies, and one case with comorbid AD with both tau and TDP-43 deposits. Finally, one case had comorbid tau and TDP-43 pathology but without comorbid AD pathology.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Our observation suggests that PPA cases could be more heterogeneous in their etiology than previously thought and underlying neurodegenerative comorbidities should be considered in routine practice, especially if the clinical presentation of PPA is atypical.</AbstractText><CopyrightInformation>Copyright © 2022 Robert Rusina et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rusina</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3864-5459</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Thomayer University Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Third Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>First Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajtosova</LastName><ForeName>Radoslava</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Thomayer University Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Third Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cséfalvay</LastName><ForeName>Zsolt</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Communication Disorders, Comenius University, Bratislava, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Jiri</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Third Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Na Homolce Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavkova</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Third Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Na Homolce Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukal</LastName><ForeName>Jaromír</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matej</LastName><ForeName>Radoslav</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Third Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>First Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Molecular Medicine, Thomayer University Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Behav Neurol</MedlineTA><NlmUniqueID>8914585</NlmUniqueID><ISSNLinking>0953-4180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018888" MajorTopicYN="Y">Aphasia, Primary Progressive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None of the authors have competing interests concerning the study or data.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>02</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120397</ArticleId><ArticleId IdType="doi">10.1155/2022/6075511</ArticleId><ArticleId IdType="pmc">PMC9477586</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuroimage. 2006 Sep;32(3):989-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16854598</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2021;1281:33-49</Citation><ArticleIdList><ArticleId IdType="pubmed">33433867</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1989 Jun;112 ( Pt 3):799-835</Citation><ArticleIdList><ArticleId IdType="pubmed">2731030</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2011 Sep;134(Pt 9):2565-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21908872</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Radiol. 2011 Dec;21(12):2618-25</Citation><ArticleIdList><ArticleId IdType="pubmed">21805370</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2004;23 Suppl 1:S208-19</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2018 Mar;24(3):259-268</Citation><ArticleIdList><ArticleId IdType="pubmed">29039275</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2009 Aug;66(2):200-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2017 Jul 4;89(1):88-100</Citation><ArticleIdList><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72</Citation><ArticleIdList><ArticleId IdType="pubmed">1431963</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2016 Jan;131(1):87-102</Citation><ArticleIdList><ArticleId IdType="pubmed">26659578</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2010 Feb;6(2):88-97</Citation><ArticleIdList><ArticleId IdType="pubmed">20139998</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2015 Jul;21(6):429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">26067425</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 2013;204:99-112</Citation><ArticleIdList><ArticleId IdType="pubmed">24041320</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortex. 2020 Apr;125:272-287</Citation><ArticleIdList><ArticleId IdType="pubmed">32061945</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2019 Jun 1;142(6):1503-1527</Citation><ArticleIdList><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">21514247</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Behav Neurol. 2017 Mar;30(1):23-29</Citation><ArticleIdList><ArticleId IdType="pubmed">28323683</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2014 Apr;137(Pt 4):1176-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24574501</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2011 Oct;134(Pt 10):3011-29</Citation><ArticleIdList><ArticleId IdType="pubmed">21666264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2002 Nov;17(3):143-55</Citation><ArticleIdList><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Lang. 2013 Nov;127(2):157-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23890877</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2019 Dec 11;11:336</Citation><ArticleIdList><ArticleId IdType="pubmed">31920619</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2011 Mar 15;76(11):1006-14</Citation><ArticleIdList><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2017 Mar;81(3):430-443</Citation><ArticleIdList><ArticleId IdType="pubmed">28133816</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 2003 Nov;50(5):1077-88</Citation><ArticleIdList><ArticleId IdType="pubmed">14587019</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurol. 2019 Mar 20;19(1):42</Citation><ArticleIdList><ArticleId IdType="pubmed">30894142</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2013 Feb;9(2):74-85</Citation><ArticleIdList><ArticleId IdType="pubmed">23338283</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neurol Neurosci Rep. 2021 Feb 4;21(3):7</Citation><ArticleIdList><ArticleId IdType="pubmed">33543347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2018 Nov;84(5):729-740</Citation><ArticleIdList><ArticleId IdType="pubmed">30255971</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2022 Jan;29(1):324-328</Citation><ArticleIdList><ArticleId IdType="pubmed">34469612</ArticleId></ArticleIdList></Reference><Reference><Citation>Handb Clin Neurol. 2015;129:177-86</Citation><ArticleIdList><ArticleId IdType="pubmed">25726269</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2011 Jul;122(1):111-3</Citation><ArticleIdList><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2007 Jun;130(Pt 6):1566-76</Citation><ArticleIdList><ArticleId IdType="pubmed">17525140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2018 May 1;77(5):405-412</Citation><ArticleIdList><ArticleId IdType="pubmed">29584904</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1993 Sep;43(9):1683-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8414012</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2013 Oct;126(4):537-544</Citation><ArticleIdList><ArticleId IdType="pubmed">23995422</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2012 Jan;123(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>eNeurologicalSci. 2021 Jan 19;22:100318</Citation><ArticleIdList><ArticleId IdType="pubmed">33532636</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2007 May;8(5):393-402</Citation><ArticleIdList><ArticleId IdType="pubmed">17431404</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2021 Dec;108:168-178</Citation><ArticleIdList><ArticleId IdType="pubmed">34653892</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cogn Neurosci. 2016 Feb;28(2):210-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26544920</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Case Rep. 2019 May 27;12(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">31133550</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2002;14(2):55-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12145451</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2020 Aug;140(2):99-119</Citation><ArticleIdList><ArticleId IdType="pubmed">32383020</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36120328</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Editorial: Kampo Medicine in a Modern Context: Ethnopharmacological Perspectives.</ArticleTitle><Pagination><MedlinePgn>971254</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2022.971254</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuchta</LastName><ForeName>Kenny</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Forschungsstelle für Fernöstliche Medizin, Department of Vegetation Analysis and Phytodiversity, Albrecht von Haller Institute of Plant Sciences, Georg August University, Göttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cameron</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic for Gastroenterology and GI-Oncology, University Medical Center Göttingen, Georg August University, Göttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Gastroenterology and General Internal Medicine, Clinic Hann. Münden, Hann. Münden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 therapeutics</Keyword><Keyword MajorTopicYN="N">Ethnopharmacology</Keyword><Keyword MajorTopicYN="N">ICD-11 (international classification of diseases)</Keyword><Keyword MajorTopicYN="N">Kampo (traditional Japanese herbal medicine)</Keyword><Keyword MajorTopicYN="N">cultural evolution</Keyword><Keyword MajorTopicYN="N">dementia—Alzheimer disease</Keyword><Keyword MajorTopicYN="N">personalised therapy</Keyword><Keyword MajorTopicYN="N">supportive cancer therapy</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36120328</ArticleId><ArticleId IdType="doi">10.3389/fphar.2022.971254</ArticleId><ArticleId IdType="pii">971254</ArticleId><ArticleId IdType="pmc">PMC9480492</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36119675</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Combining visual rating scales to identify prodromal Alzheimer's disease and Alzheimer's disease dementia in a population from a low and middle-income country.</ArticleTitle><Pagination><MedlinePgn>962192</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2022.962192</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Many low- and middle-income countries, including Latin America, lack access to biomarkers for the diagnosis of prodromal Alzheimer's Disease (AD; mild cognitive impairment due to AD) and AD dementia. MRI visual rating scales may serve as an ancillary diagnostic tool for identifying prodromal AD or AD in Latin America. We investigated the ability of brain MRI visual rating scales to distinguish between cognitively healthy controls, prodromal AD and AD.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">A cross-sectional study was conducted from a multidisciplinary neurology clinic in Lima, Peru using neuropsychological assessments, brain MRI and cerebrospinal fluid amyloid and tau levels. Medial temporal lobe atrophy (MTA), posterior atrophy (PA), white matter hyperintensity (WMH), and MTA+PA composite MRI scores were compared. Sensitivity, specificity, and area under the curve (AUC) were determined.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Fifty-three patients with prodromal AD, 69 with AD, and 63 cognitively healthy elderly individuals were enrolled. The median age was 75 (8) and 42.7% were men. Neither sex, mean age, nor years of education were significantly different between groups. The MTA was higher in patients with AD (<i>p</i> &lt; 0.0001) compared with prodromal AD and controls, and MTA scores adjusted by age range (<i>p</i> &lt; 0.0001) and PA scores (<i>p</i> &lt; 0.0001) were each significantly associated with AD diagnosis (<i>p</i> &lt; 0.0001) but not the WMH score (p=0.426). The MTA had better performance among ages &lt;75 years (AUC 0.90 [0.85-0.95]), while adjusted MTA+PA scores performed better among ages&gt;75 years (AUC 0.85 [0.79-0.92]). For AD diagnosis, MTA+PA had the best performance (AUC 1.00) for all age groups.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Combining MTA and PA scores demonstrates greater discriminative ability to differentiate controls from prodromal AD and AD, highlighting the diagnostic value of visual rating scales in daily clinical practice, particularly in Latin America where access to advanced neuroimaging and CSF biomarkers is limited in the clinical setting.</AbstractText><CopyrightInformation>Copyright © 2022 Custodio, Malaga, Chambergo-Michilot, Montesinos, Moron, Vences, Huilca, Lira, Failoc-Rojas and Diaz.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Custodio</LastName><ForeName>Nilton</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Servicio de Neurología, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Escuela Profesional de Medicina Humana, Universidad Privada San Juan Bautista, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaga</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>San Martin de Porres University, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chambergo-Michilot</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Unidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Científica del Sur, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montesinos</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moron</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departamento de Radiología, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Radiología, Centro de Diagnóstico por Imagen-DPI, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vences</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Unidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Neurología, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huilca</LastName><ForeName>José Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Unidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Neurología, Hospital Guillermo Kaelin de La Fuente, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lira</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Neurología, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Failoc-Rojas</LastName><ForeName>Virgilio E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Unidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación en Medicina Traslacional, Universidad Privada Norbert Wiener, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Monica M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Salud Pública y Administración, Universidad Peruana Cayetano Heredia, Lima, Peru.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">medial temporal atrophy score</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">visual rating scores</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36119675</ArticleId><ArticleId IdType="doi">10.3389/fneur.2022.962192</ArticleId><ArticleId IdType="pmc">PMC9477244</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimers Dement. 2021 Feb;17(2):295-313</Citation><ArticleIdList><ArticleId IdType="pubmed">33634602</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2018 Apr;14(4):535-562</Citation><ArticleIdList><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroradiology. 2019 Jun;61(6):633-642</Citation><ArticleIdList><ArticleId IdType="pubmed">30852630</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2014 Feb;10(1 Suppl):S84-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24864324</ArticleId></ArticleIdList></Reference><Reference><Citation>AJR Am J Roentgenol. 1987 Aug;149(2):351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3496763</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2021 Oct 15;13:750154</Citation><ArticleIdList><ArticleId IdType="pubmed">34720998</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Rural Pract. 2021 Jan;12(1):16-23</Citation><ArticleIdList><ArticleId IdType="pubmed">33531755</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):439-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16306153</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Radiol. 2011 Dec;21(12):2618-25</Citation><ArticleIdList><ArticleId IdType="pubmed">21805370</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Radiol. 2016 Aug;26(8):2597-610</Citation><ArticleIdList><ArticleId IdType="pubmed">26560730</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2017 Aug 22;9:278</Citation><ArticleIdList><ArticleId IdType="pubmed">28878665</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2007 Apr;22(4):294-304</Citation><ArticleIdList><ArticleId IdType="pubmed">16998781</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2017 May 09;9:117</Citation><ArticleIdList><ArticleId IdType="pubmed">28536518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intern Med. 2004 Sep;256(3):240-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Radiol. 2017 Aug;27(8):3147-3155</Citation><ArticleIdList><ArticleId IdType="pubmed">28083697</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2021 Mar 15;12:633777</Citation><ArticleIdList><ArticleId IdType="pubmed">33790849</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2004 Mar;16(1):13-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15190994</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2014 Nov;10(11):634-42</Citation><ArticleIdList><ArticleId IdType="pubmed">25266297</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 Jul;7(4):e101-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21784342</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2012 Mar;33(3):627.e1-627.e12</Citation><ArticleIdList><ArticleId IdType="pubmed">21596458</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Apr 18;7:46263</Citation><ArticleIdList><ArticleId IdType="pubmed">28417965</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2021 Mar 15;12:640525</Citation><ArticleIdList><ArticleId IdType="pubmed">33790850</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2009 Aug;21(4):622-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19505354</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2017;44(1-2):12-24</Citation><ArticleIdList><ArticleId IdType="pubmed">28614836</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2020;77(1):323-337</Citation><ArticleIdList><ArticleId IdType="pubmed">32716355</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2007 Jul;130(Pt 7):1777-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17533169</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Alzheimers Dis Other Demen. 2019 Nov-Dec;34(7-8):513-522</Citation><ArticleIdList><ArticleId IdType="pubmed">31422688</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Neurol. 2018 Jul;14(3):275-282</Citation><ArticleIdList><ArticleId IdType="pubmed">29971973</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Geriatr. 2019 Feb 28;19(1):59</Citation><ArticleIdList><ArticleId IdType="pubmed">30819102</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1225-33</Citation><ArticleIdList><ArticleId IdType="pubmed">25872513</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2008 May;29(5):669-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17208336</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2020 May 05;11:374</Citation><ArticleIdList><ArticleId IdType="pubmed">32477248</ArticleId></ArticleIdList></Reference><Reference><Citation>Insights Imaging. 2017 Feb;8(1):79-90</Citation><ArticleIdList><ArticleId IdType="pubmed">28004274</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2020 Mar 2;3:CD009628</Citation><ArticleIdList><ArticleId IdType="pubmed">32119112</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (Amst). 2020 May 22;12(1):e12026</Citation><ArticleIdList><ArticleId IdType="pubmed">32490138</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2017 Jul 13;9:221</Citation><ArticleIdList><ArticleId IdType="pubmed">28751861</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2019 May;15(5):709-719</Citation><ArticleIdList><ArticleId IdType="pubmed">30745123</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 1995 Sep;242(9):557-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8551316</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2018 Jan 30;90(5):222-231</Citation><ArticleIdList><ArticleId IdType="pubmed">29305437</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Assoc Med Bras (1992). 2020 Apr;66(4):512-515</Citation><ArticleIdList><ArticleId IdType="pubmed">32578788</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurol. 2021 Jul 24;21(1):289</Citation><ArticleIdList><ArticleId IdType="pubmed">34301202</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2018 Nov 21;10:384</Citation><ArticleIdList><ArticleId IdType="pubmed">30519185</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2015;50(3):797-806</Citation><ArticleIdList><ArticleId IdType="pubmed">26757192</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36119673</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Recent developments in the understanding of the interactions between the vestibular system, memory, the hippocampus, and the striatum.</ArticleTitle><Pagination><MedlinePgn>986302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2022.986302</ELocationID><Abstract><AbstractText>Over the last two decades, evidence has accumulated to demonstrate that the vestibular system has extensive connections with areas of the brain related to spatial memory, such as the hippocampus, and also that it has significant interactions with areas associated with voluntary motor control, such as the striatum in the basal ganglia. In fact, these functions are far from separate and it is believed that interactions between the striatum and hippocampus are important for memory processing. The data relating to vestibular-hippocampal-striatal interactions have considerable implications for the understanding and treatment of Alzheimer's Disease and Parkinson's Disease, in addition to other neurological disorders. However, evidence is accumulating rapidly, and it is difficult to keep up with the latest developments in these and related areas. The aim of this review is to summarize and critically evaluate the relevant evidence that has been published over the last 2 years (i.e., since 2021), in order to identify emerging themes in this research area.</AbstractText><CopyrightInformation>Copyright © 2022 Smith.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Paul F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, School of Biomedical Sciences and Brain Health Research Centre, University of Otago, Dunedin, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eisdell Moore Centre for Hearing and Balance Research, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">hippocampus</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">striatum</Keyword><Keyword MajorTopicYN="N">vestibular system</Keyword></KeywordList><CoiStatement>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36119673</ArticleId><ArticleId IdType="doi">10.3389/fneur.2022.986302</ArticleId><ArticleId IdType="pmc">PMC9479733</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Front Syst Neurosci. 2021 Oct 27;15:733684</Citation><ArticleIdList><ArticleId IdType="pubmed">34776883</ArticleId></ArticleIdList></Reference><Reference><Citation>Otol Neurotol. 2022 Jul 1;43(6):e663-e670</Citation><ArticleIdList><ArticleId IdType="pubmed">35761460</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2021 Apr;21(4):405-418</Citation><ArticleIdList><ArticleId IdType="pubmed">33621149</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Otorhinolaryngol. 2021 Jun;278(6):2057-2065</Citation><ArticleIdList><ArticleId IdType="pubmed">33112983</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2021 Jan 29;11(1):2695</Citation><ArticleIdList><ArticleId IdType="pubmed">33514827</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2005 Nov;128(Pt 11):2732-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16141283</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 2018 Feb 1;119(2):548-562</Citation><ArticleIdList><ArticleId IdType="pubmed">29167325</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2021 Jul 29;12:716795</Citation><ArticleIdList><ArticleId IdType="pubmed">34393985</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Jul 23;23(16):6490-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12878690</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2002;12(3):291-303</Citation><ArticleIdList><ArticleId IdType="pubmed">12099481</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neural Circuits. 2019 Oct 18;13:66</Citation><ArticleIdList><ArticleId IdType="pubmed">31680880</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2022 Jan;269(1):87-99</Citation><ArticleIdList><ArticleId IdType="pubmed">33387012</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2018 Sep 14;683:43-47</Citation><ArticleIdList><ArticleId IdType="pubmed">29936267</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Struct Funct. 2017 Sep;222(7):3319-3332</Citation><ArticleIdList><ArticleId IdType="pubmed">28349227</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Commun. 2021 May 22;3(2):fcab109</Citation><ArticleIdList><ArticleId IdType="pubmed">34704022</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Otolaryngol Head Neck Surg. 2022 Aug 1;148(8):731-739</Citation><ArticleIdList><ArticleId IdType="pubmed">35708675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2016 Dec;26(12):1509-1514</Citation><ArticleIdList><ArticleId IdType="pubmed">27569857</ArticleId></ArticleIdList></Reference><Reference><Citation>Handb Clin Neurol. 2022;184:21-34</Citation><ArticleIdList><ArticleId IdType="pubmed">35034736</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2018 Dec 11;9:1085</Citation><ArticleIdList><ArticleId IdType="pubmed">30619045</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2022 Aug;269(8):4333-4348</Citation><ArticleIdList><ArticleId IdType="pubmed">35306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2021 Nov 3;109(21):3521-3534.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">34644546</ArticleId></ArticleIdList></Reference><Reference><Citation>Hear Res. 2021 Apr;403:108173</Citation><ArticleIdList><ArticleId IdType="pubmed">33465547</ArticleId></ArticleIdList></Reference><Reference><Citation>Life (Basel). 2021 Dec 09;11(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">34947900</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2022 Feb 2;110(3):532-543.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">34788632</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2014 May;24(5):541-52</Citation><ArticleIdList><ArticleId IdType="pubmed">24449222</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2008;31:69-89</Citation><ArticleIdList><ArticleId IdType="pubmed">18284371</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Brain Res. 2021 Jun;239(6):1853-1862</Citation><ArticleIdList><ArticleId IdType="pubmed">33846841</ArticleId></ArticleIdList></Reference><Reference><Citation>Gait Posture. 2022 Mar;93:252-258</Citation><ArticleIdList><ArticleId IdType="pubmed">35227962</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2022 Mar 18;13:857736</Citation><ArticleIdList><ArticleId IdType="pubmed">35370874</ArticleId></ArticleIdList></Reference><Reference><Citation>Audiol Neurootol. 2022;27(2):122-132</Citation><ArticleIdList><ArticleId IdType="pubmed">34518461</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2022 Apr 11;12(1):6049</Citation><ArticleIdList><ArticleId IdType="pubmed">35411002</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vestib Res. 2022;32(3):261-269</Citation><ArticleIdList><ArticleId IdType="pubmed">34151877</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2021 Jun 11;11(6):e049165</Citation><ArticleIdList><ArticleId IdType="pubmed">34117049</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2021 Nov 02;12:758122</Citation><ArticleIdList><ArticleId IdType="pubmed">34795633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vestib Res. 2020;30(1):25-33</Citation><ArticleIdList><ArticleId IdType="pubmed">32083606</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Learn Mem. 2010 Oct;94(3):402-13</Citation><ArticleIdList><ArticleId IdType="pubmed">20736074</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2022 Jan 10;767:136308</Citation><ArticleIdList><ArticleId IdType="pubmed">34715273</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Brain Res. 2021 Dec;239(12):3553-3564</Citation><ArticleIdList><ArticleId IdType="pubmed">34562106</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Dis Extra. 2016 May 26;6(2):194-204</Citation><ArticleIdList><ArticleId IdType="pubmed">27350780</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pediatr Otorhinolaryngol. 2020 Mar;130:109802</Citation><ArticleIdList><ArticleId IdType="pubmed">31809971</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2017 Feb;30(1):84-89</Citation><ArticleIdList><ArticleId IdType="pubmed">27845944</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2021 Nov 03;15:756674</Citation><ArticleIdList><ArticleId IdType="pubmed">34803637</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2022;86(3):1159-1168</Citation><ArticleIdList><ArticleId IdType="pubmed">35180117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2022;86(3):1107-1121</Citation><ArticleIdList><ArticleId IdType="pubmed">35213376</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2012 Feb 28;3:20</Citation><ArticleIdList><ArticleId IdType="pubmed">22403568</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Integr Neurosci. 2014 Jun 05;8:38</Citation><ArticleIdList><ArticleId IdType="pubmed">24926239</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2021 Oct 01;15:732974</Citation><ArticleIdList><ArticleId IdType="pubmed">34658819</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2022 Aug;129(8):1001-1009</Citation><ArticleIdList><ArticleId IdType="pubmed">35753016</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Pathol. 2014 Apr;24(3):247-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24779419</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2022 Apr;269(4):2210-2213</Citation><ArticleIdList><ArticleId IdType="pubmed">34664100</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2009 May;19(5):480-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19072773</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2021 Dec 08;12:789487</Citation><ArticleIdList><ArticleId IdType="pubmed">34956067</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Ment Health. 2020 May;24(5):705-708</Citation><ArticleIdList><ArticleId IdType="pubmed">30691295</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36118969</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1662-5161</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in human neuroscience</Title><ISOAbbreviation>Front Hum Neurosci</ISOAbbreviation></Journal><ArticleTitle>Divergent patterns of cognitive deficits and structural brain alterations between older adults in mixed-sex and same-sex relationships.</ArticleTitle><Pagination><MedlinePgn>909868</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnhum.2022.909868</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Sexual minority (SM) older adults experience mental health disparities. Psychiatric disorders and neuropsychiatric symptoms (NPS) are risk factors for cognitive decline. Although older people in same-sex (SSR) compared to mixed-sex relationships (MSR) perform more poorly on cognitive screening tests, prior studies found no differences in rates of dementia diagnosis or neuropsychological profiles. We sought to explore the role of NPS on neurocognitive outcomes for SM populations. We compared cognitive performance and structural brain parameters of older adults in SSR and MSR.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">Data were originally collected at Alzheimer's Disease Research Centers (ADRCs). Inclusion criteria were: age of 55+ years, a study partner identified as a spouse/partner, and availability of T1-MRI brain volumes/thickness. Participants were labeled as either SSR or MSR based on their/their co-participant's reported sex. We identified 1,073 participants (1,037 MSR-555 cognitively unimpaired [CU]; 36 SSR-23 CU) with structural MRI data, Mini-Mental State Exam (MMSE), and Neuropsychiatric Inventory Questionnaire (NPI-Q) scores. A subset of the overall sample completed comprehensive neuropsychological assessment (<i>n</i> = 939; 908 MSR-494 CU; 31 SSR-22 CU). Covariates included in statistical models were age, sex, education, total intracranial volume, and apolipoprotein E genotype.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Multivariate general linear models showed significant diagnosis-by-relationship interaction effects on the left parahippocampal gyrus volume. After stratification by relationship group, only cognitively impaired (CI) MSR had significantly smaller left parahippocampal volumes than MSR-CU. The SSR group showed better episodic memory performance. Severity of neuropsychiatric symptoms was negatively associated with volume/thickness of bilateral fronto-temporal areas and with MMSE scores, predominantly in the MSR group.</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">In our study, MSR participants presented with a more compromised cognitive profile than SSR participants. MSR-CI participants showed significantly smaller left medio-temporal volumes, a neural signature of AD. Neuropsychiatric symptoms predicted smaller fronto-temporal volumes in the MSR more consistently than in the SSR group. These findings may be due to unexplored protective factors against cognitive decline in SM elders. Indeed, social support has been proposed as a protective factor warranting future investigation.</AbstractText><CopyrightInformation>Copyright © 2022 Manca, Correro, Gauthreaux and Flatt.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manca</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, Brunel University London, Uxbridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Correro</LastName><ForeName>Anthony N</ForeName><Initials>AN</Initials><Suffix>2nd</Suffix><AffiliationInfo><Affiliation>Mental Health Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan Health, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthreaux</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, WA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flatt</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Social and Behavioral Health, School of Public Health, University of Nevada, Las Vegas, Las Vegas, NV, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Hum Neurosci</MedlineTA><NlmUniqueID>101477954</NlmUniqueID><ISSNLinking>1662-5161</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">National Alzheimer's Coordinating Center</Keyword><Keyword MajorTopicYN="N">cognitive decline</Keyword><Keyword MajorTopicYN="N">parahippocampal gyrus</Keyword><Keyword MajorTopicYN="N">same-sex relationship</Keyword><Keyword MajorTopicYN="N">sexual minority</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36118969</ArticleId><ArticleId IdType="doi">10.3389/fnhum.2022.909868</ArticleId><ArticleId IdType="pmc">PMC9479099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gerontologist. 2013 Aug;53(4):664-75</Citation><ArticleIdList><ArticleId IdType="pubmed">23034470</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cogn Neurosci. 2007 May;19(5):776-98</Citation><ArticleIdList><ArticleId IdType="pubmed">17488204</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 2009 Sep;135(5):707-730</Citation><ArticleIdList><ArticleId IdType="pubmed">19702379</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2001;104(3):667-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11440800</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2013 Sep;9(5):529-37</Citation><ArticleIdList><ArticleId IdType="pubmed">23260866</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Sex Behav. 2020 Oct;49(7):2247-2258</Citation><ArticleIdList><ArticleId IdType="pubmed">31286339</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2010 Dec;30(8):1019-29</Citation><ArticleIdList><ArticleId IdType="pubmed">20708315</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):10-17</Citation><ArticleIdList><ArticleId IdType="pubmed">29240561</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;64(1):91-102</Citation><ArticleIdList><ArticleId IdType="pubmed">29865050</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 2020 Sep 15;60(7):1282-1290</Citation><ArticleIdList><ArticleId IdType="pubmed">31909416</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2020 Feb;16(2):316-325</Citation><ArticleIdList><ArticleId IdType="pubmed">31718906</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2022 Jan 01;73(1):39-45</Citation><ArticleIdList><ArticleId IdType="pubmed">34320831</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2020 Apr 1;143(4):1233-1248</Citation><ArticleIdList><ArticleId IdType="pubmed">32252068</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 2016 Jun;56(3):548-58</Citation><ArticleIdList><ArticleId IdType="pubmed">25213482</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1991 Sep 20;253(5026):1380-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1896849</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol B Psychol Sci Soc Sci. 2022 Jun 1;77(6):1105-1117</Citation><ArticleIdList><ArticleId IdType="pubmed">33964152</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2016 Apr-Jun;30(2):134-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26485498</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2014;42(1):119-35</Citation><ArticleIdList><ArticleId IdType="pubmed">24799342</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2017 Aug;107(8):1332-1338</Citation><ArticleIdList><ArticleId IdType="pubmed">28700299</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 2003 Sep;129(5):674-697</Citation><ArticleIdList><ArticleId IdType="pubmed">12956539</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2021 Jul 28;7(1):e12197</Citation><ArticleIdList><ArticleId IdType="pubmed">34337136</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2020;27:102262</Citation><ArticleIdList><ArticleId IdType="pubmed">32446241</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2008 Sep;131(Pt 9):2455-63</Citation><ArticleIdList><ArticleId IdType="pubmed">18669506</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gay Lesbian Ment Health. 2020;24(1):2-19</Citation><ArticleIdList><ArticleId IdType="pubmed">33014237</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2020;73(4):1343-1353</Citation><ArticleIdList><ArticleId IdType="pubmed">31903989</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2011 Oct;15(10):483-506</Citation><ArticleIdList><ArticleId IdType="pubmed">21908230</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2018 Oct-Dec;32(4):351-358</Citation><ArticleIdList><ArticleId IdType="pubmed">30376508</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 2014 Jun;54(3):488-500</Citation><ArticleIdList><ArticleId IdType="pubmed">23535500</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Sex Behav. 2015 Oct;44(7):1843-60</Citation><ArticleIdList><ArticleId IdType="pubmed">26123065</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol B Psychol Sci Soc Sci. 2021 Aug 13;76(7):1388-1399</Citation><ArticleIdList><ArticleId IdType="pubmed">33211882</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2015 Feb;11(2):111-25</Citation><ArticleIdList><ArticleId IdType="pubmed">25267715</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neuroendocrinol. 2018 Apr;49:91-105</Citation><ArticleIdList><ArticleId IdType="pubmed">29421159</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Educ Behav. 2019 Jun;46(3):426-435</Citation><ArticleIdList><ArticleId IdType="pubmed">30606058</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2007 Jul-Sep;21(3):249-58</Citation><ArticleIdList><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2021 Mar;17(3):327-406</Citation><ArticleIdList><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2020;17(12):1102-1114</Citation><ArticleIdList><ArticleId IdType="pubmed">33459235</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2014 May;26(5):749-57</Citation><ArticleIdList><ArticleId IdType="pubmed">24451183</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2003 Mar 3;14(3):371-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12634486</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):91-101</Citation><ArticleIdList><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>J Marriage Fam. 2015 Feb;77(1):96-111</Citation><ArticleIdList><ArticleId IdType="pubmed">25598552</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1996 Jul;49(7):783-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8691229</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 1998 Sep;36(9):901-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9740363</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2000 Oct;3(10):1049-56</Citation><ArticleIdList><ArticleId IdType="pubmed">11017179</ArticleId></ArticleIdList></Reference><Reference><Citation>Demography. 2020 Apr;57(2):599-626</Citation><ArticleIdList><ArticleId IdType="pubmed">32060742</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1993 Sep 27;153(18):2093-101</Citation><ArticleIdList><ArticleId IdType="pubmed">8379800</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2017 Apr;107(4):e13-e21</Citation><ArticleIdList><ArticleId IdType="pubmed">28207331</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Community Psychol. 2017 Jun;59(3-4):295-305</Citation><ArticleIdList><ArticleId IdType="pubmed">28369987</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 2021 Apr 3;61(3):352-362</Citation><ArticleIdList><ArticleId IdType="pubmed">32951038</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2015;27(5):367-85</Citation><ArticleIdList><ArticleId IdType="pubmed">26552495</ArticleId></ArticleIdList></Reference><Reference><Citation>Womens Health Issues. 2022 Jan-Feb;32(1):80-86</Citation><ArticleIdList><ArticleId IdType="pubmed">34376324</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2020 Sep;16(9):1305-1311</Citation><ArticleIdList><ArticleId IdType="pubmed">30222945</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Psychotraumatol. 2022 Feb 28;13(1):2002572</Citation><ArticleIdList><ArticleId IdType="pubmed">35251527</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Rep. 2002 Sep-Oct;117(5):426-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12500958</ArticleId></ArticleIdList></Reference><Reference><Citation>J Aging Health. 2022 Aug-Sep;34(4-5):519-528</Citation><ArticleIdList><ArticleId IdType="pubmed">34645296</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1993 Nov;43(11):2412-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Imaging Behav. 2019 Feb;13(1):53-64</Citation><ArticleIdList><ArticleId IdType="pubmed">28913718</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 Apr 15;45(3):867-79</Citation><ArticleIdList><ArticleId IdType="pubmed">19150502</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2019 Jun;34(6):828-835</Citation><ArticleIdList><ArticleId IdType="pubmed">30864178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36118839</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1748-6718</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Computational and mathematical methods in medicine</Title><ISOAbbreviation>Comput Math Methods Med</ISOAbbreviation></Journal><ArticleTitle>CX3CL1 Derived from Bone Marrow Mesenchymal Stem Cells Inhibits A<i>β</i> <sub>1-42</sub>-Induced SH-SY5Y Cell Pathological Damage through TXNIP/NLRP3 Signaling Pathway.</ArticleTitle><Pagination><MedlinePgn>1949344</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/1949344</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most commonly seen neurodegenerative brain disorder. The paracrine effects of mesenchymal stem cells (MSCs) signify to trigger immunomodulation and neural regeneration. However, the role and mechanism of bone marrow MSC- (BMSC-) derived CX3CL1 in AD remains elusive. In this study, A<i>β</i> <sub>1-42</sub>-intervened SH-SY5Y cells were used for AD cell model construction. pcDNA-ligated CX3CL1 overexpression plasmids were transfected into BMSCs. The levels of soluble and membrane-bound CX3CL1 were detected by ELISA and Western blotting (WB), respectively. The growth, apoptosis, and pathology of AD model cells were evaluated by CCK-8, flow cytometry, immunofluorescence, morphology observation, biochemical examination, and WB. It was found that A<i>β</i> <sub>1-42</sub> significantly reduced CX3CL1 expression either in soluble or membrane-bound form, cell viability, relative protein expression of synaptic markers, SOD, CAT, and GSH-Px contents, as well as Trx protein expression; in addition, it enhanced the apoptosis rate, the relative expression of cleaved caspase-3, A<i>β</i>, tau, p-Tau, Iba1, MDA, TXNIP, and NLRP3 in SH-SY5Y cells; however, the above effects were prominently reversed by the coculture of BMSCs. Moreover, overexpression of CX3CL1 in BMSCs observably strengthened the corresponding tendency caused by BMSCs. In conclusion, through the TXNIP/NLRP3 pathway, CX3CL1 derived from BMSCs inhibited pathological damage in A<i>β</i> <sub>1-42</sub>-induced SH-SY5Y.</AbstractText><CopyrightInformation>Copyright © 2022 Chuan Guo et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Chuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Chengdu Medical College, Chengdu Sichuan 610500, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu Sichuan 610500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qinxuan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Chengdu Medical College, Chengdu Sichuan 610500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Jiujia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chengdu Medical College, Chengdu Sichuan 610500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xuhui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Chengdu Medical College, Chengdu Sichuan 610500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Meichen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chengdu Medical College, Chengdu Sichuan 610500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Chengdu Medical College, Chengdu Sichuan 610500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Xun</ForeName><Initials>X</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0422-5963</Identifier><AffiliationInfo><Affiliation>Chengdu Medical College, Chengdu Sichuan 610500, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu Sichuan 610500, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Comput Math Methods Med</MedlineTA><NlmUniqueID>101277751</NlmUniqueID><ISSNLinking>1748-670X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515538">CX3CL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054428">Chemokine CX3CL1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486715">TXNIP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>M03GIQ7Z6P</RegistryNumber><NameOfSubstance UI="D012844">Sincalide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054428" MajorTopicYN="N">Chemokine CX3CL1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012844" MajorTopicYN="N">Sincalide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report that there are no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36118839</ArticleId><ArticleId IdType="doi">10.1155/2022/1949344</ArticleId><ArticleId IdType="pmc">PMC9477634</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biotechnol Appl Biochem. 2022 Aug;69(4):1633-1645</Citation><ArticleIdList><ArticleId IdType="pubmed">34342377</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2014 Aug 08;8:229</Citation><ArticleIdList><ArticleId IdType="pubmed">25152714</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells. 2017 Apr;35(4):851-858</Citation><ArticleIdList><ArticleId IdType="pubmed">28294454</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2018 Apr;14(4):483-491</Citation><ArticleIdList><ArticleId IdType="pubmed">29433981</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Nov 19;21(22):</Citation><ArticleIdList><ArticleId IdType="pubmed">33228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2020 Feb;86:81-91</Citation><ArticleIdList><ArticleId IdType="pubmed">31837910</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells Int. 2012;2012:369417</Citation><ArticleIdList><ArticleId IdType="pubmed">22754576</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Life Sci. 2005 May;62(10):1063-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15761666</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2020 Nov 15;887:173554</Citation><ArticleIdList><ArticleId IdType="pubmed">32941929</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2020 Aug 27;12:265</Citation><ArticleIdList><ArticleId IdType="pubmed">33061903</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2017 Dec;31(12):1057-1082</Citation><ArticleIdList><ArticleId IdType="pubmed">29260466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocul Immunol Inflamm. 2013 Aug;21(4):276-85</Citation><ArticleIdList><ArticleId IdType="pubmed">23718544</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2020 Oct;140(4):417-447</Citation><ArticleIdList><ArticleId IdType="pubmed">32728795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Parkinsons Dis. 2021;11(1):107-121</Citation><ArticleIdList><ArticleId IdType="pubmed">33325398</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Nutr Food Res. 2021 Mar;65(6):e2000660</Citation><ArticleIdList><ArticleId IdType="pubmed">33141510</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2018 Sep 07;12:609</Citation><ArticleIdList><ArticleId IdType="pubmed">30245615</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2019 Feb 11;16(1):30</Citation><ArticleIdList><ArticleId IdType="pubmed">30744705</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2013 Jun;10(5):524-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23036020</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Perspect Med. 2012 Nov 01;2(11):</Citation><ArticleIdList><ArticleId IdType="pubmed">23125202</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2012 May;37(5):903-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22311128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2015 Jan;23(1):17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">25195598</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2001 Oct 12;276(41):37993-8001</Citation><ArticleIdList><ArticleId IdType="pubmed">11495925</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Aug 31;537(7618):50-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2002 Aug 1;69(3):418-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12125082</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Open. 2014 Nov 13;3(12):1173-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25395671</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2003 Aug 15;102(4):1186-95</Citation><ArticleIdList><ArticleId IdType="pubmed">12714508</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Med. 2019 Dec;8(18):7728-7740</Citation><ArticleIdList><ArticleId IdType="pubmed">31642612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocul Immunol Inflamm. 2016 Dec;24(6):684-692</Citation><ArticleIdList><ArticleId IdType="pubmed">27935376</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2019 Feb 20;10(2):890-901</Citation><ArticleIdList><ArticleId IdType="pubmed">30698408</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2019 Mar;146:12-21</Citation><ArticleIdList><ArticleId IdType="pubmed">30496784</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2010 Feb;11(2):136-40</Citation><ArticleIdList><ArticleId IdType="pubmed">20023662</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2021 Mar;17(3):327-406</Citation><ArticleIdList><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2020 Dec 08;25(24):</Citation><ArticleIdList><ArticleId IdType="pubmed">33302541</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 Jan 30;450(2):136-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19084047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2000 Jun 15;164(12):6287-95</Citation><ArticleIdList><ArticleId IdType="pubmed">10843682</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2014 Sep 10;34(37):12538-46</Citation><ArticleIdList><ArticleId IdType="pubmed">25209291</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Neurodegener. 2020 May 27;9(1):20</Citation><ArticleIdList><ArticleId IdType="pubmed">32460886</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Oct 4;26(40):10129-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2000 Feb 1;28(3):418-27</Citation><ArticleIdList><ArticleId IdType="pubmed">10699754</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2022 Mar;231:107989</Citation><ArticleIdList><ArticleId IdType="pubmed">34492237</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2015 Jul;122(7):1069-76</Citation><ArticleIdList><ArticleId IdType="pubmed">25596843</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2019 Aug 31;20(17):</Citation><ArticleIdList><ArticleId IdType="pubmed">31480448</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Transplant. 2011;20(1):5-14</Citation><ArticleIdList><ArticleId IdType="pubmed">21396235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1996 Jan 17;777:121-31</Citation><ArticleIdList><ArticleId IdType="pubmed">8624074</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1997 Nov 14;91(4):521-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9390561</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Oct 17;32(42):14592-601</Citation><ArticleIdList><ArticleId IdType="pubmed">23077045</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2019 Oct 3;179(2):312-339</Citation><ArticleIdList><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Antioxid Redox Signal. 2019 Apr 10;30(11):1411-1431</Citation><ArticleIdList><ArticleId IdType="pubmed">29634349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Rep. 2019 Feb;46(1):1425-1446</Citation><ArticleIdList><ArticleId IdType="pubmed">30565076</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2018 Jun 1;141(6):1855-1870</Citation><ArticleIdList><ArticleId IdType="pubmed">29608645</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Geriatr Med. 2014 Aug;30(3):421-42</Citation><ArticleIdList><ArticleId IdType="pubmed">25037289</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2015 Jul 26;1(2):95-102</Citation><ArticleIdList><ArticleId IdType="pubmed">29854930</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2017;14(11):1140-1148</Citation><ArticleIdList><ArticleId IdType="pubmed">28164764</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Immunol. 2018 Apr;326:8-14</Citation><ArticleIdList><ArticleId IdType="pubmed">28778534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Neurobiol. 2019 Oct;39(7):985-1001</Citation><ArticleIdList><ArticleId IdType="pubmed">31172340</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Metab. 2020 Nov 3;32(5):829-843.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">32966766</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells. 2006 Apr;24(4):1030-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16253981</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36118832</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1748-6718</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Computational and mathematical methods in medicine</Title><ISOAbbreviation>Comput Math Methods Med</ISOAbbreviation></Journal><ArticleTitle>Diagnostic Values of Advanced Glycation End Products and Homocysteine in Patients with Alzheimer's Disease and Sarcopenia.</ArticleTitle><Pagination><MedlinePgn>8949048</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/8949048</ELocationID><Abstract><AbstractText>This study is aimed at exploring the diagnostic value of advanced glycation end products (AGEs) and homocysteine (Hcy) in Alzheimer's disease (AD) complicated with sarcopenia (SP) and to analyze the risk factors related to AD complicated with SP. A total of 168 patients admitted to our hospital from November 2019 to December 2021 were enrolled. Patients were divided into the NC (no SP and AD) group with 29 cases, the AD group with 39 cases, the AD+SP group with 35 cases, and the SP group with 65 cases. The general information, Mini-Mental State Examination (MMSE) scores, and serum levels of AGEs and Hcy among the four groups were compared. Unordered logistic regression was used to analyze the influencing factors of SP patients complicated with dementia. The AGE level was higher in the AD or AD+SP group than the NC or SP group (<i>P</i> &lt; 0.05). There was no significant difference between the SP group and the NC group or between the AD group and the AD+SP group (<i>P</i> &gt; 0.05). The Hcy level was higher in the SP or AD group than the NC group (<i>P</i> &lt; 0.05). There were no significant differences between the AD group and NC group or between the SP group and AD+SP group (<i>P</i> &gt; 0.05). The ROC curve of serum AGEs and Hcy for the diagnosis of AD showed that the area under curve (AUC) was 0.887, <i>P</i> &lt; 0.05 (95% CI: 0.821-0.954, sensitivity: 80.95%, specificity: 73.81%) and 0.7423, <i>P</i> &lt; 0.05 (95% CI: 0.6382-0.8465, sensitivity: 60.42%, specificity: 57.59%), respectively. The ROC curve of serum AGEs and Hcy for the diagnosis of SP showed that the AUC was 0.5533, <i>P</i> &gt; 0.05 (95% CI: 0.4294-0.6771) and 0.8744, <i>P</i> &lt; 0.05 (95% CI: 0.8006-0.9483). Age (<i>P</i> &lt; 0.001), depression (<i>P</i> = 0.001), malnutrition (<i>P</i> = 0.002), and BMI (<i>P</i> &lt; 0.001) were independent influencing factors of SP complicated with AD in elderly inpatients. In conclusion, combined serum AGEs and Hcy had a good diagnostic value for AD combined with SP, which may be helpful for early detection of patient condition.</AbstractText><CopyrightInformation>Copyright © 2022 Xuelian Zhang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuelian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Geriatrics Department, The First People's Hospital of Lianyungang, Xuzhou Medical University Affiliated Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nangjing Medical University, Jiangsu 222002, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Yunxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Geriatrics Department, The First People's Hospital of Lianyungang, Xuzhou Medical University Affiliated Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nangjing Medical University, Jiangsu 222002, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Geriatrics Department, The First People's Hospital of Lianyungang, Xuzhou Medical University Affiliated Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nangjing Medical University, Jiangsu 222002, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Luhang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Geriatrics Department, The First People's Hospital of Lianyungang, Xuzhou Medical University Affiliated Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nangjing Medical University, Jiangsu 222002, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Geriatrics Department, The First People's Hospital of Lianyungang, Xuzhou Medical University Affiliated Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nangjing Medical University, Jiangsu 222002, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Geriatrics Department, The First People's Hospital of Lianyungang, Xuzhou Medical University Affiliated Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nangjing Medical University, Jiangsu 222002, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qiaoling</ForeName><Initials>Q</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8183-0908</Identifier><AffiliationInfo><Affiliation>Geriatrics Department, The First People's Hospital of Lianyungang, Xuzhou Medical University Affiliated Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nangjing Medical University, Jiangsu 222002, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Comput Math Methods Med</MedlineTA><NlmUniqueID>101277751</NlmUniqueID><ISSNLinking>1748-670X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017127">Glycation End Products, Advanced</NameOfSubstance></Chemical><Chemical><RegistryNumber>0LVT1QZ0BA</RegistryNumber><NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017127" MajorTopicYN="N">Glycation End Products, Advanced</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006710" MajorTopicYN="N">Homocysteine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055948" MajorTopicYN="Y">Sarcopenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36118832</ArticleId><ArticleId IdType="doi">10.1155/2022/8949048</ArticleId><ArticleId IdType="pmc">PMC9481380</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurobiol Aging. 2018 Feb;62:243.e7-243.e14</Citation><ArticleIdList><ArticleId IdType="pubmed">29102475</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutrients. 2019 Aug 20;11(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">31434232</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2017 Jan 01;74(1):58-67</Citation><ArticleIdList><ArticleId IdType="pubmed">27893026</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscles Ligaments Tendons J. 2014 Feb 24;3(4):346-50</Citation><ArticleIdList><ArticleId IdType="pubmed">24596700</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem Lab Med. 2003 Nov;41(11):1427-34</Citation><ArticleIdList><ArticleId IdType="pubmed">14656021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nurs Scholarsh. 2003;35(2):133-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12854293</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Res. 2003 Sep;25(6):661-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14503021</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2016 May;131(5):659-85</Citation><ArticleIdList><ArticleId IdType="pubmed">27062261</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2005 Apr;53(4):695-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1998 Oct;153(4):1149-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9777946</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Jan 17;12(1):e0169548</Citation><ArticleIdList><ArticleId IdType="pubmed">28095426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2003 Jul;2(7):425-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12849121</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Osteoporos Rep. 2015 Oct;13(5):351-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26228522</ArticleId></ArticleIdList></Reference><Reference><Citation>Arzneimittelforschung. 2001;51(4):280-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11367867</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">32033882</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nutr. 2016 Oct;35(5):1053-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26231340</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Suisse. 2014 Apr 2;10(424):772-3</Citation><ArticleIdList><ArticleId IdType="pubmed">24772814</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Med Res. 2012;40(3):1036-45</Citation><ArticleIdList><ArticleId IdType="pubmed">22906276</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Glas (Zenica). 2017 Aug 1;14(2):257-261</Citation><ArticleIdList><ArticleId IdType="pubmed">28786967</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Biol Lett. 2014 Sep;19(3):407-37</Citation><ArticleIdList><ArticleId IdType="pubmed">25141979</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 2017 Sep 1;46(5):738-746</Citation><ArticleIdList><ArticleId IdType="pubmed">28633395</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Nov 20;10(11):e0143345</Citation><ArticleIdList><ArticleId IdType="pubmed">26587989</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychopharmacol Neurosci. 2016 Nov 30;14(4):378-382</Citation><ArticleIdList><ArticleId IdType="pubmed">27776391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Med. 2019 Oct 15;8(10):</Citation><ArticleIdList><ArticleId IdType="pubmed">31619001</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2010 Oct;45(10):744-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20211718</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2015 Feb;36(2):753-61</Citation><ArticleIdList><ArticleId IdType="pubmed">25448604</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):253-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21575869</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2017 Dec 1;99:146-150</Citation><ArticleIdList><ArticleId IdType="pubmed">29024723</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1998 Apr 9;338(15):1042-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9535670</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2011 Mar;32(3):380-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19342123</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2016 Dec;209(6):525-526</Citation><ArticleIdList><ArticleId IdType="pubmed">27758838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36118710</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-4365</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in aging neuroscience</Title><ISOAbbreviation>Front Aging Neurosci</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapeutic potential of pomegranate in age-related neurological disorders.</ArticleTitle><Pagination><MedlinePgn>955735</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnagi.2022.955735</ELocationID><Abstract><AbstractText>Age-related neurological disorders [AND] include neurodegenerative diseases [NDDs] such as Alzheimer's disease [AD] and Parkinson's disease [PD], which are the most prevalent types of dementia in the elderly. It also includes other illnesses such as migraine and epilepsy. ANDs are multifactorial, but aging is their major risk factor. The most frequent and vital pathological features of AND are oxidative stress, inflammation, and accumulation of misfolded proteins. As AND brain damage is a significant public health burden and its incidence is increasing, much has been done to overcome it. Pomegranate (<i>Punica granatum L</i>.) is one of the polyphenol-rich fruits that is widely mentioned in medical folklore. Pomegranate is commonly used to treat common disorders such as diarrhea, abdominal pain, wound healing, bleeding, dysentery, acidosis, microbial infections, infectious and noninfectious respiratory diseases, and neurological disorders. In the current review article, we aimed to summarize the data on the pharmacotherapeutic potentials of pomegranate in ANDs.</AbstractText><CopyrightInformation>Copyright © 2022 Emami Kazemabad, Asgari Toni, Tizro, Dadkhah, Amani, Akhavan Rezayat, Sheikh, Mohammadi, Alijanzadeh, Alimohammadi, Shahrokhi, Erabi, Noroozi, Karimi, Honari and Deravi.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emami Kazemabad</LastName><ForeName>Mohammad Javad</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Qom University of Medical Sciences, Qom, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asgari Toni</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tizro</LastName><ForeName>Neda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dadkhah</LastName><ForeName>Parisa Alsadat</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amani</LastName><ForeName>Hanieh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akhavan Rezayat</LastName><ForeName>Shima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Student Research Committee, Faculty of Medicine, Islamic Azad University of Mashhad, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Babol University of Medical Sciences, Babol, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alijanzadeh</LastName><ForeName>Dorsa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alimohammadi</LastName><ForeName>Farnoosh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahrokhi</LastName><ForeName>Mehregan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erabi</LastName><ForeName>Gisou</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noroozi</LastName><ForeName>Masoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Faculty of Engineering, University of Isfahan, Isfahan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karimi</LastName><ForeName>Mohammad Amin</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honari</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deravi</LastName><ForeName>Niloofar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Aging Neurosci</MedlineTA><NlmUniqueID>101525824</NlmUniqueID><ISSNLinking>1663-4365</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease (AD)</Keyword><Keyword MajorTopicYN="N">Parkinson's disease (PD)</Keyword><Keyword MajorTopicYN="N">Punica granatum L.</Keyword><Keyword MajorTopicYN="N">age-related neurological disorders</Keyword><Keyword MajorTopicYN="N">pomegranate</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36118710</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2022.955735</ArticleId><ArticleId IdType="pmc">PMC9476556</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trends Pharmacol Sci. 2002 Aug;23(8):347-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12377568</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Interv Aging. 2018 Apr 26;13:757-772</Citation><ArticleIdList><ArticleId IdType="pubmed">29731617</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Cancer Prev. 2003 Aug-Dec;4(4):281-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14728584</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Sci. 2021 Aug 25;11(9):</Citation><ArticleIdList><ArticleId IdType="pubmed">34573149</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Ment Health Syst. 2019 Aug 23;13:57</Citation><ArticleIdList><ArticleId IdType="pubmed">31462907</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Cell. 2021 Dec;20(12):e13504</Citation><ArticleIdList><ArticleId IdType="pubmed">34799977</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Aging Res. 2022 Mar-Apr;48(2):191-210</Citation><ArticleIdList><ArticleId IdType="pubmed">34384037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2004 Dec;1030:434-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15659827</ArticleId></ArticleIdList></Reference><Reference><Citation>Food Chem Toxicol. 2008 Apr;46(4):1360-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17905504</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Foods Hum Nutr. 2017 Jun;72(2):126-133</Citation><ArticleIdList><ArticleId IdType="pubmed">28303364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Exp Toxicol. 2022 Jan-Dec;41:9603271211064534</Citation><ArticleIdList><ArticleId IdType="pubmed">35179410</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr. 2001 Aug;131(8):2082-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11481398</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2017 Nov 30;551(7682):585-589</Citation><ArticleIdList><ArticleId IdType="pubmed">29143823</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2000 Nov 4;321(7269):1153-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11061746</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2018 Dec;175:33-46</Citation><ArticleIdList><ArticleId IdType="pubmed">30171934</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxid Med Cell Longev. 2012;2012:819310</Citation><ArticleIdList><ArticleId IdType="pubmed">23259029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2007 Feb;100(3):841-54</Citation><ArticleIdList><ArticleId IdType="pubmed">17144900</ArticleId></ArticleIdList></Reference><Reference><Citation>Evid Based Complement Alternat Med. 2013;2013:946298</Citation><ArticleIdList><ArticleId IdType="pubmed">23970941</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2011 Nov 07;17(11):1410-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22064431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2021 Feb 11;11(1):3569</Citation><ArticleIdList><ArticleId IdType="pubmed">33574371</ArticleId></ArticleIdList></Reference><Reference><Citation>J Anim Physiol Anim Nutr (Berl). 2022 May;106(3):655-663</Citation><ArticleIdList><ArticleId IdType="pubmed">34318525</ArticleId></ArticleIdList></Reference><Reference><Citation>Protoplasma. 2011 Jul;248(3):565-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20857150</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1629-33</Citation><ArticleIdList><ArticleId IdType="pubmed">8434026</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2010 May;6(5):256-65</Citation><ArticleIdList><ArticleId IdType="pubmed">20368741</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Nutr Soc. 2010 Aug;69(3):273-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20569521</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Jun 17;21(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">32560291</ArticleId></ArticleIdList></Reference><Reference><Citation>NeuroRehabilitation. 2004;19(1):55-67</Citation><ArticleIdList><ArticleId IdType="pubmed">14988588</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Sci. 2004 Jun;95(6):481-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15182427</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Chem Clin Biochem. 1996 Aug;34(8):599-608</Citation><ArticleIdList><ArticleId IdType="pubmed">8877334</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2013 Apr 23;61(16):1736-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23500290</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Biochem Funct. 2009 Oct;27(7):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">19757404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutrients. 2017 Apr 28;9(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">28452959</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcinogenesis. 1995 Dec;16(12):3049-55</Citation><ArticleIdList><ArticleId IdType="pubmed">8603484</ArticleId></ArticleIdList></Reference><Reference><Citation>J Res Med Sci. 2014 Mar;19(3):215-20</Citation><ArticleIdList><ArticleId IdType="pubmed">24949028</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Food. 2015 Sep;18(9):941-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25826143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ethnopharmacol. 2004 May;92(1):93-101</Citation><ArticleIdList><ArticleId IdType="pubmed">15099854</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Nurs. 2006 Sep-Oct;21(5 Suppl 1):S21-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16966926</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2019 Aug 21;14(8):e0219596</Citation><ArticleIdList><ArticleId IdType="pubmed">31433809</ArticleId></ArticleIdList></Reference><Reference><Citation>J Food Biochem. 2022 Apr;46(4):e13881</Citation><ArticleIdList><ArticleId IdType="pubmed">34346512</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Nutr Food Res. 2016 May;60(5):1139-49</Citation><ArticleIdList><ArticleId IdType="pubmed">26989875</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurotrauma. 2021 Dec;38(23):3332-3340</Citation><ArticleIdList><ArticleId IdType="pubmed">34652955</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Res. 2005 Jun;57(6):858-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15774834</ArticleId></ArticleIdList></Reference><Reference><Citation>Antioxid Redox Signal. 2014 Apr 1;20(10):1599-617</Citation><ArticleIdList><ArticleId IdType="pubmed">23581847</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 2010 Mar;39(2):156-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20051606</ArticleId></ArticleIdList></Reference><Reference><Citation>Evid Based Complement Alternat Med. 2013;2013:606212</Citation><ArticleIdList><ArticleId IdType="pubmed">23762148</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Mol Biol Plants. 2017 Apr;23(2):321-330</Citation><ArticleIdList><ArticleId IdType="pubmed">28461721</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Complement Altern Med. 2017 Jan 14;17(1):47</Citation><ArticleIdList><ArticleId IdType="pubmed">28088220</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Neuroanat. 2020 Sep;107:101798</Citation><ArticleIdList><ArticleId IdType="pubmed">32339653</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Biol. 2017 Dec;55(1):1679-1687</Citation><ArticleIdList><ArticleId IdType="pubmed">28447514</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Mar 25;10(3):e0120964</Citation><ArticleIdList><ArticleId IdType="pubmed">25807081</ArticleId></ArticleIdList></Reference><Reference><Citation>IBRO Rep. 2019 May 09;6:153-159</Citation><ArticleIdList><ArticleId IdType="pubmed">31193374</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Pharmacother. 2019 Jan;109:853-864</Citation><ArticleIdList><ArticleId IdType="pubmed">30551539</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Physiol. 1993 Jan;101(1):7-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12231660</ArticleId></ArticleIdList></Reference><Reference><Citation>Food Chem Toxicol. 2014 Nov;73:1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25092396</ArticleId></ArticleIdList></Reference><Reference><Citation>Atherosclerosis. 2006 Aug;187(2):363-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16226266</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut Microbes. 2020 Nov 9;12(1):1857515</Citation><ArticleIdList><ArticleId IdType="pubmed">33382357</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol. 1999 Dec;34(6):879-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10598133</ArticleId></ArticleIdList></Reference><Reference><Citation>J Agric Food Chem. 2008 Sep 24;56(18):8704-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18759451</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 2000 May;71(5):1062-76</Citation><ArticleIdList><ArticleId IdType="pubmed">10799367</ArticleId></ArticleIdList></Reference><Reference><Citation>Heliyon. 2021 Feb 11;7(2):e06214</Citation><ArticleIdList><ArticleId IdType="pubmed">33659742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2011 Sep;70(3):418-26</Citation><ArticleIdList><ArticleId IdType="pubmed">21425187</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Physiol Biochem. 2016;122(2):75-87</Citation><ArticleIdList><ArticleId IdType="pubmed">26822470</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr Neurosci. 2021 Aug 9;:1-18</Citation><ArticleIdList><ArticleId IdType="pubmed">34369317</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Foods Hum Nutr. 2012 Sep;67(3):309-14</Citation><ArticleIdList><ArticleId IdType="pubmed">22648092</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nutr ESPEN. 2022 Feb;47:117-127</Citation><ArticleIdList><ArticleId IdType="pubmed">35063191</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 1987;3(1):3-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3623187</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2022 Feb 28;27(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">35268707</ArticleId></ArticleIdList></Reference><Reference><Citation>Phytomedicine. 2016 Oct 15;23(11):1095-102</Citation><ArticleIdList><ArticleId IdType="pubmed">26922037</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Food. 2008 Jun;11(2):376-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18598183</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biochem Mol Toxicol. 2017 Dec;31(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">28815802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr Rev. 2009 Jan;67(1):49-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19146506</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Toxicol. 2017 Apr;91(4):1709-1725</Citation><ArticleIdList><ArticleId IdType="pubmed">27696135</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Obstet Gynecol. 2018 Jul;219(1):113.e1-113.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">29709511</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncotarget. 2016 Oct 4;7(40):64589-64604</Citation><ArticleIdList><ArticleId IdType="pubmed">27486879</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2018 May 24;9:544</Citation><ArticleIdList><ArticleId IdType="pubmed">29881352</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler. 2016 May;22(6):717-25</Citation><ArticleIdList><ArticleId IdType="pubmed">26895718</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Pediatr Neurol. 2004 Mar;11(1):24-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15132251</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychol Rev. 2010 Dec;20(4):327-48</Citation><ArticleIdList><ArticleId IdType="pubmed">21042938</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2008;70(4):808-11</Citation><ArticleIdList><ArticleId IdType="pubmed">17920207</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2010 Feb 9;74(6):465-71</Citation><ArticleIdList><ArticleId IdType="pubmed">20071664</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Prod Rep. 1996 Aug;13(4):265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8760864</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem Cell Biol. 2007;39(1):44-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16978905</ArticleId></ArticleIdList></Reference><Reference><Citation>J Tradit Complement Med. 2014 Oct;4(4):232-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25379464</ArticleId></ArticleIdList></Reference><Reference><Citation>J Agric Food Chem. 2005 Jun 15;53(12):5003-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15941348</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging (Albany NY). 2019 May 1;11(9):2542-2544</Citation><ArticleIdList><ArticleId IdType="pubmed">31043575</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Biotechnol Biochem. 1997 Nov;61(11):1800-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9404057</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1995 May 1;91(9):2488-96</Citation><ArticleIdList><ArticleId IdType="pubmed">7729036</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2014 Aug 21;110(2):61-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25010842</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nutr. 2004 Jun;23(3):423-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15158307</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Complement Med Ther. 2021 Apr 26;21(1):130</Citation><ArticleIdList><ArticleId IdType="pubmed">33902532</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Food. 2011 Jul-Aug;14(7-8):695-701</Citation><ArticleIdList><ArticleId IdType="pubmed">21631359</ArticleId></ArticleIdList></Reference><Reference><Citation>Handb Clin Neurol. 2019;167:455-475</Citation><ArticleIdList><ArticleId IdType="pubmed">31753149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambam Maimonides Med J. 2012 Oct 31;3(4):e0026</Citation><ArticleIdList><ArticleId IdType="pubmed">23908850</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathology. 2020 Feb;40(1):22-29</Citation><ArticleIdList><ArticleId IdType="pubmed">31863504</ArticleId></ArticleIdList></Reference><Reference><Citation>Food Chem Toxicol. 2013 Jan;51:446-52</Citation><ArticleIdList><ArticleId IdType="pubmed">23127597</ArticleId></ArticleIdList></Reference><Reference><Citation>Atherosclerosis. 2010 Sep;212(1):86-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20537330</ArticleId></ArticleIdList></Reference><Reference><Citation>Food Funct. 2016 Jul 13;7(7):3201-10</Citation><ArticleIdList><ArticleId IdType="pubmed">27334099</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine. 2014 Aug;10(6):1353-63</Citation><ArticleIdList><ArticleId IdType="pubmed">24704590</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Res. 2012 Jul 6;111(2):245-59</Citation><ArticleIdList><ArticleId IdType="pubmed">22773427</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res Treat. 2002 Feb;71(3):203-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12002340</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2016 Jan;157:84-104</Citation><ArticleIdList><ArticleId IdType="pubmed">26617217</ArticleId></ArticleIdList></Reference><Reference><Citation>Food Funct. 2020 Nov 18;11(11):9624-9633</Citation><ArticleIdList><ArticleId IdType="pubmed">32975274</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2020 Jan 14;94(2):e153-e157</Citation><ArticleIdList><ArticleId IdType="pubmed">31757870</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Jan 14;340(2):115-26</Citation><ArticleIdList><ArticleId IdType="pubmed">9887164</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxid Med Cell Longev. 2013;2013:685909</Citation><ArticleIdList><ArticleId IdType="pubmed">24223235</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Epidemiol. 2020 Oct 14;12:1073-1081</Citation><ArticleIdList><ArticleId IdType="pubmed">33116901</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotoxicology. 2004 Jun;25(4):617-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15183015</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chim Acta. 2004 Oct;348(1-2):63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15369737</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Biotechnol Biochem. 2020 Apr;84(4):757-763</Citation><ArticleIdList><ArticleId IdType="pubmed">31868102</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Aspects Med. 2004 Feb-Apr;25(1-2):5-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15051312</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2016 Aug;97:398-407</Citation><ArticleIdList><ArticleId IdType="pubmed">27393004</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Behav Neurosci. 2022 May 06;16:836681</Citation><ArticleIdList><ArticleId IdType="pubmed">35600992</ArticleId></ArticleIdList></Reference><Reference><Citation>Antioxid Redox Signal. 2014 Oct 10;21(11):1557-70</Citation><ArticleIdList><ArticleId IdType="pubmed">24393106</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2014 Apr 15;129(15):1551-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24481950</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr. 2008 Apr;138(4):753-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18356331</ArticleId></ArticleIdList></Reference><Reference><Citation>Antioxid Redox Signal. 2013 Sep 10;19(8):823-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23249141</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2002 Jan-Feb;23(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11755010</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr J. 2016 May 12;15(1):52</Citation><ArticleIdList><ArticleId IdType="pubmed">27175476</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Neurosci. 2007;29(4-5):363-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17762204</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Rev Food Sci Food Saf. 2010 Nov;9(6):635-654</Citation><ArticleIdList><ArticleId IdType="pubmed">33467822</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2019 Jan 15;217:202-211</Citation><ArticleIdList><ArticleId IdType="pubmed">30528774</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2005 Jan 20;113(3):423-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15455341</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2015 Oct 15;287:43-53</Citation><ArticleIdList><ArticleId IdType="pubmed">26439961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Pharmacol. 1999 May;51(5):519-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10411210</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2017 May 6;486(3):774-780</Citation><ArticleIdList><ArticleId IdType="pubmed">28343995</ArticleId></ArticleIdList></Reference><Reference><Citation>J Agric Food Chem. 2000 Oct;48(10):4581-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11052704</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res Treat. 2000 Jul;62(1):35-49</Citation><ArticleIdList><ArticleId IdType="pubmed">10989984</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Food Sci Technol. 2011;2:181-201</Citation><ArticleIdList><ArticleId IdType="pubmed">22129380</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar Drugs. 2019 Apr 13;17(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">31013932</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Nutr Food Res. 2011 Sep;55(9):1277-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21898908</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2000 May 30;101(21):2510-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10831526</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2020 Dec 14;25(24):</Citation><ArticleIdList><ArticleId IdType="pubmed">33327473</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4896-901</Citation><ArticleIdList><ArticleId IdType="pubmed">15781875</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudi J Biol Sci. 2020 Jul;27(7):1710-1716</Citation><ArticleIdList><ArticleId IdType="pubmed">32565686</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroepidemiology. 2018;51(3-4):216-223</Citation><ArticleIdList><ArticleId IdType="pubmed">30253417</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Med Chem. 2019 Dec 1;183:111724</Citation><ArticleIdList><ArticleId IdType="pubmed">31563012</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Physiol Biochem. 2010 Dec;48(12):909-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20870416</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2016 Jan 20;7(1):26-33</Citation><ArticleIdList><ArticleId IdType="pubmed">26559394</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Prod Res. 2021 May;35(10):1696-1701</Citation><ArticleIdList><ArticleId IdType="pubmed">31180248</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Res. 2016 Feb 19;118(4):535-46</Citation><ArticleIdList><ArticleId IdType="pubmed">26892956</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflammopharmacology. 2022 Jun;30(3):1021-1035</Citation><ArticleIdList><ArticleId IdType="pubmed">35348947</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2013 Sep;62:90-101</Citation><ArticleIdList><ArticleId IdType="pubmed">23200807</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Physiol Nutr Metab. 2018 Mar;43(3):266-273</Citation><ArticleIdList><ArticleId IdType="pubmed">29053933</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2005 Sep 15;96(6):810-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16169367</ArticleId></ArticleIdList></Reference><Reference><Citation>Evid Based Complement Alternat Med. 2013;2013:789764</Citation><ArticleIdList><ArticleId IdType="pubmed">23737845</ArticleId></ArticleIdList></Reference><Reference><Citation>Obstet Gynecol. 2003 Sep;102(3):628-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12962954</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 2003 Jul;249(1-2):11-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12956393</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Bot. 2004 Nov;55(407):2365-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15475377</ArticleId></ArticleIdList></Reference><Reference><Citation>ARYA Atheroscler. 2013 Nov;9(6):326-31</Citation><ArticleIdList><ArticleId IdType="pubmed">24575134</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 2013 Mar 15;85(6):705-17</Citation><ArticleIdList><ArticleId IdType="pubmed">23219527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageing Res Rev. 2014 Mar;14:19-30</Citation><ArticleIdList><ArticleId IdType="pubmed">24503004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Res. 2005 May 1;66(2):213-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15820190</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2016;22(10):1350-60</Citation><ArticleIdList><ArticleId IdType="pubmed">26806345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sci Food Agric. 2016 Aug;96(10):3462-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26564426</ArticleId></ArticleIdList></Reference><Reference><Citation>Planta Med. 2018 Oct;84(15):1068-1093</Citation><ArticleIdList><ArticleId IdType="pubmed">29847844</ArticleId></ArticleIdList></Reference><Reference><Citation>Plast Reconstr Surg. 1994 Dec;94(7):1027-37</Citation><ArticleIdList><ArticleId IdType="pubmed">7972456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler Relat Disord. 2021 Sep;54:103103</Citation><ArticleIdList><ArticleId IdType="pubmed">34243101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Oct 07;6:34246</Citation><ArticleIdList><ArticleId IdType="pubmed">27713551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageing Res Rev. 2019 May;51:67-77</Citation><ArticleIdList><ArticleId IdType="pubmed">30763619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Agric Food Chem. 2008 Feb 13;56(3):1148-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18173244</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2014;11(9):834-43</Citation><ArticleIdList><ArticleId IdType="pubmed">25274111</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogerontology. 2010 Oct;11(5):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">20549353</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotoxicology. 2016 Jan;52:222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26687397</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Toxicol. 2008 May;82(5):273-99</Citation><ArticleIdList><ArticleId IdType="pubmed">18443763</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2020;75(4):1083-1103</Citation><ArticleIdList><ArticleId IdType="pubmed">32390618</ArticleId></ArticleIdList></Reference><Reference><Citation>Complement Ther Med. 2020 Jan;48:102252</Citation><ArticleIdList><ArticleId IdType="pubmed">31987244</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Nov 19;527(7578):S151-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26580320</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogerontology. 2009 Aug;10(4):489-502</Citation><ArticleIdList><ArticleId IdType="pubmed">19020987</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Complement Altern Med. 2017 Mar 14;17(1):156</Citation><ArticleIdList><ArticleId IdType="pubmed">28288617</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr J. 2017 Oct 6;16(1):67</Citation><ArticleIdList><ArticleId IdType="pubmed">28985741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intercult Ethnopharmacol. 2016 Sep 21;5(4):415-421</Citation><ArticleIdList><ArticleId IdType="pubmed">27757273</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Complement Altern Med. 2013 Oct 21;13:274</Citation><ArticleIdList><ArticleId IdType="pubmed">24499201</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2006 Apr;7(4):278-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Food Chem Toxicol. 2009 Jan;47(1):50-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18950673</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biochem Mol Toxicol. 2018 Feb;32(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29314450</ArticleId></ArticleIdList></Reference><Reference><Citation>Atherosclerosis. 2013 May;228(1):80-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23528829</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxicol Mech Methods. 2020 Oct;30(8):620-633</Citation><ArticleIdList><ArticleId IdType="pubmed">32718261</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2017 May 1;117:21-32</Citation><ArticleIdList><ArticleId IdType="pubmed">28132781</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Trace Elem Res. 2012 Dec;150(1-3):328-36</Citation><ArticleIdList><ArticleId IdType="pubmed">22945624</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 1994 Summer;18(2):291-304</Citation><ArticleIdList><ArticleId IdType="pubmed">7914688</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nutr. 2016 Jun;55(4):1653-60</Citation><ArticleIdList><ArticleId IdType="pubmed">26155780</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxid Med Cell Longev. 2017;2017:8416763</Citation><ArticleIdList><ArticleId IdType="pubmed">28819546</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol Pharmacol. 2004 Sep;55(3):503-17</Citation><ArticleIdList><ArticleId IdType="pubmed">15381823</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lipid Res. 1994 May;35(5):803-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8071603</ArticleId></ArticleIdList></Reference><Reference><Citation>Invest New Drugs. 2005 Jan;23(1):11-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15528976</ArticleId></ArticleIdList></Reference><Reference><Citation>J AOAC Int. 2012 Jan-Feb;95(1):163-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22468355</ArticleId></ArticleIdList></Reference><Reference><Citation>Environ Res. 2021 Aug;199:111270</Citation><ArticleIdList><ArticleId IdType="pubmed">33992638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2002 Apr;959:24-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11976182</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2015 Jun;28(3):206-19</Citation><ArticleIdList><ArticleId IdType="pubmed">25887768</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Transl Res. 2016 Sep 15;8(9):3970-3975</Citation><ArticleIdList><ArticleId IdType="pubmed">27725877</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nutr. 2007 Aug;46(5):271-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17514376</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ethnopharmacol. 2007 Jan 19;109(2):177-206</Citation><ArticleIdList><ArticleId IdType="pubmed">17157465</ArticleId></ArticleIdList></Reference><Reference><Citation>New Phytol. 2010 Dec;188(4):960-76</Citation><ArticleIdList><ArticleId IdType="pubmed">21039567</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr. 2013 May;143(5):597-605</Citation><ArticleIdList><ArticleId IdType="pubmed">23468550</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharmacol Sin. 2013 Nov;34(11):1411-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24077634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Nov 09;539(7628):180-186</Citation><ArticleIdList><ArticleId IdType="pubmed">27830812</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxicology. 2008 Apr 3;246(1):24-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18083283</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 2006 Oct;290(1-2):185-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16969688</ArticleId></ArticleIdList></Reference><Reference><Citation>J Agric Food Chem. 2006 Mar 8;54(5):1928-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16506855</ArticleId></ArticleIdList></Reference><Reference><Citation>Phytother Res. 2019 May;33(5):1277-1288</Citation><ArticleIdList><ArticleId IdType="pubmed">30882964</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Obes Metab. 2008 Jan;10(1):10-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18095947</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2014 Jul;73(7):640-57</Citation><ArticleIdList><ArticleId IdType="pubmed">24918636</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2015 Sep 22;6(5):e01419-15</Citation><ArticleIdList><ArticleId IdType="pubmed">26396245</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Pharmacol. 2016 Sep;68(9):1222-32</Citation><ArticleIdList><ArticleId IdType="pubmed">27364420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2015 Sep 15;5:14014</Citation><ArticleIdList><ArticleId IdType="pubmed">26369619</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2021 Aug 10;16(8):e0255831</Citation><ArticleIdList><ArticleId IdType="pubmed">34375350</ArticleId></ArticleIdList></Reference><Reference><Citation>Food Funct. 2015 Jun;6(6):2049-57</Citation><ArticleIdList><ArticleId IdType="pubmed">26030005</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vasc Surg. 2010 Nov;52(5):1290-300</Citation><ArticleIdList><ArticleId IdType="pubmed">20692795</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Plant Sci. 2004 Oct;9(10):490-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15465684</ArticleId></ArticleIdList></Reference><Reference><Citation>Phytother Res. 2020 Dec;34(12):3262-3272</Citation><ArticleIdList><ArticleId IdType="pubmed">32592417</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2014 May;35(5):1162-76</Citation><ArticleIdList><ArticleId IdType="pubmed">24315037</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Cell Environ. 2010 Apr;33(4):453-67</Citation><ArticleIdList><ArticleId IdType="pubmed">19712065</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2012 Jan 10;3(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">22233678</ArticleId></ArticleIdList></Reference><Reference><Citation>Food Nutr Res. 2015 Sep 08;59:28551</Citation><ArticleIdList><ArticleId IdType="pubmed">26355954</ArticleId></ArticleIdList></Reference><Reference><Citation>Food Funct. 2016 Dec 7;7(12):4976-4983</Citation><ArticleIdList><ArticleId IdType="pubmed">27845788</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2019 Dec 27;21(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">31892167</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Heart Assoc. 2014 Aug 06;3(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">25099132</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2017;23(7):1042-1050</Citation><ArticleIdList><ArticleId IdType="pubmed">27748197</ArticleId></ArticleIdList></Reference><Reference><Citation>Phytomedicine. 2022 Mar;97:153923</Citation><ArticleIdList><ArticleId IdType="pubmed">35026619</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroepidemiology. 2021;55(2):100-108</Citation><ArticleIdList><ArticleId IdType="pubmed">33657567</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2018 Apr 1;198:38-45</Citation><ArticleIdList><ArticleId IdType="pubmed">29455002</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ethnopharmacol. 2003 Dec;89(2-3):295-300</Citation><ArticleIdList><ArticleId IdType="pubmed">14611895</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutat Res. 1992 Sep;275(3-6):257-66</Citation><ArticleIdList><ArticleId IdType="pubmed">1383768</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Rev. 2014 May;259(1):231-44</Citation><ArticleIdList><ArticleId IdType="pubmed">24712469</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36118272</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-3546</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Brain, behavior, &amp; immunity - health</Title><ISOAbbreviation>Brain Behav Immun Health</ISOAbbreviation></Journal><ArticleTitle>Infection and inflammation: New perspectives on Alzheimer's disease.</ArticleTitle><Pagination><MedlinePgn>100462</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbih.2022.100462</ELocationID><Abstract><AbstractText>Neuroinflammation has been recognized as a component of Alzheimer's Disease (AD) pathology since the original descriptions by Alois Alzheimer and a role for infections in AD pathogenesis has long been hypothesized. More recently, this hypothesis has gained strength as human genetics and experimental data suggest key roles for inflammatory cells in AD pathogenesis. To review this topic, Duke/University of North Carolina (Duke/UNC) Alzheimer's Disease Research Center hosted a virtual symposium: "Infection and Inflammation: New Perspectives on Alzheimer's Disease (AD)." Participants considered current evidence for and against the hypothesis that AD could be caused or exacerbated by infection or commensal microbes. Discussion focused on connecting microglial transcriptional states to functional states, mouse models that better mimic human immunity, the potential involvement of inflammasome signaling, metabolic alterations, self-reactive T cells, gut microbes and fungal infections, and lessons learned from Covid-19 patients with neurologic symptoms. The content presented in the symposium, and major topics raised in discussions are reviewed in this summary of the proceedings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Whitson</LastName><ForeName>Heather E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Duke Center for the Study of Aging and Human Development, Duke University School of Medicine, Busse Bldg Rm 3502, Durham, NC, 27710, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Durham VA Medical Center, Geriatric Research Education and Clinical Center, 508 Fulton Street, Durham, NC, 27705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colton</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University School of Medicine, 3116 N Duke St, Durham, NM, 27704, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Khoury</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Immunology &amp; Inflammatory Diseases, Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Ken &amp; Ruth Davee Dept of Neurology, Northwestern University Feinberg School of Medicine, 303 E Chicago Ave, Ward 12-140, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dept of Genetics and Genomic Sciences, Icahn School of Medicine at Mt. Sinai, One Gustave L. Levy Place, Box 1498, New York, NY, 10029-6574, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Dept of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Sigmund-Freud Str. 25, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaddurah-Daouk</LastName><ForeName>Rima</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dept of Psychiatry and Behavioral Sciences, Dept of Medicine, Duke Institute of Brain Sciences, Duke University School of Medicine, DUMC Box 3903, Blue Zone, South, Durham, NC, 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Robyn S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Center for Neuroimmunology &amp; Neuroinfectious Diseases, Depts of Medicine, Pathology &amp; Immunology, and Neuroscience, Washington University School of Medicine, 660 S Euclid Ave, Box 8015, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinohara</LastName><ForeName>Mari L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Dept of Immunology, Duke University School of Medicine, 207 Research Dr, Box 3010, Durham, NC, 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dept of Neurobiology, University of Chicago, Abbott Memorial Hall, 947 East 58th St, MC 0928, Chicago, IL, 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spudich</LastName><ForeName>Serena S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Dept of Neurology, Yale School of Medicine, PO Box 208018, New Haven, CT, 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Children's Hospital Boston, 300 Longwood Ave, Center for Life Sciences 12th Floor, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>McCance Center for Brain Health, Massachusetts General Hospital, 114 16th St, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ting</LastName><ForeName>Jenny P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Depts of Genetics, Microbiology and Immunology, Lineberger Comprehensive Cancer Center, Center for Translational Immunology, UNC School of Medicine, 125 Mason Farm Road, 6th Floor Marsico Hall, Chapel Hill, NC, 27599-7290, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garden</LastName><ForeName>Gwenn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dept of Neurology, UNC School of Medicine, Physicians Office Building, 170 Manning Drive, Campus Box 7025, Chapel Hill, NC, 27599-7025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Symposium Planning Committee members</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS120417</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Behav Immun Health</MedlineTA><NlmUniqueID>101759062</NlmUniqueID><ISSNLinking>2666-3546</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's</Keyword><Keyword MajorTopicYN="N">Fungi</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Inflammasome</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword><Keyword MajorTopicYN="N">Microbe</Keyword><Keyword MajorTopicYN="N">Microbiome</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Aiello</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiba-Falek</LastName><ForeName>Ornit</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heitman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kim G</ForeName><Initials>KG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luftig</LastName><ForeName>Micah</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moseman</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rawls</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shinohara</LastName><ForeName>Mari L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swanstrom</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terrando</LastName><ForeName>Niccolo</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>04</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36118272</ArticleId><ArticleId IdType="doi">10.1016/j.bbih.2022.100462</ArticleId><ArticleId IdType="pii">S2666-3546(22)00052-7</ArticleId><ArticleId IdType="pmc">PMC9475126</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 2019 Nov;575(7784):669-673</Citation><ArticleIdList><ArticleId IdType="pubmed">31748742</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Biol. 2019 Dec 4;17(12):e3000535</Citation><ArticleIdList><ArticleId IdType="pubmed">31800587</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2017 May 26;12(1):43</Citation><ArticleIdList><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Imaging Behav. 2014 Jun;8(2):262-73</Citation><ArticleIdList><ArticleId IdType="pubmed">24293121</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Signal. 2012 May 22;5(225):ra38</Citation><ArticleIdList><ArticleId IdType="pubmed">22623753</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2019 Nov 29;366(6469):1134-1139</Citation><ArticleIdList><ArticleId IdType="pubmed">31727856</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2021 Sep;17(9):1509-1527</Citation><ArticleIdList><ArticleId IdType="pubmed">33797837</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2016 Nov 15;142:498-511</Citation><ArticleIdList><ArticleId IdType="pubmed">27521741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2009 Jul;29(7):1251-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19401709</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2014 Aug;73(8):752-69</Citation><ArticleIdList><ArticleId IdType="pubmed">25003233</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2019 Nov 01;10:2578</Citation><ArticleIdList><ArticleId IdType="pubmed">31736980</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2022 Jan 20;19(1):19</Citation><ArticleIdList><ArticleId IdType="pubmed">35057809</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2017 Jun 15;169(7):1276-1290.e17</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2016 May 27;16(6):341-52</Citation><ArticleIdList><ArticleId IdType="pubmed">27231050</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2018 Feb;19(2):151-161</Citation><ArticleIdList><ArticleId IdType="pubmed">29292385</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2019 Jan;15(1):76-92</Citation><ArticleIdList><ArticleId IdType="pubmed">30337151</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2020 Dec;21(12):717-731</Citation><ArticleIdList><ArticleId IdType="pubmed">33067567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2019 Feb;85(2):181-193</Citation><ArticleIdList><ArticleId IdType="pubmed">30549303</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2019 Apr;15(4):191-192</Citation><ArticleIdList><ArticleId IdType="pubmed">30833695</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Nov 13;515(7526):274-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2015 Apr 15;35(15):5969-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25878270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Jan 31;493(7434):674-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2016 May 25;8(340):340ra72</Citation><ArticleIdList><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2021 Oct;42(10):891-903</Citation><ArticleIdList><ArticleId IdType="pubmed">34489167</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neuroinform. 2019 Dec 10;13:72</Citation><ArticleIdList><ArticleId IdType="pubmed">31920610</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2010 Jul 15;185(2):974-81</Citation><ArticleIdList><ArticleId IdType="pubmed">20574004</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2021 Apr;17(4):561-573</Citation><ArticleIdList><ArticleId IdType="pubmed">33480182</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2014 Oct 20;211(11):2307-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25267792</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2017 Dec 20;552(7685):355-361</Citation><ArticleIdList><ArticleId IdType="pubmed">29293211</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Microbiol. 2014 Feb;17:17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24581688</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2017 Jul 14;8:459</Citation><ArticleIdList><ArticleId IdType="pubmed">28769794</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2018 Jul;559(7715):S4-S7</Citation><ArticleIdList><ArticleId IdType="pubmed">30046080</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2021 Mar 12;12(1):1610</Citation><ArticleIdList><ArticleId IdType="pubmed">33712570</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Soc Mass Spectrom. 2021 Jun 2;32(6):1448-1458</Citation><ArticleIdList><ArticleId IdType="pubmed">34028275</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2021 Aug 15;90(4):e23-e26</Citation><ArticleIdList><ArticleId IdType="pubmed">34001372</ArticleId></ArticleIdList></Reference><Reference><Citation>J Proteome Res. 2013 Oct 4;12(10):4462-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24006891</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2021 Jun;24(6):786-798</Citation><ArticleIdList><ArticleId IdType="pubmed">33958804</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Jul;18(7):965-77</Citation><ArticleIdList><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2010 Nov 24;30(47):15811-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21106820</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2018 May 24;10:159</Citation><ArticleIdList><ArticleId IdType="pubmed">29881346</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Mar 13;11(1):1377</Citation><ArticleIdList><ArticleId IdType="pubmed">32170138</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Jul 21;6:30028</Citation><ArticleIdList><ArticleId IdType="pubmed">27443609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2020 Nov;19(11):919-929</Citation><ArticleIdList><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2018 May 25;8(1):108</Citation><ArticleIdList><ArticleId IdType="pubmed">29802260</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2019 Sep 4;103(5):820-835.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">31301936</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2018 Jun;114:24-30</Citation><ArticleIdList><ArticleId IdType="pubmed">29477641</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurotrauma. 2018 Jun 1;35(11):1294-1303</Citation><ArticleIdList><ArticleId IdType="pubmed">29295651</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2017 Aug;20(8):1052-1061</Citation><ArticleIdList><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Jun 9;6:36</Citation><ArticleIdList><ArticleId IdType="pubmed">32550001</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2021 Mar 9;54(3):484-498.e8</Citation><ArticleIdList><ArticleId IdType="pubmed">33581044</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2019 Jul 1;216(7):1542-1560</Citation><ArticleIdList><ArticleId IdType="pubmed">31097468</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Sep 3;383(10):989-992</Citation><ArticleIdList><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2018 Dec 19;100(6):1527-1532</Citation><ArticleIdList><ArticleId IdType="pubmed">30571943</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2017 Sep 8;23(9):1018-1027</Citation><ArticleIdList><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2019 Oct 3;179(2):312-339</Citation><ArticleIdList><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2019 Mar;51(3):414-430</Citation><ArticleIdList><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2019 Apr 26;37:73-95</Citation><ArticleIdList><ArticleId IdType="pubmed">31026414</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2020 Aug 1;77(8):1018-1027</Citation><ArticleIdList><ArticleId IdType="pubmed">32469387</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Jan;577(7790):399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">31915375</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2014 Sep;35(9):1992-2003</Citation><ArticleIdList><ArticleId IdType="pubmed">24746363</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2017;58(1):55-67</Citation><ArticleIdList><ArticleId IdType="pubmed">28387676</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2014 Apr;34(4):621-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24398937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2016 Jul;16(7):407-20</Citation><ArticleIdList><ArticleId IdType="pubmed">27291964</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2019 Aug;22(8):1276-1288</Citation><ArticleIdList><ArticleId IdType="pubmed">31235930</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep Med. 2021 May 18;2(5):100288</Citation><ArticleIdList><ArticleId IdType="pubmed">33969321</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2019 May 15;10(5):2560-2575</Citation><ArticleIdList><ArticleId IdType="pubmed">30817119</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36117569</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2451-8654</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Contemporary clinical trials communications</Title><ISOAbbreviation>Contemp Clin Trials Commun</ISOAbbreviation></Journal><ArticleTitle>Diminishing accelerated long-term forgetting in mild cognitive impairment: Study protocol for a prospective, double-blind, placebo-controlled, randomized controlled trial.</ArticleTitle><Pagination><MedlinePgn>100989</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.conctc.2022.100989</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Harnessing the lifelong potential of the human brain for neuroplasticity may serve to maintain the viability of neural structures and postpone the onset of cognitive decline. The absence of effective pharmacological interventions to counter memory decline has encouraged scientists to test the possibility that noninvasive electrical stimulation may serve as an additional tool to improve memory abilities.Previous research showed that electrical stimulation of the greater occipital nerve enhances memory recall performance in young and older healthy subjects. This study aims to extend these findings to determine the effect of transcutaneous electrical stimulation of the greater occipital nerve on the improvement of episodic memory in individuals with amnestic Mild Cognitive Impairment (aMCI).</AbstractText><AbstractText Label="Methods/design" NlmCategory="UNASSIGNED">This study is a prospective, double-blind, placebo-controlled, randomized parallel-group study. A total of 100 individuals with a diagnosis of aMCI according to NIA/AA will be recruited. Participants will be randomly assigned to one of four groups. One group will receive active non-invasive transcutaneous electrical stimulation of greater occipital nerve (NITESGON), while three groups will serve as controls (i.e., sham NITESGON, active NITESGON with local anesthesia, and active NITESGON on the C5/C6 nerve). The primary outcome, i.e., memory recall, will be determined by a word association task, and will be recorded at baseline, 7 days after NITESGON, and 28 days after NITESGON. The secondary outcome is neurophysiological changes determined by resting state EEG and will be assessed immediately before and after NITESGON.</AbstractText><AbstractText Label="Discussion" NlmCategory="UNASSIGNED">The results will add new insights into improving episodic memory in individuals with aMCI.</AbstractText><AbstractText Label="Trial registration" NlmCategory="UNASSIGNED">#NCT05289804 (clinicaltrial.gov).</AbstractText><AbstractText Label="Protocol approval id" NlmCategory="UNASSIGNED">#SPREC102021-23 (Ethics Committee at Trinity College Dublin, School of Psychology).</AbstractText><CopyrightInformation>© 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adcock</LastName><ForeName>Katherine S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Global Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Global Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Ian H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Global Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanneste</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Global Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05289804</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Contemp Clin Trials Commun</MedlineTA><NlmUniqueID>101671157</NlmUniqueID><ISSNLinking>2451-8654</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amnestic mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">Electrical stimulation</Keyword><Keyword MajorTopicYN="N">Episodic memory</Keyword><Keyword MajorTopicYN="N">Greater occipital nerve</Keyword><Keyword MajorTopicYN="N">Mild Alzheimer's disease</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>3</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36117569</ArticleId><ArticleId IdType="doi">10.1016/j.conctc.2022.100989</ArticleId><ArticleId IdType="pii">S2451-8654(22)00106-5</ArticleId><ArticleId IdType="pmc">PMC9478352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuropsychology. 2014 Mar;28(2):273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24219610</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2009 Mar;10(3):211-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19190638</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Stimul. 2022 May-Jun;15(3):536-545</Citation><ArticleIdList><ArticleId IdType="pubmed">35318122</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 Oct 31;346(6209):572-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25359964</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neurophysiol. 2017 Jan;128(1):56-92</Citation><ArticleIdList><ArticleId IdType="pubmed">27866120</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2014 Dec 17;312(23):2551-61</Citation><ArticleIdList><ArticleId IdType="pubmed">25514304</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2003 Mar;60(3):337-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12633144</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neurophysiol Pract. 2016 Dec 21;2:19-25</Citation><ArticleIdList><ArticleId IdType="pubmed">30214966</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2011 May;121(5):589-95</Citation><ArticleIdList><ArticleId IdType="pubmed">21516512</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2015 Oct 7;88(1):20-32</Citation><ArticleIdList><ArticleId IdType="pubmed">26447570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2018 Feb;17(2):123-132</Citation><ArticleIdList><ArticleId IdType="pubmed">29413314</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Stimul. 2016 Sep-Oct;9(5):641-661</Citation><ArticleIdList><ArticleId IdType="pubmed">27372845</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1992 Nov;32(5):667-76</Citation><ArticleIdList><ArticleId IdType="pubmed">1449247</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intern Med. 2004 Sep;256(3):183-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurorehabil Neural Repair. 2020 Nov;34(11):1020-1029</Citation><ArticleIdList><ArticleId IdType="pubmed">32964776</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):270-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Geriatr Gerontol Int. 2015 Mar;15(3):334-40</Citation><ArticleIdList><ArticleId IdType="pubmed">24661561</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2011 Sep;14(8):1133-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21320389</ArticleId></ArticleIdList></Reference><Reference><Citation>J Anaesthesiol Clin Pharmacol. 2015 Oct-Dec;31(4):450-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26702198</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2011 Feb;121(2):171-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1987;1(4):256-62</Citation><ArticleIdList><ArticleId IdType="pubmed">3453748</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1983 Nov 28;280(1):119-26</Citation><ArticleIdList><ArticleId IdType="pubmed">6228286</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1989 Sep 15;287(3):373-92</Citation><ArticleIdList><ArticleId IdType="pubmed">2570794</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2007 May 30;72(4-6):208-14</Citation><ArticleIdList><ArticleId IdType="pubmed">17452283</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 Feb 15;319(5865):966-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18276894</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathology. 2006 Dec;26(6):528-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17203588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2015 Aug;14(8):804-813</Citation><ArticleIdList><ArticleId IdType="pubmed">26139022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Adv. 2020 Nov 4;6(45):</Citation><ArticleIdList><ArticleId IdType="pubmed">33148657</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2007 Mar;28(3):327-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16574280</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2003 Jan-Feb;24(1):1-23</Citation><ArticleIdList><ArticleId IdType="pubmed">12493547</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2017 Apr 7;356(6333):73-78</Citation><ArticleIdList><ArticleId IdType="pubmed">28386011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2002 Jan;15(1):1-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36117568</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2451-8654</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Contemporary clinical trials communications</Title><ISOAbbreviation>Contemp Clin Trials Commun</ISOAbbreviation></Journal><ArticleTitle>Effects of dose change on the success of clinical trials.</ArticleTitle><Pagination><MedlinePgn>100988</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.conctc.2022.100988</ELocationID><Abstract><AbstractText>The search for disease modifying therapies in Alzheimers disease (AD) has recently led to promising results but also revealed design issues in clinical trials themselves. Of particular importance is the potential statistical challenges that can arise when dosages change after an interim analysis, which is not uncommon in contemporary AD trials. Following the recent Aducanumab trials, we sought to study the implications of dose changes on the statistical power of an AD trial. We conducted extensive simulations to calculate statistical power when the relationship between treatment effect size and time is linear or non-linear, and the investigated drug has delayed treatment effect or not. Statistical power depends on many design factors including the dose change time, correlation, population homogeneity, and treatment effect time. We recommend that researchers conduct simulation studies at the interim analysis to justify the modified sample size and/or follow-up time modification meanwhile the type I and II error rates are controlled.</AbstractText><CopyrightInformation>© 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Guogen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Florida, Gainesville, FL 32611, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritter</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, 89106, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, 89106, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, WA, 98195, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Contemp Clin Trials Commun</MedlineTA><NlmUniqueID>101671157</NlmUniqueID><ISSNLinking>2451-8654</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aducanumab trial</Keyword><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">Dose change</Keyword><Keyword MajorTopicYN="N">Statistical power</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>3</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36117568</ArticleId><ArticleId IdType="doi">10.1016/j.conctc.2022.100988</ArticleId><ArticleId IdType="pii">S2451-8654(22)00105-3</ArticleId><ArticleId IdType="pmc">PMC9478360</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimers Dement (N Y). 2018 Jun 13;4:357-365</Citation><ArticleIdList><ArticleId IdType="pubmed">30175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Contemp Clin Trials Commun. 2018 Nov 29;13:100309</Citation><ArticleIdList><ArticleId IdType="pubmed">30582068</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2018 Jul;27(7):2132-2141</Citation><ArticleIdList><ArticleId IdType="pubmed">27856958</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2021 Mar;17(3):129-130</Citation><ArticleIdList><ArticleId IdType="pubmed">33442064</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2022 Mar;18(3):531-533</Citation><ArticleIdList><ArticleId IdType="pubmed">34314093</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2012 Jul;69(7):901-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22431834</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychol. 2013 Nov 26;4:863</Citation><ArticleIdList><ArticleId IdType="pubmed">24324449</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2020 Feb;19(2):111-112</Citation><ArticleIdList><ArticleId IdType="pubmed">31978357</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2021 Apr;17(4):702-703</Citation><ArticleIdList><ArticleId IdType="pubmed">33135288</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2021 Jan;57(1):106167</Citation><ArticleIdList><ArticleId IdType="pubmed">33408032</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2014 Jul 30;33(17):2998-3012</Citation><ArticleIdList><ArticleId IdType="pubmed">24634280</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 2009 May 20;101(10):708-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19436029</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2021 May 10;13(1):98</Citation><ArticleIdList><ArticleId IdType="pubmed">33971962</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Aug 31;537(7618):50-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Dec 20;12(12):e0188709</Citation><ArticleIdList><ArticleId IdType="pubmed">29261690</ArticleId></ArticleIdList></Reference><Reference><Citation>Contemp Clin Trials. 2012 Mar;33(2):332-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22074983</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2001 May;51(5):394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11421995</ArticleId></ArticleIdList></Reference><Reference><Citation>Contemp Clin Trials Commun. 2021 Jan 23;21:100732</Citation><ArticleIdList><ArticleId IdType="pubmed">33553801</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2019 Jul 09;5:272-293</Citation><ArticleIdList><ArticleId IdType="pubmed">31334330</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Res Methodol. 2019 Apr 3;19(1):74</Citation><ArticleIdList><ArticleId IdType="pubmed">30943896</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2018 Jun 14;4:366-371</Citation><ArticleIdList><ArticleId IdType="pubmed">30175231</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2018 Jul 11;4:350-356</Citation><ArticleIdList><ArticleId IdType="pubmed">30175229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biopharm Stat. 2016;26(2):240-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25551261</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2021 Jul;27(7):1187-1196</Citation><ArticleIdList><ArticleId IdType="pubmed">34155411</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):280-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36117051</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Study of Alzheimer's disease- and frontotemporal dementia-associated genes in the Cretan Aging Cohort.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0197-4580(22)00146-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2022.07.002</ELocationID><Abstract><AbstractText>Using exome sequencing, we analyzed 196 participants of the Cretan Aging Cohort (CAC; 95 with Alzheimer's disease [AD], 20 with mild cognitive impairment [MCI], and 81 cognitively normal controls). The APOE ε4 allele was more common in AD patients (23.2%) than in controls (7.4%; p &lt; 0.01) and the PSEN2 p.Arg29His and p.Cys391Arg variants were found in 3 AD and 1 MCI patient, respectively. Also, we found the frontotemporal dementia (FTD)-associated TARDBP gene p.Ile383Val variant in 2 elderly patients diagnosed with AD and in 2 patients, non CAC members, with the amyotrophic lateral sclerosis/FTD phenotype. Furthermore, the p.Ser498Ala variant in the positively selected GLUD2 gene was less frequent in AD patients (2.11%) than in controls (16%; p &lt; 0.01), suggesting a possible protective effect. While the same trend was found in another local replication cohort (n = 406) and in section of the ADNI cohort (n = 808), this finding did not reach statistical significance and therefore it should be considered preliminary. Our results attest to the value of genetic testing to study aged adults with AD phenotype.</AbstractText><CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathioudakis</LastName><ForeName>Lambros</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Neurology/Neurogenetics Laboratory, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimovasili</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Neurology/Neurogenetics Laboratory, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourbouli</LastName><ForeName>Mara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Neurology/Neurogenetics Laboratory, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latsoudis</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Minotech Genomics Facility, Institute of Molecular Biology and Biotechnology (IMBB-FORTH), Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokosali</LastName><ForeName>Evgenia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Neurology/Neurogenetics Laboratory, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouna</LastName><ForeName>Garyfallia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Neurology/Neurogenetics Laboratory, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogiatzi</LastName><ForeName>Emmanouella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Neurology/Neurogenetics Laboratory, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basta</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Psychiatry Department, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapetanaki</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Neurology/Neurogenetics Laboratory, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panagiotakis</LastName><ForeName>Simeon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Internal Medicine Department, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanterakis</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology - Hellas (ICS-FORTH), Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boumpas</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Internal Medicine Department, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lionis</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Clinic of Social and Family Medicine, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plaitakis</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Neurology/Neurogenetics Laboratory, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simos</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Psychiatry Department, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vgontzas</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Psychiatry Department, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kafetzopoulos</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Minotech Genomics Facility, Institute of Molecular Biology and Biotechnology (IMBB-FORTH), Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaganas</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University of Crete, Medical School, Neurology/Neurogenetics Laboratory, Heraklion, Crete, Greece. Electronic address: zaganas@uoc.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Glutamate dehydrogenase</Keyword><Keyword MajorTopicYN="N">TARDBP</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>22</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36117051</ArticleId><ArticleId IdType="pii">S0197-4580(22)00146-4</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2022.07.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36116796</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-0103</ISSN><JournalIssue CitedMedium="Internet"><Volume>383</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of pharmacology and experimental therapeutics</Title><ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation></Journal><ArticleTitle>Metabotropic Glutamate Receptors Modulate Exocytotic Tau Release and Propagation.</ArticleTitle><Pagination><MedlinePgn>117-128</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.122.001307</ELocationID><Abstract><AbstractText>Using synaptosomes purified from the brains of two transgenic mouse models overexpressing mutated human tau (TgP301S and Tg4510) and brains of patients with sporadic Alzheimer's disease, we showed that aggregated and hyperphosphorylated tau was both present in purified synaptosomes and released in a calcium- and synaptosome-associated protein of 25 kDa (SNAP25)-dependent manner. In all mouse and human synaptosomal preparations, tau release was inhibited by the selective metabotropic glutamate receptor 2/3 (mGluR2/3) agonist LY379268, an effect prevented by the selective mGlu2/3 antagonist LY341495. LY379268 was also able to block pathologic tau propagation between primary neurons in an in vitro microfluidic cellular model. These novel results are transformational for our understanding of the molecular mechanisms mediating tau release and propagation at synaptic terminals in Alzheimer's disease and suggest that these processes could be inhibited therapeutically by the selective activation of presynaptic G protein-coupled receptors. SIGNIFICANCE STATEMENT: Pathological tau release and propagation are key neuropathological events underlying cognitive decline in Alzheimer's disease patients. This paper describes the role of regulated exocytosis, and the soluble N-ethylmaleimide-sensitive factor attachment receptor (SNARE) protein SNAP25, in mediating tau release from rodent and human synaptosomes. This paper also shows that a selective mGluR2/3 agonist is highly effective in blocking tau release from synaptosomes and tau propagation between neurons, opening the way to the discovery of novel therapeutic approaches to this devastating disease.</AbstractText><CopyrightInformation>Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazzo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butnaru</LastName><ForeName>Ioana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grubisha</LastName><ForeName>Olivera</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ficulle</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanger</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Griffin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasqui</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Tracey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monn</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bose</LastName><ForeName>Suchira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiavo</LastName><ForeName>Giampietro</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sher</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Ltd, Neuroscience, Bracknell, United Kingdom (F.M., O.G., E.F., H.S., Fr.P., T.M., S.B., E.S.); UK Dementia Research Institute at UCL, University College London, London, United Kingdom (I.B., G.S.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (G.F., Fe.P., J.M., X.L., M.H.); and Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, United Kingdom (G.S.) sher_emanuele@lilly.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharmacol Exp Ther</MedlineTA><NlmUniqueID>0376362</NlmUniqueID><ISSNLinking>0022-3565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018094">Receptors, Metabotropic Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="D052066">N-Ethylmaleimide-Sensitive Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005089" MajorTopicYN="N">Exocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052066" MajorTopicYN="N">N-Ethylmaleimide-Sensitive Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018094" MajorTopicYN="Y">Receptors, Metabotropic Glutamate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050600" MajorTopicYN="N">SNARE Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>20</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36116796</ArticleId><ArticleId IdType="pii">jpet.122.001307</ArticleId><ArticleId IdType="doi">10.1124/jpet.122.001307</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36116712</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5894</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Magnetic resonance imaging</Title><ISOAbbreviation>Magn Reson Imaging</ISOAbbreviation></Journal><ArticleTitle>Brain microstructure abnormalities in the 3xTg-AD mouse - A diffusion MRI and morphology correlation study.</ArticleTitle><Pagination><MedlinePgn>48-55</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0730-725X(22)00162-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mri.2022.09.002</ELocationID><Abstract><AbstractText>The widely studied triple transgenic (3xTg-AD) mouse provides a robust model of Alzheimer's disease (AD) with region dependent patterns of progressive amyloid-β (Aß) and tau pathology. Using diffusion MRI (dMRI), we investigated the sensitivity of dMRI measures in capturing AD pathology associated microstructure alterations in older 3xTg-AD mice, and the degree to which dMRI changes correlate with measurements of Aβ and tau pathology. 3xTg-AD and normal control (NC) mice, 15 to 21 months of age, were used in this study. In vivo dMRI data were acquired for the generation of diffusion tensor (DT) and diffusional kurtosis (DK) measures within the hippocampus and fimbria (Fi). For these same brain regions, Aβ and tau pathology were quantified by morphological analysis of Aß1-42 and AT8 immunoreactivity. Two-tailed, two-sample t-tests were performed to assess group differences in each brain region of interest (ROI), with the Benjamini-Hochberg false discovery rate (FDR) method being applied to adjust for multiple comparisons. Spearman correlation coefficients were calculated to investigate associations between diffusion and morphological measures. Our results revealed, depending on the brain region, DT and DK measures were able to detect group differences. In the dorsal hippocampus (HD), fractional anisotropy (FA) was significantly higher in the 3xTg-AD mice compared with NC mice. In the subiculum (SUB), FA, axial diffusivity (D<sub>||</sub>) and radial kurtosis (K<sub>┴</sub>) were significantly higher in 3xTg-AD mice compared with NC mice. Morphological quantification of Aß1-42 and AT8 immunoreactivity showed elevated Aß and tau in the Fi, ventral hippocampus (HV) and SUB of 3xTg-AD mice. The presence of Aβ and tau was significantly correlated with several DT and DK measures, particularly in the SUB, where an increase in tau correlated with an increase in mean kurtosis (MK) and K<sub>┴</sub>. This work demonstrates significant dMRI differences between older 3xTg-AD and NC mice in the hippocampus and Fi. Significant correlations were found between dMRI and morphological measures of Aβ and tau pathology. These results support the potential of dMRI-derived parameters as biomarkers of AD pathology. Since the imaging methods employed here are easily translatable to clinical MRI, our results are also relevant for human AD patients.</AbstractText><CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falangola</LastName><ForeName>Maria Fatima</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA; Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, USA. Electronic address: falangol@musc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Xingju</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA; Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voltin</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA; Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhiman</LastName><ForeName>Siddhartha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nietert</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Jens H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA; Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, USA; Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Magn Reson Imaging</MedlineTA><NlmUniqueID>8214883</NlmUniqueID><ISSNLinking>0730-725X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078331" MajorTopicYN="N">Correlation of Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018397" MajorTopicYN="N">Equidae</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3xTg-AD mouse</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Diffusion MRI</Keyword><Keyword MajorTopicYN="N">Diffusional kurtosis imaging</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36116712</ArticleId><ArticleId IdType="pii">S0730-725X(22)00162-X</ArticleId><ArticleId IdType="doi">10.1016/j.mri.2022.09.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36116491</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0953</ISSN><JournalIssue CitedMedium="Internet"><Volume>215</Volume><Issue>Pt 2</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Environmental research</Title><ISOAbbreviation>Environ Res</ISOAbbreviation></Journal><ArticleTitle>Ambient air pollution and risk of incident dementia in older men living in a region with relatively low concentrations of pollutants: The Health in Men Study.</ArticleTitle><Pagination><MedlinePgn>114349</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0013-9351(22)01676-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.envres.2022.114349</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In areas with moderate to severe air pollution, pollutant concentrations are associated with dementia risk. It is unclear whether the same relationship is present in regions with lower ambient air pollution.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether exposure to air pollution is associated with risk of incident dementia in general, and Alzheimer's disease and vascular dementia in particular, in older men living in a relatively low ambient air pollution region.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The cohort comprised 11,243 men residing in Perth, Australia. Participants were aged ≥65 years and free of a dementia diagnosis at time of recruitment in 1996-1999. Incident dementia was identified from recruitment to 2018 via ICD diagnosis codes and subsequent study waves. Concentrations for three air pollutants, nitrogen dioxide (NO<sub>2</sub>), fine particulate matter less than 2.5 μm in diameter (PM<sub>2.5</sub>), and black carbon (BC) were estimated at participants' home addresses using land-use regression models. We used Cox proportional hazards regression models adjusting for smoking status, physical activity, BMI, education, and socio-economic status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 3053 (27.2%) incident cases of dementia, 1670 (54.7%) and 355 (11.6%) had documented Alzheimer's disease and vascular dementia. The average concentration of NO<sub>2</sub> was 13.5 (SD 4.4) μg/m<sup>3</sup>, of PM<sub>2.5</sub> was 4.54 (SD 1.6) μg/m<sup>3</sup> and of BC was 0.97 (SD 0.29) ×10<sup>-5</sup> m<sup>-1</sup>. None of the air pollutants were associated with incident dementia or Alzheimer's disease. In the unadjusted model, increased exposure to PM<sub>2.5</sub> was associated with an increased risk of vascular dementia (for a 5 μg/m<sup>3</sup> increase: HR 1.62, 95% CI 1.13, 2.31). However, this association was attenuated following adjustment for confounders (HR 1.39, 95% CI 0.93, 2.08). NO<sub>2</sub> and BC were not associated with vascular dementia incidence.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Exposure to air pollution is not associated with increased risk of incident dementia in older men living in a region with relatively low ambient air pollution.</AbstractText><CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trevenen</LastName><ForeName>Michelle L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Western Australian Centre for Health and Ageing, University of Western Australia, Perth, Western Australia, Australia. Electronic address: michelle.trevenen@uwa.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyworth</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Osvaldo P</ForeName><Initials>OP</Initials><AffiliationInfo><Affiliation>Western Australian Centre for Health and Ageing, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeap</LastName><ForeName>Bu B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Perth, Western Australia, Australia; Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hankey</LastName><ForeName>Graeme J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golledge</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Queensland Research Centre for Peripheral Vascular Disease, James Cook University and Townsville University Hospital, Townsville, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etherton-Beer</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Western Australian Centre for Health and Ageing, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Population Health, Curtin University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieuwenhuijsen</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Centre for Research in Environmental Epidemiology, ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flicker</LastName><ForeName>Leon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Western Australian Centre for Health and Ageing, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Environ Res</MedlineTA><NlmUniqueID>0147621</NlmUniqueID><ISSNLinking>0013-9351</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000393">Air Pollutants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004785">Environmental Pollutants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052638">Particulate Matter</NameOfSubstance></Chemical><Chemical><RegistryNumber>7440-44-0</RegistryNumber><NameOfSubstance UI="D002244">Carbon</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7G510RUBH</RegistryNumber><NameOfSubstance UI="D009585">Nitrogen Dioxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000393" MajorTopicYN="Y">Air Pollutants</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000397" MajorTopicYN="Y">Air Pollution</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002244" MajorTopicYN="N">Carbon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="Y">Dementia, Vascular</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004781" MajorTopicYN="N">Environmental Exposure</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004785" MajorTopicYN="Y">Environmental Pollutants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009585" MajorTopicYN="N">Nitrogen Dioxide</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052638" MajorTopicYN="N">Particulate Matter</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Air pollution</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Cohort</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Nitrogen dioxide</Keyword><Keyword MajorTopicYN="N">Particulate matter</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36116491</ArticleId><ArticleId IdType="pii">S0013-9351(22)01676-0</ArticleId><ArticleId IdType="doi">10.1016/j.envres.2022.114349</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36116359</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-460X</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>10</Month></PubDate></JournalIssue><Title>Journal of diabetes and its complications</Title><ISOAbbreviation>J Diabetes Complications</ISOAbbreviation></Journal><ArticleTitle>Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular risk.</ArticleTitle><Pagination><MedlinePgn>108303</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1056-8727(22)00215-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jdiacomp.2022.108303</ELocationID><Abstract><AbstractText Label="AIMS">We addressed the question whether chronic kidney disease (CKD) may contribute to cognitive decline in type 2 diabetes.</AbstractText><AbstractText Label="METHODS">Participants with type 2 diabetes with elevated cardiovascular risk or CKD from cognition substudies of two large trials were studied prospectively (CARMELINA: n = 2666, mean ± SD age 68.1 ± 8.7 years, CAROLINA: n = 4296; 64.7 ± 9.4 years). Estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) at baseline were related to cognitive performance (Mini-Mental State Examination (MMSE) and attention and executive functioning score (A&amp;E)) in linear regression analyses, adjusted for demographics, cardiovascular risk factors and treatment, at baseline and follow-up.</AbstractText><AbstractText Label="RESULTS">CKD at baseline was more common in CARMELINA than CAROLINA (eGFR&lt;60 in 72.6 % and 19.6 %, macroalbuminuria in 35.0 % and 4.1 %, respectively). Baseline eGFR was related to A&amp;E in CARMELINA (b = 0.02 per 10 ml/min/1.73m<sup>2</sup>, 95%CI [0.01,0.03]). Baseline UACR was related to A&amp;E in CAROLINA (b = -0.01 per doubling of UACR mg/g, 95%CI [-0.02,-0.002]). Baseline UACR predicted decline in A&amp;E in CAROLINA (median 6.1 years follow-up; b = -0.01, 95%CI [-0.03,-0.0001] per doubling of UACR mg/g).</AbstractText><AbstractText Label="CONCLUSIONS">eGFR and UACR were associated with A&amp;E in two cohorts with type 2 diabetes, enriched for CKD and cardiovascular disease. The small effect size estimates indicate limited impact of kidney dysfunction on cognition in this setting.</AbstractText><AbstractText Label="CLINICALTRIALS"/><AbstractText Label="GOV IDENTIFIERS">NCT01897532 NCT01243424.</AbstractText><CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verhagen</LastName><ForeName>Chloë</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, the Netherlands. Electronic address: C.Verhagen-5@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>Jolien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, the Netherlands. Electronic address: J.Janssen-9@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minderhoud</LastName><ForeName>Crista A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, the Netherlands. Electronic address: c.a.minderhoud-2@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, the Netherlands. Electronic address: E.vandenberg@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanner</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Nephrology, Würzburg University Clinic, Würzburg, Germany. Electronic address: Wanner_C@ukw.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passera</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Development &amp; Analytics, Novartis Pharma, Basel, Switzerland. Electronic address: Anna.Passera@novartis.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansen</LastName><ForeName>Odd Erik</ForeName><Initials>OE</Initials><AffiliationInfo><Affiliation>Cardiometabolic Clinical Development, Nestlé Health Science, Vevey, Switzerland. Electronic address: odd_erikj@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biessels</LastName><ForeName>Geert Jan</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, the Netherlands. Electronic address: G.J.Biessels@umcutrecht.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01243424</AccessionNumber><AccessionNumber>NCT01897532</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Diabetes Complications</MedlineTA><NlmUniqueID>9204583</NlmUniqueID><ISSNLinking>1056-8727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000419" MajorTopicYN="N">Albuminuria</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082742" MajorTopicYN="N">Heart Disease Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Albuminuria</Keyword><Keyword MajorTopicYN="N">Attention and executive functioning</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Chronic kidney disease</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Cognitive decline</Keyword><Keyword MajorTopicYN="N">Kidney parameters</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. OEJ was previously employed by Boehringer Ingelheim. The UMC Utrecht has received research support from Boehringer Ingelheim for GJBs projects. CW has received grant support, fees for advisory services and lecturing from Boehringer Ingelheim.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36116359</ArticleId><ArticleId IdType="pii">S1056-8727(22)00215-X</ArticleId><ArticleId IdType="doi">10.1016/j.jdiacomp.2022.108303</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36116296</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1973-8102</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><PubDate><Year>2022</Year><Month>10</Month></PubDate></JournalIssue><Title>Cortex; a journal devoted to the study of the nervous system and behavior</Title><ISOAbbreviation>Cortex</ISOAbbreviation></Journal><ArticleTitle>I'm looking through you: Mentalizing in frontotemporal dementia and progressive supranuclear palsy.</ArticleTitle><Pagination><MedlinePgn>373-389</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0010-9452(22)00230-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cortex.2022.07.015</ELocationID><Abstract><AbstractText>Mentalizing and emotion recognition are impaired in behavioral variant frontotemporal dementia (bvFTD). It is not clear whether these abilities are also disturbed in other conditions with prominent frontal lobe involvement, such as progressive supranuclear palsy (PSP). Our aim was to investigate social cognition (facial emotion recognition, recognition of social norms violation and mentalizing) in bvFTD and PSP. The neural basis of these functions in PSP and bvFTD groups, by analysis of structural neuroimaging, were also investigated. Twenty-three bvFTD patients, 21 PSP patients and 23 healthy controls were included. All participants underwent 3T brain MRI and a full cognitive exam including the short version of Social and Emotional Assessment (Mini-SEA), which is composed of a facial emotion recognition test (FERT) and the faux pas test. Two components of the faux pas test were distinguished: a score assessing the recognition of social norms violation and a score assessing mentalizing. Compared to controls, bvFTD and PSP patients had significantly reduced scores in all tests of social cognition but did not differ on these measures. PSP and bvFTD had cerebral atrophy in critical regions for social cognition processes, when compared to controls. The cortical correlates of emotion recognition partially overlapped in bvFTD and PSP, with correlations retrieved within the frontal medial cortex, cingulate, insula and limbic structures. PSP and bvFTD patients also displayed similar patterns of brain correlations for the composite score of social norms, with a significant cluster in anterior temporal lobes. Mentalizing scores were associated with frontal and temporal poles bilaterally, in both bvFTD and PSP. These findings support previous observations that PSP patients exhibit impairment in complex cognitive abilities, such as mentalizing. Moreover, these data extend previous findings showing that PSP and bvFTD share key clinical, cognitive and neuroimaging features.</AbstractText><CopyrightInformation>Copyright © 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Leonardo Cruz</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Neurociências, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Departamento de Clínica Médica, Faculdade de Medicina, UFMG, Belo Horizonte, MG, Brazil; Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address: leocruzsouza@ufmg.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoux</LastName><ForeName>Maxime</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, Lille, France; Licend - Lille Centre of Excellence for Neurodegenerative Disorders &amp; DISTALZ - Development of Innovative Strategies for a Transdisciplinary Approach to ALZheimer's disease Lab, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radakovic</LastName><ForeName>Ratko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Science, University of East Anglia, Norwich, United Kingdom; Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, United Kingdom; Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornberger</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Science, University of East Anglia, Norwich, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariano</LastName><ForeName>Luciano Inácio</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Neurociências, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resende</LastName><ForeName>Elisa de Paula França</ForeName><Initials>EPF</Initials><AffiliationInfo><Affiliation>Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quesque</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guimarães</LastName><ForeName>Henrique Cerqueira</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambogi</LastName><ForeName>Leandro Boson</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tumas</LastName><ForeName>Vítor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camargos</LastName><ForeName>Sarah Teixeira</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Neurociências, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Departamento de Clínica Médica, Faculdade de Medicina, UFMG, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardoso</LastName><ForeName>Francisco Eduardo Costa</ForeName><Initials>FEC</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Neurociências, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Departamento de Clínica Médica, Faculdade de Medicina, UFMG, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixeira</LastName><ForeName>Antônio Lúcio</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; Santa Casa BH Ensino e Pesquisa, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caramelli</LastName><ForeName>Paulo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Neurociências, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Departamento de Clínica Médica, Faculdade de Medicina, UFMG, Belo Horizonte, MG, Brazil; Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Cortex</MedlineTA><NlmUniqueID>0100725</NlmUniqueID><ISSNLinking>0010-9452</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076563" MajorTopicYN="Y">Mentalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="Y">Pick Disease of the Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="Y">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Emotion recognition</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Progressive supranuclear palsy</Keyword><Keyword MajorTopicYN="N">Richardson’ syndrome</Keyword><Keyword MajorTopicYN="N">Theory of mind</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>05</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>18</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36116296</ArticleId><ArticleId IdType="pii">S0010-9452(22)00230-1</ArticleId><ArticleId IdType="doi">10.1016/j.cortex.2022.07.015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36115980</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Cumulative effect of simvastatin, L-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer's disease.</ArticleTitle><Pagination><MedlinePgn>134</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-022-01076-7</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Vascular disease is a known risk factor for Alzheimer's disease (AD). Endothelial dysfunction has been linked to reduced cerebral blood flow. Endothelial nitric oxide synthase pathway (eNOS) upregulation is known to support endothelial health. This single-center, proof-of-concept study tested whether the use of three medications known to augment the eNOS pathway activity improves cognition and cerebral blood flow (CBF).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subjects with mild AD or mild cognitive impairment (MCI) were sequentially treated with the HMG-CoA reductase synthesis inhibitor simvastatin (weeks 0-16), L-arginine (weeks 4-16), and tetrahydrobiopterin (weeks 8-16). The primary outcome of interest was the change in CBF as measured by MRI from baseline to week 16. Secondary outcomes included standard assessments of cognition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 11 subjects were deemed eligible and enrolled. One subject withdrew from the study after enrollment, leaving 10 subjects for data analysis. There was a significant increase in CBF from baseline to week 8 by ~13% in the limbic and ~15% in the cerebral cortex. Secondary outcomes indicated a modest but significant increase in the MMSE from baseline (24.2±3.2) to week 16 (26.0±2.7). Exploratory analysis indicated that subjects with cognitive improvement (reduction of the ADAS-cog 13) had a significant increase in their respective limbic and cortical CBF.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment of mild AD/MCI subjects with medications shown to augment the eNOS pathway was well tolerated and associated with modestly increased cerebral blood flow and cognitive improvement.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This study is registered in https://www.</AbstractText><AbstractText Label="CLINICALTRIALS" NlmCategory="RESULTS">gov ; registration identifier: NCT01439555; date of registration submitted to registry: 09/23/2011; date of first subject enrollment: 11/2011.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Degrush</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, 55 Lake Ave, North, Worcester, MA, 01655, USA. Elizabeth.Degrush@umassmemorial.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Massachusetts Chan Medical School, 55 Lake Ave, North, Worcester, MA, 01655, USA. Elizabeth.Degrush@umassmemorial.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Shazeeb</LastName><ForeName>Mohammed Salman</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Image Processing and Analysis Core (iPAC), Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New England Center for Stroke Research, Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drachman</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, 55 Lake Ave, North, Worcester, MA, 01655, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardar</LastName><ForeName>Zeynep</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Image Processing and Analysis Core (iPAC), Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New England Center for Stroke Research, Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindsay</LastName><ForeName>Clifford</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Image Processing and Analysis Core (iPAC), Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gounis</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Image Processing and Analysis Core (iPAC), Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New England Center for Stroke Research, Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henninger</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, 55 Lake Ave, North, Worcester, MA, 01655, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Massachusetts Chan Medical School, 55 Lake Ave, North, Worcester, MA, 01655, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>22150-76-1</RegistryNumber><NameOfSubstance UI="D001708">Biopterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>94ZLA3W45F</RegistryNumber><NameOfSubstance UI="D001120">Arginine</NameOfSubstance></Chemical><Chemical><RegistryNumber>AGG2FN16EV</RegistryNumber><NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052250">Nitric Oxide Synthase Type III</NameOfSubstance></Chemical><Chemical><RegistryNumber>EGX657432I</RegistryNumber><NameOfSubstance UI="C003402">sapropterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001708" MajorTopicYN="N">Biopterin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052250" MajorTopicYN="N">Nitric Oxide Synthase Type III</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075082" MajorTopicYN="N">Proof of Concept Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">Arterial spin labeling</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Endothelial nitric oxide synthase</Keyword><Keyword MajorTopicYN="N">Perfusion-weighted imaging</Keyword><Keyword MajorTopicYN="N">Statin</Keyword><Keyword MajorTopicYN="N">Vascular disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36115980</ArticleId><ArticleId IdType="doi">10.1186/s13195-022-01076-7</ArticleId><ArticleId IdType="pii">10.1186/s13195-022-01076-7</ArticleId><ArticleId IdType="pmc">PMC9482313</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curr Alzheimer Res. 2012 Oct;9(8):990-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22175654</ArticleId></ArticleIdList></Reference><Reference><Citation>Comput Methods Programs Biomed. 2011 Dec;104(3):e148-57</Citation><ArticleIdList><ArticleId IdType="pubmed">21458099</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):13-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18931004</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10325453</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2004 Feb;6(1):11-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15004323</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Pharmacother. 2009 Jan;63(1):19-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18162361</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Image Anal. 2002 Jun;6(2):129-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12045000</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1996 Oct;9(4):200-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8970013</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1993 Nov;43(11):2412-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2002 Feb;59(2):223-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11843693</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 2011 Feb;37(1):56-74</Citation><ArticleIdList><ArticleId IdType="pubmed">20946471</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1998 Mar 31;97(12):1129-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9537338</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2018 Sep 18;10:279</Citation><ArticleIdList><ArticleId IdType="pubmed">30279656</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2021 Nov;191(11):1906-1916</Citation><ArticleIdList><ArticleId IdType="pubmed">33713686</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2018;63(2):423-444</Citation><ArticleIdList><ArticleId IdType="pubmed">29660938</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Res Int. 2014;2014:601515</Citation><ArticleIdList><ArticleId IdType="pubmed">24860826</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2000 Nov 11;356(9242):1627-31</Citation><ArticleIdList><ArticleId IdType="pubmed">11089820</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2000 Sep;6(9):1004-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10973320</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1999 Sep;30(9):1969-73</Citation><ArticleIdList><ArticleId IdType="pubmed">10471452</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 Mar;7(2):185-96</Citation><ArticleIdList><ArticleId IdType="pubmed">21074500</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetologia. 2000 Nov;43(11):1435-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11126415</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2020 Sep 7;10(1):14693</Citation><ArticleIdList><ArticleId IdType="pubmed">32895407</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2000 Apr;20(4):709-17</Citation><ArticleIdList><ArticleId IdType="pubmed">10779015</ArticleId></ArticleIdList></Reference><Reference><Citation>IEEE Trans Biomed Eng. 2009 May;56(5):1287-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19188118</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2000 Sep;12(3):403-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11081960</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2009 Jan;30(1):48-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19042039</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2017;57(1):1-28</Citation><ArticleIdList><ArticleId IdType="pubmed">28222507</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerebrovasc Dis. 2006;21(3):180-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16388193</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2011;23(3):375-89</Citation><ArticleIdList><ArticleId IdType="pubmed">21098977</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomedicines. 2020 Aug 06;8(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">32781796</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Apr 4;32(14):4705-15</Citation><ArticleIdList><ArticleId IdType="pubmed">22492027</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2009 May;116(5):587-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19370387</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2785-91</Citation><ArticleIdList><ArticleId IdType="pubmed">18441206</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):171-3</Citation><ArticleIdList><ArticleId IdType="pubmed">22019547</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2012 Nov;32(11):1973-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22929438</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2000 Oct;57(10):1439-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1991 Apr;6(4):487-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerebrovasc Dis. 2011;31(4):358-64</Citation><ArticleIdList><ArticleId IdType="pubmed">21252504</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Res. 2003 Jan;57(1):253-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12504836</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2021;82(1):293-305</Citation><ArticleIdList><ArticleId IdType="pubmed">34024834</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1984 Nov;141(11):1356-64</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart. 2006 Nov;92(11):1603-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16709697</ArticleId></ArticleIdList></Reference><Reference><Citation>Endothelium. 2007 Mar-Apr;14(2):73-80</Citation><ArticleIdList><ArticleId IdType="pubmed">17497363</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Nov 30;10(11):e0142756</Citation><ArticleIdList><ArticleId IdType="pubmed">26618360</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2018 Jun 18;6:CD001190</Citation><ArticleIdList><ArticleId IdType="pubmed">29923184</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8880-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9671773</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Alzheimers Dis. 2017;2017:5479597</Citation><ArticleIdList><ArticleId IdType="pubmed">28573062</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2017 Feb 17;9(1):10</Citation><ArticleIdList><ArticleId IdType="pubmed">28212683</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 2021 Jun;77(6):2075-2083</Citation><ArticleIdList><ArticleId IdType="pubmed">33866797</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurotrauma. 2004 Sep;21(9):1196-203</Citation><ArticleIdList><ArticleId IdType="pubmed">15453989</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurol Scand. 2011 Oct;124(4):269-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21198449</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2007 Apr 4;116(3):300-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16860889</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">36115967</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation.</ArticleTitle><Pagination><MedlinePgn>135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-022-01077-6</ELocationID><Abstract><AbstractText>Aquaporin-4 (AQP4) is a channel protein that plays a fundamental role in glymphatic system, a newly described pathway for fluid exchange in the central nervous system, as well as a central figure in a fascinating new theory for the pathophysiology of neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). In this study, cerebrospinal fluid (CSF) concentration of AQP4, amyloid-β, total tau and P-tau were determined in 103 CSF samples from patients affected by neurodegenerative dementias (AD and FTD) or psychiatric diseases and 21 controls. Significantly higher levels of AQP4 were found in AD and FTD patients compared to subjects not affected by neurodegenerative diseases, and a significant, positive correlation between AQP4 and total tau levels was found. This evidence may pave the way for future studies focused on the role of this channel protein in the clinical assessment of the glymphatic function and degree of neurodegeneration.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arighi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy. andrea.arighi@policlinico.mi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arcaro</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Giorgio Giulio</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carandini</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietroboni</LastName><ForeName>Anna Margherita</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacchi</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serpente</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isgrò</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turkheimer</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Disease Unit, via Francesco Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496030">AQP4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051401" MajorTopicYN="Y">Aquaporin 4</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077502" MajorTopicYN="Y">Glymphatic System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">Amyloid-β</Keyword><Keyword MajorTopicYN="N">Aquaporin 4</Keyword><Keyword MajorTopicYN="N">Cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Glymphatic system</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36115967</ArticleId><ArticleId IdType="doi">10.1186/s13195-022-01077-6</ArticleId><ArticleId IdType="pii">10.1186/s13195-022-01077-6</ArticleId><ArticleId IdType="pmc">PMC9482276</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1221-1233</Citation><ArticleIdList><ArticleId IdType="pubmed">31542723</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Mol Biol Transl Sci. 2019;168:3-23</Citation><ArticleIdList><ArticleId IdType="pubmed">31699324</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1999 Mar;56(3):303-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Biol. 2011 May-Jun;23(3):333-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21484913</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2014 Dec 3;34(49):16180-93</Citation><ArticleIdList><ArticleId IdType="pubmed">25471560</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2015 May;16(5):249-63</Citation><ArticleIdList><ArticleId IdType="pubmed">25891508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Med. 2003 Mar-Apr;9(3-4):112-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12865947</ArticleId></ArticleIdList></Reference><Reference><Citation>Metab Brain Dis. 2022 Apr;37(4):851-857</Citation><ArticleIdList><ArticleId IdType="pubmed">35286534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Res. 2018 Sep 1;114(11):1462-1473</Citation><ArticleIdList><ArticleId IdType="pubmed">29726891</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Clin. 2017 May;35(2):339-374</Citation><ArticleIdList><ArticleId IdType="pubmed">28410663</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2018 Mar 15;9(1):1097</Citation><ArticleIdList><ArticleId IdType="pubmed">29545515</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 Jan;7(1):80-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21255746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2014 Dec;76(6):845-61</Citation><ArticleIdList><ArticleId IdType="pubmed">25204284</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2016 Sep;93:215-25</Citation><ArticleIdList><ArticleId IdType="pubmed">27234656</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2018 Apr;14(4):535-562</Citation><ArticleIdList><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Transl Neurol. 2021 Jul;8(7):1456-1470</Citation><ArticleIdList><ArticleId IdType="pubmed">34129723</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2011 Sep;134(Pt 9):2456-77</Citation><ArticleIdList><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2015 Nov 02;10:58</Citation><ArticleIdList><ArticleId IdType="pubmed">26526066</ArticleId></ArticleIdList></Reference><Reference><Citation>Elife. 2017 Aug 21;6:</Citation><ArticleIdList><ArticleId IdType="pubmed">28826498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 1999 May 3;108(2):165-72</Citation><ArticleIdList><ArticleId IdType="pubmed">10400309</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2017 Jan 01;74(1):91-99</Citation><ArticleIdList><ArticleId IdType="pubmed">27893874</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2020 Aug 1;143(8):2576-2593</Citation><ArticleIdList><ArticleId IdType="pubmed">32705145</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2012 Aug 15;4(147):147ra111</Citation><ArticleIdList><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2021 Oct 1;16(10):e0258165</Citation><ArticleIdList><ArticleId IdType="pubmed">34597351</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluids Barriers CNS. 2022 Feb 3;19(1):9</Citation><ArticleIdList><ArticleId IdType="pubmed">35115036</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2022;85(3):1009-1020</Citation><ArticleIdList><ArticleId IdType="pubmed">34897084</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2018 Nov;14(11):1505-1521</Citation><ArticleIdList><ArticleId IdType="pubmed">30316776</ArticleId></ArticleIdList></Reference><Reference><Citation>Handb Clin Neurol. 2019;167:139-148</Citation><ArticleIdList><ArticleId IdType="pubmed">31753130</ArticleId></ArticleIdList></Reference><Reference><Citation>Elife. 2018 Dec 18;7:</Citation><ArticleIdList><ArticleId IdType="pubmed">30561329</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2019;69(3):663-669</Citation><ArticleIdList><ArticleId IdType="pubmed">31156164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2014 Jun;13(6):614-29</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2015 Aug;11(8):457-70</Citation><ArticleIdList><ArticleId IdType="pubmed">26195256</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2020 Oct;16(10):1358-1371</Citation><ArticleIdList><ArticleId IdType="pubmed">32573951</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis (Berl). 2016 Mar 1;3(1):9-12</Citation><ArticleIdList><ArticleId IdType="pubmed">29540044</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2015 Jun;138(Pt 6):1454-76</Citation><ArticleIdList><ArticleId IdType="pubmed">25888551</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2016 May 3;86(18):1736-43</Citation><ArticleIdList><ArticleId IdType="pubmed">27037234</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Med. 2021 Mar 02;10(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">33801197</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumour Biol. 2013 Feb;34(1):387-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23111756</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36115552</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>174</Volume><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>Microglial ion channels: Key players in non-cell autonomous neurodegeneration.</ArticleTitle><Pagination><MedlinePgn>105861</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(22)00253-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2022.105861</ELocationID><Abstract><AbstractText>Neuroinflammation is a critical pathophysiological hallmark of neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), and traumatic brain injury (TBI). Microglia, the first responders of the brain, are the drivers of this neuroinflammation. Microglial activation, leading to induction of pro-inflammatory factors, like Interleukin 1-β (IL-1β), Tumor necrosis factor-α (TNFα), nitrites, and others, have been shown to induce neurodegeneration. Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce the risk of developing PD, but the mechanism underlying the microglial activation is still under active research. Recently, microglial ion channels have come to the forefront as potential drug targets in multiple neurodegenerative disorders, including AD and PD. Microglia expresses a variety of ion channels, including potassium channels, calcium channels, chloride channels, sodium channels, and proton channels. The diversity of channels present on microglia is responsible for the dynamic nature of these immune cells of the brain. These ion channels regulate microglial proliferation, chemotaxis, phagocytosis, antigen recognition and presentation, apoptosis, and cell signaling leading to inflammation, among other critical critical functions. Understanding the role of these ion channels and the signaling mechanism these channels regulate under pathological conditions is an active area of research. This review will be focusing on the roles of different microglial ion channels, and their potential role in regulating microglial functions in neurodegenerative disorders.</AbstractText><CopyrightInformation>Copyright © 2022 The Author. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Souvarish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dept. of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: rakras26@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K99 ES033723</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Channels</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36115552</ArticleId><ArticleId IdType="pii">S0969-9961(22)00253-4</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2022.105861</ArticleId><ArticleId IdType="pmc">PMC9617777</ArticleId><ArticleId IdType="mid">NIHMS1837552</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14861-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18818304</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1995 Nov 17;270(5239):1166-70</Citation><ArticleIdList><ArticleId IdType="pubmed">7502040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2006 Dec;33(4):401-11</Citation><ArticleIdList><ArticleId IdType="pubmed">17055293</ArticleId></ArticleIdList></Reference><Reference><Citation>NPJ Parkinsons Dis. 2017 Oct 17;3:30</Citation><ArticleIdList><ArticleId IdType="pubmed">29057315</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2012 Jan 20;9:16</Citation><ArticleIdList><ArticleId IdType="pubmed">22264228</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2015 Oct;63(10):1870-82</Citation><ArticleIdList><ArticleId IdType="pubmed">26010461</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Aug 3;25(31):7139-49</Citation><ArticleIdList><ArticleId IdType="pubmed">16079396</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotox Res. 2016 Oct;30(3):467-78</Citation><ArticleIdList><ArticleId IdType="pubmed">27260222</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2015 May 12;9:185</Citation><ArticleIdList><ArticleId IdType="pubmed">26029054</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1251-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20114030</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Sep 9;333(6048):1456-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 1996 Jul;17(3):225-36</Citation><ArticleIdList><ArticleId IdType="pubmed">8840164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2020 Aug 3;130(8):4195-4212</Citation><ArticleIdList><ArticleId IdType="pubmed">32597830</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2018 Feb 1;141(2):596-612</Citation><ArticleIdList><ArticleId IdType="pubmed">29272333</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1991 Jul 4;352(6330):26</Citation><ArticleIdList><ArticleId IdType="pubmed">2062374</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2018 Mar 25;498(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">28676401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Jan 3;27(1):234-44</Citation><ArticleIdList><ArticleId IdType="pubmed">17202491</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2013 Nov;126(5):725-39</Citation><ArticleIdList><ArticleId IdType="pubmed">24002225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2017 Jul;82:167-175</Citation><ArticleIdList><ArticleId IdType="pubmed">28552341</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1990 Dec;87(23):9411-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2251283</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmune Pharmacol. 2017 Dec;12(4):624-660</Citation><ArticleIdList><ArticleId IdType="pubmed">28466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2020 Jan 31;11:33</Citation><ArticleIdList><ArticleId IdType="pubmed">32082315</ArticleId></ArticleIdList></Reference><Reference><Citation>Antioxid Redox Signal. 2017 Nov 10;27(14):1048-1066</Citation><ArticleIdList><ArticleId IdType="pubmed">28375739</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2012 May;60(5):761-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22331560</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1984 Nov 8-14;312(5990):121-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6209577</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2015;21(41):6023-35</Citation><ArticleIdList><ArticleId IdType="pubmed">26510437</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2009 Nov 30;216(1-2):118-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19683814</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Jan 31;493(7434):674-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2012 Jun 15;188(12):5877-86</Citation><ArticleIdList><ArticleId IdType="pubmed">22581856</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 Apr;12(3):317-27</Citation><ArticleIdList><ArticleId IdType="pubmed">18700057</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2012 May 10;516(1):94-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22487729</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2016 Jun 01;13(1):130</Citation><ArticleIdList><ArticleId IdType="pubmed">27246103</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2015 Apr 28;9:148</Citation><ArticleIdList><ArticleId IdType="pubmed">25972780</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2009 Aug 1;57(10):1072-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19115387</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2017 Aug 22;14(1):166</Citation><ArticleIdList><ArticleId IdType="pubmed">28830445</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2008 Aug;9(8):857-65</Citation><ArticleIdList><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2014 Feb 7;444(2):212-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24462864</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Signal. 2019 Jan 08;12(563):</Citation><ArticleIdList><ArticleId IdType="pubmed">30622196</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotoxicology. 2018 Jan;64:204-218</Citation><ArticleIdList><ArticleId IdType="pubmed">28539244</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1983 Sep 8-14;305(5930):147-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6310409</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2015;33:291-353</Citation><ArticleIdList><ArticleId IdType="pubmed">25861976</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Aug 22;9(8):e106087</Citation><ArticleIdList><ArticleId IdType="pubmed">25148577</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2014 May;171(9):2426-39</Citation><ArticleIdList><ArticleId IdType="pubmed">24641282</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2014 Apr 24;11:82</Citation><ArticleIdList><ArticleId IdType="pubmed">24761998</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Biosci (Schol Ed). 2011 Jun 01;3(3):884-900</Citation><ArticleIdList><ArticleId IdType="pubmed">21622239</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2012 Mar 04;15(4):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22388960</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11013-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9380751</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2014 Oct;35(10):537-47</Citation><ArticleIdList><ArticleId IdType="pubmed">25223574</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Nov 9;31(45):16298-308</Citation><ArticleIdList><ArticleId IdType="pubmed">22072681</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2018 Feb;110:102-121</Citation><ArticleIdList><ArticleId IdType="pubmed">29197620</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Stroke Res. 2014 Feb;5(1):99-108</Citation><ArticleIdList><ArticleId IdType="pubmed">24323712</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2013 Nov;61(11):1807-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24038428</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharmacol Sin. 2011 Jun;32(6):765-80</Citation><ArticleIdList><ArticleId IdType="pubmed">21602835</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):</Citation><ArticleIdList><ArticleId IdType="pubmed">33649184</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2005 Dec;57(4):463-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16382103</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2001 Mar 1;33(3):181-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11241736</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1993 Sep 17;160(1):69-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7504220</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 1998 Dec;24(4):408-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9814821</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2007 Dec 28;282(52):37350-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17962183</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxicol Sci. 2021 Aug 3;182(2):159-167</Citation><ArticleIdList><ArticleId IdType="pubmed">34076689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Mar 14;32(11):3931-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22423113</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 1985 Nov;10(1):71-95</Citation><ArticleIdList><ArticleId IdType="pubmed">2414315</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2015;44(3):797-808</Citation><ArticleIdList><ArticleId IdType="pubmed">25362031</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2017 Jun 26;14(1):128</Citation><ArticleIdList><ArticleId IdType="pubmed">28651603</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2008 Jan 15;586(2):427-39</Citation><ArticleIdList><ArticleId IdType="pubmed">17991695</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2015 Jul 08;35(27):10058-77</Citation><ArticleIdList><ArticleId IdType="pubmed">26157004</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2022 Jul 4;13(1):3854</Citation><ArticleIdList><ArticleId IdType="pubmed">35788586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2016 Oct;139(1):96-105</Citation><ArticleIdList><ArticleId IdType="pubmed">27470181</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neuropharmacol. 2012 Dec;10(4):321-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23730256</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2018 May 21;13(1):24</Citation><ArticleIdList><ArticleId IdType="pubmed">29784049</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2013 Aug 15;4:e773</Citation><ArticleIdList><ArticleId IdType="pubmed">23949222</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2013 Aug 15;261(1-2):21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23735284</ArticleId></ArticleIdList></Reference><Reference><Citation>Mediators Inflamm. 2020 Dec 5;2020:9694012</Citation><ArticleIdList><ArticleId IdType="pubmed">33376453</ArticleId></ArticleIdList></Reference><Reference><Citation>Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3004-17</Citation><ArticleIdList><ArticleId IdType="pubmed">18362111</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2017 Jan;65(1):106-121</Citation><ArticleIdList><ArticleId IdType="pubmed">27696527</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1984 Feb 2-8;307(5950):468-71</Citation><ArticleIdList><ArticleId IdType="pubmed">6320008</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3112-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14981264</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2013;37(2):439-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23948887</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 May 30;8(5):e64904</Citation><ArticleIdList><ArticleId IdType="pubmed">23738010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Signal. 2019 Mar 12;12(572):</Citation><ArticleIdList><ArticleId IdType="pubmed">30862700</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2014 Dec;62(12):2080-95</Citation><ArticleIdList><ArticleId IdType="pubmed">25043721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 2017 Oct;92(4):469-480</Citation><ArticleIdList><ArticleId IdType="pubmed">28760780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2015 Jan;64:104-15</Citation><ArticleIdList><ArticleId IdType="pubmed">25497271</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2016 Dec;64(12):2231-2246</Citation><ArticleIdList><ArticleId IdType="pubmed">27641912</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2004 Feb 5;41(3):389-404</Citation><ArticleIdList><ArticleId IdType="pubmed">14766178</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 1998 May 1;508 ( Pt 3):647-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9518722</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1999 Feb 6;818(1):168-70</Citation><ArticleIdList><ArticleId IdType="pubmed">9914452</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2005 Jan 15;49(2):220-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15390090</ArticleId></ArticleIdList></Reference><Reference><Citation>IUBMB Life. 2003 Jun;55(6):307-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12938732</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2011 Feb 4;286(5):3693-706</Citation><ArticleIdList><ArticleId IdType="pubmed">20971854</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Mol Med. 2008 Sep-Oct;12(5A):1559-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19012619</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):E2239-48</Citation><ArticleIdList><ArticleId IdType="pubmed">23729813</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Environ Health Rep. 2021 Sep;8(3):203-211</Citation><ArticleIdList><ArticleId IdType="pubmed">34043217</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Aug 26;4(8):e6770</Citation><ArticleIdList><ArticleId IdType="pubmed">19707551</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2012 Jan 19;3:e254</Citation><ArticleIdList><ArticleId IdType="pubmed">22258405</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2011 Dec;31(12):2363-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21750563</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17414-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17088564</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1958 Dec;30(3):653-4</Citation><ArticleIdList><ArticleId IdType="pubmed">13618284</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2015 Feb;36(2):1209-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25480524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Sep 26;6:34064</Citation><ArticleIdList><ArticleId IdType="pubmed">27666530</ArticleId></ArticleIdList></Reference><Reference><Citation>NPJ Parkinsons Dis. 2020 Dec 11;6(1):40</Citation><ArticleIdList><ArticleId IdType="pubmed">33311497</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36115465</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3476</ISSN><JournalIssue CitedMedium="Internet"><Volume>627</Volume><PubDate><Year>2022</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>International journal of pharmaceutics</Title><ISOAbbreviation>Int J Pharm</ISOAbbreviation></Journal><ArticleTitle>Review of lipoic acid: From a clinical therapeutic agent to various emerging biomaterials.</ArticleTitle><Pagination><MedlinePgn>122201</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0378-5173(22)00755-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2022.122201</ELocationID><Abstract><AbstractText>Lipoic acid (LA), an endogenous small molecule in organisms, has been extensively used for the highly efficient clinical treatment of malignant diseases, which include diabetes, Alzheimer's disease, and cancer over the past seven decades. Tremendous progresses have been made on the use of LA in nanomedicine for the development of various biomaterials because of its unique biological properties and highly adaptable structure since the first discovery. However, there are few reviews thus far, to our knowledge, summarizing this hot subject of research of LA and its derived biomaterials. For this purpose, we present herein the first comprehensive summary on the design and development of LA and its derived materials for biomedical applications. This review first discusses the therapeutic use of LA followed by the description of synthesis and preclinical study of LA-derived-small molecules. The applications of various LA and poly (lipoic acid) (PLA)-derived-biomaterials are next summarized in detail with an emphasis on the use of LA for the design of biomaterials and the diverse properties. This review describes the development of LA from a clinical therapeutic agent to a building unit of various biomaterials field, which will promote the further discovery of new therapeutic uses of LA as therapeutic agents and facile development of LA-based derivates with greater performance for biomedical applications.</AbstractText><CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Shao-Yang</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Suisui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Xiao-Li</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yue-Qin</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Jin-Rong</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jia-Qi</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China. Electronic address: weih@usc.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Cui-Yun</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy &amp; Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China. Electronic address: yucuiyunusc@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Pharm</MedlineTA><NlmUniqueID>7804127</NlmUniqueID><ISSNLinking>0378-5173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73Y7P0K73Y</RegistryNumber><NameOfSubstance UI="D008063">Thioctic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001672">Biocompatible Materials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011091">Polyesters</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008063" MajorTopicYN="Y">Thioctic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001672" MajorTopicYN="N">Biocompatible Materials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011091" MajorTopicYN="N">Polyesters</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomaterial</Keyword><Keyword MajorTopicYN="N">Lipoic acid</Keyword><Keyword MajorTopicYN="N">Poly (lipoic acid)</Keyword><Keyword MajorTopicYN="N">Therapeutic application</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36115465</ArticleId><ArticleId IdType="pii">S0378-5173(22)00755-4</ArticleId><ArticleId IdType="doi">10.1016/j.ijpharm.2022.122201</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36115457</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>298</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Early stage β-amyloid-membrane interactions modulate lipid dynamics and influence structural interfaces and fibrillation.</ArticleTitle><Pagination><MedlinePgn>102491</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(22)00934-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbc.2022.102491</ELocationID><Abstract><AbstractText>Molecular interactions between β-amyloid (Aβ) peptide and membranes contribute to the neuronal toxicity of Aβ and the pathology of Alzheimer's disease. Neuronal plasma membranes serve as biologically relevant environments for the Aβ aggregation process as well as affect the structural polymorphisms of Aβ aggregates. However, the nature of these interactions is unknown. Here, we utilized solid-state NMR spectroscopy to explore the site-specific interactions between Aβ peptides and lipids in synaptic plasma membranes at the membrane-associated nucleation stage. The key results show that different segments in the hydrophobic sequence of Aβ initiate membrane binding and interstrand assembling. We demonstrate early stage Aβ-lipid interactions modulate lipid dynamics, leading to more rapid lipid headgroup motion and reduced lateral diffusive motion. These early events influence the structural polymorphisms of yielded membrane-associated Aβ fibrils with distinct C-terminal quaternary interface structure compared to fibrils grown in aqueous solutions. Based on our results, we propose a schematic mechanism by which Aβ-lipid interactions drive membrane-associated nucleation processes, providing molecular insights into the early events of fibrillation in biological environments.</AbstractText><CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kenyaga</LastName><ForeName>June M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Binghamton University, The State University of New York, Vestal, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Qinghui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Binghamton University, The State University of New York, Vestal, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Binghamton University, The State University of New York, Vestal, New York, USA. Electronic address: wqiang@binghamton.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057927" MajorTopicYN="N">Hydrophobic and Hydrophilic Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">amyloid-beta</Keyword><Keyword MajorTopicYN="N">biophysics</Keyword><Keyword MajorTopicYN="N">membrane</Keyword><Keyword MajorTopicYN="N">solid-state NMR</Keyword></KeywordList><CoiStatement>Conflicts of interest The authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36115457</ArticleId><ArticleId IdType="pii">S0021-9258(22)00934-6</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2022.102491</ArticleId><ArticleId IdType="pmc">PMC9556791</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36115352</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>10</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Advances in Alzheimer's disease research over the past two decades.</ArticleTitle><Pagination><MedlinePgn>866-869</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(22)00298-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(22)00298-8</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN 55905, USA. Electronic address: jack.clifford@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>CRJ has received funding from the National Institute on Aging (R37 AG011378), GHR Foundation, and the Alexander Family Professorship. CRJ serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. I would like to thank Stephen D Weigand for creating the illustration, and David S Knopman and Ronald C Petersen for editing advice.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>19</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36115352</ArticleId><ArticleId IdType="pii">S1474-4422(22)00298-8</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(22)00298-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36115219</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>442</Volume><PubDate><Year>2022</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Relationship between CSF tau biomarkers and structural brain MRI measures in frontotemporal lobar degeneration.</ArticleTitle><Pagination><MedlinePgn>120415</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0022-510X(22)00277-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2022.120415</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recently in the field neurodegenerative diseases increasing attention has been pointed to CSF biomarkers and their integration with neuroimaging (1). Frontotemporal lobar degeneration (FTLD) refers to a heterogeneous group of clinical syndromes with different underlying proteinopathies including tau pathology. CSF biomarkers have been proposed as diagnostic and prognostic factors. Aim of our study was to evaluate the relationship between CSF tau biomarkers and structural MRI brain measures in FTLD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included early FTLD patient. All included patients underwent lumbar puncture to evaluate amyloid, total-tau (t-tau), phospho-tau 181 (p-tau); p-tau/t-tau ratio was also calculated; brain MRI was performed to estimate whole brain volume, volume of principal deep grey matter structures and regional cortical thickness.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Demographic characteristics of the 28 included patients were as follows: female/male: 9/19; mean ± SD age: 68.1 ± 7.8 years. The p-tau/t-tau ratio was significantly correlated with whole brain volume (r = 0.69; p: 0.001), left putamen volume (r = 0.55 p: 0.009), left pallidum volume (r = 0.41; p: 0.01), right accumbens area (r = 0.47; p: 0.02). P-tau/t tau ratio showed also a significant correlation with cortical thickness of left temporal lobe (r = 0.74; p: 0.001) and right lateral orbital frontal cortex (r = 0.45; p: 0.03). Linear regression showed a significant relationship between p-tau/t-tau ratio and left temporal pole (p = 0.01; r<sup>2</sup>: 0.60) and brain volume (p:0.002; r<sup>2</sup>: 0.56) after controlling for age and gender.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data suggest that CSF biomarkers, especially p-tau/t-tau ratio, could play a role as prognostic factor in FTLD. Further longitudinal investigations are needed to confirm these findings.</AbstractText><CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fenu</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy. Electronic address: giusefenu@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oppo</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorefice</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Sfefano</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deagostini</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancosu</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fadda</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melis</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siotto</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Radiology Unit, ARNAS Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cocco</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melis</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cossu</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Brain volume</Keyword><Keyword MajorTopicYN="N">Cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">Frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">Tau</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no conflict of interest regarding this research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36115219</ArticleId><ArticleId IdType="pii">S0022-510X(22)00277-5</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2022.120415</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>